{"meta":{"query_hash":"6de10d7fb825","filters":{"venue":"Journal for ImmunoTherapy of Cancer"},"cohort_total":261,"direct_labels_cover":0,"predictions_cover":261,"exported":261,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6de10d7fb825","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+for+ImmunoTherapy+of+Cancer"},"results":[{"id":"W1517732299","doi":"10.1186/s40425-015-0066-0","title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Ipilimumab; Medicine; Liver transplantation; Melanoma; Transplantation; Metastatic melanoma; Oncology; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.020230095732515482,"score_gpt":0.3295934070659579,"score_spread":0.3093633113334424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1517732299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97767204,0.014497771,0.0018476039,0.00075790955,0.000107889275,0.00008913127,0.000100320176,0.000036501027,0.0048907096],"genre_scores_gemma":[0.9982913,0.000856578,0.000251615,0.00017193166,0.00011276414,0.000017728018,0.00006446491,0.000004406713,0.00022911359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997069,0.00012637791,0.000037257614,0.00003078701,0.000060065606,0.00003852225],"domain_scores_gemma":[0.9987936,0.00043654634,0.00031856098,0.00011367842,0.00011061414,0.00022692652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088776473,0.0001517069,0.00046617366,0.00020439248,0.0002504204,0.00036123808,0.0001867806,0.0002740802,0.00078597263],"category_scores_gemma":[0.0017847985,0.00004793559,0.0003523061,0.00016736126,0.00024148753,0.0002165364,0.00013732164,0.0009009659,0.00021731057],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04563254,0.005843937,0.09504945,0.0012198862,0.00062463206,0.013718216,0.0006590399,0.0038159403,0.12371869,0.0012537583,0.0031634308,0.70530045],"study_design_scores_gemma":[0.0075303447,0.2930274,0.42438093,0.0005897044,0.002193431,0.07455602,0.00055445556,0.015708797,0.11548147,0.0028310774,0.06304985,0.000096501484],"about_ca_topic_score_codex":0.00017741123,"about_ca_topic_score_gemma":0.00022625114,"teacher_disagreement_score":0.00088776473,"about_ca_system_score_codex":0.00027527573,"about_ca_system_score_gemma":0.00026966265,"threshold_uncertainty_score":0.0046949983},"labels":[],"label_agreement":null},{"id":"W1924107806","doi":"10.1186/s40425-015-0085-x","title":"Immune monitoring technology primer: flow and mass cytometry","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Flow cytometry; Mass cytometry; Fluorescence; Immune system; Antibody; Fluorescent labelling; Cytometry; Multiplex; Computational biology; Molecular biology; Chemistry; Immunology; Biology; Bioinformatics; Biochemistry; Physics","score_opus":0.021556233595377113,"score_gpt":0.30390766704808864,"score_spread":0.2823514334527115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924107806","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002980283,0.022133004,0.8408016,0.02364522,0.018340014,0.0034171736,0.0045112288,0.010522023,0.07364937],"genre_scores_gemma":[0.01337898,0.022569759,0.7630533,0.03372541,0.00823505,0.0055725365,0.0055511263,0.0032532075,0.14466067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959443,0.00084237073,0.00033758383,0.00083165016,0.0017554999,0.0002885985],"domain_scores_gemma":[0.9964657,0.0009459351,0.00024117282,0.0004879032,0.0015716249,0.00028769247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056662234,0.0016409773,0.001225801,0.0035396265,0.0009180348,0.0028916837,0.0024805109,0.0036992428,0.038846493],"category_scores_gemma":[0.0048884735,0.0010480268,0.0009796787,0.001540947,0.0016750203,0.0033277378,0.0023211131,0.006470809,0.03380768],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046917482,0.00043924444,0.0012111267,0.0020675848,0.00005376908,0.00035090328,0.00031260785,0.00069253857,0.10489262,0.10445201,0.3126579,0.47240058],"study_design_scores_gemma":[0.000045597622,0.00021090322,0.0005267598,0.0003515169,0.000030048015,0.00092875503,0.00004929931,0.0012013271,0.03822534,0.0127178,0.9456478,0.00006483709],"about_ca_topic_score_codex":0.00052905746,"about_ca_topic_score_gemma":0.000689537,"teacher_disagreement_score":0.038846493,"about_ca_system_score_codex":0.0012339031,"about_ca_system_score_gemma":0.0021480485,"threshold_uncertainty_score":0.12995446},"labels":[],"label_agreement":null},{"id":"W2010401950","doi":"10.1186/2051-1426-1-s1-p27","title":"ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; Lymphoma; Neuroblastoma; Anaplastic large-cell lymphoma; Medicine; Pathology; Biology; Internal medicine; Cell culture; Receptor","score_opus":0.045372139869788504,"score_gpt":0.35913235344989697,"score_spread":0.31376021358010847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010401950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6134733,0.2920734,0.037530724,0.007258108,0.0018457506,0.00064820866,0.0012292133,0.001475456,0.044465862],"genre_scores_gemma":[0.7482504,0.1786507,0.026103154,0.0011200578,0.0006341763,0.0003787414,0.0011958448,0.00012686937,0.043539982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999902,0.000015853897,0.000005773391,0.000013252049,0.000036089445,0.000027014103],"domain_scores_gemma":[0.99994755,0.000011875591,0.000008597224,0.000002441287,0.0000121354815,0.000017445089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041636964,0.00044720882,0.00025266255,0.00044747646,0.00017679554,0.0005234797,0.00031938014,0.00055854116,0.004694857],"category_scores_gemma":[0.00015246288,0.00018034637,0.00025733892,0.0002728116,0.0001695811,0.0006620718,0.00032158644,0.00087187975,0.0015530156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006973234,0.0003366058,0.0007230487,0.00058984675,0.000034819914,0.0005530125,0.00014133936,0.0009356204,0.72159773,0.003965146,0.012265106,0.2581604],"study_design_scores_gemma":[0.0005386326,0.0025266772,0.0046167755,0.00017587004,0.00013038516,0.0033951038,0.0001318899,0.005092316,0.6655481,0.0010906911,0.3166941,0.000059525322],"about_ca_topic_score_codex":0.00040047686,"about_ca_topic_score_gemma":0.00076007936,"teacher_disagreement_score":0.004694857,"about_ca_system_score_codex":0.00046122164,"about_ca_system_score_gemma":0.0003164384,"threshold_uncertainty_score":0.015705824},"labels":[],"label_agreement":null},{"id":"W2030838608","doi":"10.1186/2051-1426-2-s3-o3","title":"Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Somatic cell; Cancer research; Melanoma; Metastatic melanoma; Gastrointestinal cancer; Cancer; Colorectal cancer; Immunology; Internal medicine; Biology; Gene; Genetics","score_opus":0.02094606342333718,"score_gpt":0.2891011124387091,"score_spread":0.26815504901537196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030838608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95670617,0.010326282,0.010911327,0.0026994965,0.00059003313,0.0005000944,0.00011598056,0.00024194217,0.01790865],"genre_scores_gemma":[0.985126,0.004539767,0.0036755144,0.00043899415,0.0003693093,0.00018006492,0.00009178898,0.00001508364,0.0055634617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998561,0.000044964174,0.000006126846,0.000017068201,0.000035014764,0.000040692234],"domain_scores_gemma":[0.99994767,0.000021310485,0.0000059931876,0.000006544642,0.000008104825,0.000010377545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043672847,0.0003474831,0.0002321105,0.0002798228,0.00015799404,0.00037492855,0.00020751734,0.0005245376,0.0034058448],"category_scores_gemma":[0.0002325797,0.000102100355,0.00023820876,0.00011010069,0.00021271124,0.00020231011,0.00026570435,0.0011102939,0.00086432113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016966005,0.0019693433,0.0022328016,0.0003946639,0.00005828775,0.00082698476,0.00025562348,0.0018642346,0.8323999,0.0053643556,0.00589248,0.14704469],"study_design_scores_gemma":[0.0021947848,0.022863798,0.011093522,0.00018117114,0.00029402436,0.0064958916,0.00017065612,0.012362059,0.8254754,0.0039896234,0.11484802,0.000031038417],"about_ca_topic_score_codex":0.000106470994,"about_ca_topic_score_gemma":0.00012304526,"teacher_disagreement_score":0.0034058448,"about_ca_system_score_codex":0.00017210095,"about_ca_system_score_gemma":0.00015457608,"threshold_uncertainty_score":0.011393666},"labels":[],"label_agreement":null},{"id":"W2056397238","doi":"10.1186/2051-1426-2-s3-p17","title":"Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Modular design; Antigen; Receptor; T cell; Cell biology; Cancer research; Biology; Immunology; Computer science; Chemistry; Immune system; Genetics","score_opus":0.034115129421557464,"score_gpt":0.360206308257852,"score_spread":0.3260911788362945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056397238","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.630815,0.01811819,0.30377185,0.0017731445,0.0010710495,0.0005675602,0.0007952676,0.0033095707,0.039778285],"genre_scores_gemma":[0.88808054,0.005760076,0.075085945,0.0005900849,0.0001706091,0.00025585876,0.00066730136,0.00022274253,0.029166833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980265,0.00003347616,0.000014064309,0.000047420846,0.000067218745,0.000035181216],"domain_scores_gemma":[0.99992096,0.000013473092,0.000019828143,0.000010462179,0.000013203832,0.000022062652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003166014,0.00041315006,0.00018406323,0.0006207556,0.00022991956,0.00045714856,0.0004087067,0.0005799919,0.003528785],"category_scores_gemma":[0.00013684701,0.00025961502,0.0003039629,0.0002447195,0.00026983858,0.00046704258,0.00032131918,0.0010245611,0.0015911456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045955814,0.000039385883,0.000029861672,0.000051366762,0.000005215301,0.000066379514,0.000016529268,0.00010122933,0.99223316,0.00076782814,0.00051440054,0.0061286837],"study_design_scores_gemma":[0.000025886553,0.00021601537,0.00029494616,0.0000059282916,0.000019484927,0.0005484756,0.000009476735,0.0016733592,0.9830589,0.00012914461,0.014005214,0.000013061728],"about_ca_topic_score_codex":0.00031991221,"about_ca_topic_score_gemma":0.00045706358,"teacher_disagreement_score":0.003528785,"about_ca_system_score_codex":0.00030559095,"about_ca_system_score_gemma":0.00021668366,"threshold_uncertainty_score":0.011804938},"labels":[],"label_agreement":null},{"id":"W2058130577","doi":"10.1186/2051-1426-2-s2-p36","title":"P62. Effectiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Melatonin; Proinflammatory cytokine; Cancer research; Cytokine; Medicine; Apoptosis; Breast cancer; Biology; Immunology; Cancer; Internal medicine; Inflammation","score_opus":0.006679934714977232,"score_gpt":0.25558503115788644,"score_spread":0.2489050964429092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058130577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821322,0.004546875,0.0024854613,0.0004207334,0.00043878256,0.00012106634,0.001663464,0.00038294293,0.007808427],"genre_scores_gemma":[0.97528297,0.0019251951,0.00269517,0.0001404241,0.000034630022,0.00027288802,0.0020848357,0.00007374722,0.017490078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99963796,0.00004773539,0.000053504406,0.00007716348,0.00010311198,0.00008050766],"domain_scores_gemma":[0.9998648,0.000030567055,0.000017513903,0.000025588392,0.000032412867,0.00002904917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003045236,0.00030074565,0.00048190894,0.00032829275,0.00039673265,0.00052220817,0.000308855,0.00044020556,0.005010094],"category_scores_gemma":[0.00014590014,0.00015875167,0.00042500292,0.00029630834,0.0002509929,0.00029221995,0.0001679872,0.0006332277,0.0013590604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071630906,0.00021817857,0.00015186587,0.0000929521,0.000010430259,0.000062601255,0.00009902818,0.00007200325,0.99405354,0.00024927992,0.00057871,0.0036951108],"study_design_scores_gemma":[0.000066510016,0.00075431867,0.0016926305,0.00000697355,0.00002682004,0.00005870759,0.000071383816,0.00064648566,0.9899234,0.000031715128,0.00671645,0.00000462439],"about_ca_topic_score_codex":0.0020267707,"about_ca_topic_score_gemma":0.0021787705,"teacher_disagreement_score":0.005010094,"about_ca_system_score_codex":0.0003230602,"about_ca_system_score_gemma":0.00043578964,"threshold_uncertainty_score":0.016760468},"labels":[],"label_agreement":null},{"id":"W2060260809","doi":"10.1186/s40425-015-0055-3","title":"Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Immunotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Surgery; Urology; Gastroenterology; Overall survival; Clinical trial; Cancer","score_opus":0.023501342217022044,"score_gpt":0.31248380080424937,"score_spread":0.2889824585872273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060260809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987072,0.0005700512,0.00015030419,0.00005890276,0.000012463929,0.0001262879,0.000114217335,0.000018051962,0.00024256049],"genre_scores_gemma":[0.9979463,0.00038721648,0.00044713414,0.00008409673,0.000029632796,0.00016695567,0.00053621817,0.000007632441,0.00039487268],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998016,0.000083281746,0.0000128479605,0.000036120797,0.000029729279,0.000036449434],"domain_scores_gemma":[0.99974614,0.00003674179,0.00005368014,0.000016549138,0.000017767745,0.00012911862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008618499,0.00070773944,0.0009243816,0.0001978206,0.00021417529,0.00046038663,0.00029726955,0.00037152637,0.0011098571],"category_scores_gemma":[0.0003012223,0.00017296034,0.0006741517,0.0001602708,0.00036963617,0.0002686872,0.00017247663,0.0011071444,0.00022859276],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55321044,0.06604856,0.044982333,0.0007940667,0.0021407774,0.0004981002,0.0004640956,0.005314764,0.14728218,0.00016609888,0.0026800956,0.17641842],"study_design_scores_gemma":[0.21392551,0.66786975,0.088111475,0.00003733647,0.0011015069,0.0008142737,0.00007159962,0.0034685007,0.021022659,0.00013401636,0.0034002298,0.000043184813],"about_ca_topic_score_codex":0.00052840234,"about_ca_topic_score_gemma":0.0013201445,"teacher_disagreement_score":0.0011098571,"about_ca_system_score_codex":0.00053400325,"about_ca_system_score_gemma":0.00073194964,"threshold_uncertainty_score":0.004557967},"labels":[],"label_agreement":null},{"id":"W2070037020","doi":"10.1186/2051-1426-2-s3-p5","title":"A clinical grade cell-based artificial APT, aAPC/mOKT3, for unbiased expansion of CD3+ T lymphocytes","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; CD3; Medicine; Tumor-infiltrating lymphocytes; T cell; Cancer research; Cancer; Immunology; Internal medicine; Immunotherapy; CD8; Immune system","score_opus":0.07337979631303736,"score_gpt":0.4284327000562539,"score_spread":0.3550529037432165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070037020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8685954,0.005387342,0.10779922,0.0010174857,0.0002071427,0.00056117587,0.0019555222,0.0012856615,0.01319098],"genre_scores_gemma":[0.9421931,0.0014066609,0.045569494,0.00023110368,0.00003509327,0.00016208479,0.0013677654,0.00014044016,0.008894289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975234,0.000055494078,0.000022298276,0.00004799549,0.000096440555,0.000025475367],"domain_scores_gemma":[0.999861,0.000035624285,0.00002105685,0.000027029562,0.000026418285,0.000028801209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035065014,0.00026724424,0.0001427556,0.00024576893,0.0001779152,0.000458072,0.00017169477,0.00029519427,0.0026173387],"category_scores_gemma":[0.00038425822,0.000100379184,0.00010232922,0.00017770057,0.00020766756,0.0001486405,0.0001809432,0.0006038221,0.00097378355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011007462,0.000030809584,0.00042752872,0.00003484707,0.0000051811307,0.000024091933,0.000015251516,0.00030922194,0.9919012,0.00028139167,0.00033489993,0.006525432],"study_design_scores_gemma":[0.000021598453,0.00013678818,0.000933679,0.000004448625,0.000014153567,0.00020387793,0.000004987881,0.0016671437,0.98890847,0.00009003949,0.008011357,0.0000034760208],"about_ca_topic_score_codex":0.00044066887,"about_ca_topic_score_gemma":0.0009272299,"teacher_disagreement_score":0.0026173387,"about_ca_system_score_codex":0.0002624299,"about_ca_system_score_gemma":0.00034111712,"threshold_uncertainty_score":0.008755863},"labels":[],"label_agreement":null},{"id":"W2088712063","doi":"10.1186/2051-1426-1-s1-p146","title":"Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Ovarian cancer; Nitric oxide; Endogeny; Cancer; Cancer research; Nitric oxide synthase; Ascites; RAR-related orphan receptor gamma; Cancer cell; Medicine; Chemistry; Cell biology; Immunology; Biology; Internal medicine; Immune system","score_opus":0.03533179665720833,"score_gpt":0.2758429772357749,"score_spread":0.24051118057856657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088712063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971987,0.0011068133,0.00054042693,0.000059750222,0.00002517209,0.000012372631,0.00021286942,0.00002112341,0.0008227696],"genre_scores_gemma":[0.9970906,0.0003017696,0.00035796405,0.000030787454,0.000023932222,0.000023007053,0.0002833347,0.000008910706,0.0018798184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985087,0.00002377999,0.000014262437,0.000029909253,0.000025998821,0.000055084456],"domain_scores_gemma":[0.9998233,0.000021455075,0.000034000434,0.000029482759,0.000028655573,0.00006326447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014855845,0.00011030056,0.00015493525,0.00028201632,0.00021027711,0.00036500898,0.00009413107,0.00017741225,0.0027635454],"category_scores_gemma":[0.00017654791,0.00012704013,0.00019176325,0.00012139351,0.00016955087,0.00018446558,0.00018370521,0.00058664544,0.0005110842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050853094,0.000049755236,0.0035691306,0.000028264587,0.000004956615,0.00011256861,0.00003208808,0.00003710884,0.99305576,0.00009390045,0.00008813932,0.002419725],"study_design_scores_gemma":[0.0001398654,0.0013668909,0.21210337,0.000031286203,0.00005624073,0.0020172496,0.00047377645,0.0017232366,0.7721363,0.00041916964,0.009516627,0.000016026237],"about_ca_topic_score_codex":0.0003400717,"about_ca_topic_score_gemma":0.0005453408,"teacher_disagreement_score":0.0027635454,"about_ca_system_score_codex":0.0002243062,"about_ca_system_score_gemma":0.00017410901,"threshold_uncertainty_score":0.009244978},"labels":[],"label_agreement":null},{"id":"W2104319926","doi":"10.1186/s40425-014-0046-9","title":"CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"L'Alliance Boviteq","funders":"Randy Shaver Cancer Research and Community Fund; National Institutes of Health; Morgan Adams Foundation; National Cancer Institute; American Brain Tumor Association","keywords":"Immunosuppression; Blockade; Immunotherapy; Medicine; Immunology; Cancer research; Immune system; Receptor; Internal medicine","score_opus":0.023796700130092264,"score_gpt":0.3004235208515833,"score_spread":0.27662682072149103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104319926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9008657,0.080367275,0.009242722,0.0012874678,0.0001449965,0.00014619813,0.00024617618,0.00022766166,0.0074719135],"genre_scores_gemma":[0.9719358,0.021330535,0.0039470885,0.00042199195,0.00009947168,0.00008863071,0.00021127918,0.00001772942,0.0019474524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996555,0.000007345352,0.0000028094241,0.000005517908,0.000007948023,0.000010716644],"domain_scores_gemma":[0.99995637,0.0000096498925,0.0000121519415,0.0000038730304,0.0000054515235,0.000012414209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016894488,0.00029075844,0.00019979388,0.00022230102,0.00006402904,0.00026876866,0.00018795041,0.00027594552,0.00089036964],"category_scores_gemma":[0.00009511277,0.00004710388,0.0001304893,0.00012565595,0.00016152917,0.00023117008,0.00012370489,0.0005295691,0.00020850344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002133976,0.00086295645,0.0023497085,0.00063905143,0.00007640133,0.0004686628,0.000041546216,0.0017507623,0.7410329,0.0022284836,0.0014535051,0.24696201],"study_design_scores_gemma":[0.00089133036,0.01287351,0.018194735,0.00023504555,0.00029248628,0.0047490536,0.00007075705,0.009409927,0.88923764,0.0033026845,0.060702972,0.00003992458],"about_ca_topic_score_codex":0.00017620869,"about_ca_topic_score_gemma":0.00036167313,"teacher_disagreement_score":0.00089036964,"about_ca_system_score_codex":0.00029339327,"about_ca_system_score_gemma":0.00020161763,"threshold_uncertainty_score":0.002978623},"labels":[],"label_agreement":null},{"id":"W2105562405","doi":"10.1186/2051-1426-2-2","title":"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer; Bristol-Myers Squibb; Genentech; Amgen","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Pharmacokinetics; Pharmacodynamics; Pharmacology; Internal medicine; Rash; Oncology; Immunotherapy; Toxicity; Gastroenterology; Hepatocellular carcinoma; Cancer","score_opus":0.04145423578145745,"score_gpt":0.3631940069784667,"score_spread":0.32173977119700925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105562405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223727,0.0034193043,0.0005398155,0.00044669263,0.00013597292,0.0019876126,0.00047515708,0.000085096326,0.0006730079],"genre_scores_gemma":[0.988009,0.0037936245,0.0020816154,0.0007526836,0.0003503607,0.002111181,0.0014127443,0.00003972101,0.0014490422],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993593,0.00031607732,0.000030141748,0.000103011895,0.00008822948,0.00010316113],"domain_scores_gemma":[0.9991648,0.00014438717,0.00017829982,0.000071995,0.00006766097,0.0003729113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023553083,0.0019619882,0.0025265203,0.0005291364,0.00041207997,0.0010472824,0.001139674,0.0013000328,0.0024780403],"category_scores_gemma":[0.001084296,0.00073545787,0.0014445866,0.0004630377,0.0010731325,0.0008862831,0.00032687705,0.0026302275,0.0006609506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50525135,0.23437938,0.0069520404,0.0030333323,0.0031023843,0.001138504,0.00060542126,0.00457584,0.11445532,0.00030193865,0.00549049,0.12071406],"study_design_scores_gemma":[0.4367766,0.54829955,0.0060322834,0.000038280174,0.0004982138,0.00057626306,0.000045435725,0.001128194,0.004675062,0.00008292167,0.0018156663,0.00003141031],"about_ca_topic_score_codex":0.000930966,"about_ca_topic_score_gemma":0.0021369716,"teacher_disagreement_score":0.0025265203,"about_ca_system_score_codex":0.0009907708,"about_ca_system_score_gemma":0.0022406154,"threshold_uncertainty_score":0.012456179},"labels":[],"label_agreement":null},{"id":"W2108739705","doi":"10.1186/2051-1426-1-s1-p58","title":"Reciprocal expression of tumour-associated carbohydrate antigens (Tn/sTn) and nuclear factor-B serves as an indicator of the prognosis of oral squamous cell carcinoma","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Antigen; Basal cell; Medicine; Cancer research; Oncology; Pathology; Immunology","score_opus":0.01342541917021205,"score_gpt":0.29276383277377677,"score_spread":0.2793384136035647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108739705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981406,0.0004343517,0.00017368112,0.00004145967,0.0000144752,0.000009351152,0.000091694405,0.000007825476,0.0010866417],"genre_scores_gemma":[0.9958615,0.00043120323,0.00031293058,0.000016279795,0.000018201756,0.000014896443,0.0002039481,0.000002563188,0.0031386563],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999082,0.00001609698,0.000009595002,0.000011148552,0.0000327627,0.000022255328],"domain_scores_gemma":[0.9998902,0.00001589748,0.00002252856,0.0000074583354,0.000022833152,0.000041066294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021151215,0.000161414,0.00013872406,0.0003723057,0.00017872437,0.00025403648,0.00008419934,0.0001599409,0.0039693504],"category_scores_gemma":[0.00027634462,0.000061400075,0.00011395003,0.0002617335,0.00012362281,0.00014011716,0.00015515758,0.0001963432,0.00056541525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027414598,0.00017500982,0.08007694,0.00009629474,0.000031162428,0.00031426584,0.000089236775,0.00009615507,0.8990891,0.0001614714,0.00055700436,0.016571915],"study_design_scores_gemma":[0.00008538163,0.0025034402,0.76529044,0.000020597508,0.00009584383,0.002259335,0.00054393895,0.0011204504,0.22234617,0.00026728152,0.005452147,0.000014978718],"about_ca_topic_score_codex":0.0005686347,"about_ca_topic_score_gemma":0.0006995218,"teacher_disagreement_score":0.0039693504,"about_ca_system_score_codex":0.00020206565,"about_ca_system_score_gemma":0.0001680987,"threshold_uncertainty_score":0.013278782},"labels":[],"label_agreement":null},{"id":"W2157899115","doi":"10.1186/s40425-014-0041-1","title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Retinal vasculitis; Extravasation; Pembrolizumab; Melanoma; Vasculitis; Metastasis; Retinal; Nivolumab; Optic nerve; Vitreous hemorrhage; Immune system; Immunotherapy; Pathology; Ophthalmology; Cancer research; Immunology; Retinal detachment; Internal medicine; Cancer; Disease","score_opus":0.013111459045823767,"score_gpt":0.301956724692727,"score_spread":0.2888452656469032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157899115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876896,0.002749339,0.0011637171,0.0016370221,0.00011713039,0.000100705074,0.00014179619,0.0001028081,0.006297829],"genre_scores_gemma":[0.9982572,0.00051043706,0.00030803276,0.0002733961,0.000115490046,0.000005699514,0.00003563474,0.0000071729196,0.00048692193],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997117,0.000046500834,0.000026668087,0.00007158461,0.000041967996,0.00010158518],"domain_scores_gemma":[0.99925965,0.0002196048,0.00015906156,0.00005890983,0.000042774394,0.00026001458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034116444,0.0006978465,0.00068458286,0.0009407852,0.0013069168,0.00082358776,0.00050458766,0.0020969664,0.0013411005],"category_scores_gemma":[0.0018380212,0.0005135936,0.00072157657,0.0005262508,0.00069237605,0.0006578458,0.00045301986,0.0018219147,0.0003717735],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019598246,0.00007330918,0.023626842,0.00003827587,0.00002173114,0.9711316,0.00022969993,0.00012560376,0.0019047961,0.00013756081,0.00019398463,0.0023205718],"study_design_scores_gemma":[0.000035661546,0.0005493844,0.023898141,0.000016132275,0.000049390517,0.97304565,0.0001367597,0.00046630518,0.0010415855,0.00012580333,0.00061952305,0.00001565608],"about_ca_topic_score_codex":0.0019371695,"about_ca_topic_score_gemma":0.0025691201,"teacher_disagreement_score":0.0020969664,"about_ca_system_score_codex":0.0007087424,"about_ca_system_score_gemma":0.0004118797,"threshold_uncertainty_score":0.005142331},"labels":[],"label_agreement":null},{"id":"W2173070859","doi":"10.1186/2051-1426-3-s2-p259","title":"Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Metastatic melanoma; Internal medicine; Oncology; Stage (stratigraphy); Melanoma; Biomarker; Nivolumab; Chemotherapy; Immunotherapy; Cancer; Cisplatin; Cancer research","score_opus":0.03410340619736896,"score_gpt":0.33195909338164753,"score_spread":0.2978556871842786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173070859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240077,0.0032052884,0.0004397747,0.00042133362,0.0001092727,0.000336779,0.0009861898,0.000035494468,0.0020651198],"genre_scores_gemma":[0.99514574,0.0004886795,0.00043726692,0.00063467247,0.00012601695,0.00019682209,0.0018796978,0.00001010583,0.0010809493],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976104,0.00007860387,0.000020761141,0.000046771813,0.000048524962,0.000044324282],"domain_scores_gemma":[0.9993697,0.00017274656,0.00011454408,0.00004395492,0.00007628338,0.00022286033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011004966,0.0004468558,0.0007050433,0.00023432588,0.00025516815,0.00054293225,0.00023457086,0.0003877209,0.0022988294],"category_scores_gemma":[0.0010838618,0.0001674053,0.00054001366,0.00025629633,0.00019769388,0.0003203065,0.00019135539,0.0012551862,0.0003736987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20086886,0.01242555,0.2803003,0.00095488934,0.0022702531,0.00053217437,0.00023678305,0.001568243,0.14002043,0.00022142372,0.012585929,0.34801525],"study_design_scores_gemma":[0.020387838,0.16273299,0.76600814,0.000045273802,0.002949126,0.001193776,0.000090786125,0.0012551069,0.030809734,0.0001978631,0.014294205,0.0000351571],"about_ca_topic_score_codex":0.000403902,"about_ca_topic_score_gemma":0.0006458151,"teacher_disagreement_score":0.0022988294,"about_ca_system_score_codex":0.00035731486,"about_ca_system_score_gemma":0.00030470625,"threshold_uncertainty_score":0.00769037},"labels":[],"label_agreement":null},{"id":"W2205469793","doi":"10.1186/s40425-015-0093-x","title":"A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial","year":2015,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Medicine; Cancer vaccine; Clinical trial; Adjuvant; Cancer; Oncology; Phase (matter); Internal medicine; Immunotherapy","score_opus":0.1487543164012257,"score_gpt":0.5064022692511208,"score_spread":0.35764795284989503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205469793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057850257,0.97048193,0.010914527,0.0020637354,0.000686529,0.0015738306,0.0021641434,0.00010887159,0.006221454],"genre_scores_gemma":[0.07345257,0.87779677,0.029630622,0.0050293384,0.0011640094,0.0042794547,0.0034831548,0.00014750067,0.005016592],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923544,0.0034108958,0.0012305742,0.00070032204,0.0020637014,0.00024017366],"domain_scores_gemma":[0.9784728,0.01280111,0.004381433,0.000713161,0.003271123,0.00036032128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020081747,0.00094984635,0.0023799152,0.0027632194,0.0001940018,0.0020849886,0.001159265,0.0010657294,0.0039499835],"category_scores_gemma":[0.024439603,0.00037911953,0.002200405,0.0028882995,0.0005628145,0.0017369228,0.0007577571,0.0015586064,0.0009947086],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002013578,0.00018546334,0.0021321878,0.04317598,0.0020191567,0.00009451425,0.000106792606,0.0016319879,0.005643518,0.0056672976,0.015010445,0.9223192],"study_design_scores_gemma":[0.0016373975,0.0074015097,0.03028568,0.05076384,0.0093517145,0.0020591114,0.00029936145,0.0027436498,0.014134236,0.017450629,0.86367905,0.00019378384],"about_ca_topic_score_codex":0.0004168498,"about_ca_topic_score_gemma":0.00089692813,"teacher_disagreement_score":0.020081747,"about_ca_system_score_codex":0.0015597593,"about_ca_system_score_gemma":0.0030664576,"threshold_uncertainty_score":0.106203675},"labels":[],"label_agreement":null},{"id":"W2208379272","doi":"10.1186/2051-1426-3-s2-p160","title":"Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Pembrolizumab; Dexamethasone; Medicine; Multiple myeloma; Oncology; Internal medicine; Cancer research; Pharmacology; Immunotherapy; Cancer","score_opus":0.04112271902787046,"score_gpt":0.3538140881746188,"score_spread":0.31269136914674833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208379272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7692603,0.15072992,0.0019695417,0.017697312,0.005659684,0.0014124585,0.0012831424,0.0005017419,0.051485922],"genre_scores_gemma":[0.92958575,0.03625712,0.0029480408,0.0032035473,0.00357838,0.00026563127,0.000986651,0.000045234614,0.023129674],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988365,0.000034185967,0.000015664438,0.000013536339,0.000020840065,0.00003216164],"domain_scores_gemma":[0.99992776,0.00001585589,0.000008019833,0.000002083863,0.000008163339,0.00003821035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043683674,0.000463207,0.00065485603,0.00030256467,0.00035210917,0.0003564794,0.0003943511,0.0005393786,0.0054875384],"category_scores_gemma":[0.0002609113,0.00017182776,0.00044302648,0.00020230605,0.00014929716,0.00023430666,0.00018508856,0.0010312472,0.0008478582],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07805106,0.0050501246,0.0053074267,0.0013468559,0.00065879076,0.0063987155,0.00017298319,0.0010854815,0.07796521,0.00082947005,0.08999329,0.7331405],"study_design_scores_gemma":[0.09423455,0.13918993,0.20346922,0.0011972704,0.0033546302,0.023016788,0.00042742744,0.007910256,0.06504734,0.0012422145,0.46071792,0.00019250493],"about_ca_topic_score_codex":0.0016910125,"about_ca_topic_score_gemma":0.0049931244,"teacher_disagreement_score":0.0054875384,"about_ca_system_score_codex":0.0004923569,"about_ca_system_score_gemma":0.000424236,"threshold_uncertainty_score":0.018357635},"labels":[],"label_agreement":null},{"id":"W2221239533","doi":"10.1186/s40425-015-0099-4","title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Terry Fox Foundation; Government of Ontario","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Degranulation; Ankyrin repeat; Tumor antigen; Antibody; Biology; Cancer research; Immunology; Cell biology; Receptor; Immunotherapy; Immune system; In vitro; Gene; Genetics","score_opus":0.04065385021059447,"score_gpt":0.38164280807278034,"score_spread":0.34098895786218586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221239533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311397,0.00177644,0.063999586,0.00013383535,0.000060207243,0.00016223463,0.00022485373,0.00037172745,0.002131428],"genre_scores_gemma":[0.95803905,0.0008000017,0.03706901,0.00008108515,0.000011846339,0.00014252891,0.0003923571,0.00007139775,0.0033927064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997662,0.00006126176,0.000020442767,0.00003847595,0.00007676759,0.000036800913],"domain_scores_gemma":[0.9998487,0.000036580317,0.00006276662,0.000016915477,0.000017493592,0.00001741494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024482055,0.00038634913,0.00018111597,0.00019237236,0.00010494081,0.0002725849,0.000320998,0.00037296113,0.0010857013],"category_scores_gemma":[0.00026920976,0.00015682362,0.00022286618,0.0001379395,0.00020059406,0.0002445371,0.0002480872,0.00050378963,0.0005573948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000778341,0.000025020507,0.00013012266,0.00006205747,0.000009634147,0.00011658804,0.000017035107,0.000928398,0.9951082,0.0005020392,0.000083162144,0.002939865],"study_design_scores_gemma":[0.000033919965,0.00033046718,0.0005056878,0.000008248386,0.000018945966,0.0005994943,0.0000113765,0.0023496323,0.9891767,0.0001441932,0.00681279,0.00000850655],"about_ca_topic_score_codex":0.00009922423,"about_ca_topic_score_gemma":0.00015330694,"teacher_disagreement_score":0.0010857013,"about_ca_system_score_codex":0.00032965798,"about_ca_system_score_gemma":0.00014387535,"threshold_uncertainty_score":0.003632009},"labels":[],"label_agreement":null},{"id":"W2298802783","doi":"10.1186/s40425-016-0116-2","title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of California, San Diego; U.S. Food and Drug Administration; Amgen","keywords":"Medicine; Oncolytic virus; Melanoma; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.02881937285232573,"score_gpt":0.35726615096828074,"score_spread":0.328446778115955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298802783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989875,0.000317187,0.00013151379,0.00002088196,0.000008406538,0.00019829131,0.0000956214,0.0000096988515,0.00023093169],"genre_scores_gemma":[0.9983467,0.00020868196,0.00029747645,0.00009531059,0.000042405652,0.0002859101,0.00041671525,0.00000464371,0.00030217314],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999642,0.00016934471,0.000021372018,0.00006194321,0.00004269627,0.00006265581],"domain_scores_gemma":[0.9994018,0.00013778766,0.00014089858,0.00006947076,0.000034620312,0.00021534701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012809907,0.00051743345,0.00091806456,0.00023344126,0.00024488312,0.00042438085,0.0002916238,0.0004144753,0.0014494578],"category_scores_gemma":[0.00052018865,0.00022630337,0.0004591131,0.00022504975,0.00039804704,0.00032643141,0.00021010033,0.0011388502,0.00021437836],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3735938,0.075864226,0.09979652,0.00065905205,0.0015918154,0.0004852661,0.00045329414,0.003021291,0.33991235,0.00014295221,0.0017601433,0.102719285],"study_design_scores_gemma":[0.04952855,0.78900707,0.12662159,0.00002514325,0.0006732255,0.0007076529,0.00011737348,0.001607188,0.029845867,0.00006129153,0.0017790119,0.000025941532],"about_ca_topic_score_codex":0.00021954103,"about_ca_topic_score_gemma":0.0004533011,"teacher_disagreement_score":0.0014494578,"about_ca_system_score_codex":0.00032640807,"about_ca_system_score_gemma":0.0004213724,"threshold_uncertainty_score":0.0067746043},"labels":[],"label_agreement":null},{"id":"W2314244103","doi":"10.1186/s40425-016-0123-3","title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Immunosuppression; Asymptomatic; Exacerbation; Bullous pemphigoid; Pemphigoid; Dermatology; Immunotherapy; Disease; Immunology; Internal medicine; Cancer; Antibody","score_opus":0.017347688674117994,"score_gpt":0.32649352927772024,"score_spread":0.30914584060360223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314244103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838431,0.007741957,0.00079813536,0.0015459014,0.00006651213,0.00005768301,0.00002644656,0.00004783978,0.0058724335],"genre_scores_gemma":[0.99874276,0.00046242515,0.00015724298,0.00027467974,0.00007081415,0.000007033786,0.000026283655,0.0000018615561,0.00025691144],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998388,0.000041663578,0.000018873163,0.000022480552,0.000024105166,0.00005413792],"domain_scores_gemma":[0.99964166,0.0001109446,0.00007250054,0.000022443755,0.000021579131,0.0001308765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043001975,0.00024288592,0.00041635535,0.0002807086,0.00068261183,0.00035051545,0.00024225938,0.0006662983,0.00071021373],"category_scores_gemma":[0.0011235131,0.00008790125,0.00034068013,0.00014744597,0.00032525623,0.00025032443,0.00023811815,0.0010141946,0.0001623624],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052106637,0.0008642472,0.24069148,0.000620822,0.0002839771,0.5350737,0.0011197231,0.0010378248,0.06729694,0.001218788,0.0038620962,0.14271969],"study_design_scores_gemma":[0.0006841939,0.006514289,0.30077785,0.0002880387,0.00038051233,0.66114,0.0004542228,0.0047037667,0.011280242,0.0010838362,0.0126467915,0.000046246514],"about_ca_topic_score_codex":0.00058087846,"about_ca_topic_score_gemma":0.0014743634,"teacher_disagreement_score":0.00071021373,"about_ca_system_score_codex":0.00040610574,"about_ca_system_score_gemma":0.00026541218,"threshold_uncertainty_score":0.002946496},"labels":[],"label_agreement":null},{"id":"W2430573464","doi":"10.1186/s40425-016-0142-0","title":"Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Common Rule; Medicine; Government (linguistics); Declaration; Cancer immunotherapy; Standardization; Cancer; Immunotherapy; Alternative medicine; Engineering ethics; Informed consent; Political science; Pathology; Law; Internal medicine","score_opus":0.03576900875414307,"score_gpt":0.36246891781178425,"score_spread":0.3266999090576412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430573464","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000665017,0.0037263632,0.0043696524,0.8855386,0.0838043,0.0003919053,0.0003933092,0.00018058212,0.020930262],"genre_scores_gemma":[0.0052973526,0.0019996916,0.009509162,0.9477653,0.018144188,0.000713737,0.00035998056,0.0001033064,0.016107412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.90803087,0.025023447,0.016326902,0.0065879165,0.03359984,0.010431106],"domain_scores_gemma":[0.8523746,0.0728891,0.008881052,0.007944463,0.04509596,0.01281483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0909131,0.0017866531,0.0034639733,0.0020327826,0.007835696,0.016386084,0.0097085405,0.120833404,0.005142418],"category_scores_gemma":[0.16722925,0.0025101188,0.00785754,0.0024771118,0.016346559,0.007794678,0.010481596,0.12455342,0.007051712],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007526421,0.000106770305,0.00043629404,0.00027288529,0.000049780916,0.000447433,0.0007095309,0.00049103843,0.0003726003,0.08102101,0.90233725,0.013680154],"study_design_scores_gemma":[0.000088961904,0.00008147448,0.00042136776,0.00097031717,0.00006317403,0.0003241281,0.00022273514,0.00043181505,0.0004451749,0.021942327,0.97487384,0.00013461997],"about_ca_topic_score_codex":0.017599499,"about_ca_topic_score_gemma":0.01835391,"teacher_disagreement_score":0.120833404,"about_ca_system_score_codex":0.010143446,"about_ca_system_score_gemma":0.078071676,"threshold_uncertainty_score":0.4808002},"labels":[],"label_agreement":null},{"id":"W2528626295","doi":"10.1186/s40425-016-0168-3","title":"Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Society for Immunotherapy of Cancer","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Melanoma; Immune system; Ipilimumab; Cancer; Renal cell carcinoma; Breast cancer; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.03410942348087324,"score_gpt":0.370393223925771,"score_spread":0.33628380044489775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528626295","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027080313,0.4683412,0.0018829426,0.23031332,0.25674552,0.00026185397,0.0011702778,0.0002086418,0.038368277],"genre_scores_gemma":[0.027639374,0.33416852,0.0042520077,0.10055679,0.23179491,0.00038329617,0.002826881,0.00024298257,0.29813522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992142,0.00016061687,0.000051002935,0.00012799949,0.00022739868,0.00021883487],"domain_scores_gemma":[0.9987953,0.00015615627,0.00007401626,0.00003098425,0.0003644344,0.0005790119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00256052,0.0013636359,0.00059515,0.00092698564,0.0008180166,0.002580881,0.0008456506,0.0040502464,0.026039846],"category_scores_gemma":[0.0015456489,0.00025765193,0.0010024642,0.0005135307,0.00043807083,0.0017685639,0.0015818923,0.004093941,0.0112392865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020148941,0.000089927926,0.0002255871,0.00044863005,0.000021604055,0.00016605837,0.000037679078,0.00012033938,0.0013048348,0.0016794261,0.91242933,0.08327514],"study_design_scores_gemma":[0.000031305695,0.00009730157,0.00086753885,0.00026049733,0.00002028607,0.00015071483,0.00004625067,0.0000684747,0.0005599799,0.00087167014,0.99701595,0.000010003306],"about_ca_topic_score_codex":0.0013459284,"about_ca_topic_score_gemma":0.0032841628,"teacher_disagreement_score":0.026039846,"about_ca_system_score_codex":0.0013921964,"about_ca_system_score_gemma":0.0024625163,"threshold_uncertainty_score":0.08711195},"labels":[],"label_agreement":null},{"id":"W2529221862","doi":"10.1186/s40425-016-0171-8","title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Nivolumab; Hemodialysis; Ipilimumab; Transplantation; Immunosuppression; Internal medicine; Malignancy; Cancer; Intensive care medicine; Oncology; Immunotherapy","score_opus":0.015400382094347695,"score_gpt":0.31423989675110625,"score_spread":0.29883951465675856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529221862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894968,0.004280779,0.0014332068,0.0007926848,0.00013051818,0.000047635844,0.00002710127,0.0000565844,0.0037346436],"genre_scores_gemma":[0.99887985,0.00028187176,0.00017859064,0.0002331061,0.000054465094,0.0000037930029,0.000026475956,0.0000029673827,0.00033884813],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99987876,0.000034304026,0.000012068425,0.000018277098,0.00002454026,0.0000320171],"domain_scores_gemma":[0.99970704,0.00010034014,0.000054553053,0.000026463838,0.000029246406,0.00008231383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023131912,0.00014782451,0.0003103364,0.00018851557,0.00043380598,0.00030110712,0.00022739042,0.00051533617,0.0004121238],"category_scores_gemma":[0.0008063333,0.00005109606,0.00031054477,0.00010144228,0.00017050853,0.0002012692,0.00015468089,0.00074607943,0.00009450388],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075804614,0.0030492079,0.18803486,0.0006077271,0.00030896955,0.4328355,0.0013334311,0.0033121984,0.07513012,0.0017037415,0.0034719105,0.28263196],"study_design_scores_gemma":[0.0008556667,0.020549206,0.17792186,0.00029213107,0.00053398474,0.6275103,0.00064470153,0.017672617,0.11070981,0.00190177,0.04131897,0.00008903072],"about_ca_topic_score_codex":0.00053046073,"about_ca_topic_score_gemma":0.00090602995,"teacher_disagreement_score":0.00053046073,"about_ca_system_score_codex":0.00046815735,"about_ca_system_score_gemma":0.0003281313,"threshold_uncertainty_score":0.003396809},"labels":[],"label_agreement":null},{"id":"W2531271615","doi":"10.1186/s40425-016-0174-5","title":"High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Oncology; Renal cell carcinoma","score_opus":0.04813171222505309,"score_gpt":0.33063154148190993,"score_spread":0.28249982925685685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531271615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970746,0.00070498546,0.00047872923,0.000077680525,0.000016143826,0.00004924592,0.0001259812,0.000013344804,0.0014592023],"genre_scores_gemma":[0.99834585,0.0002791057,0.00044066808,0.00009821875,0.00004140556,0.000025851328,0.00030605277,0.0000067331957,0.00045616363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982256,0.000057073983,0.000021142987,0.000030907544,0.00002351284,0.00004485722],"domain_scores_gemma":[0.9996581,0.000057535308,0.00007413935,0.000033935637,0.00002368843,0.00015257114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004241948,0.00018055145,0.00027430843,0.0001560429,0.00033590978,0.00037818085,0.00014634292,0.0002445336,0.0010503457],"category_scores_gemma":[0.0005967882,0.0000709804,0.00039696327,0.00020002549,0.0001962167,0.00019441918,0.00032082852,0.0002898722,0.00034543313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007937121,0.0046507283,0.7329523,0.00022386941,0.00029108772,0.010230324,0.0010959564,0.003380669,0.02667585,0.00020960225,0.003952695,0.20839994],"study_design_scores_gemma":[0.0006288247,0.022090418,0.93651253,0.000051167543,0.00014714099,0.02211619,0.0005023785,0.0015354041,0.00801029,0.00015623648,0.008197183,0.000052246694],"about_ca_topic_score_codex":0.0005094198,"about_ca_topic_score_gemma":0.0014520495,"teacher_disagreement_score":0.0010503457,"about_ca_system_score_codex":0.00027100137,"about_ca_system_score_gemma":0.00029159294,"threshold_uncertainty_score":0.0035137534},"labels":[],"label_agreement":null},{"id":"W2538528785","doi":"10.1186/s40425-016-0169-2","title":"Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre; Canada Research Chairs; Immunovaccine (Canada)","funders":"National Institutes of Health; Adaptive Biotechnologies; National Cancer Institute; University of Pittsburgh; University of Southern California","keywords":"ELISPOT; Immune system; Immunogenicity; Cytotoxic T cell; Immunology; CD8; Antigen; Medicine; Tumor antigen; Cancer vaccine; Spleen; Cancer research; Immunotherapy; Biology; In vitro","score_opus":0.016867753634658537,"score_gpt":0.27429946924626936,"score_spread":0.2574317156116108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538528785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979213,0.00047364758,0.0007593583,0.000048876384,0.000024978975,0.000021183698,0.00008109398,0.000044555283,0.0006249681],"genre_scores_gemma":[0.997703,0.0002586924,0.00075541134,0.00004286575,0.000012179408,0.000028746885,0.00011405865,0.000009891624,0.0010753283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998913,0.000015514399,0.000005743608,0.000023309538,0.00002210085,0.000042155538],"domain_scores_gemma":[0.9999182,0.000015313108,0.000023116745,0.0000069212606,0.000008238372,0.00002815169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102420105,0.00024677083,0.00023615721,0.0001321319,0.0000697862,0.0001719861,0.00010902523,0.0002281279,0.00095777644],"category_scores_gemma":[0.00008004243,0.000103607315,0.00014522336,0.00006960443,0.00012883588,0.00012375621,0.00010346476,0.00074843084,0.00018000774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003008721,0.00015960114,0.00022157958,0.000021849022,0.0000038416783,0.0000147745,0.0000090178555,0.00012532149,0.99626523,0.00003844374,0.000059694292,0.0027799343],"study_design_scores_gemma":[0.00007878268,0.0040807673,0.004377487,0.0000059695767,0.000021468568,0.00016048599,0.00001748089,0.0015273709,0.98846453,0.00004068567,0.0012218566,0.0000031337777],"about_ca_topic_score_codex":0.0002912487,"about_ca_topic_score_gemma":0.00059120014,"teacher_disagreement_score":0.00095777644,"about_ca_system_score_codex":0.00014086455,"about_ca_system_score_gemma":0.00020451119,"threshold_uncertainty_score":0.0032041073},"labels":[],"label_agreement":null},{"id":"W2560342953","doi":"10.1186/s40425-016-0191-4","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College; University Health Network; Princess Margaret Cancer Centre; Université Laval","funders":"National Center for Advancing Translational Sciences; lékařská fakulta Univerzity Karlovy; Radboud Universitair Medisch Centrum; Université Paris Descartes; EMD Serono; Kindai University; Radboud Universiteit; Karolinska Institutet; Institut National de la Santé et de la Recherche Médicale; Université Pierre et Marie Curie; Dr. Ralph and Marian Falk Medical Research Trust; Sidra Medicine; Graduate School, University of Maryland; Pennsylvania Department of Health; University of Bern; Univerzita Karlova v Praze; National Cancer Institute; Alliance for Cancer Gene Therapy; National Institutes of Health; Keio University; National Science Foundation","keywords":"Durvalumab; Lung cancer; CD8; Immunotherapy; Cancer immunotherapy; Oncology; Medicine; Cancer research; Internal medicine; Cancer; Immunology; Immune system; Nivolumab","score_opus":0.017529416612312148,"score_gpt":0.31854342246694217,"score_spread":0.30101400585463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560342953","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02192852,0.06633167,0.010697085,0.1690581,0.423239,0.0031457022,0.01499857,0.0019265102,0.28867483],"genre_scores_gemma":[0.042263385,0.043441612,0.00815381,0.01210741,0.14639258,0.0020221726,0.021215543,0.0010326607,0.72337073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985672,0.00025693685,0.00013233256,0.00013230529,0.00060449704,0.00030660443],"domain_scores_gemma":[0.99439174,0.00022197429,0.0004327086,0.00019124855,0.0023210156,0.0024413296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003835452,0.001417466,0.0008565664,0.002048002,0.0011660324,0.0035000956,0.0012534442,0.0022306372,0.081546806],"category_scores_gemma":[0.0030928836,0.00039010352,0.0008376892,0.0010911443,0.0004194679,0.0012725409,0.0025800045,0.0028852306,0.0475476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003361761,0.00018056681,0.0013211994,0.00025747906,0.000016916229,0.00007169155,0.000021696376,0.00017539081,0.0016831866,0.0005122855,0.8866516,0.10877183],"study_design_scores_gemma":[0.00008343777,0.00021929968,0.0062655425,0.0002449724,0.00002020213,0.00015602773,0.00005881328,0.00069048797,0.0010843701,0.00080092624,0.990357,0.000018944998],"about_ca_topic_score_codex":0.00162561,"about_ca_topic_score_gemma":0.0037621362,"teacher_disagreement_score":0.081546806,"about_ca_system_score_codex":0.0014164709,"about_ca_system_score_gemma":0.004578165,"threshold_uncertainty_score":0.27280128},"labels":[],"label_agreement":null},{"id":"W2564318420","doi":"10.1186/s40425-016-0173-6","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Columbia College; Caprion (Canada)","funders":"National Institute of Neurological Disorders and Stroke; Stand Up To Cancer; National Institutes of Health; Knight Cancer Institute, Oregon Health and Science University; Cancer Research Society; European Commission; U.S. Department of Defense; Breast Cancer Research Foundation; Oregon Health and Science University; Prostate Cancer Foundation; Movember Foundation; Cancer League of Colorado; Harry J. Lloyd Charitable Trust; National Cancer Institute; Dendreon Pharmaceuticals; Melanoma Research Alliance; Susan G. Komen for the Cure; Pharmaceutical Research and Manufacturers of America Foundation; Amgen; Collins Medical Trust","keywords":"Prostate cancer; Immunotherapy; Cancer immunotherapy; Myeloid cells; Cancer; Medicine; Gerontology; Immunology; Oncology; Cancer research; Myeloid; Internal medicine","score_opus":0.019952623559447987,"score_gpt":0.3311051548978156,"score_spread":0.3111525313383676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564318420","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010597542,0.047019538,0.008501466,0.09180977,0.27646738,0.003652807,0.010552249,0.0019648012,0.5494344],"genre_scores_gemma":[0.0123876585,0.035470325,0.0044797296,0.0087888,0.07224985,0.0013565284,0.01127149,0.0005351713,0.8534604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921095,0.00012616796,0.0000664466,0.00008476359,0.0003778747,0.00013377855],"domain_scores_gemma":[0.99687886,0.00019987118,0.00022392924,0.00012674186,0.0013505241,0.0012201305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001949545,0.0011530585,0.00078877044,0.0014717284,0.0007779325,0.0022452904,0.0011214436,0.0023235881,0.17367838],"category_scores_gemma":[0.0026835469,0.00032598295,0.00074848504,0.0008041231,0.00036014876,0.001005457,0.0014749785,0.0022651474,0.12986593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022648601,0.00019198058,0.00046962706,0.00033357725,0.000012411018,0.000094958195,0.00001532359,0.00014937852,0.00238342,0.0005375224,0.8581689,0.13741642],"study_design_scores_gemma":[0.000038022587,0.00010811926,0.001441502,0.0001411045,0.000008076999,0.0001617575,0.000016356958,0.00021178595,0.0006028499,0.00044499015,0.9968178,0.000007517105],"about_ca_topic_score_codex":0.0010723543,"about_ca_topic_score_gemma":0.0025219698,"teacher_disagreement_score":0.17367838,"about_ca_system_score_codex":0.0010323919,"about_ca_system_score_gemma":0.0030338361,"threshold_uncertainty_score":0.58101207},"labels":[],"label_agreement":null},{"id":"W2592274279","doi":"10.1186/s40425-017-0223-8","title":"Systematic evaluation of immune regulation and modulation","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; U.S. National Library of Medicine; National Cancer Institute; National Institutes of Health; Trent University; Sidra Medicine; Nottingham Trent University","keywords":"Immune system; Immunotherapy; Medicine; Computational biology; Tumor microenvironment; Identification (biology); Cancer immunotherapy; Task force; Cancer; Bioinformatics; Computer science; Immunology; Data science; Biology; Internal medicine; Political science","score_opus":0.13558746605105143,"score_gpt":0.4619861904541074,"score_spread":0.32639872440305595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592274279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027850212,0.9983923,0.0002788093,0.00028434218,0.00013906677,0.000032599604,0.000042552947,0.000004421822,0.00054736366],"genre_scores_gemma":[0.00344394,0.9949523,0.0007820757,0.00034032634,0.000119801894,0.00006480763,0.00006766089,0.0000022147399,0.0002269695],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978794,0.0007837749,0.00037155102,0.00023714697,0.00064852694,0.000079623445],"domain_scores_gemma":[0.9969997,0.0016562488,0.0003928282,0.00012661515,0.00077122974,0.00005334503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041861203,0.0008746139,0.0023568035,0.002519149,0.0002075761,0.0014477107,0.0010343583,0.0011480761,0.0016000598],"category_scores_gemma":[0.005680413,0.0002843387,0.0013767797,0.0019323758,0.0005830953,0.0013603793,0.0007325236,0.0011148847,0.00051078276],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017148872,0.00009246809,0.0008436914,0.100237265,0.00079971214,0.00011567554,0.000103065635,0.00040402272,0.0031749404,0.0038946357,0.009672943,0.8804901],"study_design_scores_gemma":[0.00014517436,0.00078292727,0.006747405,0.06453133,0.0037260328,0.0015256488,0.00026882754,0.0004097446,0.0075315074,0.0045841127,0.9096693,0.00007800203],"about_ca_topic_score_codex":0.0010140177,"about_ca_topic_score_gemma":0.0019725938,"teacher_disagreement_score":0.0041861203,"about_ca_system_score_codex":0.00080546323,"about_ca_system_score_gemma":0.0034518156,"threshold_uncertainty_score":0.022138596},"labels":[],"label_agreement":null},{"id":"W2594276295","doi":"10.1186/s40425-017-0225-6","title":"Immunotherapy biomarkers 2016: overcoming the barriers","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"U.S. Food and Drug Administration; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Data science; Computer science; Cancer; Internal medicine","score_opus":0.023611641771029142,"score_gpt":0.3512964664018322,"score_spread":0.32768482463080306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594276295","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082961115,0.14604841,0.0061445646,0.81863654,0.021106565,0.000096465745,0.00024612303,0.0002164171,0.0066751977],"genre_scores_gemma":[0.03765482,0.32195124,0.03852816,0.48519257,0.095386356,0.0007300525,0.002014946,0.00051826565,0.018023668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9556288,0.016809445,0.0061974246,0.0035089126,0.015365434,0.0024899615],"domain_scores_gemma":[0.8437248,0.072906986,0.009679007,0.006882353,0.051743064,0.015063771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1517642,0.0012614328,0.0025622025,0.003120124,0.0036513521,0.015622244,0.0043240353,0.009902653,0.017146531],"category_scores_gemma":[0.1173784,0.0015267965,0.0019616522,0.0016132755,0.008707115,0.02494951,0.01247719,0.024506848,0.014911132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030255262,0.00015629253,0.0019111724,0.002951418,0.00010460113,0.00016524919,0.00055345503,0.00039477748,0.0016796477,0.057907604,0.55360425,0.38026896],"study_design_scores_gemma":[0.000025474823,0.00014572794,0.00066187256,0.0017564566,0.000034124016,0.00045678072,0.00047950874,0.00027705333,0.0005721691,0.021792049,0.9737526,0.000046119752],"about_ca_topic_score_codex":0.0033434755,"about_ca_topic_score_gemma":0.004192273,"teacher_disagreement_score":0.1517642,"about_ca_system_score_codex":0.0060968804,"about_ca_system_score_gemma":0.020451447,"threshold_uncertainty_score":0.8026154},"labels":[],"label_agreement":null},{"id":"W2612327959","doi":"10.1186/s40425-017-0243-4","title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Immunotherapy; Immune system; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Immunology; Baseline (sea); Biomarker; Bioinformatics; Oncology; Internal medicine; Biology","score_opus":0.18568744673297063,"score_gpt":0.511312647124004,"score_spread":0.3256252003910334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612327959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001958372,0.99818146,0.00027017444,0.00061913236,0.00023097411,0.000008707899,0.000031589676,0.000007332534,0.0004547493],"genre_scores_gemma":[0.0030669523,0.9950369,0.00062519475,0.00043502758,0.00033176274,0.000028023265,0.000096600954,0.0000027503909,0.00037676698],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99937135,0.00017682873,0.00010832606,0.000104881925,0.00018582318,0.00005283077],"domain_scores_gemma":[0.99825984,0.0009426897,0.00021017628,0.000041897936,0.0004844348,0.00006099754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022490069,0.0010710587,0.0026304955,0.002360835,0.00018924985,0.001375084,0.0012038104,0.0014554516,0.0014721685],"category_scores_gemma":[0.0036644447,0.00026179565,0.0010600187,0.0015760516,0.0005477995,0.0013566602,0.00065605424,0.0026641225,0.0010855141],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019824377,0.00009252194,0.002371559,0.0107409675,0.00032374833,0.00013125363,0.000043165703,0.00055397855,0.0010444671,0.0033534053,0.022038665,0.9591081],"study_design_scores_gemma":[0.00009811177,0.00044918736,0.013496,0.024171982,0.0014329028,0.0028272269,0.00018469454,0.0009485946,0.0027428933,0.009749535,0.9437911,0.00010774977],"about_ca_topic_score_codex":0.00091794954,"about_ca_topic_score_gemma":0.0011934299,"teacher_disagreement_score":0.0026304955,"about_ca_system_score_codex":0.0009295869,"about_ca_system_score_gemma":0.0014530682,"threshold_uncertainty_score":0.011893988},"labels":[],"label_agreement":null},{"id":"W2766923414","doi":"10.1186/s40425-017-0290-x","title":"Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; Université du Québec à Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Bristol-Myers Squibb Canada; Réseau de cancérologie Rossy; Bristol-Myers Squibb","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Blockade; Immune checkpoint; Chemotherapy; Immunotherapy; Cancer research; Cancer; Receptor; Cisplatin; Biology","score_opus":0.0230277490862044,"score_gpt":0.3553829253992408,"score_spread":0.3323551763130364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766923414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989951,0.00026684717,0.00012600713,0.00007323707,0.000010462514,0.00014876026,0.000086117594,0.000013421393,0.00027996162],"genre_scores_gemma":[0.9981851,0.00012177957,0.0004868905,0.0002269815,0.000025995985,0.0001637105,0.00047363795,0.000006015974,0.0003099222],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997861,0.00010094576,0.00001157844,0.000029400575,0.000028263687,0.000043757875],"domain_scores_gemma":[0.9996363,0.00006726682,0.000078451114,0.000023567047,0.000021652237,0.00017278011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010943688,0.00035972326,0.00053555355,0.00018450376,0.00017962951,0.00043709372,0.00015998102,0.00031880426,0.0010123873],"category_scores_gemma":[0.0004849621,0.00021445197,0.0003681287,0.00015076697,0.00030289165,0.00018269398,0.00013475305,0.0009619655,0.00016968121],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2931849,0.035166964,0.1667528,0.00038525026,0.0010059294,0.00068295095,0.00037226386,0.0027739212,0.30140024,0.00020839795,0.0050398554,0.19302653],"study_design_scores_gemma":[0.09658905,0.34966263,0.475676,0.00004922084,0.00093759486,0.0023679156,0.00015086186,0.008106679,0.061520945,0.00034564384,0.00454261,0.000050876348],"about_ca_topic_score_codex":0.00054318924,"about_ca_topic_score_gemma":0.0011060686,"teacher_disagreement_score":0.0010943688,"about_ca_system_score_codex":0.00036219312,"about_ca_system_score_gemma":0.00063462876,"threshold_uncertainty_score":0.0057876706},"labels":[],"label_agreement":null},{"id":"W2795166918","doi":"10.1186/s40425-017-0313-7","title":"Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Tumor microenvironment; Tumor progression; Cancer research; Angiogenesis; Macrophage; Population; Cancer; Medicine; Monocyte; Immunology; Chemistry; Internal medicine; Tumor cells; In vitro","score_opus":0.015898953830463896,"score_gpt":0.30018411644753457,"score_spread":0.28428516261707065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795166918","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22139215,0.004408223,0.7057743,0.00487822,0.00035038157,0.00020809441,0.0014959768,0.00042471098,0.061067916],"genre_scores_gemma":[0.93250966,0.002506212,0.03701955,0.0004639323,0.00017577661,0.0005294404,0.0005620663,0.00014666948,0.02608671],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997073,0.00011577986,0.000011591524,0.000041522882,0.000058331418,0.00006559848],"domain_scores_gemma":[0.9991365,0.00046865302,0.000160066,0.000029521403,0.00013888908,0.00006636275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005541906,0.000985265,0.00079486414,0.00075647177,0.0005763689,0.0013759532,0.0012276442,0.0025297091,0.0024110957],"category_scores_gemma":[0.001821106,0.0005627708,0.001252218,0.00061349093,0.0008543379,0.00084125286,0.0012177796,0.0009287915,0.000459868],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016225522,0.000020520863,0.00078410195,0.000037484617,0.000017350945,0.00010439598,0.00003163962,0.9836377,0.0012143459,0.0127069345,0.00042600665,0.0010033518],"study_design_scores_gemma":[0.000004301702,0.000005779714,0.00009835165,0.0000045505712,0.000003851199,0.000016130482,0.000008011942,0.99773943,0.00007586651,0.0016617859,0.00037827066,0.0000036697895],"about_ca_topic_score_codex":0.013444803,"about_ca_topic_score_gemma":0.005190592,"teacher_disagreement_score":0.013444803,"about_ca_system_score_codex":0.0012012778,"about_ca_system_score_gemma":0.0012658408,"threshold_uncertainty_score":0.0267331},"labels":[],"label_agreement":null},{"id":"W2800200585","doi":"10.1186/s40425-018-0332-z","title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Mucositis; Internal medicine; Esophagitis; Gastroenterology; Durvalumab; Oncology; Cancer; Radiation therapy; Surgery; Immunotherapy; Disease","score_opus":0.01402107771542368,"score_gpt":0.2911977492456359,"score_spread":0.27717667153021225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800200585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98571396,0.007544811,0.0008503192,0.00057301926,0.00008760918,0.00015022473,0.00009874826,0.00007861524,0.004902556],"genre_scores_gemma":[0.9981559,0.00096271496,0.00020439361,0.00019535654,0.00008766447,0.00001256026,0.00004775585,0.0000043487894,0.0003292345],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99975747,0.00003872934,0.000028356644,0.00004100265,0.000036193655,0.00009817329],"domain_scores_gemma":[0.9996737,0.000056933994,0.00010591666,0.000026361648,0.00002963753,0.00010732789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028483412,0.0011333358,0.00092950935,0.00065647135,0.0011596461,0.00053161656,0.00045358526,0.0015908206,0.0013769004],"category_scores_gemma":[0.00094180036,0.00044424084,0.0007700653,0.0005053477,0.00058938435,0.0005252333,0.0005414328,0.0012039108,0.00034548665],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000306955,0.000070889415,0.039370403,0.00018555827,0.000048442253,0.9518995,0.00012477458,0.00015745287,0.003956806,0.0001218427,0.00035200786,0.003405406],"study_design_scores_gemma":[0.00008492322,0.0004181949,0.07148591,0.00007108489,0.00009154059,0.9249591,0.00014610424,0.00051202456,0.0011721236,0.00012021521,0.0009257284,0.000013006094],"about_ca_topic_score_codex":0.001803823,"about_ca_topic_score_gemma":0.0030946808,"teacher_disagreement_score":0.001803823,"about_ca_system_score_codex":0.00084087375,"about_ca_system_score_gemma":0.0003984884,"threshold_uncertainty_score":0.006101012},"labels":[],"label_agreement":null},{"id":"W2800568511","doi":"10.1186/s40425-018-0328-8","title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institutes of Health; National Cancer Institute; Melanoma Research Alliance","keywords":"Medicine; Immunotherapy; Melanoma; CTLA-4; Biomarker; Blockade; Oncology; Ipilimumab; Immune checkpoint; Predictive value; Immunology; Immune system; Internal medicine; T cell; Cancer research; Biology; Receptor","score_opus":0.015536892900585509,"score_gpt":0.32959102357534525,"score_spread":0.31405413067475973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800568511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974745,0.0008675866,0.00070591044,0.00010820833,0.000013719936,0.000021775779,0.00031463537,0.000022366326,0.00047120696],"genre_scores_gemma":[0.9986456,0.0001137684,0.0005842018,0.000042089494,0.00001719065,0.000027418419,0.00038116166,0.00000402311,0.00018464761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997845,0.000055154393,0.000021830292,0.000055063785,0.000038274604,0.000045161643],"domain_scores_gemma":[0.999141,0.0003329129,0.0002538672,0.000035817015,0.00011721535,0.000119201766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007811796,0.0004370404,0.0005104766,0.0010605383,0.00025042254,0.0007463909,0.00030259523,0.0006039413,0.0013999816],"category_scores_gemma":[0.0018619584,0.00014021581,0.0003610706,0.0005908129,0.00021605715,0.0004015551,0.00029811615,0.00066419214,0.00036951475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013521323,0.00009645613,0.98117805,0.00003469379,0.000079677506,0.00013917474,0.00004775052,0.0011144588,0.0043012295,0.000057694222,0.00030856338,0.0112901125],"study_design_scores_gemma":[0.000059875547,0.0008679999,0.9775959,0.000032336833,0.00026802823,0.00087560824,0.00022227186,0.013476405,0.004870213,0.00053762336,0.0011742773,0.000019581958],"about_ca_topic_score_codex":0.00038952494,"about_ca_topic_score_gemma":0.00043277233,"teacher_disagreement_score":0.0013999816,"about_ca_system_score_codex":0.00029200327,"about_ca_system_score_gemma":0.0002207143,"threshold_uncertainty_score":0.004683435},"labels":[],"label_agreement":null},{"id":"W2808122948","doi":"10.1186/s40425-018-0363-5","title":"Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Royal Adelaide Hospital; Peter MacCallum Cancer Centre","keywords":"Medicine; Adverse effect; Pharmacology; Immune system; Toxicity; Clinical trial; Cancer; Immunology; Internal medicine","score_opus":0.031095811614531836,"score_gpt":0.39464869929133467,"score_spread":0.3635528876768028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808122948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8466146,0.14157574,0.0035411455,0.0011477876,0.00006708003,0.000255326,0.00046730664,0.00015172383,0.006179293],"genre_scores_gemma":[0.9570185,0.037039347,0.0032294397,0.00044803947,0.00022300374,0.0001448276,0.0005446167,0.000020339556,0.0013317773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99987674,0.00004995029,0.00000945754,0.000018251978,0.000027676424,0.000017940618],"domain_scores_gemma":[0.99977857,0.00008428498,0.00006960666,0.000014616575,0.00001992276,0.000033026714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006771474,0.0004203057,0.0004826811,0.00029964576,0.00010843922,0.0006536246,0.00029081388,0.0002934517,0.0013760226],"category_scores_gemma":[0.00035539086,0.0000973939,0.00031451142,0.00022111955,0.00036495572,0.00035943155,0.0001608302,0.000801791,0.00019546304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009987814,0.0033014938,0.007083012,0.0017680388,0.0002589534,0.00065803033,0.00023706391,0.0027529693,0.51386255,0.0011156678,0.0021656328,0.4568088],"study_design_scores_gemma":[0.0060920976,0.2255456,0.059377562,0.00046961717,0.0015156646,0.0067681423,0.00025522345,0.008200031,0.5795375,0.0016536129,0.11050375,0.000081282014],"about_ca_topic_score_codex":0.00011513806,"about_ca_topic_score_gemma":0.00029947326,"teacher_disagreement_score":0.0013760226,"about_ca_system_score_codex":0.00028030985,"about_ca_system_score_gemma":0.00022744961,"threshold_uncertainty_score":0.0046032667},"labels":[],"label_agreement":null},{"id":"W2809418671","doi":"10.1186/s40425-018-0366-2","title":"Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; RNA interference; Virotherapy; Biology; Virology; Virus; Vesicular stomatitis virus; Interferon; Viral replication; Cancer research; RNA; Gene; Genetics","score_opus":0.016475318795310445,"score_gpt":0.361522493068755,"score_spread":0.34504717427344456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809418671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648094,0.0005029212,0.0019906762,0.00002702962,0.000008589967,0.000022643206,0.0001030828,0.000047421003,0.0008166927],"genre_scores_gemma":[0.9966563,0.00022504717,0.001566609,0.000012193625,0.0000017657129,0.000025643989,0.00023826686,0.000011066134,0.0012630313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999056,0.00001741447,0.000009855958,0.000022543738,0.00002362437,0.000020975112],"domain_scores_gemma":[0.9999385,0.00001667928,0.000013609286,0.0000110527535,0.0000070168803,0.000013181115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010648643,0.00027731407,0.00022846441,0.0001701136,0.00010122545,0.00024552277,0.00009664425,0.00021841942,0.00071820425],"category_scores_gemma":[0.00008137214,0.00012918499,0.00020275175,0.00009598262,0.00017794913,0.00012635645,0.00014976085,0.0003301395,0.00018837344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002353664,0.000005966002,0.00005254738,0.0000062572617,0.0000022242798,0.000009299937,0.000004866983,0.00003231323,0.9996718,0.000035946192,0.000004120801,0.0001510529],"study_design_scores_gemma":[0.000004289989,0.00013589417,0.00084557396,9.36787e-7,0.000005310475,0.00008916552,0.000005959765,0.0004907337,0.9979517,0.0000109979255,0.00045791254,0.0000014929537],"about_ca_topic_score_codex":0.00053839834,"about_ca_topic_score_gemma":0.0005343507,"teacher_disagreement_score":0.00071820425,"about_ca_system_score_codex":0.00019110176,"about_ca_system_score_gemma":0.00018132194,"threshold_uncertainty_score":0.0024026632},"labels":[],"label_agreement":null},{"id":"W2886177168","doi":"10.1186/s40425-018-0381-3","title":"White paper on microbial anti-cancer therapy and prevention","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"National Cancer Institute","keywords":"Cancer therapy; Oncolytic virus; Medicine; Cancer; Cancer treatment; Commercialization; Intensive care medicine; Business; Internal medicine","score_opus":0.054621532462975804,"score_gpt":0.42136258989701986,"score_spread":0.36674105743404406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886177168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001308202,0.9672268,0.0005186781,0.005450151,0.015553254,0.000028502522,0.000060360213,0.000030024321,0.011001401],"genre_scores_gemma":[0.0014045186,0.9699251,0.0005501241,0.0068021435,0.0048064357,0.000029093668,0.000108852604,0.000016480035,0.016357224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951303,0.000071614624,0.00005160688,0.000080594546,0.0002363365,0.00004681804],"domain_scores_gemma":[0.99940777,0.00023001361,0.000055513694,0.000026816215,0.00019507845,0.00008484014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009317319,0.00084994716,0.00075449585,0.00150729,0.0005458731,0.0014778058,0.0009360973,0.0022260745,0.010822655],"category_scores_gemma":[0.001691527,0.0002793968,0.0005953086,0.0011975459,0.00081790984,0.0023425426,0.0010717125,0.0046202308,0.0069159875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060921902,0.0000693669,0.000101735444,0.003933858,0.000038183258,0.00022383421,0.00007557344,0.00017146464,0.0012018684,0.015198983,0.34868214,0.6302421],"study_design_scores_gemma":[0.0000039536553,0.00001558951,0.0000612872,0.00048301084,0.000006839381,0.00023458393,0.000008662368,0.00001112911,0.0001562624,0.00081363315,0.9982015,0.0000034975105],"about_ca_topic_score_codex":0.0009401732,"about_ca_topic_score_gemma":0.0016121477,"teacher_disagreement_score":0.010822655,"about_ca_system_score_codex":0.0008604115,"about_ca_system_score_gemma":0.0014881117,"threshold_uncertainty_score":0.03620541},"labels":[],"label_agreement":null},{"id":"W2888941300","doi":"10.1186/s40425-018-0398-7","title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society","keywords":"Medicine; Immunosuppression; Immunotherapy; Perioperative; Cancer; Immune system; Surgical stress; Cancer immunotherapy; Intensive care medicine; Immunology; Bioinformatics; Surgery; Internal medicine","score_opus":0.0573483934805771,"score_gpt":0.39911118877289015,"score_spread":0.341762795292313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888941300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015992856,0.9981206,0.00014798425,0.00042704836,0.00029158546,0.0000038478966,0.000007280428,0.000005031149,0.0008367519],"genre_scores_gemma":[0.0013564706,0.99744606,0.00019228013,0.0003016999,0.0002733738,0.00000633987,0.000012134296,0.0000011517258,0.00041050755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976665,0.00006001777,0.000035486988,0.00003898755,0.00007638686,0.000022440247],"domain_scores_gemma":[0.9997193,0.0001558878,0.000038637812,0.000008393839,0.000057511952,0.000020239215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050616625,0.00059959356,0.0007388551,0.0014193511,0.00026113578,0.0009789355,0.00055439933,0.0010169835,0.0026599853],"category_scores_gemma":[0.00073134794,0.0001683377,0.00047610296,0.0010369201,0.0005653266,0.001293097,0.00062840566,0.0015966463,0.00074230693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007177277,0.000083831925,0.0003028581,0.023789154,0.00012944231,0.00021377324,0.00010808454,0.00031714473,0.0029764313,0.006855274,0.02641338,0.9387389],"study_design_scores_gemma":[0.00001653207,0.00015506831,0.0011170505,0.0062349513,0.00013548859,0.00197691,0.00013549931,0.000117554104,0.0009884243,0.004106207,0.9849978,0.00001850431],"about_ca_topic_score_codex":0.00046403828,"about_ca_topic_score_gemma":0.00096029893,"teacher_disagreement_score":0.0026599853,"about_ca_system_score_codex":0.00039515906,"about_ca_system_score_gemma":0.0008805861,"threshold_uncertainty_score":0.008898497},"labels":[],"label_agreement":null},{"id":"W2895870246","doi":"10.1186/s40425-018-0420-0","title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Pazopanib; Nivolumab; Sunitinib; Renal cell carcinoma; Tolerability; Discontinuation; Adverse effect; Internal medicine; Clinical endpoint; Oncology; Peripheral edema; Urology; Clinical trial; Cancer; Immunotherapy","score_opus":0.02981774737536692,"score_gpt":0.33283564118325626,"score_spread":0.30301789380788935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895870246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453175,0.0031947042,0.00018256891,0.00013421125,0.000031981435,0.00025639095,0.00057891855,0.000027787491,0.0010617101],"genre_scores_gemma":[0.996309,0.0012130953,0.00029793597,0.0002469571,0.00006983631,0.0001692546,0.0011241918,0.00000982683,0.00055992824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948055,0.00027637254,0.000031248,0.00007941642,0.00009427498,0.00003819541],"domain_scores_gemma":[0.99916303,0.00016899308,0.00025564033,0.00007108217,0.00006467837,0.00027658342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021650512,0.00066005957,0.001325783,0.0002811516,0.00027968438,0.0008126523,0.00064466515,0.0008794177,0.001381268],"category_scores_gemma":[0.0010023859,0.00026111313,0.0012172376,0.00029873327,0.00036547447,0.00037253043,0.0002787428,0.0013572703,0.00031861194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6551614,0.027021205,0.07376736,0.0015130909,0.008250867,0.0005173732,0.00029267432,0.004881903,0.05189932,0.0001606336,0.0051354994,0.17139876],"study_design_scores_gemma":[0.3618235,0.44721985,0.1551079,0.00011606836,0.0053256457,0.0012606115,0.00007104487,0.0048202183,0.014708512,0.00015729276,0.009310246,0.000079151905],"about_ca_topic_score_codex":0.0007478277,"about_ca_topic_score_gemma":0.0017287971,"teacher_disagreement_score":0.0021650512,"about_ca_system_score_codex":0.00081559207,"about_ca_system_score_gemma":0.0009339249,"threshold_uncertainty_score":0.011449993},"labels":[],"label_agreement":null},{"id":"W2901169611","doi":"10.1186/s40425-018-0433-8","title":"Immunoregulatory functions of innate lymphoid cells","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"IL-33, ST2, and ILC Pathways","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canada First Research Excellence Fund; Canada Research Chairs; Cancer Research Society","keywords":"Innate lymphoid cell; Innate immune system; Immunology; Medicine; Biology; Computational biology; Immune system","score_opus":0.013621574783314511,"score_gpt":0.2786182288879217,"score_spread":0.2649966541046072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901169611","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5415586,0.3927199,0.017373169,0.0027179772,0.00054193207,0.0001734371,0.00086685107,0.0003071481,0.043740973],"genre_scores_gemma":[0.93050987,0.056711562,0.0049265833,0.00068019854,0.00029452876,0.00010416305,0.00041646097,0.000019085453,0.006337491],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997421,0.00007564894,0.00001950861,0.000034248344,0.000059114744,0.000069406124],"domain_scores_gemma":[0.99988055,0.000024728863,0.000025988587,0.000011665613,0.000022713371,0.000034251192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031532446,0.00039008848,0.00019718125,0.0005372894,0.0002392373,0.0005365847,0.00018136535,0.00032370578,0.001288534],"category_scores_gemma":[0.00018890802,0.000068773494,0.00021665021,0.00025728127,0.0003987027,0.00033493445,0.00047362063,0.00057833456,0.0003884403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002901035,0.00006799628,0.0024340341,0.0009058496,0.000020224781,0.00079642696,0.00034536648,0.00019786302,0.90050054,0.0068659014,0.001091806,0.08648399],"study_design_scores_gemma":[0.00011276129,0.0012622151,0.056397293,0.00065109855,0.00011840045,0.0060752463,0.0014642454,0.0018881756,0.6584313,0.009816104,0.26372984,0.000053377036],"about_ca_topic_score_codex":0.00022905417,"about_ca_topic_score_gemma":0.00030354355,"teacher_disagreement_score":0.001288534,"about_ca_system_score_codex":0.00027443556,"about_ca_system_score_gemma":0.00028022862,"threshold_uncertainty_score":0.0043105483},"labels":[],"label_agreement":null},{"id":"W2905817704","doi":"10.1186/s40425-018-0479-7","title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":571,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Immunotherapy; Medicine; Melanoma; Phenotype; Immune checkpoint; Immunology; Cancer research; Cancer; Biology; Internal medicine; Gene","score_opus":0.015517749621850001,"score_gpt":0.3085602037906005,"score_spread":0.2930424541687505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905817704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966462,0.0014397216,0.00010999498,0.00016392223,0.000016644097,0.000008418159,0.00019443905,0.0000061256615,0.0014145196],"genre_scores_gemma":[0.99909115,0.00016097445,0.00005302874,0.000056537643,0.00002149175,0.0000068984355,0.00015611108,0.0000022852782,0.0004515794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997111,0.000081351296,0.000025789006,0.000047734833,0.000053948104,0.000080112826],"domain_scores_gemma":[0.99882907,0.00036800216,0.0004539984,0.00004221554,0.000057564288,0.00024913932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042404927,0.00009942919,0.00026933325,0.00040088134,0.00013459752,0.00044912015,0.00011475782,0.00030109106,0.002478888],"category_scores_gemma":[0.0014734939,0.000065945904,0.00023061554,0.00025772367,0.00019099283,0.0003659014,0.00018348097,0.00042438833,0.00021135248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008600721,0.00027027723,0.9520963,0.00007633741,0.00017940534,0.0002869299,0.00010206807,0.00034310715,0.009671254,0.00022213157,0.0007601972,0.02739131],"study_design_scores_gemma":[0.000025916746,0.00062326906,0.9967344,0.000011230885,0.000052770974,0.00054065464,0.00012273049,0.00027365985,0.000836559,0.00016561989,0.00060851127,0.0000046848427],"about_ca_topic_score_codex":0.00029819718,"about_ca_topic_score_gemma":0.00056700106,"teacher_disagreement_score":0.002478888,"about_ca_system_score_codex":0.00018925543,"about_ca_system_score_gemma":0.00010822155,"threshold_uncertainty_score":0.008292735},"labels":[],"label_agreement":null},{"id":"W2905883696","doi":"10.1186/s40425-018-0480-1","title":"Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis","year":2018,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Infliximab; Medicine; Immune system; Enterocolitis; Adverse effect; Immune dysregulation; Immune checkpoint; CTLA-4; Immunology; Intensive care medicine; Sepsis; Ipilimumab; Cancer; Oncology; Tumor necrosis factor alpha; Internal medicine; Immunotherapy; T cell","score_opus":0.051706465511070686,"score_gpt":0.3364134831832456,"score_spread":0.28470701767217493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905883696","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013260526,0.004989061,0.0002186687,0.95232767,0.03742934,0.000022805345,0.00004154725,0.000054454827,0.003590415],"genre_scores_gemma":[0.010069091,0.0051628407,0.00039803408,0.885336,0.0935021,0.000029808372,0.000038695387,0.000029312001,0.0054340847],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99849296,0.00058412534,0.00017672051,0.0001841722,0.0004029567,0.00015900515],"domain_scores_gemma":[0.99717194,0.0014479709,0.00026712817,0.00007600602,0.00063795893,0.0003989931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013081428,0.00063526846,0.0007234811,0.0006730321,0.0019814104,0.0018145863,0.0009995755,0.016622437,0.0035524447],"category_scores_gemma":[0.014451376,0.00030072674,0.00082813326,0.00046940113,0.0014994458,0.0031648595,0.00073088147,0.017044535,0.0033134443],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007036653,0.00006544355,0.0011714315,0.0001349781,0.000016499698,0.016510395,0.00028850522,0.00011121987,0.00027012423,0.0022669157,0.9592199,0.019874316],"study_design_scores_gemma":[0.00017374588,0.0002451902,0.0021848814,0.0010173823,0.00005925527,0.06139253,0.001003364,0.00087278185,0.0005413182,0.01029103,0.9221189,0.00009964264],"about_ca_topic_score_codex":0.001919179,"about_ca_topic_score_gemma":0.0028252513,"teacher_disagreement_score":0.016622437,"about_ca_system_score_codex":0.0031087527,"about_ca_system_score_gemma":0.001789223,"threshold_uncertainty_score":0.022555709},"labels":[],"label_agreement":null},{"id":"W2906255446","doi":"10.1186/s40425-018-0457-0","title":"PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"PI3K/AKT/mTOR pathway; Tumor microenvironment; Immune system; CD8; Cancer research; T cell; Effector; Cytotoxic T cell; Immunosuppression; Immunotherapy; Biology; Chemistry; Pharmacology; Immunology; Medicine; Cell biology; In vitro; Signal transduction; Biochemistry","score_opus":0.015916303764539324,"score_gpt":0.30009173386688,"score_spread":0.28417543010234064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906255446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176097,0.0021496874,0.0034455126,0.000117528,0.00004531501,0.00007080552,0.00038634162,0.00017555313,0.0018482364],"genre_scores_gemma":[0.99494296,0.0010343947,0.0021574504,0.00004558935,0.000012713884,0.000054941815,0.00024928938,0.0000110395895,0.0014916373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989724,0.000013025746,0.000011244111,0.000023237251,0.00002698969,0.000028325256],"domain_scores_gemma":[0.99996305,0.000005678379,0.000011814087,0.0000050448316,0.0000035534517,0.000010821372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011565854,0.00041284555,0.00023677021,0.00018181864,0.00006699296,0.00023160226,0.00021022298,0.00014790912,0.0011138009],"category_scores_gemma":[0.00006223794,0.00009335436,0.00014889555,0.0001110036,0.00014969731,0.000168167,0.00012867835,0.0009803515,0.00029076927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004470925,0.00013814807,0.00015446317,0.00006810202,0.00000945689,0.000019612744,0.0000069336843,0.00017298575,0.9925991,0.000074850024,0.00009006423,0.006219211],"study_design_scores_gemma":[0.00008934114,0.001978256,0.00200046,0.00000567078,0.000025803969,0.00014955077,0.000009028429,0.0010969013,0.992698,0.00004321714,0.0019013367,0.0000024349422],"about_ca_topic_score_codex":0.00022726385,"about_ca_topic_score_gemma":0.0004995072,"teacher_disagreement_score":0.0011138009,"about_ca_system_score_codex":0.00016523773,"about_ca_system_score_gemma":0.00020776916,"threshold_uncertainty_score":0.0037260652},"labels":[],"label_agreement":null},{"id":"W2914393875","doi":"10.1186/s40425-018-0485-9","title":"Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; Swim Across America; National Institute of General Medical Sciences; KWF Kankerbestrijding; National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas; National Institute of Allergy and Infectious Diseases; Deutsche Krebshilfe; Irving Medical Center, Columbia University; Owens Foundation; University of Texas MD Anderson Cancer Center","keywords":"Tumor microenvironment; Immune system; Head and neck squamous-cell carcinoma; Cancer research; Medicine; CD8; T cell; Mass cytometry; Myeloid; Antigen; Immunology; Cancer; Head and neck cancer; Biology; Internal medicine","score_opus":0.008691542132802798,"score_gpt":0.2691522417700022,"score_spread":0.26046069963719937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914393875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563134,0.0020236417,0.00095716724,0.000053065898,0.000021610804,0.000042612817,0.00007611306,0.00006165522,0.0011327675],"genre_scores_gemma":[0.998466,0.00047597356,0.00051442784,0.000023469585,0.00001452782,0.000021587717,0.000057497506,0.0000060033026,0.00042047608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999018,0.00002332061,0.000006635948,0.00001939237,0.00002215257,0.000026703574],"domain_scores_gemma":[0.9999256,0.00001600639,0.000022414251,0.000008399936,0.000008233445,0.00001937893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009678425,0.00020682024,0.00025592686,0.0001432376,0.00008244219,0.00019352957,0.000096654854,0.00015557195,0.0013903832],"category_scores_gemma":[0.000085220694,0.00005133244,0.0001521193,0.00006414571,0.00016910686,0.00012008997,0.00012334011,0.00037266078,0.00019122478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021845048,0.000093712944,0.0002988536,0.000044286877,0.000004830837,0.000021268033,0.000006579236,0.000122062454,0.9966878,0.000032217544,0.00002759647,0.002442218],"study_design_scores_gemma":[0.000043653752,0.0025697374,0.007910986,0.000010642436,0.00003913437,0.00026697392,0.000015049132,0.00068219047,0.98606247,0.000029892088,0.0023661049,0.0000031841375],"about_ca_topic_score_codex":0.000088193025,"about_ca_topic_score_gemma":0.00016142122,"teacher_disagreement_score":0.0013903832,"about_ca_system_score_codex":0.00015118661,"about_ca_system_score_gemma":0.0001365144,"threshold_uncertainty_score":0.0046513677},"labels":[],"label_agreement":null},{"id":"W2916703154","doi":"10.1186/s40425-019-0507-2","title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Lung cancer; Cancer; Cancer research; Ligand (biochemistry); Medicine; Computational biology; Bioinformatics; Chemistry; Biology; Immunology; Oncology; Receptor; Internal medicine","score_opus":0.01122254260838088,"score_gpt":0.2874408932894919,"score_spread":0.276218350681111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916703154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946697,0.0037856598,0.004079039,0.000110842186,0.000048512156,0.00007380253,0.00021926501,0.000080289945,0.0021355653],"genre_scores_gemma":[0.996021,0.0007738114,0.0015669271,0.00007391012,0.000019279045,0.000041202475,0.00024248275,0.000007901578,0.0012536556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998611,0.000026557122,0.000016134429,0.000036500966,0.000028791983,0.000030814383],"domain_scores_gemma":[0.9999105,0.000014515202,0.000028769306,0.000013679585,0.00000989176,0.000022672479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001342435,0.00033200392,0.00020834764,0.00011398796,0.00007813845,0.00030132796,0.00013661128,0.00024068599,0.0014984366],"category_scores_gemma":[0.00013541085,0.00006151494,0.00016565293,0.00007503331,0.0001667429,0.0001786833,0.00017341545,0.00042277598,0.00042136858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024255952,0.000060481343,0.00097440346,0.000075966585,0.000007977993,0.00015101148,0.000020860849,0.00010940388,0.9930408,0.00015306062,0.0001176965,0.0050457246],"study_design_scores_gemma":[0.00014696186,0.0024916546,0.0067175115,0.000036281963,0.00008787209,0.004316618,0.000059144546,0.001994362,0.9703681,0.00021331782,0.013557982,0.000010295234],"about_ca_topic_score_codex":0.00007245526,"about_ca_topic_score_gemma":0.00013512193,"teacher_disagreement_score":0.0014984366,"about_ca_system_score_codex":0.00016130783,"about_ca_system_score_gemma":0.00011339668,"threshold_uncertainty_score":0.0050127506},"labels":[],"label_agreement":null},{"id":"W2921822469","doi":"10.1186/s40425-019-0521-4","title":"The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Worldwide Cancer Research","keywords":"Inflammasome; Signal transducing adaptor protein; Pancreatic cancer; Secretion; Cancer research; Cancer; Receptor; Medicine; Chemistry; Internal medicine","score_opus":0.0037357993382672663,"score_gpt":0.23353054729258363,"score_spread":0.22979474795431637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921822469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626931,0.021280114,0.006736189,0.00043505256,0.00009855282,0.00011552138,0.0064971736,0.0004071168,0.0017373092],"genre_scores_gemma":[0.9807623,0.0065058125,0.0064538694,0.00012074594,0.000082719765,0.00011501974,0.004940842,0.000042051433,0.0009766548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995413,0.000059688737,0.0000707509,0.00010765583,0.00014658377,0.0000740909],"domain_scores_gemma":[0.9994056,0.00007051761,0.00032945725,0.000033866098,0.000067786896,0.000092812894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041983416,0.00055279105,0.00047584157,0.0008231637,0.00024214856,0.0008207142,0.000178753,0.0003157206,0.0020294036],"category_scores_gemma":[0.00040409763,0.00016219019,0.0005335293,0.0006977242,0.0002200805,0.0004128129,0.000290315,0.00052310433,0.00073408335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010603956,0.00007334107,0.01289637,0.0006404848,0.000056428413,0.0007381816,0.00008591047,0.0002941633,0.97221583,0.00014418448,0.0004376909,0.011356991],"study_design_scores_gemma":[0.00019960075,0.0011295694,0.259243,0.00015694794,0.0004389406,0.0068693035,0.0005295866,0.005976787,0.70074356,0.0010362383,0.023614416,0.00006211292],"about_ca_topic_score_codex":0.00014949076,"about_ca_topic_score_gemma":0.00021523755,"teacher_disagreement_score":0.0020294036,"about_ca_system_score_codex":0.00030106035,"about_ca_system_score_gemma":0.00031528325,"threshold_uncertainty_score":0.006788969},"labels":[],"label_agreement":null},{"id":"W2929415048","doi":"10.1186/s40425-019-0535-y","title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Center for AIDS Research, University of Washington; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; Sarnoff Cardiovascular Research Foundation; American Heart Association","keywords":"Myocarditis; Vaccination; Medicine; Immunology; Immune system; Internal medicine","score_opus":0.02585979424590361,"score_gpt":0.3620537790854431,"score_spread":0.3361939848395395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929415048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991036,0.00041270873,0.000018414206,0.00003719733,0.000008935646,0.000005535564,0.000041630003,0.0000010144024,0.00037106188],"genre_scores_gemma":[0.9997404,0.0000971702,0.000017719889,0.000027238586,0.0000141766,0.0000037456039,0.00004389882,3.5230929e-7,0.00005535103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996853,0.000090844405,0.000032245847,0.00006237063,0.0000622408,0.000067072484],"domain_scores_gemma":[0.99925476,0.00016025297,0.00034488685,0.000024986295,0.000050263312,0.00016487607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043179613,0.00017755321,0.0002880248,0.00031340483,0.00039745952,0.00033262838,0.00012201927,0.00052425545,0.0013849594],"category_scores_gemma":[0.0014284961,0.00014917266,0.00030484863,0.0003020505,0.00016769831,0.00025477217,0.00019806123,0.0004508168,0.00014188989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035144362,0.00006529265,0.9978613,0.00001132006,0.000026134661,0.00012873148,0.000040566305,0.000012482337,0.00029834188,0.000007507706,0.000056216097,0.0011406359],"study_design_scores_gemma":[0.000018585191,0.0006080921,0.9982089,0.000011347278,0.000025692561,0.0007307799,0.000111842695,0.00008036137,0.000055549248,0.00001063031,0.00013633035,0.0000018383712],"about_ca_topic_score_codex":0.0007058699,"about_ca_topic_score_gemma":0.0008640202,"teacher_disagreement_score":0.0013849594,"about_ca_system_score_codex":0.00018369767,"about_ca_system_score_gemma":0.00016412002,"threshold_uncertainty_score":0.0046331882},"labels":[],"label_agreement":null},{"id":"W2933590268","doi":"10.1186/s40425-019-0519-y","title":"Correction to: 33rd Annual Meeting &amp; Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)","year":2019,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Council South Australia; Stand Up To Cancer; National Institutes of Health; Government of South Australia; Melanoma Research Alliance; South Australian Health and Medical Research Institute; Johns Hopkins University; Damon Runyon Cancer Research Foundation","keywords":"Cancer immunotherapy; Library science; Medicine; Immunotherapy; Cancer; Computer science; Internal medicine","score_opus":0.025540044931796076,"score_gpt":0.34468516163508495,"score_spread":0.3191451167032889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933590268","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095931195,0.0008554491,0.00062592025,0.04234622,0.9483013,0.000033030075,0.0013866109,0.0004293503,0.0059261676],"genre_scores_gemma":[0.0087581165,0.0104701575,0.005732669,0.095521614,0.3815946,0.0003892588,0.007879914,0.0031911505,0.4864625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99571985,0.0006230327,0.0007614644,0.00052405155,0.0020048076,0.00036676112],"domain_scores_gemma":[0.9711548,0.0049111983,0.0016859857,0.001412664,0.019328918,0.0015063487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003945847,0.0019698679,0.0012956138,0.003567048,0.0025873221,0.004746148,0.0022264672,0.0040030223,0.16178992],"category_scores_gemma":[0.056728642,0.0008620548,0.0012465436,0.0021330086,0.0014127427,0.002287764,0.0021160669,0.007713612,0.11718196],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017495462,0.0000026978876,0.000025324387,0.000042583586,0.000002539296,0.00004643542,0.000007994301,0.000012676554,0.00001964953,0.0002008427,0.99524635,0.004375529],"study_design_scores_gemma":[0.000018015407,0.00001149385,0.00022444125,0.00022274686,0.000009132986,0.00019893875,0.000032385888,0.00006311979,0.0001345186,0.00048099263,0.9985904,0.000013805371],"about_ca_topic_score_codex":0.011476936,"about_ca_topic_score_gemma":0.014028008,"teacher_disagreement_score":0.16178992,"about_ca_system_score_codex":0.003663858,"about_ca_system_score_gemma":0.0053251996,"threshold_uncertainty_score":0.5412412},"labels":[],"label_agreement":null},{"id":"W2935816391","doi":"10.1186/s40425-019-0538-8","title":"Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Hyundai Hope On Wheels; National Cancer Institute; Stand Up To Cancer; U.S. Department of Health and Human Services; National Institutes of Health; University of Wisconsin Carbone Cancer Center; ECOG-ACRIN Cancer Research Group; Midwest Athletes Against Childhood Cancer; American College of Radiology Imaging Network; U.S. Public Health Service; St. Baldrick's Foundation; American Association for Cancer Research; University of Wisconsin-Madison","keywords":"Rituximab; Follicular lymphoma; Human leukocyte antigen; Follicular phase; Medicine; Immunology; Lymphoma; Internal medicine; Antigen","score_opus":0.00666545812998804,"score_gpt":0.2356607765638207,"score_spread":0.22899531843383267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935816391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994605,0.0001972226,0.00006736873,0.00002081532,0.0000033153508,0.000017981065,0.00004467387,0.000005244439,0.00018283946],"genre_scores_gemma":[0.9995065,0.000040464274,0.0001489466,0.000036579826,0.000010010358,0.000019505353,0.00015060391,0.0000012161722,0.0000861238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996985,0.00009311461,0.00002574651,0.00006318791,0.00004790744,0.00007152048],"domain_scores_gemma":[0.9993469,0.00020171038,0.00019636023,0.00004302459,0.00004258949,0.00016937917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000741212,0.00024957804,0.0006425719,0.0001568673,0.00024288661,0.00025726043,0.00019680898,0.00029926063,0.0009997527],"category_scores_gemma":[0.00070729514,0.0001226479,0.00041154394,0.0001841138,0.00019484137,0.0003007184,0.00014489886,0.00046955445,0.0001404603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086535044,0.0031814107,0.7857486,0.00014897936,0.0009919131,0.00047762837,0.00022952196,0.0008373934,0.058366638,0.00007044076,0.00091801694,0.06249442],"study_design_scores_gemma":[0.0052916687,0.044673044,0.9367944,0.000020659967,0.0008917534,0.0025083341,0.00012409796,0.0007545195,0.0073847855,0.00012297908,0.0014100462,0.000023693368],"about_ca_topic_score_codex":0.00039873333,"about_ca_topic_score_gemma":0.0010238478,"teacher_disagreement_score":0.0009997527,"about_ca_system_score_codex":0.0003643102,"about_ca_system_score_gemma":0.00030795616,"threshold_uncertainty_score":0.003919959},"labels":[],"label_agreement":null},{"id":"W2937370179","doi":"10.1186/s40425-019-0543-y","title":"Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Advanced Fluorescence Microscopy Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Institute of Biomedical Imaging and Bioengineering; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; Victoria University; Cancer Prevention and Research Institute of Texas","keywords":"Motility; Bone marrow; Tumor microenvironment; Intravital microscopy; Immune system; Tumor hypoxia; Pathology; Hypoxia (environmental); Lymphocyte; Leukemia; Oxygen; Cancer research; Chemistry; Immunology; Medicine; Biology; Cell biology; Radiation therapy; Internal medicine; Microcirculation","score_opus":0.006129024459720525,"score_gpt":0.33289727716882284,"score_spread":0.3267682527091023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937370179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981575,0.0005145198,0.016724713,0.00006328199,0.000006422114,0.000012988501,0.00006539409,0.000085081185,0.0009526042],"genre_scores_gemma":[0.9868802,0.00036134254,0.011476391,0.000039164137,0.000008424178,0.00004575019,0.000116337,0.000031125903,0.0010411161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989474,0.000016033884,0.0000040070186,0.00002759285,0.000027816,0.000029827588],"domain_scores_gemma":[0.9998635,0.000049637973,0.0000308873,0.000012221775,0.000021582355,0.000022214766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023718641,0.000181649,0.00014358357,0.0003245398,0.00012193716,0.00025084143,0.00030628513,0.00032875972,0.0005729915],"category_scores_gemma":[0.0002129322,0.00014707232,0.00017802908,0.00015038202,0.00021262484,0.0002775685,0.00033638565,0.00041377556,0.00012750494],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013854905,0.00002350562,0.0010432949,0.000029519228,0.0000047327744,0.00004143332,0.000027243941,0.00026295226,0.99507964,0.00019771898,0.00003744581,0.0031140302],"study_design_scores_gemma":[0.000019535957,0.00029332613,0.01612101,0.000007604071,0.000017784943,0.00035902136,0.000070893315,0.015968606,0.9660867,0.0001770484,0.0008653665,0.000013104118],"about_ca_topic_score_codex":0.0004541951,"about_ca_topic_score_gemma":0.00052959105,"teacher_disagreement_score":0.0005729915,"about_ca_system_score_codex":0.0002728098,"about_ca_system_score_gemma":0.0001756779,"threshold_uncertainty_score":0.0019794106},"labels":[],"label_agreement":null},{"id":"W2937848504","doi":"10.1186/s40425-018-0488-6","title":"Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Immune system; Tumor microenvironment; CD8; Cell; T cell; Cytotoxic T cell; Lung cancer; Biology; Cancer research; Adenocarcinoma; Pathology; Cancer; Medicine; Immunology; Internal medicine; In vitro","score_opus":0.013211437999701406,"score_gpt":0.320314737866742,"score_spread":0.3071032998670406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937848504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183804,0.00020750603,0.006563912,0.000060869334,0.0000053432996,0.000009503123,0.00023712582,0.00010386721,0.00097378116],"genre_scores_gemma":[0.9965024,0.00007211739,0.0027588273,0.000025020914,0.000005842186,0.000017018918,0.00023130624,0.000011308752,0.00037618075],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999224,0.000009073022,0.0000033382973,0.000022143608,0.00002601817,0.00001709139],"domain_scores_gemma":[0.99986994,0.00002410872,0.0000495801,0.000007859883,0.000026280113,0.000022205419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013342472,0.00010294651,0.00013105504,0.00058585504,0.000124675,0.00024104219,0.00013289346,0.00017262438,0.0013635915],"category_scores_gemma":[0.0001936527,0.00009072571,0.000099715566,0.00032995542,0.00019836835,0.00018291325,0.00016613016,0.00017134937,0.000206062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047137824,0.00010139643,0.13953833,0.00007343987,0.00005374083,0.00024380101,0.0001691239,0.0035245712,0.8236023,0.00058658735,0.0010506586,0.030584663],"study_design_scores_gemma":[0.000013234016,0.00017250776,0.73418593,0.000007336542,0.000057654386,0.0012136251,0.00040153536,0.075240284,0.18584006,0.00078632444,0.0020505702,0.00003098302],"about_ca_topic_score_codex":0.0013697598,"about_ca_topic_score_gemma":0.0019854456,"teacher_disagreement_score":0.0013697598,"about_ca_system_score_codex":0.00030731794,"about_ca_system_score_gemma":0.00009897683,"threshold_uncertainty_score":0.0045617223},"labels":[],"label_agreement":null},{"id":"W2943155654","doi":"10.1186/s40425-019-0542-z","title":"Radiotherapy enhances responses of lung cancer to CTLA-4 blockade","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Abscopal effect; Ipilimumab; Medicine; Radiation therapy; Immunotherapy; CTLA-4; Immune system; Lung cancer; Oncology; Clinical trial; Blockade; Immune checkpoint; Biological response modifiers; Immunology; Internal medicine; T cell; Receptor","score_opus":0.02045189570884703,"score_gpt":0.3664423344238244,"score_spread":0.34599043871497737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943155654","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90932363,0.012030002,0.0015285973,0.042694323,0.0028984146,0.00032316777,0.00027890306,0.00045320697,0.03046978],"genre_scores_gemma":[0.9720005,0.002682108,0.00064392353,0.014394699,0.0027593572,0.00010374585,0.00017852656,0.000034857683,0.007202368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997291,0.00011862726,0.000020645568,0.000028797956,0.000048496764,0.000054337317],"domain_scores_gemma":[0.9991811,0.0005664412,0.000053348525,0.000055300596,0.00007534168,0.00006837086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005869052,0.00022580613,0.00045987373,0.00016406355,0.00024087976,0.0004382707,0.00015318318,0.0015670925,0.0017644917],"category_scores_gemma":[0.0015924271,0.00010629915,0.00036903442,0.00010743805,0.00022652441,0.00018847533,0.00014276526,0.0011590867,0.00068617734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019105336,0.003030035,0.04551101,0.0014424998,0.00021643637,0.049790017,0.0006488665,0.0024661147,0.45075485,0.002879266,0.07842618,0.3457294],"study_design_scores_gemma":[0.004089761,0.045769073,0.19775757,0.00017204716,0.00041406284,0.07607812,0.00043570393,0.010114888,0.3358104,0.0051682196,0.3240822,0.00010799044],"about_ca_topic_score_codex":0.00020682496,"about_ca_topic_score_gemma":0.00028924,"teacher_disagreement_score":0.0017644917,"about_ca_system_score_codex":0.0004549493,"about_ca_system_score_gemma":0.00015871624,"threshold_uncertainty_score":0.0059028864},"labels":[],"label_agreement":null},{"id":"W2943665137","doi":"10.1186/s40425-019-0578-0","title":"Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Dental and Craniofacial Research","keywords":"Medicine; Cetuximab; Nivolumab; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Docetaxel; Clinical trial; Immunotherapy; Head and neck cancer; Cancer","score_opus":0.06821629106114331,"score_gpt":0.4354250672816484,"score_spread":0.36720877622050513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943665137","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97244,0.013186611,0.0024588208,0.00039505356,0.00021747297,0.0012108807,0.006280762,0.00007642483,0.0037339106],"genre_scores_gemma":[0.9882995,0.0013969317,0.0016178787,0.0005292551,0.000114036695,0.00068730605,0.006297669,0.000023436005,0.0010339937],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9937797,0.0039127246,0.0005558409,0.0008626407,0.00053173554,0.0003574109],"domain_scores_gemma":[0.98640114,0.006527228,0.003556639,0.0018196554,0.00074315676,0.0009520997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012485207,0.0008163864,0.0017557414,0.0006116151,0.00021501644,0.0011781013,0.00071560097,0.0011391302,0.0041370513],"category_scores_gemma":[0.011984693,0.00028671054,0.0048058876,0.000998072,0.0005031972,0.0007904408,0.0005839301,0.001408578,0.00041022667],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7938236,0.0047979103,0.045789763,0.0036440825,0.04446996,0.00022695938,0.00016811123,0.007862444,0.019069305,0.0016161135,0.0051390775,0.07339267],"study_design_scores_gemma":[0.19378749,0.4218678,0.2955543,0.00031740384,0.03957049,0.0011044953,0.00019253959,0.008545484,0.014140168,0.0019498428,0.022764847,0.0002052061],"about_ca_topic_score_codex":0.00029842614,"about_ca_topic_score_gemma":0.00077178655,"teacher_disagreement_score":0.012485207,"about_ca_system_score_codex":0.00073668297,"about_ca_system_score_gemma":0.0009351421,"threshold_uncertainty_score":0.06602889},"labels":[],"label_agreement":null},{"id":"W2944068250","doi":"10.1186/s40425-019-0544-x","title":"Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Mitacs; Canadian Cancer Society Research Institute; Institute of Cancer Research; Institut Du Cancer de Montréal; Terry Fox Research Institute; Canada Foundation for Innovation","keywords":"Multiplex; Medicine; Immune system; Immune checkpoint; Profiling (computer programming); Lung cancer; Oncology; Risk stratification; Immunology; Immunotherapy; Internal medicine; Bioinformatics; Biology; Computer science","score_opus":0.017285490871467562,"score_gpt":0.31139325831436837,"score_spread":0.2941077674429008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944068250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831444,0.0013660629,0.011999368,0.00010105598,0.000014072358,0.0001234921,0.0019626745,0.00016604623,0.0011227361],"genre_scores_gemma":[0.98743445,0.00036165374,0.009863228,0.00006878731,0.000013290262,0.000122709,0.0015398079,0.000015157241,0.00058091106],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997811,0.000035030338,0.000014842004,0.000078806384,0.00005064358,0.00003958656],"domain_scores_gemma":[0.9998209,0.000051778035,0.000042873013,0.000019346988,0.000031539163,0.000033462788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037913147,0.0002758274,0.00030190308,0.00075523864,0.00019790472,0.00041039585,0.00018274259,0.00029047998,0.0016917291],"category_scores_gemma":[0.00044924478,0.000110015695,0.00019908686,0.0003919734,0.0001295305,0.0002131386,0.00027520774,0.00027368253,0.00039679377],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059582497,0.000107543,0.117068484,0.00017202688,0.000072922914,0.00012222904,0.00007770611,0.0007171786,0.861092,0.00017354336,0.00040664995,0.019394029],"study_design_scores_gemma":[0.00005797886,0.0009389536,0.5526967,0.000057622055,0.00029696475,0.0017179578,0.00033020132,0.016160846,0.42057633,0.0008098629,0.006334091,0.000022464397],"about_ca_topic_score_codex":0.00049141777,"about_ca_topic_score_gemma":0.0012849107,"teacher_disagreement_score":0.0016917291,"about_ca_system_score_codex":0.0002252928,"about_ca_system_score_gemma":0.00023990887,"threshold_uncertainty_score":0.0056594014},"labels":[],"label_agreement":null},{"id":"W2944392072","doi":"10.1186/s40425-019-0541-0","title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Ontario Ministry of Research, Innovation and Science; Canada Research Chairs; Government of Ontario; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Immunophenotyping; Oncology; Immune system; CD8; Tumor-infiltrating lymphocytes; Interim analysis; Clinical trial; Immunotherapy; Immunology; Antigen","score_opus":0.10289923724578354,"score_gpt":0.4450525707470737,"score_spread":0.3421533335012902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944392072","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18153526,0.034963325,0.04015115,0.056619015,0.04524094,0.08980184,0.30529195,0.0026727014,0.24372391],"genre_scores_gemma":[0.32075277,0.016506413,0.03436469,0.050361957,0.021420147,0.057893917,0.21211241,0.0011186922,0.28546908],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975783,0.0009737321,0.00018858664,0.0002624691,0.0006889948,0.00030789318],"domain_scores_gemma":[0.99465936,0.0010221127,0.0006764598,0.00035919243,0.0014301301,0.0018528018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008429753,0.0011879853,0.0011770973,0.00037839435,0.000700811,0.0018326325,0.0016179988,0.0027758689,0.034016185],"category_scores_gemma":[0.0055978983,0.00044508348,0.0008819199,0.00041009564,0.00026424188,0.0009075501,0.00075166224,0.0024428929,0.010058872],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08538035,0.009574292,0.008742911,0.0018399872,0.0014018364,0.00080523,0.00014738094,0.0011543581,0.015649712,0.0018684139,0.6696813,0.20375423],"study_design_scores_gemma":[0.10078501,0.08921354,0.044081558,0.00065261056,0.0013334793,0.0013611934,0.00010130914,0.0031591852,0.010539786,0.002990128,0.74566597,0.00011618473],"about_ca_topic_score_codex":0.0006991486,"about_ca_topic_score_gemma":0.001542003,"teacher_disagreement_score":0.034016185,"about_ca_system_score_codex":0.00084651326,"about_ca_system_score_gemma":0.0029001806,"threshold_uncertainty_score":0.11379552},"labels":[],"label_agreement":null},{"id":"W2946884236","doi":"10.1186/s40425-019-0575-3","title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Roche Innovation Center Zurich; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Sociedad Española de Oncología Médica; Cancer Research UK; Wellcome Trust","keywords":"Medicine; Colorectal cancer; Immunotherapy; Cancer immunotherapy; Organoid; Bispecific antibody; Cancer research; Antibody; Immunology; Cancer; Monoclonal antibody; Biology; Internal medicine; Genetics","score_opus":0.017888921491295666,"score_gpt":0.34024556078457385,"score_spread":0.3223566392932782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946884236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985973,0.000107919324,0.0004605256,0.000020310574,0.0000048681964,0.000012487732,0.00020295868,0.000019426081,0.0005741684],"genre_scores_gemma":[0.99838996,0.00007388905,0.00039433566,0.000024263556,0.000002380659,0.000018860252,0.00043660137,0.0000102246895,0.000649485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998549,0.000019073083,0.00001694398,0.000032837586,0.000029382978,0.000046786063],"domain_scores_gemma":[0.99985504,0.00003332749,0.000022117063,0.000024080327,0.000013626019,0.000051793882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090387635,0.00013420651,0.00017587685,0.00018804631,0.00013885932,0.00032135812,0.00010431156,0.00018963024,0.001429497],"category_scores_gemma":[0.00016652126,0.00015336309,0.00021138514,0.00014728858,0.00013540479,0.00014373507,0.00019335306,0.0005402695,0.00037139817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020597516,0.0000432617,0.0017070405,0.000010171872,0.000005815991,0.00011281008,0.000045164135,0.00007858456,0.9968862,0.000096588796,0.000065344466,0.00074304134],"study_design_scores_gemma":[0.00005271381,0.0012242433,0.074068494,0.000006162948,0.0000442749,0.0023523667,0.00026127213,0.003302259,0.9153796,0.00011522344,0.00317913,0.000014313931],"about_ca_topic_score_codex":0.0016391722,"about_ca_topic_score_gemma":0.0015788918,"teacher_disagreement_score":0.0016391722,"about_ca_system_score_codex":0.00024552768,"about_ca_system_score_gemma":0.00013696293,"threshold_uncertainty_score":0.0047821403},"labels":[],"label_agreement":null},{"id":"W2947794723","doi":"10.1186/s40425-019-0602-4","title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Caprion (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Premise; Cancer; Cancer immunotherapy; Immune escape; Immune system; Immunotherapy; Computational biology; Bioinformatics; Medicine; Immunology; Psychology; Biology; Genetics","score_opus":0.11245442319226147,"score_gpt":0.4196030258259771,"score_spread":0.30714860263371563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947794723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057056936,0.43374592,0.0024114016,0.32404324,0.2295256,0.00016156268,0.00031597103,0.0000826057,0.009143153],"genre_scores_gemma":[0.0072677727,0.52415776,0.0036842225,0.25721902,0.18437104,0.00055579166,0.0008343969,0.00023008871,0.021679914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635327,0.0010760407,0.00043612687,0.0005067581,0.0011838641,0.00044393627],"domain_scores_gemma":[0.9935801,0.0021106438,0.00022305652,0.00017891415,0.0021163798,0.0017909964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010146525,0.002395454,0.0019616587,0.0039632902,0.0028303408,0.008150669,0.0034531103,0.009085089,0.005288097],"category_scores_gemma":[0.008615364,0.0010573096,0.0023382471,0.0034693254,0.004061347,0.007973913,0.007830068,0.028084002,0.0034338636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006813205,0.00005773008,0.00014210561,0.0013999263,0.000022919552,0.00024786778,0.00063485926,0.00042486037,0.0004958942,0.011761851,0.9498606,0.03488324],"study_design_scores_gemma":[0.000009962909,0.00003125441,0.00018893545,0.0018210086,0.000009340222,0.00020423825,0.00027550728,0.00006660007,0.00006670941,0.003470203,0.9938356,0.000020656405],"about_ca_topic_score_codex":0.0056759305,"about_ca_topic_score_gemma":0.0070044324,"teacher_disagreement_score":0.010146525,"about_ca_system_score_codex":0.008663019,"about_ca_system_score_gemma":0.0099388305,"threshold_uncertainty_score":0.062854886},"labels":[],"label_agreement":null},{"id":"W2947924669","doi":"10.1186/s40425-019-0595-z","title":"Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epitope; Antigen; Computational biology; Major histocompatibility complex; T cell; CD8; Cancer immunotherapy; Immunotherapy; MHC class I; Peptide; Biology; Epitope mapping; Immunology; Immune system; Biochemistry","score_opus":0.03674745316633686,"score_gpt":0.30496311464875525,"score_spread":0.2682156614824184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947924669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561659,0.002247352,0.022573961,0.00025601842,0.00005163546,0.000095736556,0.013685821,0.0012726877,0.0036508888],"genre_scores_gemma":[0.9482319,0.0006282668,0.023357885,0.00014065504,0.000021339109,0.00016340641,0.02651576,0.00008954624,0.0008512338],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996512,0.000046021385,0.000023168122,0.00014147346,0.00008680216,0.00005140298],"domain_scores_gemma":[0.99923265,0.00047721155,0.00008855875,0.000058239482,0.000110384084,0.000032992633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062525016,0.0006023418,0.00057432154,0.00077552296,0.00026509934,0.0010946029,0.00052959635,0.0006543485,0.0019335146],"category_scores_gemma":[0.0020603272,0.00013435069,0.00045279818,0.00065249775,0.00014272075,0.0005162007,0.0002746853,0.00057105167,0.0009876221],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020905158,0.000733957,0.40849173,0.0015987261,0.00061134016,0.00040121545,0.00016055016,0.1537033,0.10028394,0.0010481738,0.019940954,0.31093562],"study_design_scores_gemma":[0.00008726757,0.0004144626,0.13527314,0.00012073271,0.00034598866,0.0008194602,0.00015783604,0.76981723,0.07868703,0.00227409,0.01195812,0.000044682565],"about_ca_topic_score_codex":0.0020321172,"about_ca_topic_score_gemma":0.002038016,"teacher_disagreement_score":0.0020321172,"about_ca_system_score_codex":0.00058645953,"about_ca_system_score_gemma":0.00040504037,"threshold_uncertainty_score":0.0064682364},"labels":[],"label_agreement":null},{"id":"W2948662515","doi":"10.1186/s40425-019-0623-z","title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":438,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Royal Ottawa Mental Health Centre","funders":"National Institute for Health and Care Research; Amgen","keywords":"Medicine; Oncolytic virus; Internal medicine; Melanoma; Confidence interval; Oncology; Hazard ratio; Randomized controlled trial; Cancer; Cancer research","score_opus":0.05177845107064362,"score_gpt":0.3877663574224503,"score_spread":0.3359879063518067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948662515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96177065,0.004861686,0.0044558784,0.0015722783,0.00046177488,0.010631412,0.009451811,0.00035512232,0.0064392807],"genre_scores_gemma":[0.96808213,0.0012533594,0.0060987147,0.0014675533,0.00033943987,0.007901907,0.008872935,0.00010769229,0.0058763246],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721426,0.0019836244,0.000103943756,0.00026713542,0.00022068192,0.00021047237],"domain_scores_gemma":[0.9971034,0.0010714259,0.0007735911,0.00028366005,0.00025384652,0.000514064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009030502,0.0014946985,0.0019639034,0.0004883294,0.00033740717,0.0011173828,0.0008740836,0.0010445477,0.0055122483],"category_scores_gemma":[0.0056949533,0.0006002408,0.0037672226,0.00025717777,0.00069791405,0.00068763416,0.00053955265,0.002523195,0.0008337867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97163796,0.002518622,0.0022590866,0.0003864958,0.0025015376,0.000050986244,0.0000591453,0.0017245127,0.0035714505,0.00025264884,0.0034424644,0.011595128],"study_design_scores_gemma":[0.81879014,0.15113221,0.013494365,0.00007465982,0.0049636196,0.00013626595,0.000043134034,0.0029409165,0.0032031161,0.0008562024,0.0043203346,0.000045060064],"about_ca_topic_score_codex":0.00035559267,"about_ca_topic_score_gemma":0.00094369694,"teacher_disagreement_score":0.009030502,"about_ca_system_score_codex":0.00086982234,"about_ca_system_score_gemma":0.0013590804,"threshold_uncertainty_score":0.04775846},"labels":[],"label_agreement":null},{"id":"W2948878352","doi":"10.1186/s40425-019-0619-8","title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Queen's University","keywords":"Immunoediting; Bladder cancer; Immune checkpoint; DNA repair; Immune system; Gene; Cancer; Cancer research; DNA mismatch repair; Immunotherapy; Tumor microenvironment; Medicine; Bioinformatics; Biology; Immunology; Genetics; Internal medicine","score_opus":0.010395492579599383,"score_gpt":0.275885229973412,"score_spread":0.26548973739381265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948878352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832064,0.00047112885,0.00015932803,0.000015342743,0.00000149189,0.000006622094,0.0008156151,0.0000070384813,0.00020282797],"genre_scores_gemma":[0.9981275,0.00019408304,0.00034088243,0.000018039886,0.000002783016,0.0000179295,0.0010603201,0.0000034457187,0.00023512443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987197,0.000015672338,0.0000123660875,0.000046248482,0.00002806327,0.00002567878],"domain_scores_gemma":[0.99970007,0.00006556867,0.00014924121,0.000019694158,0.00003373963,0.00003175363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001813733,0.00010128222,0.00018164261,0.0008022644,0.00014765996,0.0003065317,0.000119440505,0.0001762082,0.00088320486],"category_scores_gemma":[0.00043251293,0.000072533316,0.00015778914,0.0006477871,0.00012157782,0.00009520596,0.0001623477,0.00019608242,0.0001248487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006745294,0.00003407739,0.9334603,0.000112573805,0.000100295045,0.00012330855,0.000152101,0.00023596268,0.054502293,0.00004846109,0.00021618365,0.01033987],"study_design_scores_gemma":[0.0000030079038,0.00006397384,0.994003,0.000008060922,0.000041121348,0.0004106709,0.000106745734,0.00035088425,0.0045161806,0.000040963685,0.0004525707,0.0000029104017],"about_ca_topic_score_codex":0.00085600506,"about_ca_topic_score_gemma":0.0019558475,"teacher_disagreement_score":0.00088320486,"about_ca_system_score_codex":0.0001692422,"about_ca_system_score_gemma":0.000108356624,"threshold_uncertainty_score":0.0029545426},"labels":[],"label_agreement":null},{"id":"W2952406594","doi":"10.1186/s40425-017-0215-8","title":"Gene expression markers of Tumor Infiltrating Leukocytes","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Immune system; Biology; Gene; Gene expression; Immunotherapy; Flow cytometry; Gene expression profiling; Computational biology; Genetics","score_opus":0.02844187749003703,"score_gpt":0.34877392438913074,"score_spread":0.3203320468990937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952406594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851362,0.0022413093,0.006993376,0.00006798115,0.000016538905,0.000037223464,0.004231487,0.00011484787,0.001161029],"genre_scores_gemma":[0.9877484,0.0007033324,0.006948308,0.00005829076,0.000021354097,0.00010279697,0.0037529077,0.000023338007,0.0006413253],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99973315,0.000037444966,0.000021838496,0.0001035902,0.000063075466,0.000040997784],"domain_scores_gemma":[0.99952066,0.00014901435,0.0001872036,0.000033708875,0.00006678738,0.000042535517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024910067,0.0002208427,0.00021605445,0.0010501377,0.00011934055,0.0004252799,0.00015429303,0.00022131889,0.001092231],"category_scores_gemma":[0.00066869374,0.00006253993,0.00017120417,0.0014412949,0.00014771192,0.00015992398,0.000179141,0.00019857309,0.00036337698],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096373906,0.00011330131,0.37115607,0.0003836287,0.00014400532,0.00022777247,0.0001603168,0.0014888297,0.56720805,0.0004395972,0.00075498805,0.05695971],"study_design_scores_gemma":[0.000048236136,0.0006616111,0.74530065,0.000047620964,0.00028765795,0.0012531332,0.00028428726,0.006368665,0.23623098,0.0010937998,0.008399409,0.00002382237],"about_ca_topic_score_codex":0.0002194979,"about_ca_topic_score_gemma":0.0003329466,"teacher_disagreement_score":0.001092231,"about_ca_system_score_codex":0.0002006591,"about_ca_system_score_gemma":0.00014751108,"threshold_uncertainty_score":0.003653884},"labels":[],"label_agreement":null},{"id":"W2954038428","doi":"10.1186/s40425-019-0632-y","title":"Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Imperial Experimental Cancer Medicine Centre; National Institute for Health and Care Research; University of Leeds; Yorkshire Cancer Research; Kay Kendall Leukaemia Fund; Cancer Research UK; NHS Blood and Transplant","keywords":"Medicine; Oncolytic virus; Immune system; Immunology; Acquired immune system; Cancer; Immunotherapy; Internal medicine","score_opus":0.023023416088482497,"score_gpt":0.32839453528579615,"score_spread":0.30537111919731363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954038428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390537,0.0012599475,0.0015717836,0.00013384063,0.00003459187,0.0001451962,0.0003727347,0.000044210312,0.0025323394],"genre_scores_gemma":[0.99662566,0.00056833227,0.0011598555,0.0001051688,0.000039984934,0.000118825614,0.00027236805,0.00001019308,0.0010995219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996569,0.000089685855,0.000027084216,0.00007026852,0.00005416711,0.000101904465],"domain_scores_gemma":[0.99981695,0.00003278565,0.000043333806,0.00002174232,0.00003399026,0.000051228217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031409404,0.0002645769,0.00028385926,0.0002949245,0.00019325166,0.0004552352,0.00013542364,0.00026322753,0.0015527265],"category_scores_gemma":[0.00026386854,0.00012594517,0.00026792256,0.00014495122,0.0002559781,0.00019876518,0.0004310378,0.0007702689,0.00047847853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076189224,0.00015572303,0.0033231685,0.00012127525,0.000010584399,0.00023951,0.00016523676,0.0002021741,0.98891795,0.00034355832,0.00022994341,0.005528989],"study_design_scores_gemma":[0.0007974853,0.004845719,0.11553725,0.00010733579,0.00019372508,0.0028319668,0.0013978581,0.008254555,0.84018964,0.0013979641,0.02441262,0.000033909706],"about_ca_topic_score_codex":0.00014806363,"about_ca_topic_score_gemma":0.00029595147,"teacher_disagreement_score":0.0015527265,"about_ca_system_score_codex":0.00027342953,"about_ca_system_score_gemma":0.00032027476,"threshold_uncertainty_score":0.0051944256},"labels":[],"label_agreement":null},{"id":"W2954377994","doi":"10.1186/s40425-019-0640-y","title":"Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Ontario Institute for Cancer Research; Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Library science; Computer science; Psychology","score_opus":0.03021381831505963,"score_gpt":0.3515596864330823,"score_spread":0.3213458681180226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954377994","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000572788,0.0032744054,0.0004333966,0.13714322,0.85765386,0.000018275865,0.00026985482,0.00008721981,0.0010624813],"genre_scores_gemma":[0.0041369726,0.013175074,0.0017556706,0.21546333,0.721309,0.00015430935,0.0008696503,0.0006522548,0.04248373],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355,0.0014416262,0.0009421137,0.0007992417,0.0026128055,0.00065430487],"domain_scores_gemma":[0.9634658,0.010623826,0.0014922882,0.0013019551,0.020178637,0.0029374433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007186609,0.0020589288,0.0015024737,0.0026490553,0.0025673565,0.005222377,0.0029969737,0.0069501307,0.028814027],"category_scores_gemma":[0.07225895,0.00068038254,0.0017668449,0.0016013674,0.0024794245,0.0033647493,0.003331847,0.017746245,0.020150267],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015168968,0.0000018686347,0.000019309702,0.000059824346,0.0000039250176,0.00004620866,0.000020806374,0.000014729059,0.000018152783,0.00023107833,0.9968136,0.0027554904],"study_design_scores_gemma":[0.000017174621,0.000012622691,0.00019623621,0.0003807677,0.00001193376,0.0002504381,0.00005525308,0.000053642627,0.00008336373,0.0006170464,0.9983026,0.000018967798],"about_ca_topic_score_codex":0.007814277,"about_ca_topic_score_gemma":0.010948956,"teacher_disagreement_score":0.028814027,"about_ca_system_score_codex":0.0050674337,"about_ca_system_score_gemma":0.00809195,"threshold_uncertainty_score":0.09639251},"labels":[],"label_agreement":null},{"id":"W2956407203","doi":"10.1186/s40425-019-0673-2","title":"Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Hyundai Hope On Wheels; Mayo Clinic","keywords":"Medicine; Immunotherapy; Toxicity; Oncolytic virus; Immunology; Immune system; Brainstem; Cancer research; Internal medicine","score_opus":0.022841207930643707,"score_gpt":0.34046279427430043,"score_spread":0.3176215863436567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956407203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687959,0.0069283242,0.01979491,0.00021187238,0.00007693096,0.00025828613,0.00031537778,0.00026094547,0.0033574547],"genre_scores_gemma":[0.98635525,0.0039764084,0.008054988,0.00009252349,0.000013582088,0.00013346999,0.000320344,0.000030310435,0.001023086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000010127736,0.0000066687844,0.000019995834,0.000026932523,0.000024122848],"domain_scores_gemma":[0.9999521,0.000006797092,0.000015984602,0.000007504804,0.000006268448,0.000011366194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001497283,0.00053312315,0.00027106647,0.00034660602,0.00009464304,0.0002634148,0.0002747039,0.00030064702,0.00059739745],"category_scores_gemma":[0.00008122066,0.00008587519,0.00021121287,0.00017191429,0.00023491959,0.00024105805,0.00018763776,0.0006461944,0.00024524273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007793381,0.00011962513,0.00021251017,0.000121215446,0.000015437821,0.00006317535,0.000017852426,0.00061506574,0.9896243,0.0002705003,0.00013492364,0.008727372],"study_design_scores_gemma":[0.00007652849,0.00232221,0.0036158608,0.000032015996,0.00008380735,0.00092397747,0.000045220848,0.002266238,0.9831049,0.00025940512,0.0072618052,0.0000081080925],"about_ca_topic_score_codex":0.00024200292,"about_ca_topic_score_gemma":0.0007905972,"teacher_disagreement_score":0.00059739745,"about_ca_system_score_codex":0.0002812827,"about_ca_system_score_gemma":0.00024482334,"threshold_uncertainty_score":0.0020409226},"labels":[],"label_agreement":null},{"id":"W2958648554","doi":"10.1186/s40425-019-0662-5","title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":738,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institute for Health and Care Research; Cancer Research UK; Yale University; Society for Immunotherapy of Cancer; Università degli Studi di Milano; Brigham and Women's Hospital; Yale Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Pembrolizumab; Medicine; Nivolumab; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Immunotherapy; Cancer; Head and neck cancer; Population","score_opus":0.02314064955390921,"score_gpt":0.33343247864077485,"score_spread":0.31029182908686564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958648554","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034198319,0.30944094,0.010300687,0.3505876,0.16836455,0.0029060782,0.007953015,0.001528193,0.145499],"genre_scores_gemma":[0.021995312,0.44417024,0.03303759,0.227615,0.058984455,0.00875379,0.03698345,0.000975058,0.16748515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.989902,0.0030927723,0.000909292,0.00066228467,0.004283715,0.00114982],"domain_scores_gemma":[0.9817842,0.0015218101,0.0024721588,0.0006777036,0.010527342,0.0030167624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011357114,0.0018071642,0.0025172194,0.002422689,0.0017822464,0.0050309934,0.004121441,0.009889809,0.010928413],"category_scores_gemma":[0.0128998235,0.0008665551,0.0025148285,0.0033314326,0.0015237528,0.002489641,0.0049349214,0.013909526,0.014507146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009909927,0.00010635694,0.0003724275,0.0011900592,0.00007245432,0.000084718115,0.00006212976,0.00025612852,0.00083678396,0.0026077977,0.8801046,0.114207365],"study_design_scores_gemma":[0.000111785375,0.00012174932,0.0006203785,0.0010286702,0.00004833971,0.00023109757,0.000041119976,0.000116194955,0.00028175325,0.0012341946,0.9961457,0.000019086945],"about_ca_topic_score_codex":0.0055128075,"about_ca_topic_score_gemma":0.009769385,"teacher_disagreement_score":0.011357114,"about_ca_system_score_codex":0.004541694,"about_ca_system_score_gemma":0.023629395,"threshold_uncertainty_score":0.060062885},"labels":[],"label_agreement":null},{"id":"W2961644267","doi":"10.1186/s40425-019-0643-8","title":"Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer; Yale Cancer Center; Li Ka Shing Foundation; National Cancer Institute; National Institutes of Health; National Science Foundation; Yale University; AstraZeneca; Symphogen; Memorial Sloan-Kettering Cancer Center; National Center for Advancing Translational Sciences; Chugai Pharmaceutical","keywords":"Erlotinib; Infiltration (HVAC); Medicine; Immune system; Cancer research; Mutant; Lung; Oncology; Immunology; Internal medicine; Epidermal growth factor receptor; Biology; Receptor; Gene","score_opus":0.008928297133187109,"score_gpt":0.3020364498705301,"score_spread":0.293108152737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961644267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964173,0.00096538215,0.0010539851,0.00006987201,0.000033070988,0.00003324919,0.00021446431,0.00005655047,0.0011560939],"genre_scores_gemma":[0.9966658,0.00046350205,0.0010856878,0.0000535819,0.000026071903,0.000057692483,0.00028674322,0.00001394117,0.0013470361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982697,0.00003152669,0.000018307079,0.00002872737,0.00003764312,0.000056823752],"domain_scores_gemma":[0.9998647,0.00003054205,0.00003551803,0.000012588435,0.000012068565,0.000044579854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019997438,0.00035765892,0.00028765982,0.00023767697,0.000111878064,0.00025928207,0.00010054464,0.0002535951,0.0015069024],"category_scores_gemma":[0.00009653455,0.0001140669,0.00029724263,0.00013689151,0.00017349483,0.00021244794,0.00015845239,0.0008486705,0.00036073083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031693644,0.00008245952,0.00028127094,0.00003998419,0.0000033029517,0.00007535449,0.000013946864,0.000031344734,0.9982298,0.000033955406,0.000029844421,0.00086176535],"study_design_scores_gemma":[0.00005916983,0.0014831433,0.011910068,0.000011719667,0.000025948008,0.0005003308,0.00006154314,0.0009263428,0.98365384,0.00004602709,0.0013174149,0.0000044276885],"about_ca_topic_score_codex":0.00013147811,"about_ca_topic_score_gemma":0.0002683554,"teacher_disagreement_score":0.0015069024,"about_ca_system_score_codex":0.00018353782,"about_ca_system_score_gemma":0.00015859978,"threshold_uncertainty_score":0.005041063},"labels":[],"label_agreement":null},{"id":"W2961709931","doi":"10.1186/s40425-019-0641-x","title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Cancer Institute, University of Pittsburgh; National Cancer Institute; National Institutes of Health; Ovarian Cancer Research Fund Alliance; Roswell Park Cancer Institute; Ovarian Cancer Research Fund","keywords":"Oncolytic virus; Medicine; Tumor microenvironment; Ovarian cancer; Immunotherapy; Immune checkpoint; Immune system; Blockade; CD8; Cancer research; Cancer immunotherapy; Immunology; Adjuvant; Cancer; Internal medicine; Receptor","score_opus":0.016154443909586744,"score_gpt":0.3142447476610089,"score_spread":0.29809030375142215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961709931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840385,0.00046130948,0.00062124594,0.000031387353,0.0000104081,0.000014076827,0.00003609852,0.000026230546,0.00039550025],"genre_scores_gemma":[0.9989178,0.0001673903,0.00047581558,0.000009840739,0.000006095878,0.000014283276,0.000048171365,0.000004766001,0.0003559825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999372,0.00001096267,0.0000029580683,0.000011159864,0.000013978476,0.000023793296],"domain_scores_gemma":[0.9999511,0.000012547931,0.000009818242,0.0000072006833,0.0000045928045,0.000014675642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117905816,0.00015750623,0.00018859505,0.00018230105,0.00010079729,0.00019216428,0.000100017445,0.00017537613,0.0006072596],"category_scores_gemma":[0.00016626265,0.000096485135,0.00010441795,0.0001165699,0.00016766936,0.00013854614,0.000098169025,0.00043657966,0.000120580626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007315308,0.00019203027,0.0004673009,0.000026965012,0.000006618814,0.000039944774,0.000024557332,0.00035590338,0.99328786,0.000088795634,0.000056970126,0.004721479],"study_design_scores_gemma":[0.00015213425,0.0052426537,0.0092089875,0.000006381641,0.000045618777,0.00046257896,0.000039550607,0.007036096,0.97585416,0.00013357449,0.001811639,0.0000066376665],"about_ca_topic_score_codex":0.0004947272,"about_ca_topic_score_gemma":0.0006192137,"teacher_disagreement_score":0.0006072596,"about_ca_system_score_codex":0.00022417813,"about_ca_system_score_gemma":0.00017210619,"threshold_uncertainty_score":0.0020314455},"labels":[],"label_agreement":null},{"id":"W2967093625","doi":"10.1186/s40425-019-0700-3","title":"PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FujiFilm VisualSonics (Canada)","funders":"Leids Universitair Medisch Centrum; H2020 Marie Skłodowska-Curie Actions; KWF Kankerbestrijding; European Commission","keywords":"Tumor microenvironment; Immunotherapy; Cancer immunotherapy; Blockade; Immune system; Cancer research; Mass cytometry; Medicine; CD8; T cell; Immune checkpoint; Flow cytometry; In vivo; Colorectal cancer; Cancer; Immunology; Receptor; Biology; Internal medicine; Phenotype","score_opus":0.014173682057967981,"score_gpt":0.320614542574468,"score_spread":0.3064408605165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967093625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958584,0.0005991686,0.00181457,0.00009984,0.000015780193,0.000028119006,0.00014416406,0.00005850413,0.0013814965],"genre_scores_gemma":[0.9971878,0.00017200764,0.0013449861,0.000068700414,0.000013595425,0.000043147367,0.00013032225,0.000009299177,0.0010301088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984217,0.000020970101,0.000009218731,0.000027403377,0.00003122546,0.00006907187],"domain_scores_gemma":[0.99994934,0.000010806868,0.0000118274975,0.0000070334577,0.0000043626314,0.000016650281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001432779,0.0003498349,0.00020290684,0.00014080358,0.0001272392,0.00028012096,0.00013829983,0.0001984722,0.0016004972],"category_scores_gemma":[0.000064503074,0.000109413704,0.00017403398,0.000086308326,0.00017482316,0.00010794606,0.0001539355,0.0007957811,0.000339192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019939238,0.00009671225,0.000289917,0.000019441462,0.0000037626614,0.000023003771,0.00000899685,0.00011298971,0.9977549,0.00009612733,0.00007361179,0.0013211563],"study_design_scores_gemma":[0.0000681559,0.00070168875,0.0035619321,0.000004979295,0.000015128699,0.00025213443,0.000016522177,0.0018304636,0.99126655,0.00005528162,0.0022241522,0.0000028957124],"about_ca_topic_score_codex":0.00059368805,"about_ca_topic_score_gemma":0.0008893513,"teacher_disagreement_score":0.0016004972,"about_ca_system_score_codex":0.00035131484,"about_ca_system_score_gemma":0.0002578446,"threshold_uncertainty_score":0.0053542256},"labels":[],"label_agreement":null},{"id":"W2968230578","doi":"10.1186/s40425-019-0698-6","title":"Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Irving Medical Center, Columbia University; National Institute of Dental and Craniofacial Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Tumor microenvironment; Cancer research; Immune checkpoint; Immune system; Cytotoxic T cell; T cell; Immunology; Immunotherapy; Biology","score_opus":0.012831285176136567,"score_gpt":0.28629095324417336,"score_spread":0.2734596680680368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968230578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943421,0.0025377804,0.0015797846,0.00007526997,0.000035097884,0.000039881677,0.00005841823,0.00006113193,0.0012705364],"genre_scores_gemma":[0.99789727,0.0007574884,0.00079446286,0.00003294923,0.000024036866,0.000031224456,0.00007503599,0.0000061886044,0.00038132485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998882,0.000020971307,0.000008650944,0.000024094817,0.000021522234,0.000036406906],"domain_scores_gemma":[0.999913,0.000023636061,0.00002633049,0.000012327148,0.000005285332,0.000019435985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016828474,0.0003045869,0.00027832747,0.00018331833,0.00006981482,0.00019961242,0.00021532152,0.00023367394,0.0011502742],"category_scores_gemma":[0.00013628056,0.00007008879,0.00021655169,0.00008512136,0.0002444143,0.00023572259,0.00016659495,0.00057396747,0.00013451836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009916691,0.00029107236,0.00069143565,0.00009292884,0.000020656673,0.000051441504,0.000013585647,0.000566293,0.98617816,0.0002072304,0.000058507732,0.010836977],"study_design_scores_gemma":[0.00017644966,0.007874184,0.005469423,0.000017095848,0.00008911429,0.00040214616,0.000019229668,0.0013783928,0.98182356,0.00008807078,0.0026574628,0.0000047940525],"about_ca_topic_score_codex":0.00009339755,"about_ca_topic_score_gemma":0.00018630462,"teacher_disagreement_score":0.0011502742,"about_ca_system_score_codex":0.00015823345,"about_ca_system_score_gemma":0.00021968363,"threshold_uncertainty_score":0.0038480759},"labels":[],"label_agreement":null},{"id":"W2973724679","doi":"10.1186/s40425-019-0734-6","title":"Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Qatar National Research Fund; Istituto Oncologico Veneto; Fondazione Italiana per la Ricerca sul Cancro; Università degli Studi di Verona; Università Cattolica del Sacro Cuore; Università degli Studi di Padova; Cancer Research Institute; Fondazione Italiana per la ricerca sulle Malattie del Pancreas; EuroNanoMed III; Associazione Italiana per la Ricerca sul Cancro; Agence Nationale de la Recherche","keywords":"CD14; Myeloid-derived Suppressor Cell; Immunosuppression; Medicine; Immune system; Cancer research; Myeloid; Flow cytometry; STAT3; Immunology; CD16; Suppressor; Biology; Internal medicine; Cancer; Apoptosis","score_opus":0.005649180257663867,"score_gpt":0.23961331054345023,"score_spread":0.23396413028578636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973724679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924964,0.0003563853,0.00006521939,0.000022924354,0.0000026641744,0.000004112612,0.00007780693,0.0000056525605,0.00021564221],"genre_scores_gemma":[0.99967134,0.00008655072,0.000057169556,0.000010813955,0.000006333245,0.0000034178236,0.000107236985,0.0000011717237,0.000055838245],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989796,0.000021618325,0.000010565109,0.000026774693,0.000021492846,0.000021633668],"domain_scores_gemma":[0.9998011,0.000044460856,0.00007893802,0.000013601084,0.000017191956,0.000044836837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015939373,0.00015734711,0.0002677178,0.0003338916,0.00027772973,0.00026774357,0.00010397679,0.00015682602,0.0008966471],"category_scores_gemma":[0.00036499745,0.00010167994,0.00014777067,0.00038748627,0.0001485569,0.00016022436,0.00016177702,0.00028502676,0.0001227867],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015904988,0.00007423728,0.9706147,0.000033130396,0.00003632903,0.00089640426,0.00012959131,0.00010857974,0.01646032,0.00004390082,0.00023137516,0.009780863],"study_design_scores_gemma":[0.000032056254,0.00037907457,0.9939194,0.0000074212253,0.00004894852,0.0027832198,0.00012011109,0.0003185787,0.0017343708,0.00006419238,0.0005888479,0.000003705038],"about_ca_topic_score_codex":0.0002815204,"about_ca_topic_score_gemma":0.000467815,"teacher_disagreement_score":0.0008966471,"about_ca_system_score_codex":0.00016345583,"about_ca_system_score_gemma":0.00016140168,"threshold_uncertainty_score":0.0029995441},"labels":[],"label_agreement":null},{"id":"W2981595408","doi":"10.1186/s40425-019-0762-2","title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Eisai; Servier; Amgen; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company; Eurostars; GlaxoSmithKline","keywords":"Medicine; T cell; Immunology; Fludarabine; Tumor microenvironment; Progressive disease; Synovial sarcoma; Cytotoxic T cell; Immune system; Cancer research; Internal medicine; Pathology; Sarcoma; Biology; Disease; Chemotherapy","score_opus":0.018535859971319776,"score_gpt":0.3255511113769634,"score_spread":0.3070152514056436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981595408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941945,0.00014821878,0.00015030873,0.000011635528,0.000005415706,0.00001385424,0.000028227794,0.000009555647,0.0002134153],"genre_scores_gemma":[0.9994355,0.00007825813,0.000110835856,0.000020206318,0.000008473102,0.000017935523,0.0000930958,0.0000027467006,0.00023291435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998747,0.000029520796,0.000009058523,0.000024183537,0.00002479401,0.00003766194],"domain_scores_gemma":[0.99988115,0.000023524199,0.00002698668,0.000015977892,0.0000064046317,0.000045929974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021629148,0.00022970789,0.00033420496,0.0001393574,0.00010059537,0.00016463775,0.000107881955,0.00015671241,0.0006482766],"category_scores_gemma":[0.00018799253,0.00009354417,0.00018393411,0.000098855904,0.0002139918,0.00014930443,0.00015756903,0.0004849665,0.00017136145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011510734,0.0025837747,0.014624357,0.00010383191,0.00005811337,0.0005418268,0.00019529626,0.0013771591,0.9300939,0.0001034563,0.00045218246,0.038355503],"study_design_scores_gemma":[0.0017987012,0.14307064,0.21944879,0.00003221348,0.00032533932,0.0038811765,0.00044054972,0.006317065,0.6208394,0.00026132603,0.003554866,0.00002982566],"about_ca_topic_score_codex":0.00028451442,"about_ca_topic_score_gemma":0.0004487594,"teacher_disagreement_score":0.0006482766,"about_ca_system_score_codex":0.00015931365,"about_ca_system_score_gemma":0.00015836312,"threshold_uncertainty_score":0.0021687746},"labels":[],"label_agreement":null},{"id":"W2991173919","doi":"10.1186/s40425-019-0783-x","title":"Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Chemotherapy Foundation; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Blockade; Medicine; Concomitant; Immunotherapy; Oncology; Cyclophosphamide; Immune system; Doxorubicin; Radiation therapy; Internal medicine; Cisplatin; Clinical trial; Chemotherapy; Immunology; Receptor","score_opus":0.04260303808485426,"score_gpt":0.39823958657665026,"score_spread":0.355636548491796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991173919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00996988,0.015453651,0.0018285129,0.945966,0.016094476,0.00010503171,0.00016747596,0.00012529979,0.010289649],"genre_scores_gemma":[0.071281664,0.011353319,0.0038172302,0.87418795,0.029725926,0.00029893956,0.00019150841,0.00008286855,0.009060577],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779165,0.0013154335,0.00020098357,0.00017912334,0.00035234814,0.00016047938],"domain_scores_gemma":[0.98762965,0.009242618,0.00047200816,0.00049947103,0.0011409681,0.0010153445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007412814,0.0003923968,0.00068305404,0.00028644878,0.0006614386,0.001629263,0.00073235086,0.00625604,0.0025892474],"category_scores_gemma":[0.016650809,0.00017916049,0.00062002684,0.00023646386,0.0013478628,0.0021973983,0.0007362131,0.009519571,0.001399429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029911539,0.0005280946,0.0028647024,0.00060838094,0.0001841383,0.0023661545,0.00019695767,0.000639063,0.0027612306,0.022127183,0.61383045,0.3509025],"study_design_scores_gemma":[0.0058680065,0.0033815608,0.0035040888,0.0008786293,0.00020141083,0.0028784194,0.00021320953,0.002177356,0.0027207804,0.04236086,0.9357244,0.000091218455],"about_ca_topic_score_codex":0.00043694564,"about_ca_topic_score_gemma":0.0013627354,"teacher_disagreement_score":0.007412814,"about_ca_system_score_codex":0.0016545611,"about_ca_system_score_gemma":0.0012426871,"threshold_uncertainty_score":0.039203227},"labels":[],"label_agreement":null},{"id":"W2992570001","doi":"10.1186/s40425-019-0559-3","title":"Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2019,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Pazopanib; Sunitinib; Nivolumab; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.02364807024486524,"score_gpt":0.32243165102808974,"score_spread":0.2987835807832245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992570001","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019238437,0.00097122975,0.00037395582,0.0637272,0.9315496,0.00003184805,0.00097109354,0.00017548096,0.0020071648],"genre_scores_gemma":[0.014537254,0.0076263333,0.0037671158,0.17962338,0.6452239,0.00026131442,0.0030160346,0.0010502517,0.14489442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958554,0.0007817232,0.00091188453,0.0004663762,0.0015955762,0.00038913416],"domain_scores_gemma":[0.9744125,0.006966953,0.0014778585,0.0009910061,0.014563771,0.0015879016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049614,0.002038815,0.0018768455,0.002441528,0.0018496924,0.0032123087,0.0026550817,0.0063488316,0.029218389],"category_scores_gemma":[0.052417677,0.0009347902,0.0018522139,0.0014243537,0.0012384475,0.0014197783,0.000980977,0.0090840375,0.015939672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042558313,0.0000065584118,0.00007580851,0.00008441861,0.000011515158,0.00015117384,0.000010892377,0.0000231582,0.00002401348,0.00016946028,0.99598265,0.0034177396],"study_design_scores_gemma":[0.00022811808,0.00006183304,0.0016251397,0.0008216195,0.00009247425,0.0011043295,0.000064254185,0.00039828385,0.0003227447,0.00095745816,0.9942684,0.000055374836],"about_ca_topic_score_codex":0.017016612,"about_ca_topic_score_gemma":0.020955328,"teacher_disagreement_score":0.029218389,"about_ca_system_score_codex":0.0037712909,"about_ca_system_score_gemma":0.0047723046,"threshold_uncertainty_score":0.09774518},"labels":[],"label_agreement":null},{"id":"W2995191565","doi":"10.1186/s40425-019-0777-8","title":"Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Immunotherapy; Cancer research; CD8; Immune system; Immunology; Cancer; Cancer immunotherapy; Medicine; Interleukin 15; Leukemia; Cytotoxic T cell; Cancer cell; Interleukin 2; Cytokine; Interleukin; Biology; Internal medicine","score_opus":0.03037206175191861,"score_gpt":0.31059204252489875,"score_spread":0.28021998077298016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995191565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991002,0.001764425,0.0044822833,0.00028645876,0.00015095662,0.00021478784,0.0006489125,0.0002110807,0.0012391469],"genre_scores_gemma":[0.9867921,0.0013662163,0.008168301,0.00012184614,0.000043485164,0.00024562175,0.0005912835,0.00004413497,0.002626973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996549,0.000059869755,0.00004941726,0.000078103796,0.000079206446,0.00007844285],"domain_scores_gemma":[0.999801,0.000022851764,0.00006982031,0.000024708319,0.000011824671,0.00006981039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028816515,0.000778817,0.0005443619,0.0005662059,0.00017384939,0.0005630562,0.00043127267,0.0008527677,0.0011795795],"category_scores_gemma":[0.00011305711,0.00019675137,0.0004999314,0.00034457303,0.0005356771,0.0005241035,0.0003037966,0.0018505212,0.00045421007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008080028,0.0004099925,0.00014837053,0.000077791956,0.0000111743675,0.0000538066,0.00003503874,0.00033029576,0.9963475,0.00031108683,0.00005545513,0.001411465],"study_design_scores_gemma":[0.0001358746,0.0036574027,0.00065594754,0.000009819003,0.000032494387,0.00022290627,0.000019654972,0.0013576737,0.99211484,0.000058911606,0.001728462,0.0000059446493],"about_ca_topic_score_codex":0.0007510082,"about_ca_topic_score_gemma":0.0007165543,"teacher_disagreement_score":0.0011795795,"about_ca_system_score_codex":0.0005399264,"about_ca_system_score_gemma":0.00043429193,"threshold_uncertainty_score":0.003946066},"labels":[],"label_agreement":null},{"id":"W2997299711","doi":"10.1186/s40425-019-0816-5","title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Stromal cell; Tumor microenvironment; Immune system; Cancer research; Immune checkpoint; Biology; Granzyme B; Ovarian cancer; CD8; Immunology; Cancer; Immunotherapy","score_opus":0.014381859020029834,"score_gpt":0.28372799322185854,"score_spread":0.26934613420182874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997299711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805814,0.00049800734,0.00046304293,0.000017951828,0.000001992752,0.000010639922,0.00013620684,0.00001533394,0.00079852634],"genre_scores_gemma":[0.9987884,0.00016189854,0.0003879465,0.000025882577,0.0000045523157,0.000020281437,0.0002463759,0.0000068197196,0.00035781233],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998797,0.00001521882,0.000010961507,0.000028276905,0.000027234744,0.00003868402],"domain_scores_gemma":[0.999881,0.000020015246,0.000036557118,0.00001035382,0.000012899578,0.000039157276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009938683,0.000089807705,0.000114836635,0.00046997063,0.00019264879,0.0002876291,0.000074020456,0.00016862397,0.0019626652],"category_scores_gemma":[0.00012675468,0.00009932695,0.00010269551,0.00024118702,0.00025710915,0.00012298883,0.00019559335,0.00019315165,0.0002473477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006376307,0.00005122647,0.050322816,0.00005613163,0.000016822283,0.00029619868,0.00009987563,0.00006801547,0.94466627,0.00016236975,0.00010271479,0.0035200207],"study_design_scores_gemma":[0.00006139148,0.00036011066,0.6704769,0.000014973819,0.000045148245,0.004206514,0.0006261895,0.0013849234,0.31912884,0.00028566917,0.0033976329,0.00001163526],"about_ca_topic_score_codex":0.00078375125,"about_ca_topic_score_gemma":0.0008868382,"teacher_disagreement_score":0.0019626652,"about_ca_system_score_codex":0.00019358529,"about_ca_system_score_gemma":0.00014862716,"threshold_uncertainty_score":0.0065657496},"labels":[],"label_agreement":null},{"id":"W3006887831","doi":"10.1136/jitc-2019-000186","title":"On the mechanism of anti-CD39 immune checkpoint therapy","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Institute of Cancer Research; Terry Fox Research Institute","keywords":"Adenosinergic; Medicine; Immunotherapy; Adenosine; Mechanism of action; Cancer immunotherapy; Regulator; Adenosine receptor; Immune system; Targeted therapy; Pharmacology; Immunology; Cancer; Receptor; Cancer research; Biology; Internal medicine; In vitro; Gene","score_opus":0.03803198016739658,"score_gpt":0.34506916345052707,"score_spread":0.3070371832831305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006887831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030387595,0.9959925,0.0002032921,0.00055487873,0.00059282215,0.000009459982,0.000022373022,0.000010099797,0.002310715],"genre_scores_gemma":[0.0013821621,0.9958034,0.00016863443,0.0005921319,0.00033157913,0.000013550602,0.000030571195,0.0000016430345,0.0016763564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989414,0.000017910774,0.000011942781,0.000019448858,0.000040846004,0.000015689016],"domain_scores_gemma":[0.99992836,0.000029132943,0.000010292689,0.0000025146412,0.000020723546,0.000008961619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036083112,0.0006060659,0.0008515072,0.0011748234,0.00022886122,0.0007839077,0.0007243793,0.0009840108,0.0030984269],"category_scores_gemma":[0.00025321214,0.00021588191,0.00041380656,0.0008729967,0.00036333004,0.0010028955,0.00044641068,0.0020391073,0.0019729186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013270185,0.000093518276,0.00010710876,0.010727862,0.00007022984,0.00039033534,0.00006137929,0.0006027704,0.005949179,0.011665386,0.042477433,0.9277222],"study_design_scores_gemma":[0.000029623661,0.00012558763,0.0004557962,0.0018218681,0.000049365353,0.0010566864,0.000023803372,0.0001297576,0.0009351724,0.0026524474,0.99270827,0.0000115784],"about_ca_topic_score_codex":0.00048067738,"about_ca_topic_score_gemma":0.0010030656,"teacher_disagreement_score":0.0030984269,"about_ca_system_score_codex":0.0006383762,"about_ca_system_score_gemma":0.0007275327,"threshold_uncertainty_score":0.010365248},"labels":[],"label_agreement":null},{"id":"W3011282656","doi":"10.1136/jitc-2019-000282","title":"Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University; Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Institute of Diabetes and Digestive and Kidney Diseases; American Cancer Society; Vanderbilt University Medical Center; Vanderbilt University; Stand Up To Cancer; National Cancer Institute; Entertainment Industry Foundation; National Science Foundation; Canadian Institutes of Health Research; Alex's Lemonade Stand Foundation for Childhood Cancer; Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center; American Association for Cancer Research; National Institutes of Health","keywords":"Sting; Stimulator of interferon genes; Cancer research; Neuroblastoma; Immunogenic cell death; Immunotherapy; CD8; Programmed cell death; T cell; Cancer immunotherapy; Medicine; Apoptosis; Blockade; Interferon; Immune checkpoint; Immunogenicity; Immune system; Cell cycle checkpoint; Immunology; Biology; Cell cycle; Cell culture; Cancer; Innate immune system; Receptor; Internal medicine","score_opus":0.022959950127284797,"score_gpt":0.32842297215300525,"score_spread":0.30546302202572045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011282656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593866,0.0008827776,0.0022098518,0.000028794713,0.000012389093,0.000026142257,0.00009821655,0.000021729524,0.00078155595],"genre_scores_gemma":[0.996296,0.0006614901,0.002038981,0.000021450047,0.0000063688326,0.000032795684,0.00011551326,0.0000046478517,0.0008228068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999471,0.000007923666,0.000004972359,0.000009480077,0.000019294848,0.000011188354],"domain_scores_gemma":[0.999972,0.000006161972,0.000008365812,0.000003180617,0.0000042804127,0.000005979284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009119653,0.00019426094,0.0001356352,0.00008292876,0.000055891585,0.00010679444,0.00008375953,0.00012848806,0.00076003914],"category_scores_gemma":[0.000047407248,0.000053743814,0.00014084374,0.00006277524,0.00010549595,0.00011676191,0.00009707865,0.00029615778,0.00011850604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027751408,0.0000104221135,0.000053379208,0.000021902542,9.771289e-7,0.000012604205,0.0000065954355,0.000049928054,0.99934393,0.00002582885,0.000008987833,0.0004376928],"study_design_scores_gemma":[0.000008440739,0.00027955702,0.0011033422,0.0000036810632,0.0000044480125,0.000079046404,0.000008216402,0.0006397775,0.9971385,0.0000149643865,0.0007190606,0.0000010662216],"about_ca_topic_score_codex":0.00019525479,"about_ca_topic_score_gemma":0.00040323738,"teacher_disagreement_score":0.00076003914,"about_ca_system_score_codex":0.00017429603,"about_ca_system_score_gemma":0.000110374,"threshold_uncertainty_score":0.002542615},"labels":[],"label_agreement":null},{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","score_opus":0.021021986374473327,"score_gpt":0.3722325480268819,"score_spread":0.35121056165240855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011361209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996062,0.00073943025,0.0005123816,0.00025809134,0.000049038004,0.0011781956,0.0004337815,0.000057237103,0.0007099414],"genre_scores_gemma":[0.9921217,0.0007037473,0.0020586338,0.0006996525,0.00011704829,0.0013569329,0.0015908467,0.000025723797,0.0013256456],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957865,0.000190298,0.000020343316,0.00007437969,0.000047736292,0.0000885515],"domain_scores_gemma":[0.9993261,0.00012471172,0.00011377255,0.00006836069,0.000050658928,0.00031649543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016780277,0.001460201,0.001528732,0.00039239172,0.00041387792,0.0006902326,0.0006443501,0.0008763353,0.0025565384],"category_scores_gemma":[0.00088568253,0.00055975147,0.0010169632,0.00031432227,0.000774541,0.00068052486,0.0003307349,0.003491574,0.00068410323],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45406735,0.2262675,0.02059254,0.0010547814,0.001424893,0.0006918402,0.0008945968,0.0057353983,0.11204125,0.00035652742,0.0073688417,0.16950448],"study_design_scores_gemma":[0.37893343,0.59143317,0.018094987,0.00002268703,0.0002659811,0.00047113397,0.000042989075,0.0015121083,0.0058093173,0.00019593745,0.00318945,0.000028757562],"about_ca_topic_score_codex":0.00060897577,"about_ca_topic_score_gemma":0.001071094,"teacher_disagreement_score":0.0025565384,"about_ca_system_score_codex":0.0008663404,"about_ca_system_score_gemma":0.0014002656,"threshold_uncertainty_score":0.008874416},"labels":[],"label_agreement":null},{"id":"W3011642937","doi":"10.1136/jitc-2019-000337","title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1061,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"National Institute of General Medical Sciences; Associazione Italiana per la Ricerca sul Cancro; Rosetrees Trust; National Institute for Health and Care Research; Compagnia di San Paolo; National Cancer Institute; Cancer Research UK; Weill Cornell Medical College; U.S. Department of Defense","keywords":"Acquired immune system; Immune system; Programmed cell death; Immunogenic cell death; Antigenicity; Immunology; Medicine; Computer science; Biology; Antigen; Immunotherapy; Apoptosis","score_opus":0.10250403975799036,"score_gpt":0.38873547545808607,"score_spread":0.2862314357000957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011642937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016856389,0.97110915,0.005809102,0.00925325,0.006271072,0.00020568848,0.00040748058,0.00013500963,0.0066407127],"genre_scores_gemma":[0.0018145097,0.9660817,0.016236149,0.0067054555,0.0025897285,0.0005087176,0.0011084616,0.0000549359,0.0049003894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99586946,0.0010162449,0.001122992,0.0003751587,0.0014017827,0.00021430652],"domain_scores_gemma":[0.9915645,0.0035076684,0.00088750565,0.00039238844,0.0032657124,0.00038217803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010063131,0.0018213729,0.0025652593,0.0060524913,0.00076495105,0.0027053594,0.004641632,0.004501206,0.0067253336],"category_scores_gemma":[0.01143872,0.00071662257,0.0022587928,0.0036775651,0.0021343436,0.0031014802,0.0021607184,0.005543126,0.0060913432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012351871,0.00010362625,0.00028783723,0.02947993,0.00017407785,0.00043350397,0.00025013267,0.00051372225,0.0021322314,0.026031852,0.21456118,0.7259083],"study_design_scores_gemma":[0.000020386133,0.00004895559,0.00029534756,0.009770341,0.00013259763,0.000880503,0.0000736178,0.000078727244,0.00052791194,0.005808486,0.9823308,0.00003220838],"about_ca_topic_score_codex":0.0024563111,"about_ca_topic_score_gemma":0.002794253,"teacher_disagreement_score":0.010063131,"about_ca_system_score_codex":0.002526477,"about_ca_system_score_gemma":0.007920339,"threshold_uncertainty_score":0.053219557},"labels":[],"label_agreement":null},{"id":"W3015097837","doi":"10.1136/jitc-2019-000371","title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Incidence (geometry); Cumulative incidence; Renal cell carcinoma; Cancer; Cohort; Oncology","score_opus":0.014567779285653172,"score_gpt":0.2799380632421677,"score_spread":0.2653702839565145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015097837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974033,0.0009946391,0.00022700994,0.000055052846,0.000007046924,0.000018030236,0.0004658757,0.0000075673443,0.00082148035],"genre_scores_gemma":[0.99925774,0.00015766622,0.00006875025,0.000021512089,0.000013015107,0.000007818672,0.00039895126,0.0000017801497,0.000072834584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937904,0.00012793542,0.000094473035,0.000119463155,0.00018095101,0.000098131546],"domain_scores_gemma":[0.9962412,0.00052872463,0.0024563733,0.000138892,0.0002800261,0.00035478867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082280184,0.00012077315,0.00034591823,0.0005189397,0.00024997527,0.0005102601,0.00024176974,0.00021302074,0.0012062048],"category_scores_gemma":[0.0038523797,0.00010290019,0.0005726374,0.00082404463,0.00017078304,0.00029798318,0.00038939036,0.00048560137,0.0001368286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018779875,0.000014272805,0.99738616,0.000014538732,0.00004394229,0.00013420667,0.000013834231,0.00011921583,0.00011792091,0.000019034174,0.00008363016,0.0018655271],"study_design_scores_gemma":[0.000011575125,0.00014125199,0.997996,0.000005653734,0.000044945333,0.001026421,0.000023460552,0.0003386353,0.000090247515,0.00002905264,0.0002892099,0.0000036301687],"about_ca_topic_score_codex":0.0013330748,"about_ca_topic_score_gemma":0.0013213331,"teacher_disagreement_score":0.0013330748,"about_ca_system_score_codex":0.00047655858,"about_ca_system_score_gemma":0.0004068406,"threshold_uncertainty_score":0.004351437},"labels":[],"label_agreement":null},{"id":"W3015555708","doi":"10.1136/jitc-2019-000313","title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck KGaA; Pfizer","keywords":"Avelumab; Merkel cell carcinoma; Medicine; Expanded access; Merkel cell polyomavirus; Progressive disease; Merkel cell; Internal medicine; Oncology; Clinical trial; Chemotherapy; Carcinoma; Immunotherapy; Cancer; Nivolumab","score_opus":0.024885778206527105,"score_gpt":0.3496780509239403,"score_spread":0.3247922727174132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015555708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933469,0.0042596664,0.0004132892,0.0002446383,0.000009636844,0.00005570528,0.00010356691,0.000016608057,0.0015499669],"genre_scores_gemma":[0.9968779,0.0016699584,0.00047664213,0.0002501642,0.00006458942,0.000034146447,0.00029131467,0.000008909128,0.00032633785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996264,0.00019497082,0.000025600302,0.000046976813,0.000057581896,0.0000484196],"domain_scores_gemma":[0.99910176,0.00032538708,0.00019724735,0.00005485296,0.00006081127,0.00025988204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013339677,0.0002391039,0.00032074776,0.00013915756,0.00020758044,0.00041449373,0.00020460131,0.00020823126,0.000983492],"category_scores_gemma":[0.0013035999,0.00007370111,0.00028557537,0.0002336617,0.00031604947,0.00037185824,0.00030962654,0.0005841216,0.00019930261],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03046205,0.008219473,0.24796894,0.0005416927,0.00082397414,0.0032265368,0.0019778972,0.0027482468,0.04248637,0.0004506866,0.0047735265,0.6563206],"study_design_scores_gemma":[0.021851469,0.19352855,0.7015995,0.00029413513,0.000859186,0.018857809,0.0006590215,0.003341098,0.021239577,0.00044429177,0.037243865,0.00008143252],"about_ca_topic_score_codex":0.00028908093,"about_ca_topic_score_gemma":0.0004640867,"teacher_disagreement_score":0.0013339677,"about_ca_system_score_codex":0.00044093252,"about_ca_system_score_gemma":0.00028461398,"threshold_uncertainty_score":0.007054746},"labels":[],"label_agreement":null},{"id":"W3017204401","doi":"10.1136/jitc-2019-000323","title":"Immune involvement of the contralateral hemisphere in a glioblastoma mouse model","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"H2020 European Research Council; Amsterdam University Medical Centers; Vanderbilt University Medical Center","keywords":"Immune system; Immunotherapy; Cancer research; Brain tumor; CD8; Myeloid; Immune checkpoint; Medicine; Immunology; Antigen; T cell; Glioma; Biology; Pathology","score_opus":0.02062743560339773,"score_gpt":0.2963018037683911,"score_spread":0.27567436816499336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017204401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685741,0.004222977,0.01517573,0.0005026899,0.0002862074,0.0003756081,0.0041871136,0.0010176199,0.0056580207],"genre_scores_gemma":[0.9684029,0.0028952498,0.011030462,0.00037618945,0.0000685169,0.00065010897,0.00343259,0.00024611768,0.012897823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966264,0.000021977185,0.00002252979,0.000116876836,0.00009574646,0.000080327125],"domain_scores_gemma":[0.9997632,0.000009278674,0.000096286385,0.00002557974,0.000027086371,0.00007862151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025703045,0.0018184278,0.0004953789,0.0019253157,0.00033325842,0.00053223537,0.0003978564,0.0006971041,0.0029142282],"category_scores_gemma":[0.00007203653,0.00034813877,0.00068146456,0.000379104,0.0006842209,0.0005098466,0.00045860352,0.00121603,0.00088193465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035569372,0.00018545025,0.00032897544,0.00009723763,0.000017401157,0.00032873082,0.000029647403,0.00009016885,0.9963456,0.00028382856,0.00021137738,0.0017258142],"study_design_scores_gemma":[0.00014860854,0.002889263,0.010365989,0.000068103705,0.00019204525,0.003170414,0.00012157135,0.0018180615,0.9724347,0.0004956638,0.008263735,0.00003173729],"about_ca_topic_score_codex":0.0010501407,"about_ca_topic_score_gemma":0.0016560347,"teacher_disagreement_score":0.0029142282,"about_ca_system_score_codex":0.0005276539,"about_ca_system_score_gemma":0.0005177694,"threshold_uncertainty_score":0.009749055},"labels":[],"label_agreement":null},{"id":"W3034105569","doi":"10.1136/jitc-2019-000266","title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Israel Science Foundation; Hebrew University of Jerusalem; Centre in Green Chemistry and Catalysis; Israel Cancer Research Fund","keywords":"TIGIT; Cancer research; Medicine; Computational biology; Computer science; Internal medicine; Biology; Immunotherapy; Cancer","score_opus":0.026157666394454025,"score_gpt":0.2801342962558834,"score_spread":0.2539766298614293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034105569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436474,0.023344046,0.019631697,0.00092787115,0.00019325007,0.00018197396,0.00041382018,0.00038233952,0.011277566],"genre_scores_gemma":[0.9661483,0.005003535,0.02089062,0.00047112507,0.00006871182,0.00011225228,0.0010544377,0.000033324097,0.006217562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998764,0.000025937474,0.000009098608,0.000027676519,0.000030414138,0.00003054217],"domain_scores_gemma":[0.9999435,0.000006871097,0.000013797644,0.0000054181473,0.000009557421,0.000020793308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014117463,0.0004896099,0.00025536286,0.00024495763,0.00019977521,0.0003145492,0.00044515755,0.0005762527,0.0012941153],"category_scores_gemma":[0.0001307132,0.000102353806,0.00026723658,0.00018297185,0.0002070051,0.00027966066,0.00034436976,0.0004782847,0.00040086455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094766045,0.000053778676,0.00047743632,0.00007958236,0.000016255923,0.00018066877,0.0000104912,0.00040774714,0.9904517,0.00038051239,0.00030128393,0.00754573],"study_design_scores_gemma":[0.000087118446,0.0011553636,0.0027991459,0.000024821036,0.00006134244,0.004408065,0.000021767963,0.0027452933,0.96132195,0.00023729696,0.027120959,0.000016957174],"about_ca_topic_score_codex":0.00040187142,"about_ca_topic_score_gemma":0.0006561023,"teacher_disagreement_score":0.0012941153,"about_ca_system_score_codex":0.0007537367,"about_ca_system_score_gemma":0.0003172498,"threshold_uncertainty_score":0.005468726},"labels":[],"label_agreement":null},{"id":"W3036508677","doi":"10.1136/jitc-2020-000840","title":"Chronic immune checkpoint inhibitor pneumonitis","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Pneumonitis; Immunosuppression; Hypersensitivity pneumonitis; Internal medicine; Bronchoalveolar lavage; Immunology; Gastroenterology; Lung","score_opus":0.024502063692747628,"score_gpt":0.3195411143344083,"score_spread":0.2950390506416607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036508677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97963595,0.010267396,0.0007111939,0.00025625748,0.000028470444,0.000110980814,0.0011571725,0.00003995564,0.0077926307],"genre_scores_gemma":[0.997349,0.0009497335,0.00021746094,0.000120721685,0.00005867687,0.000021682323,0.0007651436,0.0000027570557,0.0005146876],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99953353,0.0000618784,0.00009908474,0.000096916534,0.00010710447,0.0001014542],"domain_scores_gemma":[0.9984664,0.00015212643,0.001032043,0.00005411416,0.00011946725,0.00017581042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004092104,0.0001774696,0.0003452185,0.00036595162,0.00029589474,0.0004942677,0.00020840028,0.00021806383,0.0032814606],"category_scores_gemma":[0.0007927812,0.00008433409,0.00026552455,0.0004953688,0.00019295892,0.00028373752,0.00030004056,0.00029493435,0.00039093205],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022283247,0.00005456528,0.9824516,0.00013645244,0.00006967182,0.0017217452,0.000035174533,0.000055180735,0.0012923942,0.0000806261,0.0006972962,0.013182384],"study_design_scores_gemma":[0.00006631569,0.00054767414,0.95535433,0.00014079124,0.00010448935,0.03439927,0.00011597395,0.0004979202,0.0013074748,0.00010602131,0.007352754,0.000007042764],"about_ca_topic_score_codex":0.00077631924,"about_ca_topic_score_gemma":0.0012313179,"teacher_disagreement_score":0.0032814606,"about_ca_system_score_codex":0.0003128233,"about_ca_system_score_gemma":0.0003708277,"threshold_uncertainty_score":0.010977626},"labels":[],"label_agreement":null},{"id":"W3037575240","doi":"10.1136/jitc-2019-000467","title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"University Health Network","keywords":"Medicine; Acute kidney injury; Internal medicine; Creatinine; Incidence (geometry); Kidney disease; Adverse effect; Cancer; Gastroenterology; Oncology","score_opus":0.017823289581633112,"score_gpt":0.3066846269328215,"score_spread":0.2888613373511884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037575240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934156,0.0037396548,0.00023105618,0.00017566099,0.000016433152,0.000033547454,0.001513805,0.000009272511,0.00086500234],"genre_scores_gemma":[0.9979602,0.0007872102,0.00011226252,0.00004742609,0.000046616737,0.000019547411,0.0009528587,0.0000018084943,0.00007213155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992218,0.00014191025,0.00013366675,0.0001747648,0.0001972214,0.00013065907],"domain_scores_gemma":[0.9962658,0.0003146944,0.0027936324,0.00010048975,0.00022811054,0.0002971422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008450179,0.00020722706,0.00045182413,0.0008623156,0.0002792905,0.00068126334,0.0002998807,0.00028379893,0.0011830408],"category_scores_gemma":[0.0022875944,0.0001567426,0.0004906537,0.0019578564,0.00022219782,0.0004750664,0.000505969,0.00064162334,0.00015822696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012054067,0.000031355736,0.9981079,0.000032471467,0.00007270139,0.00003183233,0.00000815785,0.000034345703,0.000034744462,0.000011695437,0.000100124234,0.0014141375],"study_design_scores_gemma":[0.000013462866,0.00009849751,0.9988391,0.00002914737,0.00006372428,0.0004053467,0.00003565191,0.00021441246,0.000054101383,0.000038733007,0.00020490719,0.0000029249995],"about_ca_topic_score_codex":0.0016621866,"about_ca_topic_score_gemma":0.0015980835,"teacher_disagreement_score":0.0016621866,"about_ca_system_score_codex":0.0004945662,"about_ca_system_score_gemma":0.0005314468,"threshold_uncertainty_score":0.004468918},"labels":[],"label_agreement":null},{"id":"W3039466405","doi":"10.1136/jitc-2020-001119","title":"BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune responses and vaccinations","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Ontario Ministry of Research, Innovation and Science; Queen's University","keywords":"Medicine; Vaccination; Immunotherapy; Immunology; Blockade; Immunity; Immune checkpoint; Tuberculosis; Pandemic; Immune system; Intensive care medicine; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.04891834536234258,"score_gpt":0.413397048402426,"score_spread":0.36447870304008345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039466405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047381724,0.9980883,0.00005929797,0.0008644783,0.00054048887,0.0000021735414,0.0000061065775,0.0000033414024,0.00038838247],"genre_scores_gemma":[0.00045897445,0.99749917,0.00012356235,0.0006680342,0.0006753414,0.000006382602,0.000015089539,0.0000013557965,0.0005520237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974495,0.00006827739,0.000029424806,0.0000361835,0.00008852662,0.000032589556],"domain_scores_gemma":[0.9995072,0.0002526493,0.000056263678,0.000013997646,0.0001140637,0.000055924145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008505916,0.00067991734,0.0011246519,0.0017558277,0.00024797794,0.0009226903,0.0008135193,0.0018710766,0.0031571244],"category_scores_gemma":[0.0011496828,0.0002332539,0.00054087286,0.0013771862,0.0006578881,0.0018748473,0.0007187024,0.0032413693,0.0017405355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009778519,0.00009039056,0.00015367595,0.01260218,0.000060331622,0.00019186774,0.00007686514,0.00040453835,0.0017611007,0.0086843865,0.07248298,0.9033939],"study_design_scores_gemma":[0.000014953856,0.00008809151,0.00045395448,0.0032118761,0.00003268497,0.00058453967,0.00004313869,0.000071048016,0.00019483901,0.0027498202,0.9925436,0.000011483094],"about_ca_topic_score_codex":0.0008654081,"about_ca_topic_score_gemma":0.0016224193,"teacher_disagreement_score":0.0031571244,"about_ca_system_score_codex":0.00083060085,"about_ca_system_score_gemma":0.0011666763,"threshold_uncertainty_score":0.010561705},"labels":[],"label_agreement":null},{"id":"W3042095160","doi":"10.1136/jitc-2020-000891","title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center","keywords":"Nivolumab; Medicine; Sunitinib; Ipilimumab; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immunotherapy; Cancer","score_opus":0.04926157250532811,"score_gpt":0.3799343260798284,"score_spread":0.3306727535745003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042095160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915285,0.0031203334,0.0003493703,0.0005246765,0.00020565487,0.0022973449,0.0009241567,0.00006133151,0.000988566],"genre_scores_gemma":[0.99333644,0.0008134764,0.00060853513,0.00057600834,0.0002694159,0.0026608966,0.0010806394,0.000012373137,0.0006423135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99707115,0.0018831012,0.00019822373,0.00038740397,0.00019560967,0.0002643907],"domain_scores_gemma":[0.99539065,0.0009848466,0.0017105282,0.00045470733,0.0003017235,0.0011575458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007920773,0.0015495592,0.0028628567,0.00044728984,0.0008058517,0.0015144122,0.001059998,0.0019437317,0.0035758042],"category_scores_gemma":[0.0045077144,0.00057888875,0.0045157243,0.0005394498,0.0012080566,0.0016783095,0.0006867353,0.0038694295,0.00071014435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9717891,0.0075411885,0.004788685,0.0002691463,0.0020461788,0.000032022308,0.000067734545,0.00048523553,0.0010915983,0.000045151024,0.0006943506,0.011149578],"study_design_scores_gemma":[0.80522466,0.17058402,0.018569086,0.000053245032,0.0021129514,0.000084943684,0.000047429432,0.0013297646,0.0008039385,0.00031225666,0.0008401073,0.00003769583],"about_ca_topic_score_codex":0.0007487682,"about_ca_topic_score_gemma":0.0017471777,"teacher_disagreement_score":0.007920773,"about_ca_system_score_codex":0.0015714533,"about_ca_system_score_gemma":0.0019373695,"threshold_uncertainty_score":0.04188955},"labels":[],"label_agreement":null},{"id":"W3047494536","doi":"10.1136/jitc-2020-000883","title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Foundation; Canada Research Chairs; AstraZeneca; Celgene; Canadian Institutes of Health Research; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Regimen; Hypomethylating agent; Internal medicine; Adverse effect; Breast cancer; Oncology; Gastroenterology; Immunology; DNA methylation; Cancer; Immunotherapy; Nivolumab; Biology","score_opus":0.0510288598174325,"score_gpt":0.42536665460349565,"score_spread":0.37433779478606316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047494536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724495,0.00060110615,0.0003269796,0.00010922883,0.00007357002,0.0010540184,0.00021648193,0.000031208805,0.00034250275],"genre_scores_gemma":[0.9940236,0.00068246305,0.0013552448,0.00026795053,0.00017801212,0.0016106758,0.00046168006,0.000018491708,0.0014019321],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99937326,0.00030542808,0.0000314288,0.00011513019,0.00006566198,0.00010913465],"domain_scores_gemma":[0.9991197,0.00017031062,0.00016597238,0.0001201686,0.000052824016,0.0003708556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001829709,0.0012711593,0.002804904,0.00045810235,0.0005222472,0.000958594,0.0010520492,0.0011826019,0.0028333513],"category_scores_gemma":[0.0009970668,0.0007632559,0.00088991754,0.00041268853,0.0012413877,0.0012646001,0.00034502632,0.002848865,0.00061608606],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7662504,0.13690831,0.003022279,0.00039708152,0.00084630575,0.00009393578,0.00019209062,0.0013545483,0.040599886,0.0001408772,0.00089162716,0.04930263],"study_design_scores_gemma":[0.38697538,0.6023699,0.004563338,0.000012174419,0.00026627196,0.00010339457,0.000051177583,0.0007311639,0.0038379198,0.00011152506,0.0009566571,0.000021110995],"about_ca_topic_score_codex":0.0006860949,"about_ca_topic_score_gemma":0.0019018857,"teacher_disagreement_score":0.0028333513,"about_ca_system_score_codex":0.0008408873,"about_ca_system_score_gemma":0.0014760899,"threshold_uncertainty_score":0.009676576},"labels":[],"label_agreement":null},{"id":"W3047919807","doi":"10.1136/jitc-2020-000915","title":"Discovery and validation of surface <i>N</i>-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; University of Toronto; Midwest Athletes Against Childhood Cancer","keywords":"Flow cytometry; Immunotherapy; Cell; Proteome; Medicine; Glycoprotein; Cell culture; Mass cytometry; Cancer research; Computational biology; Bioinformatics; Chemistry; Immunology; Biology; Molecular biology; Internal medicine; Cancer; Biochemistry","score_opus":0.02659038686089481,"score_gpt":0.3168505820342918,"score_spread":0.29026019517339696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047919807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914324,0.0009821242,0.0051704505,0.00014738328,0.000025796104,0.00012911638,0.0009384047,0.00007948298,0.0010948001],"genre_scores_gemma":[0.9833361,0.00093695545,0.011529009,0.00027847916,0.000020302696,0.00014663824,0.002758677,0.000024978723,0.0009688139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996903,0.000054630123,0.000028922288,0.00006449771,0.00011898181,0.000042728963],"domain_scores_gemma":[0.9998462,0.000029922381,0.000030525876,0.00001813393,0.000054704025,0.000020502099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057113956,0.00037669158,0.00022759518,0.000414468,0.00022688604,0.00034203965,0.00018179664,0.00035620152,0.0007492154],"category_scores_gemma":[0.00045187323,0.00008506423,0.00028184615,0.0003231403,0.00022257568,0.000103596845,0.00021271325,0.00044463226,0.00035536053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025506373,0.00009913743,0.017431607,0.00008819341,0.000039277184,0.00015497585,0.00007177428,0.00024285281,0.9730864,0.00009026763,0.00035084598,0.008089525],"study_design_scores_gemma":[0.000037415564,0.000800064,0.08625121,0.00003710829,0.00009903068,0.0017819838,0.00011807822,0.003133726,0.90198493,0.00013621889,0.0056111654,0.000009067823],"about_ca_topic_score_codex":0.00091062725,"about_ca_topic_score_gemma":0.0010086476,"teacher_disagreement_score":0.00091062725,"about_ca_system_score_codex":0.00035970184,"about_ca_system_score_gemma":0.00032540946,"threshold_uncertainty_score":0.003020525},"labels":[],"label_agreement":null},{"id":"W3048730325","doi":"10.1136/jitc-2020-000981","title":"Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"Terry Fox Foundation; Seerave Foundation; Ontario Institute for Cancer Research","keywords":"Medicine; Oncolytic virus; Immunology; Antigen; Vaccination; CD8; Melanoma; Cytotoxic T cell; Cancer; Cancer research; Cancer immunotherapy; Cyclophosphamide; Immunotherapy; Virus; Immune system; Chemotherapy; Biology; Internal medicine","score_opus":0.029711833246047814,"score_gpt":0.33559406518981433,"score_spread":0.3058822319437665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048730325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749494,0.0006812873,0.001005508,0.000025063995,0.000020390142,0.00007567812,0.00008284014,0.000034309716,0.0005800319],"genre_scores_gemma":[0.9979862,0.00049365626,0.000837168,0.00001709412,0.000007952385,0.000041976946,0.000112273156,0.000005507695,0.00049812626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994695,0.0000100125935,0.0000034123098,0.000010158752,0.000010049585,0.000019344758],"domain_scores_gemma":[0.9999682,0.000006657574,0.00000785177,0.0000040877844,0.000003931803,0.000009267186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107065265,0.0002972823,0.00017658983,0.00011308061,0.00005529528,0.00016245298,0.00012222832,0.0002098873,0.0006308937],"category_scores_gemma":[0.00007756162,0.00007045131,0.00010889878,0.000092523864,0.00013633995,0.00014327203,0.00009509917,0.00043447348,0.00011095917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002814741,0.00014806242,0.00009939777,0.00003528616,0.000003008875,0.000021767699,0.000012014881,0.00027639893,0.9963163,0.000044932844,0.000028119517,0.0027331884],"study_design_scores_gemma":[0.000074497504,0.0076016043,0.0027142407,0.000008111787,0.000026707918,0.00013632856,0.000007980917,0.0014275904,0.98696184,0.000026587486,0.0010102964,0.0000042404163],"about_ca_topic_score_codex":0.0003218993,"about_ca_topic_score_gemma":0.0004963368,"teacher_disagreement_score":0.0006308937,"about_ca_system_score_codex":0.00012631078,"about_ca_system_score_gemma":0.00013823628,"threshold_uncertainty_score":0.0021105409},"labels":[],"label_agreement":null},{"id":"W3090525098","doi":"10.1136/jitc-2020-001180","title":"Regulation of tumor growth by leukocyte-specific protein 1 in T cells","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; National Research Foundation","keywords":"Cancer research; Immunology; Computational biology; Biology; Medicine","score_opus":0.032812834537790075,"score_gpt":0.32360810513992944,"score_spread":0.2907952706021394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090525098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840973,0.009347242,0.0033804332,0.00030466187,0.00007847148,0.00006454795,0.00043477167,0.00017143834,0.0021211035],"genre_scores_gemma":[0.9923943,0.0038680076,0.0015321131,0.00011828028,0.000055582965,0.000107451364,0.0003308321,0.000018428838,0.0015749783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985695,0.000028629278,0.000009553487,0.000036557525,0.000024849222,0.00004349304],"domain_scores_gemma":[0.9998913,0.000019052704,0.0000451622,0.00000870181,0.000010981398,0.00002483451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014286672,0.000541773,0.0002235131,0.00021869116,0.0001254285,0.00026553846,0.00015946077,0.0003174098,0.0012123488],"category_scores_gemma":[0.00011400948,0.0000957907,0.0002241777,0.00013476782,0.00026096555,0.00014967618,0.00021684341,0.0006809267,0.00042462224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025251575,0.000050793053,0.00033004093,0.00014171861,0.0000035336468,0.000064738444,0.000015852072,0.00013740608,0.9956566,0.00016366906,0.000104367886,0.0030787808],"study_design_scores_gemma":[0.00012934353,0.0019543401,0.009430868,0.000043867305,0.000043778917,0.0005490753,0.000053064512,0.0020927412,0.97672576,0.00033736922,0.008631485,0.000008380019],"about_ca_topic_score_codex":0.00014590069,"about_ca_topic_score_gemma":0.00014848806,"teacher_disagreement_score":0.0012123488,"about_ca_system_score_codex":0.00028259744,"about_ca_system_score_gemma":0.00016370742,"threshold_uncertainty_score":0.0040557384},"labels":[],"label_agreement":null},{"id":"W3091948129","doi":"10.1136/jitc-2020-001006","title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen","keywords":"Pembrolizumab; Medicine; Rash; Maculopapular rash; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Lung cancer; Oncology; Cancer; Immunotherapy","score_opus":0.013646745651569215,"score_gpt":0.32535753150538355,"score_spread":0.31171078585381434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091948129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950577,0.0039183376,0.00020827315,0.000119697404,0.00001610498,0.0000540245,0.00009178787,0.000013665355,0.00052038726],"genre_scores_gemma":[0.9983734,0.0008582794,0.00026505179,0.00013746247,0.000046012556,0.000050794373,0.00014909919,0.0000022308,0.0001175678],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996767,0.00014953534,0.000037719536,0.000046427824,0.000062226965,0.000027368653],"domain_scores_gemma":[0.99940646,0.00015051015,0.00025871478,0.000019610943,0.000035705103,0.00012890056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007423221,0.00037932975,0.0007753718,0.00020225532,0.00018607365,0.00033073837,0.00019046706,0.0003719263,0.00053127133],"category_scores_gemma":[0.0010738596,0.00014770178,0.0003765133,0.00018750096,0.00023622632,0.00026923418,0.00015080204,0.0006616451,0.00020435722],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19081476,0.0077916034,0.32701805,0.0010598615,0.0018025389,0.0012696797,0.00044738376,0.0029388634,0.06911827,0.0001524449,0.0026676075,0.39491898],"study_design_scores_gemma":[0.03709998,0.3678747,0.54737407,0.000264807,0.002037343,0.0061734044,0.00019710959,0.0059782895,0.022116072,0.00019542,0.010641448,0.000047463927],"about_ca_topic_score_codex":0.00023290899,"about_ca_topic_score_gemma":0.00046408648,"teacher_disagreement_score":0.0007753718,"about_ca_system_score_codex":0.00043169243,"about_ca_system_score_gemma":0.0003499587,"threshold_uncertainty_score":0.0039258003},"labels":[],"label_agreement":null},{"id":"W3092016117","doi":"10.1136/jitc-2020-001095","title":"Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Durvalumab; Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Internal medicine; Clinical endpoint; Oncology; Radiation therapy; Pharmacokinetics; Toxicity; Gastroenterology; Urology; Nivolumab; Adverse effect; Cancer; Phases of clinical research; Clinical trial; Immunotherapy","score_opus":0.020610346657450037,"score_gpt":0.33996781776810464,"score_spread":0.3193574711106546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092016117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692434,0.0017905779,0.00017414047,0.0000701296,0.0000113962615,0.000086234635,0.00017609322,0.000019143188,0.0007479128],"genre_scores_gemma":[0.9985669,0.000586328,0.0002291657,0.000066916546,0.000027449954,0.00005813966,0.00023188893,0.000003951167,0.00022930824],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974626,0.00010885589,0.000019560166,0.000045408753,0.00004714029,0.00003274459],"domain_scores_gemma":[0.9996294,0.000091732705,0.00013880408,0.00003193852,0.000018026378,0.00009011926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000588744,0.00037503007,0.0006894342,0.00018585238,0.00016082851,0.0004062552,0.00029648692,0.0003475901,0.0011982563],"category_scores_gemma":[0.0006651962,0.00017034294,0.00045823972,0.00024492585,0.00036881337,0.00038043957,0.0001408483,0.0010258324,0.0003569514],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3877987,0.024545135,0.061841972,0.0008265273,0.0014647542,0.0006499433,0.00042007753,0.0055438797,0.14547087,0.00025953524,0.0025864067,0.36859214],"study_design_scores_gemma":[0.08164272,0.6884431,0.17021097,0.00007932216,0.0013305885,0.0021106363,0.00016661013,0.005758793,0.043593396,0.00024506796,0.0063645737,0.000054258042],"about_ca_topic_score_codex":0.00031588017,"about_ca_topic_score_gemma":0.0007079516,"teacher_disagreement_score":0.0011982563,"about_ca_system_score_codex":0.00055039336,"about_ca_system_score_gemma":0.0004174879,"threshold_uncertainty_score":0.004008591},"labels":[],"label_agreement":null},{"id":"W3093348721","doi":"10.1136/jitc-2020-001154","title":"Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Outbreak; Family medicine; Cancer; Medical prescription; Internal medicine; Disease; Virology; Nursing; Infectious disease (medical specialty)","score_opus":0.15187442515706576,"score_gpt":0.5055723031600233,"score_spread":0.3536978780029576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093348721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967174,0.00051469944,0.00004178583,0.0006463509,0.000016770686,0.000040694496,0.00042814936,0.000005352571,0.0015888802],"genre_scores_gemma":[0.9979461,0.0006416717,0.00010838355,0.0005315208,0.00004743003,0.000058236765,0.00031862536,0.0000037774923,0.00034432992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999374,0.00017485194,0.000058669808,0.00008176262,0.00011553492,0.00019524418],"domain_scores_gemma":[0.9974847,0.0004281401,0.0011943263,0.000070337046,0.00020981289,0.00061270106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010783195,0.00013534579,0.00016627359,0.00079679827,0.00040917506,0.0005821036,0.00022434254,0.0004305339,0.0019344572],"category_scores_gemma":[0.0032939173,0.00015911295,0.00027147692,0.0009783673,0.00037330063,0.00032591863,0.0006809209,0.00039361892,0.00031283466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054836437,0.00005079504,0.9905584,0.00009648016,0.000011441114,0.00020161188,0.0025735158,0.000033614124,0.00024475832,0.00004510701,0.0016633156,0.0044661583],"study_design_scores_gemma":[0.0000053586928,0.00012672151,0.99425054,0.00004815617,0.000007763123,0.00029558537,0.0030448542,0.000060465805,0.00004181256,0.000009393513,0.002104774,0.0000046830146],"about_ca_topic_score_codex":0.013718093,"about_ca_topic_score_gemma":0.014615574,"teacher_disagreement_score":0.013718093,"about_ca_system_score_codex":0.0008054667,"about_ca_system_score_gemma":0.0011931469,"threshold_uncertainty_score":0.027276516},"labels":[],"label_agreement":null},{"id":"W3095965358","doi":"10.1136/jitc-2020-001389","title":"Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute","keywords":"Immunotherapy; Cancer immunotherapy; Medicine; Data science; Volume (thermodynamics); Resource (disambiguation); Cancer; Computer science; Internal medicine","score_opus":0.13094875820765697,"score_gpt":0.413158312917038,"score_spread":0.282209554709381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095965358","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019779473,0.0037631257,0.038029574,0.86117715,0.025053186,0.0055831205,0.0032960589,0.00086036726,0.060259443],"genre_scores_gemma":[0.048539866,0.0137780085,0.2534452,0.46192256,0.036535833,0.021293666,0.023759343,0.002745614,0.13797982],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.74721724,0.11101801,0.03017891,0.009348248,0.09263287,0.009604733],"domain_scores_gemma":[0.5210918,0.17224559,0.023655174,0.06905204,0.17610382,0.037851572],"candidate_categories":["metaresearch","open_science"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.31160307,0.0013565897,0.002832278,0.0050849775,0.010085421,0.03342396,0.014682495,0.017014977,0.017905409],"category_scores_gemma":[0.29278412,0.0023016909,0.0030429359,0.007197698,0.011793187,0.021181753,0.02427028,0.02957891,0.015367008],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007153729,0.0001352404,0.0011468135,0.00064695155,0.000053009964,0.00010586852,0.00086736795,0.00079005107,0.00050003384,0.11285596,0.8243809,0.05844626],"study_design_scores_gemma":[0.000059717404,0.00008263447,0.00073190074,0.0012781374,0.000032391148,0.0001589172,0.0006148505,0.0009908385,0.000460594,0.02278509,0.972719,0.00008599585],"about_ca_topic_score_codex":0.021037633,"about_ca_topic_score_gemma":0.015647976,"teacher_disagreement_score":0.9853175,"about_ca_system_score_codex":0.020511592,"about_ca_system_score_gemma":0.19902062,"threshold_uncertainty_score":0.848916},"labels":[],"label_agreement":null},{"id":"W3101654075","doi":"10.1136/jitc-2020-001583","title":"Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Subspecialty; Clinical trial; Medical physics; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine; Pathology","score_opus":0.37732158310077407,"score_gpt":0.5774039456333534,"score_spread":0.20008236253257933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101654075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045160158,0.8705199,0.007833961,0.10188959,0.010614507,0.0013070923,0.0007235652,0.00015689946,0.0065028025],"genre_scores_gemma":[0.0043000393,0.8910012,0.046573635,0.045896526,0.004502976,0.0024760147,0.0018008872,0.00012577513,0.0033230057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96840537,0.013302207,0.008443315,0.0012067771,0.0075439904,0.0010984001],"domain_scores_gemma":[0.9162956,0.039768424,0.009207445,0.0024828291,0.02952206,0.0027236799],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08618702,0.00138638,0.003955103,0.0048081507,0.001082539,0.004341935,0.0061124507,0.007859815,0.0028404521],"category_scores_gemma":[0.06580418,0.0009351261,0.0039981203,0.0040704235,0.0023149247,0.004371104,0.0037404667,0.010056336,0.0036356635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001997188,0.00015029099,0.00059757766,0.028313741,0.0002829935,0.00026384022,0.00033794742,0.0006092491,0.0011325042,0.009567227,0.2581174,0.7004275],"study_design_scores_gemma":[0.00013563398,0.00014227693,0.0012974547,0.056626003,0.00042773865,0.0005911435,0.00020681083,0.00024453382,0.0008071694,0.007295205,0.9321554,0.00007063559],"about_ca_topic_score_codex":0.0031426223,"about_ca_topic_score_gemma":0.0041625444,"teacher_disagreement_score":0.913813,"about_ca_system_score_codex":0.0034960501,"about_ca_system_score_gemma":0.029146444,"threshold_uncertainty_score":0.45580596},"labels":[],"label_agreement":null},{"id":"W3108323391","doi":"10.1136/jitc-2020-001128","title":"PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre for Drug Research and Development; University of British Columbia","funders":"Canadian Institutes of Health Research; Centre for Blood Research, University of British Columbia; National Research Foundation; Danmarks Grundforskningsfond; Stem Cell Network; Cancer Research Institute","keywords":"Podocalyxin; Cancer research; Epitope; Antigen; Cancer; Metastasis; Ovarian cancer; Antibody; Tumor microenvironment; Medicine; Biology; Kidney; Immunology; Internal medicine","score_opus":0.03868869120217639,"score_gpt":0.3684224076571678,"score_spread":0.32973371645499144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108323391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97078156,0.003636435,0.017099436,0.00051425566,0.0001363931,0.0002701552,0.00031666225,0.00038998295,0.0068549933],"genre_scores_gemma":[0.9640248,0.003042505,0.022290245,0.0006838328,0.00013170321,0.0002450433,0.0023310538,0.000056181096,0.0071947165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998061,0.0000300652,0.000011307766,0.000041918276,0.00004510167,0.000065529486],"domain_scores_gemma":[0.9999068,0.000016277028,0.000011416215,0.000008932482,0.00001896573,0.000037569553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002084957,0.00070673216,0.0002773109,0.00046700696,0.00018296645,0.00032613188,0.0005341272,0.00079363264,0.0017477027],"category_scores_gemma":[0.00018655739,0.0001977214,0.00032662286,0.00019535274,0.00016689417,0.00029261387,0.00038074213,0.00069443515,0.00077906647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014743651,0.0002673746,0.00058554404,0.000098331606,0.000016252614,0.0002251333,0.00001766058,0.00019874936,0.9840724,0.00032030957,0.0005049915,0.013545661],"study_design_scores_gemma":[0.00027799286,0.00234223,0.0074866423,0.000041360243,0.000087747634,0.0035071133,0.00003149145,0.0067366506,0.95273435,0.00040681422,0.02632024,0.00002723043],"about_ca_topic_score_codex":0.0002981366,"about_ca_topic_score_gemma":0.0003433023,"teacher_disagreement_score":0.0017477027,"about_ca_system_score_codex":0.00037644422,"about_ca_system_score_gemma":0.00030244442,"threshold_uncertainty_score":0.0058466196},"labels":[],"label_agreement":null},{"id":"W3112961014","doi":"10.1136/jitc-2020-001849","title":"Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"TIGIT; Cytotoxic T cell; T cell; Downregulation and upregulation; IL-2 receptor; Cancer research; Interleukin 21; Immunology; Galectin; CD8; Biology; Medicine; Immune system; In vitro","score_opus":0.010907829551133298,"score_gpt":0.2508194246248309,"score_spread":0.23991159507369764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112961014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994099,0.00024420093,0.000066375214,0.000008025586,0.0000017533613,0.00000845241,0.000041695104,0.0000030843962,0.00021643877],"genre_scores_gemma":[0.999765,0.000038462735,0.000058864964,0.000009574561,0.0000027538363,0.000004192777,0.00007074049,0.0000010281722,0.00004943972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998703,0.000032750522,0.000015747177,0.000040946863,0.000015614236,0.000024659746],"domain_scores_gemma":[0.9997589,0.00006111309,0.00008207055,0.000017196362,0.000019486828,0.000061093044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024835274,0.00023425528,0.00036159056,0.00030112523,0.00018246505,0.00045770037,0.00013073914,0.00026520502,0.0012892534],"category_scores_gemma":[0.00042735657,0.00015206911,0.00020612785,0.00024163265,0.000247243,0.00025025834,0.00023948424,0.0003161417,0.00016298317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010208529,0.0003624462,0.89036363,0.00012450313,0.00015416338,0.0014579432,0.00020540704,0.0003735489,0.07630726,0.00012214709,0.00023378489,0.020086586],"study_design_scores_gemma":[0.00038114493,0.0056702835,0.97518367,0.000026252113,0.00018531072,0.007966247,0.00026064928,0.0011993863,0.007899214,0.00023261334,0.0009828456,0.000012424035],"about_ca_topic_score_codex":0.00013093362,"about_ca_topic_score_gemma":0.00013852619,"teacher_disagreement_score":0.0012892534,"about_ca_system_score_codex":0.00017105488,"about_ca_system_score_gemma":0.000102035054,"threshold_uncertainty_score":0.004312992},"labels":[],"label_agreement":null},{"id":"W3124346768","doi":"10.1136/jitc-2020-001933","title":"Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"Blockade; Medicine; Lung cancer; Oncology; Cancer; Cancer research; Internal medicine; Receptor","score_opus":0.01249308043643551,"score_gpt":0.29473688144387794,"score_spread":0.28224380100744245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124346768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658537,0.00086368254,0.0010631772,0.000087095556,0.000039454724,0.000050264036,0.0001296672,0.000058858273,0.0011223587],"genre_scores_gemma":[0.99746394,0.0002874799,0.0006319062,0.00010659279,0.000019001558,0.000052036452,0.00040164776,0.000008626004,0.0010288121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998956,0.000020145413,0.000013177483,0.00002673039,0.000022327988,0.00002206712],"domain_scores_gemma":[0.99993217,0.000019112831,0.000008661809,0.000014646059,0.0000067991605,0.000018555715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116919895,0.00017370953,0.00035085145,0.00010981623,0.0000959044,0.0002380387,0.0001173544,0.00016533496,0.0020359396],"category_scores_gemma":[0.000181006,0.00008096872,0.0001728375,0.00006201772,0.000125925,0.00013769454,0.00029311507,0.00061384327,0.0003895697],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009942122,0.00032834188,0.0038136519,0.00008937586,0.00002495461,0.00032061257,0.00011837363,0.00044619286,0.9697692,0.00016919766,0.0005912282,0.023334607],"study_design_scores_gemma":[0.00043005624,0.0071229874,0.037492175,0.000028670234,0.00011381898,0.0055236164,0.0001438686,0.0034952639,0.9260518,0.00034570886,0.01922945,0.000022520488],"about_ca_topic_score_codex":0.0001076797,"about_ca_topic_score_gemma":0.00019866797,"teacher_disagreement_score":0.0020359396,"about_ca_system_score_codex":0.000099369674,"about_ca_system_score_gemma":0.0001242615,"threshold_uncertainty_score":0.0068109035},"labels":[],"label_agreement":null},{"id":"W3125964008","doi":"10.1136/jitc-2020-001642","title":"Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Medicine; Neuroblastoma RAS viral oncogene homolog; Oncology; Internal medicine; Melanoma; Cohort; Proportional hazards model; Nivolumab; Immune checkpoint; Progression-free survival; Retrospective cohort study; Cancer; Immunotherapy; Cancer research; Overall survival; KRAS","score_opus":0.025299693950167255,"score_gpt":0.3139723413321364,"score_spread":0.2886726473819692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125964008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976357,0.0013021389,0.00022916346,0.000080100974,0.000019631498,0.000008694875,0.0002428666,0.000007821063,0.00047397107],"genre_scores_gemma":[0.9994355,0.0001239195,0.00009020349,0.000022989092,0.000030641822,0.0000041353164,0.00018610469,0.0000022235715,0.00010436421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947506,0.00014924988,0.000043947734,0.00017527852,0.00008156348,0.000074875556],"domain_scores_gemma":[0.99779296,0.00073364703,0.0009219168,0.00015084149,0.00009086877,0.0003097863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011894058,0.00025088235,0.00044088103,0.00031219618,0.00018477469,0.0005641561,0.00031244213,0.00032923458,0.0017440435],"category_scores_gemma":[0.0025093835,0.00021235357,0.0010610425,0.00025972223,0.0001973338,0.00040666398,0.00029281565,0.0006294465,0.00019261021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019830673,0.000036876834,0.99083436,0.000020676245,0.00027212844,0.000049601247,0.000013426707,0.00037570987,0.0006655573,0.000037531,0.0001149721,0.0055959984],"study_design_scores_gemma":[0.00009542718,0.0009112915,0.9933549,0.000019343865,0.00050592504,0.00048109583,0.000056217803,0.003417863,0.0004111714,0.00017598759,0.0005613067,0.000009556876],"about_ca_topic_score_codex":0.0009550552,"about_ca_topic_score_gemma":0.0014390684,"teacher_disagreement_score":0.0017440435,"about_ca_system_score_codex":0.0002792695,"about_ca_system_score_gemma":0.00031330297,"threshold_uncertainty_score":0.006290257},"labels":[],"label_agreement":null},{"id":"W3125966940","doi":"10.1136/jitc-2020-001931","title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital","funders":"National Health and Medical Research Council; Melanoma Institute Australia; University of Sydney; Cancer Institute NSW","keywords":"Coronavirus disease 2019 (COVID-19); Immune checkpoint; Medicine; Immune system; 2019-20 coronavirus outbreak; Cancer; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cancer research; Bioinformatics; Immunology; Immunotherapy; Virology; Internal medicine; Biology; Disease","score_opus":0.06330711220933358,"score_gpt":0.46447215231227634,"score_spread":0.40116504010294274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125966940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988839,0.00042583607,0.00004354687,0.000062126055,0.00000562358,0.000009629537,0.00012886636,0.0000022699073,0.0004382091],"genre_scores_gemma":[0.999514,0.00013695337,0.000042634776,0.00003956448,0.0000131871475,0.000005293401,0.00020712303,9.11846e-7,0.000040272513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995859,0.00012439831,0.00005034311,0.00006853777,0.00007313627,0.00009767116],"domain_scores_gemma":[0.99741167,0.00043790115,0.0014444999,0.00006739394,0.00016474423,0.00047376184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000372267,0.00018313961,0.00045799563,0.00031751697,0.00041721595,0.0005654252,0.00019826509,0.00023639713,0.0011967255],"category_scores_gemma":[0.0018403935,0.00011310273,0.0004093998,0.000514361,0.00034193322,0.00025248723,0.00043753747,0.0006364872,0.00010532728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001867061,0.000018511493,0.99815434,0.000014403709,0.000028851478,0.00019185578,0.000024445055,0.00005345323,0.0002025607,0.000008234599,0.000077338795,0.0010392795],"study_design_scores_gemma":[0.000010127691,0.00025340464,0.9981901,0.000013351697,0.000028909444,0.000905629,0.00012689053,0.0001621284,0.00010391576,0.0000169098,0.00018563542,0.0000030297601],"about_ca_topic_score_codex":0.0014973889,"about_ca_topic_score_gemma":0.0021735395,"teacher_disagreement_score":0.0014973889,"about_ca_system_score_codex":0.00048247888,"about_ca_system_score_gemma":0.00053289684,"threshold_uncertainty_score":0.0040034056},"labels":[],"label_agreement":null},{"id":"W3129135562","doi":"10.1136/jitc-2020-001580","title":"Immunotherapy for sarcomas: new frontiers and unveiled opportunities","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Medicine; Immunotherapy; Malignancy; Sarcoma; Radiation therapy; Disease; Cancer; Soft tissue sarcoma; Cancer immunotherapy; Oncology; Cancer research; Pathology; Internal medicine","score_opus":0.12473750641321807,"score_gpt":0.41549837843333776,"score_spread":0.2907608720201197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129135562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011101622,0.9983285,0.000106735366,0.00063271215,0.00020027449,0.0000031785164,0.00001025353,0.000006166271,0.00060118944],"genre_scores_gemma":[0.0006747649,0.99824286,0.00014629329,0.00034667188,0.00022851201,0.000004653303,0.000019078669,0.0000013674763,0.00033577462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979585,0.00005072297,0.000022321523,0.000030202864,0.00007341918,0.000027566135],"domain_scores_gemma":[0.9995376,0.00025940445,0.000040150553,0.0000145623,0.00010715885,0.00004116825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008739034,0.0005761256,0.0010242634,0.0015056352,0.00023411596,0.0012161487,0.0006326652,0.001133203,0.0030996555],"category_scores_gemma":[0.00082551467,0.00019282963,0.0005060838,0.0012983871,0.00060092716,0.0017701067,0.0006538981,0.002629306,0.0012822701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008704102,0.00009899387,0.0001483821,0.01048758,0.00005684902,0.00016921267,0.00007520284,0.00040856417,0.0020694868,0.0069542667,0.03036113,0.94908327],"study_design_scores_gemma":[0.000021468526,0.000118023534,0.00041943917,0.0030993023,0.000058251026,0.0008540726,0.00006081748,0.00011133291,0.00035114106,0.0033401023,0.9915537,0.000012359651],"about_ca_topic_score_codex":0.00053775846,"about_ca_topic_score_gemma":0.0012585674,"teacher_disagreement_score":0.0030996555,"about_ca_system_score_codex":0.0005611235,"about_ca_system_score_gemma":0.0010439508,"threshold_uncertainty_score":0.01036936},"labels":[],"label_agreement":null},{"id":"W3132046910","doi":"10.1136/jitc-2020-001387","title":"In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; Natural Sciences and Engineering Research Council of Canada; Institute of Cancer Research; NIH Clinical Center; National Institutes of Health; Institut Du Cancer de Montréal; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Fondation du cancer du sein du Québec; U.S. Department of Energy","keywords":"Oncolytic virus; Vesicular stomatitis virus; In silico; Clinical trial; Medicine; Vaccinia; Enhancer; Immune system; Virus; Computational biology; Oncology; Bioinformatics; Immunology; Biology; Internal medicine","score_opus":0.031052805369189425,"score_gpt":0.3725765579536491,"score_spread":0.34152375258445966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132046910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79409724,0.0012321858,0.18130302,0.0024655834,0.00033829542,0.0006465437,0.0049285125,0.0009332675,0.014055305],"genre_scores_gemma":[0.9733988,0.0003435043,0.022567604,0.0004918863,0.000025956564,0.00041241516,0.0014901224,0.0001013486,0.001168314],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99935526,0.00027947,0.0000410865,0.00012740615,0.00011787325,0.00007897155],"domain_scores_gemma":[0.9961067,0.0030276494,0.00033219543,0.00017378289,0.00022335027,0.00013628723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029889683,0.0007315299,0.00078021275,0.00032980792,0.00022214338,0.0010144521,0.0006629185,0.00079689163,0.0031295088],"category_scores_gemma":[0.0077330675,0.00043281773,0.0009926131,0.00025205308,0.00039102207,0.0007227537,0.00041108302,0.0008242704,0.00058458664],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050139526,0.00024086892,0.0145954285,0.00024800608,0.00016159195,0.00013011596,0.00004172677,0.9613038,0.0048312796,0.002496326,0.0025760962,0.012873408],"study_design_scores_gemma":[0.00017731465,0.00073951954,0.0024492245,0.000036221292,0.00018228944,0.00009158365,0.000034820456,0.9826721,0.0050172075,0.0058010365,0.0027743306,0.000024285935],"about_ca_topic_score_codex":0.0022306968,"about_ca_topic_score_gemma":0.003158678,"teacher_disagreement_score":0.0031295088,"about_ca_system_score_codex":0.0009499002,"about_ca_system_score_gemma":0.0015960466,"threshold_uncertainty_score":0.01580733},"labels":[],"label_agreement":null},{"id":"W3134221665","doi":"10.1136/jitc-2020-001901","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Clinical trial; Limiting; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.08771796083704402,"score_gpt":0.4250182670291007,"score_spread":0.3373003061920567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134221665","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027856647,0.9968124,0.0001333671,0.0015126163,0.00032706602,0.000013448228,0.000028328954,0.0000050601975,0.0008890941],"genre_scores_gemma":[0.0040625664,0.99145246,0.00063307665,0.002339109,0.00056848803,0.00006238977,0.00007373998,0.000005527862,0.00080259744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991404,0.00030588475,0.00021988076,0.00009364568,0.00018979562,0.00005046355],"domain_scores_gemma":[0.99796665,0.001448166,0.00026527603,0.000025987272,0.00023425424,0.000059720558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002692412,0.00046962095,0.0020114905,0.00093924196,0.0002325234,0.0010461659,0.0011928912,0.0014855221,0.002692334],"category_scores_gemma":[0.004225287,0.00020801595,0.0009095533,0.0008001804,0.00049260573,0.0011966354,0.00047386423,0.0030025356,0.0009987145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043980018,0.00006681093,0.00036496826,0.020339804,0.00016439274,0.00012189945,0.00008719358,0.00032867672,0.00080768415,0.004406571,0.031466436,0.9414058],"study_design_scores_gemma":[0.000389273,0.00046787882,0.0037170006,0.02800214,0.0005416414,0.0017123978,0.00016248667,0.00025028086,0.0005970799,0.00555445,0.9585628,0.000042615295],"about_ca_topic_score_codex":0.0010394121,"about_ca_topic_score_gemma":0.0024271598,"teacher_disagreement_score":0.002692412,"about_ca_system_score_codex":0.00093200704,"about_ca_system_score_gemma":0.0011372057,"threshold_uncertainty_score":0.014239013},"labels":[],"label_agreement":null},{"id":"W3135804634","doi":"10.1136/jitc-2020-002007","title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Myocarditis; Medicine; Mace; Internal medicine; QRS complex; Cardiology; PR interval; QT interval; Viral Myocarditis; Electrocardiography; Odds ratio; Heart rate; Blood pressure; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.011009566007240729,"score_gpt":0.298156691801623,"score_spread":0.2871471257943823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135804634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941129,0.0010026706,0.0006148964,0.00010665608,0.000022457489,0.000038002243,0.00040684288,0.000017904826,0.0036775616],"genre_scores_gemma":[0.9988626,0.00029092754,0.00013888556,0.000050516057,0.000041861353,0.000008532579,0.00032527072,0.0000030401459,0.00027829123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980444,0.000040847484,0.000022743223,0.000043873675,0.000056610766,0.000031455347],"domain_scores_gemma":[0.9988871,0.00016371318,0.000616441,0.000044618148,0.000097633325,0.00019049217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030754012,0.00024622862,0.0003110746,0.00042317458,0.0001337975,0.00023791935,0.00014854089,0.00024959087,0.002316781],"category_scores_gemma":[0.0013986536,0.00008914024,0.00017594041,0.00041543655,0.00017383017,0.00019934462,0.00017936662,0.00034222985,0.00028837158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039361787,0.0000393707,0.9910443,0.000027923174,0.00004581901,0.0017531847,0.000045888628,0.000069646114,0.0021480254,0.00004787826,0.00020552112,0.0041789566],"study_design_scores_gemma":[0.000014087356,0.00021587494,0.99375486,0.00000916827,0.00002094341,0.005454999,0.00002952683,0.00010005588,0.00014161841,0.000031071602,0.0002249918,0.0000028106572],"about_ca_topic_score_codex":0.00048059536,"about_ca_topic_score_gemma":0.0004472498,"teacher_disagreement_score":0.002316781,"about_ca_system_score_codex":0.00012574116,"about_ca_system_score_gemma":0.00010919659,"threshold_uncertainty_score":0.007750392},"labels":[],"label_agreement":null},{"id":"W3136309976","doi":"10.1136/jitc-2020-002096","title":"Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; University of Calgary; Dalhousie University","funders":"Cancer Research Institute; Terry Fox Research Institute; Institute of Infection and Immunity; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Dalhousie University; Beatrice Hunter Cancer Research Institute","keywords":"Oncolytic virus; Vesicular stomatitis virus; Immunotherapy; Cancer research; Ovarian cancer; Natural killer T cell; Immunology; Virotherapy; Medicine; Antigen; Biology; Cancer; Virus; Virology; T cell; Immune system; Internal medicine","score_opus":0.016448385815238987,"score_gpt":0.30610441907018493,"score_spread":0.28965603325494593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136309976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435484,0.0015310482,0.0016912406,0.00012180717,0.0000794514,0.000107037085,0.00057686423,0.00017645363,0.0013613711],"genre_scores_gemma":[0.9900473,0.0014847853,0.0026541504,0.000066438326,0.00003499598,0.00028405103,0.0009358625,0.000054101874,0.004438194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996419,0.00004634185,0.00003247114,0.000081710314,0.00007556997,0.00012211104],"domain_scores_gemma":[0.99980503,0.000029858722,0.000054936616,0.000026719126,0.000017013896,0.00006641679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029086714,0.00084086455,0.0006649113,0.0008083728,0.00014609085,0.00035878588,0.00031227234,0.00042645494,0.0011383275],"category_scores_gemma":[0.00011198032,0.00022142862,0.0005540269,0.00028226434,0.00043102913,0.0003153043,0.00017599795,0.0013818522,0.00031280812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010393256,0.0004043184,0.00029123962,0.000074599906,0.000018832512,0.000048311424,0.00003446119,0.00020516785,0.9953407,0.000101614176,0.000103962404,0.002337438],"study_design_scores_gemma":[0.0001543596,0.0058079055,0.0023240673,0.000012937429,0.00005638294,0.00018166717,0.000027344824,0.00085302966,0.988997,0.000053585252,0.0015231892,0.000008607574],"about_ca_topic_score_codex":0.000515245,"about_ca_topic_score_gemma":0.0007137504,"teacher_disagreement_score":0.0011383275,"about_ca_system_score_codex":0.00039105825,"about_ca_system_score_gemma":0.000350721,"threshold_uncertainty_score":0.0038080812},"labels":[],"label_agreement":null},{"id":"W3137265803","doi":"10.1136/jitc-2020-001803","title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Faculty of Medicine and Health, University of Leeds; University of Leeds; Kay Kendall Leukaemia Fund; Yorkshire Cancer Research; Cancer Research UK; NHS Blood and Transplant","keywords":"Bone marrow; Multiple myeloma; Immunity; Niche; Immunology; Medicine; Cancer research; Biology; Immune system; Ecology","score_opus":0.030523131196094705,"score_gpt":0.33210019707983307,"score_spread":0.30157706588373834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137265803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97173697,0.016008249,0.008664346,0.00019040855,0.00011818543,0.00023571367,0.000436266,0.00023900675,0.0023709456],"genre_scores_gemma":[0.9901224,0.0034785725,0.0043317783,0.000063237414,0.000026495338,0.0000939464,0.000431668,0.000014738116,0.0014372887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989045,0.000021264725,0.0000076072747,0.000018990106,0.00003512456,0.00002654253],"domain_scores_gemma":[0.9999691,0.0000037902141,0.000011288501,0.000004881104,0.000003439861,0.0000074479917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001316048,0.0003147826,0.0002599811,0.0002810476,0.00009446711,0.00025997023,0.00023664835,0.00025592736,0.0009458704],"category_scores_gemma":[0.000044630102,0.000071800256,0.00029052846,0.00013622688,0.00016506309,0.00015236261,0.00019044892,0.0006711496,0.00023159056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023483287,0.00014807971,0.00019501313,0.0001661932,0.0000135174105,0.00005418956,0.000015038085,0.00023359523,0.98851997,0.00017049363,0.00010154731,0.0101475],"study_design_scores_gemma":[0.00014329549,0.0034482842,0.0043515675,0.000031702617,0.00010683452,0.00077972666,0.000028296183,0.0015294008,0.97968286,0.0001237154,0.009765326,0.000009015396],"about_ca_topic_score_codex":0.00026530717,"about_ca_topic_score_gemma":0.0004763113,"teacher_disagreement_score":0.0009458704,"about_ca_system_score_codex":0.00019780286,"about_ca_system_score_gemma":0.00019535572,"threshold_uncertainty_score":0.0031642318},"labels":[],"label_agreement":null},{"id":"W3137963785","doi":"10.1136/jitc-2020-001831","title":"Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dermatology; Immunosuppression; Adverse effect; Refractory (planetary science); Immune system; Ultraviolet b; Immunology; Internal medicine","score_opus":0.024746355654553263,"score_gpt":0.3409145376868956,"score_spread":0.31616818203234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137963785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9471729,0.017586078,0.00723892,0.0046777083,0.0005862389,0.00039855656,0.00025125968,0.00036717695,0.021721134],"genre_scores_gemma":[0.9889888,0.004055477,0.0018603603,0.0011148698,0.0009811448,0.000047378307,0.000079482015,0.000030648367,0.0028417362],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99915266,0.00011687405,0.00008142582,0.00018748855,0.00015270806,0.0003088467],"domain_scores_gemma":[0.9989599,0.0002885339,0.0002557344,0.00011613603,0.000054771528,0.00032499604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004496715,0.0024319536,0.0015033516,0.0029017683,0.003367142,0.0022279094,0.0011499806,0.006014353,0.002387163],"category_scores_gemma":[0.0017708314,0.001266117,0.0016654839,0.0016186007,0.0017051761,0.0022150772,0.0014627317,0.0032361632,0.0011844531],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000120293935,0.000050560415,0.0015484202,0.000028293689,0.0000093867,0.99631613,0.00010092164,0.000040895313,0.0003982646,0.00010265611,0.000195913,0.0011965864],"study_design_scores_gemma":[0.000006054579,0.00003140399,0.00084378576,0.000009706789,0.000009834405,0.99827874,0.000046904977,0.00013036159,0.00020804047,0.000047080972,0.00038227896,0.000005710682],"about_ca_topic_score_codex":0.002042067,"about_ca_topic_score_gemma":0.0028222103,"teacher_disagreement_score":0.006014353,"about_ca_system_score_codex":0.0013443885,"about_ca_system_score_gemma":0.0007837643,"threshold_uncertainty_score":0.0097542405},"labels":[],"label_agreement":null},{"id":"W3139360595","doi":"10.1136/jitc-2020-001965","title":"High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Institute of Cancer Research; National Cancer Institute; National Institutes of Health; Université de Montréal; Terry Fox Research Institute","keywords":"Immune system; Ovarian cancer; Cancer research; Gene signature; Transcriptome; Tumor microenvironment; Cancer; CD8; Biology; Medicine; Microarray; Microarray analysis techniques; Immunology; Gene expression; Internal medicine; Gene","score_opus":0.02410786326807273,"score_gpt":0.33656913096828533,"score_spread":0.3124612677002126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139360595","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98599523,0.0015529189,0.008638805,0.00007827434,0.000017780649,0.000038334958,0.0026323686,0.00015697091,0.00088937936],"genre_scores_gemma":[0.980677,0.0007149857,0.014086586,0.00005608544,0.000019876932,0.00007670439,0.0037790365,0.000031766067,0.0005578333],"study_design_codex":"bench_or_experimental","study_design_gemma":"systematic_review","domain_scores_codex":[0.9999118,0.000010079456,0.000006878688,0.000021047257,0.000032788947,0.000017439324],"domain_scores_gemma":[0.99991083,0.000022687324,0.000020757838,0.00000772102,0.000023209395,0.000014797626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016527837,0.00019114914,0.00018982272,0.0011680519,0.00021245462,0.00046478267,0.00009754038,0.00022065705,0.0006879066],"category_scores_gemma":[0.00016386124,0.000121047204,0.00027878798,0.0008006075,0.000101023914,0.00011876622,0.00024231714,0.00019832749,0.000184413],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005348724,0.00006610606,0.070929185,0.0002756054,0.00012348247,0.0003796107,0.00019609867,0.001842247,0.89552987,0.00016783306,0.0007615618,0.02919353],"study_design_scores_gemma":[0.000026221462,0.00023746537,0.7616723,0.000040823765,0.0002527989,0.0021382608,0.0006989317,0.036004078,0.18897599,0.0006149024,0.009288824,0.000049278],"about_ca_topic_score_codex":0.0008380501,"about_ca_topic_score_gemma":0.0015749796,"teacher_disagreement_score":0.0011680519,"about_ca_system_score_codex":0.00017570134,"about_ca_system_score_gemma":0.00017369744,"threshold_uncertainty_score":0.0023012161},"labels":[],"label_agreement":null},{"id":"W3152586353","doi":"10.1136/jitc-2020-001955","title":"Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Cancer League of Colorado","keywords":"CD137; Cancer research; Immunotherapy; Medicine; CD8; CD80; Immune system; T cell; Dendritic cell; Immunology; IL-2 receptor; Cytotoxic T cell; Biology; In vitro; CD40","score_opus":0.00901117220919158,"score_gpt":0.27719306309205965,"score_spread":0.2681818908828681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152586353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932863,0.0020996958,0.0027247479,0.00015024298,0.000049403287,0.000065153035,0.00028180826,0.00009164064,0.0012509675],"genre_scores_gemma":[0.9969056,0.0007980444,0.0011610143,0.00007859795,0.000024529412,0.00006869185,0.00021107707,0.000013913229,0.00073849456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998411,0.00001894955,0.000011465086,0.00003409433,0.000036988997,0.000057448455],"domain_scores_gemma":[0.9999291,0.000009874055,0.000020051762,0.000009622859,0.0000095094065,0.000021810636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020984527,0.0002642235,0.00034717927,0.00018436184,0.00014299755,0.00037446507,0.00017886315,0.0002077967,0.0013199458],"category_scores_gemma":[0.00008192448,0.000082509745,0.00030270778,0.00009190822,0.00024311275,0.00017455682,0.00020438021,0.0007556429,0.0002991562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021946269,0.00011470769,0.0008224241,0.000103634906,0.00000970169,0.00003223683,0.000017987897,0.00021312477,0.99385875,0.00018262223,0.0001224955,0.004302956],"study_design_scores_gemma":[0.000109991866,0.0027347829,0.0080940975,0.000029284081,0.00009099829,0.0004057513,0.000103421946,0.0015963214,0.9796428,0.00020390672,0.0069812047,0.0000074913896],"about_ca_topic_score_codex":0.00021451619,"about_ca_topic_score_gemma":0.00046664762,"teacher_disagreement_score":0.0013199458,"about_ca_system_score_codex":0.00020040825,"about_ca_system_score_gemma":0.00025065904,"threshold_uncertainty_score":0.0044156313},"labels":[],"label_agreement":null},{"id":"W3157675313","doi":"10.1136/jitc-2021-002535","title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Canadian Cancer Society; ECOG-ACRIN Cancer Research Group; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Rash; Internal medicine; Adverse effect; Adjuvant; Melanoma; Oncology; Multivariate analysis; Proportional hazards model; Immunotherapy; Cancer","score_opus":0.024259388212844894,"score_gpt":0.3273518728818649,"score_spread":0.30309248466902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157675313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973464,0.0014935575,0.000131785,0.00002004152,0.0000065726804,0.000025740374,0.0006440582,0.0000037544376,0.0003280183],"genre_scores_gemma":[0.9988776,0.00022509105,0.00005054982,0.000021719698,0.000016260197,0.00001999535,0.0006487864,0.000001961185,0.00013794923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950564,0.00018872012,0.00006684073,0.00010793408,0.000078578174,0.00005232997],"domain_scores_gemma":[0.997964,0.00037078798,0.0011850261,0.00014554602,0.00008841588,0.0002461864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001734582,0.00045356064,0.0005957834,0.00048736238,0.00014668703,0.0005447369,0.00039672267,0.0003443261,0.0009935957],"category_scores_gemma":[0.0011800448,0.00018150425,0.001440111,0.00069528254,0.00018779743,0.00039420265,0.00045049717,0.0005693644,0.00016527617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006700414,0.00008361088,0.98800164,0.00009937848,0.0015255932,0.00007842075,0.000014874486,0.00039400687,0.00034108505,0.000019487232,0.00015588573,0.0025855391],"study_design_scores_gemma":[0.00046293202,0.001613855,0.9949409,0.000027583616,0.0010727815,0.00032075876,0.000038509977,0.0007864195,0.0001790999,0.000052264346,0.00049662095,0.000008251852],"about_ca_topic_score_codex":0.0005385328,"about_ca_topic_score_gemma":0.00083507,"teacher_disagreement_score":0.001734582,"about_ca_system_score_codex":0.0002342517,"about_ca_system_score_gemma":0.00019084047,"threshold_uncertainty_score":0.009173453},"labels":[],"label_agreement":null},{"id":"W3158940958","doi":"10.1136/jitc-2020-002189","title":"Expanded antigen-experienced CD160<sup>+</sup>CD8<sup>+</sup>effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Calcium signaling and nucleotide metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta","keywords":"CD8; Chronic lymphocytic leukemia; Immunology; T cell; Cytokine; Receptor; Cytotoxic T cell; Proinflammatory cytokine; Leukemia; Medicine; Antigen; Chemistry; Biology; Immune system; Internal medicine; Inflammation; In vitro; Biochemistry","score_opus":0.010714209973224212,"score_gpt":0.2843837342926516,"score_spread":0.2736695243194274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158940958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99947375,0.00024072283,0.00008506222,0.000005813735,0.0000012843913,0.000002709541,0.00004480515,0.000005139491,0.0001407195],"genre_scores_gemma":[0.999542,0.000086505934,0.00006463702,0.000014064585,0.0000046568534,0.0000066335856,0.0001279331,0.0000023603022,0.00015125108],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998857,0.00001914341,0.000016075663,0.000029589724,0.000019366054,0.000030210647],"domain_scores_gemma":[0.99978954,0.000039751278,0.00009059121,0.000016728243,0.000018719602,0.000044726054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018160588,0.00028103127,0.00023536124,0.0004188957,0.00019364455,0.00031362422,0.00011411095,0.0002632767,0.001376119],"category_scores_gemma":[0.00031400507,0.00014497223,0.00012621206,0.00026151424,0.00023552644,0.00022053359,0.00031216105,0.00026700253,0.00027783992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039447574,0.00020324867,0.33152846,0.0001937462,0.000057492736,0.00190525,0.00044605418,0.0003820807,0.64641446,0.0001146428,0.00029825815,0.014511605],"study_design_scores_gemma":[0.00013821847,0.0019948916,0.9159763,0.000026418025,0.00009796129,0.012795584,0.00040013608,0.0007461253,0.06496631,0.00023752675,0.00260774,0.000012858],"about_ca_topic_score_codex":0.0001952546,"about_ca_topic_score_gemma":0.0001620679,"teacher_disagreement_score":0.001376119,"about_ca_system_score_codex":0.00017447396,"about_ca_system_score_gemma":0.00007096024,"threshold_uncertainty_score":0.0046035647},"labels":[],"label_agreement":null},{"id":"W3162235708","doi":"10.1136/jitc-2021-002449","title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; NIH Clinical Center; National Institutes of Health","keywords":"Medicine; Melanoma; CD8; Tumor-infiltrating lymphocytes; Adoptive cell transfer; Antigen; Dendritic cell; Immunology; Immunotherapy; T cell; Population; Leukapheresis; Immune system; Cancer research; Biology; Stem cell","score_opus":0.01341338405052177,"score_gpt":0.2848127047442006,"score_spread":0.27139932069367884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162235708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800729,0.0025463433,0.0012156388,0.0015166734,0.0014749167,0.009328501,0.0010002278,0.00018610754,0.0026586656],"genre_scores_gemma":[0.97209454,0.001733201,0.0025706242,0.0024054165,0.0010136539,0.012615698,0.0014147499,0.000048456866,0.006103751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999161,0.00043162986,0.000038005546,0.00015259843,0.000056542834,0.00016018598],"domain_scores_gemma":[0.99879944,0.00028336348,0.0001723369,0.00012599854,0.000066782675,0.0005520485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022096543,0.0026424823,0.00408898,0.0006171098,0.0005732439,0.0016426945,0.0013811653,0.0026387523,0.0071822456],"category_scores_gemma":[0.0018203718,0.0010453839,0.0013256579,0.00062090496,0.0025199074,0.0015373651,0.0006147868,0.0046649077,0.0015171148],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9583856,0.023049647,0.0005700467,0.00030725534,0.0003301848,0.00005280254,0.00006149363,0.0004384215,0.0043655764,0.00015729478,0.0008321484,0.01144964],"study_design_scores_gemma":[0.8940122,0.104305714,0.00043988661,0.000010223067,0.00009466227,0.000020424548,0.000011605549,0.00026378664,0.00029783268,0.00010437437,0.00043135806,0.0000078469875],"about_ca_topic_score_codex":0.00080501934,"about_ca_topic_score_gemma":0.0017630106,"teacher_disagreement_score":0.0071822456,"about_ca_system_score_codex":0.0011305193,"about_ca_system_score_gemma":0.0021172704,"threshold_uncertainty_score":0.02402699},"labels":[],"label_agreement":null},{"id":"W3169390234","doi":"10.1136/jitc-2021-002856","title":"IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; H2020 European Research Council; BC Cancer Agency; Horizon 2020 Framework Programme; Cancer Research UK","keywords":"Progenitor cell; Cancer research; Haematopoiesis; Bone marrow; Myeloid; Immune system; Monocyte; Dendritic cell; Metastasis; Biology; Immunology; Medicine; Cancer; Stem cell; Cell biology; Internal medicine","score_opus":0.014086607990613006,"score_gpt":0.3005891664180392,"score_spread":0.28650255842742617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169390234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850332,0.004881993,0.0046415585,0.00045255636,0.00009884659,0.000071657414,0.0012846045,0.0001677801,0.003367735],"genre_scores_gemma":[0.99385405,0.0017896476,0.0015865011,0.000118844066,0.000050198418,0.000037700393,0.00082016765,0.000024544444,0.0017184353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984336,0.000027930944,0.000010928864,0.000030662864,0.000037204998,0.0000498398],"domain_scores_gemma":[0.9998586,0.000012270836,0.00003951148,0.00001056679,0.00001711855,0.000061889084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001246069,0.00037568295,0.00018196485,0.00019413169,0.00016442405,0.00036027443,0.00010825985,0.00022763012,0.0022163908],"category_scores_gemma":[0.00012792522,0.00012076705,0.0002665732,0.000107590095,0.00015647901,0.00014817505,0.0002588254,0.00097501406,0.00077659375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054297486,0.0000842089,0.0047864127,0.00016528816,0.000011590572,0.00038375676,0.000049126957,0.0001599933,0.9884843,0.00029184626,0.0003904556,0.004650058],"study_design_scores_gemma":[0.0002372869,0.0014713478,0.118301146,0.00011690954,0.000145897,0.0037061675,0.00052195677,0.0055418597,0.839832,0.001120842,0.028979382,0.000025360205],"about_ca_topic_score_codex":0.00018512369,"about_ca_topic_score_gemma":0.00029469345,"teacher_disagreement_score":0.0022163908,"about_ca_system_score_codex":0.00017419868,"about_ca_system_score_gemma":0.00023185568,"threshold_uncertainty_score":0.0074145794},"labels":[],"label_agreement":null},{"id":"W3171665778","doi":"10.1136/jitc-2020-002140","title":"Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Medical Research Council; Breast Cancer Now; Academy of Medical Sciences; Cancer Research UK","keywords":"Immunotherapy; Medicine; Antigen; Immunoglobulin E; Cancer immunotherapy; Immunology; Cancer research; Immune system; Antibody","score_opus":0.0655862087547177,"score_gpt":0.4044719527983389,"score_spread":0.3388857440436212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171665778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97182953,0.004786654,0.0178535,0.00039492492,0.00008358284,0.00016513646,0.0004815396,0.0005763532,0.0038287858],"genre_scores_gemma":[0.9896142,0.001515114,0.006027693,0.00019460126,0.000025089099,0.00007541212,0.00048485122,0.000030078882,0.0020328842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998758,0.000013342752,0.0000066119733,0.00003443582,0.000034437657,0.00003538407],"domain_scores_gemma":[0.9999627,0.0000064376964,0.000012566206,0.0000046717114,0.000005896727,0.000007834463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001344377,0.00037472005,0.00021181688,0.00019895763,0.00008882671,0.0003048425,0.00019259864,0.0004565206,0.0016571458],"category_scores_gemma":[0.000083220846,0.00008373596,0.00038681438,0.000118002885,0.00022695486,0.0001434102,0.00018451836,0.0005601534,0.00036989382],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009268602,0.00004723274,0.00042033734,0.000085973785,0.000021054462,0.00010765085,0.000012915828,0.00031740262,0.9936367,0.0002135815,0.00023433636,0.0048101214],"study_design_scores_gemma":[0.000078228964,0.0008281014,0.0021271706,0.000016359445,0.000102261554,0.00092916394,0.00002128948,0.0024082228,0.9841511,0.00015049348,0.009178704,0.000008879076],"about_ca_topic_score_codex":0.00032150428,"about_ca_topic_score_gemma":0.00041320897,"teacher_disagreement_score":0.0016571458,"about_ca_system_score_codex":0.00029611573,"about_ca_system_score_gemma":0.00021197651,"threshold_uncertainty_score":0.0055437684},"labels":[],"label_agreement":null},{"id":"W3173127935","doi":"10.1136/jitc-2020-002157","title":"Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Ligue Contre le Cancer; Agence Nationale de la Recherche; Université de Franche-Comté; Fondation de France; Université Laval; Université de Bourgogne; Association pour la Recherche sur le Cancer","keywords":"Germinal center; Cytotoxic T cell; Immune system; CD8; Chemokine; Immunology; Cancer research; Biology; T cell; Adoptive cell transfer; Antibody; Flow cytometry; Cytokine; B cell; In vitro","score_opus":0.02059658743093797,"score_gpt":0.3176562006179244,"score_spread":0.2970596131869864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173127935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869419,0.0026965924,0.004468854,0.00023607431,0.00014487885,0.00011438694,0.0010709699,0.00067869975,0.003647877],"genre_scores_gemma":[0.9892653,0.0005668508,0.0033087933,0.00018599648,0.00007900796,0.00010179935,0.0012080225,0.00008907501,0.005195128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998386,0.000015565034,0.0000133755075,0.000033721142,0.000034059925,0.00006466372],"domain_scores_gemma":[0.99983597,0.000022034115,0.000042177333,0.000020207495,0.000022784234,0.000056840363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014119901,0.00032804435,0.00027927774,0.0002818013,0.00011522275,0.00031941885,0.00021228656,0.00027227504,0.0028759048],"category_scores_gemma":[0.0001420888,0.0000787973,0.00024869203,0.00010899519,0.00019807972,0.0001734004,0.00018447156,0.00092457625,0.00096071244],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074980664,0.00030395112,0.00055676297,0.00012736655,0.000013112612,0.00009653565,0.000027523129,0.00015922204,0.9806262,0.00021266533,0.00064103166,0.016485814],"study_design_scores_gemma":[0.00025756878,0.003170287,0.004893912,0.000024318226,0.000057547328,0.0007625833,0.00006356679,0.0013618399,0.9677337,0.00036236626,0.021303045,0.000009227042],"about_ca_topic_score_codex":0.00019617443,"about_ca_topic_score_gemma":0.00025394227,"teacher_disagreement_score":0.0028759048,"about_ca_system_score_codex":0.00020780739,"about_ca_system_score_gemma":0.00024715392,"threshold_uncertainty_score":0.009620845},"labels":[],"label_agreement":null},{"id":"W3180594295","doi":"10.1136/jitc-2021-002642","title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Human Genome Research Institute; Swim Across America; International Association for the Study of Lung Cancer; Mark Foundation For Cancer Research; LUNGevity Foundation; Commonwealth Foundation; National Cancer Institute; National Institutes of Health; Bloomberg Philanthropies","keywords":"Blockade; T-cell receptor; Immune system; Confounding; Immune checkpoint; T cell; Medicine; Cell; Immunology; Immunotherapy; Cancer research; Biology; Receptor; Internal medicine; Genetics","score_opus":0.0552863817777128,"score_gpt":0.405616804043211,"score_spread":0.3503304222654982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180594295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70296586,0.0068924488,0.27698794,0.0018037527,0.0007914913,0.0008114624,0.0008562439,0.00042770585,0.008463155],"genre_scores_gemma":[0.94701964,0.0005273036,0.049505293,0.00093012647,0.00023464476,0.00065525,0.00029901075,0.00018166869,0.0006471561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8911146,0.07420375,0.011415106,0.008510675,0.013084832,0.0016710156],"domain_scores_gemma":[0.78256816,0.15602666,0.01779204,0.032593183,0.009838474,0.0011813805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11498759,0.00095564267,0.001375215,0.0025471784,0.0013640735,0.002703474,0.0016135651,0.0010356545,0.0013798875],"category_scores_gemma":[0.1677028,0.0006120909,0.0010020522,0.0019802877,0.0035543207,0.0015918093,0.0026466867,0.002116956,0.0002766032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030673943,0.00025632823,0.76492184,0.0020725762,0.0033310729,0.0022633858,0.0056810933,0.0049679466,0.06548403,0.008380724,0.0023873344,0.1371863],"study_design_scores_gemma":[0.00013841139,0.0018489308,0.8147697,0.00089697976,0.001887355,0.00633289,0.0036597769,0.0299183,0.090034686,0.027527152,0.022845864,0.0001399145],"about_ca_topic_score_codex":0.0019727207,"about_ca_topic_score_gemma":0.003611165,"teacher_disagreement_score":0.11498759,"about_ca_system_score_codex":0.0007523001,"about_ca_system_score_gemma":0.001151998,"threshold_uncertainty_score":0.6081197},"labels":[],"label_agreement":null},{"id":"W3181256475","doi":"10.1136/jitc-2021-002552","title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Society for Immunotherapy of Cancer; Bladder Cancer Advocacy Network","keywords":"Medicine; Immunotherapy; Urothelial cancer; Guideline; Bladder cancer; Cancer; Atezolizumab; Intensive care medicine; Oncology; Cancer immunotherapy; Internal medicine; Pembrolizumab; Pathology","score_opus":0.06021223239992654,"score_gpt":0.45781727494001123,"score_spread":0.39760504254008466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181256475","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003709558,0.16198678,0.035220325,0.4617437,0.034202833,0.016268441,0.023289248,0.0015778263,0.26200125],"genre_scores_gemma":[0.03203793,0.25525564,0.18439704,0.34117353,0.00898933,0.021948338,0.07283872,0.0005322733,0.08282732],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915258,0.0033616617,0.0017798764,0.00031067862,0.0024930302,0.0005289632],"domain_scores_gemma":[0.9834946,0.0040117176,0.0016697407,0.00029058612,0.00962595,0.0009074518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071744365,0.0010136048,0.0016109424,0.003853192,0.00136436,0.0021220199,0.0036688957,0.00787011,0.0068958397],"category_scores_gemma":[0.022184383,0.0007305771,0.003129455,0.0037850568,0.0010813284,0.0014365441,0.0022166723,0.008557389,0.0059236153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004638835,0.000110984285,0.0005930216,0.003365801,0.00008283028,0.00021210698,0.00017917466,0.0007361238,0.00046132275,0.003365642,0.90951246,0.08133402],"study_design_scores_gemma":[0.00018403883,0.000087687506,0.001778231,0.011132541,0.00018946102,0.0007098923,0.00011177518,0.0005170231,0.00027818597,0.0037102096,0.9812617,0.00003921119],"about_ca_topic_score_codex":0.025009347,"about_ca_topic_score_gemma":0.048157893,"teacher_disagreement_score":0.025009347,"about_ca_system_score_codex":0.005211862,"about_ca_system_score_gemma":0.022244498,"threshold_uncertainty_score":0.0497275},"labels":[],"label_agreement":null},{"id":"W3184786167","doi":"10.1186/s40425-016-0172-7","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; Université de Montréal; Trillium Therapeutics (Canada); Telesta Therapeutics (Canada); Campbell Scientific (Canada); Ontario Institute for Cancer Research; McMaster University","funders":"National Cancer Institute; Kite Pharma; Cancer Institute, University of Pittsburgh; Oregon Clinical and Translational Research Institute; Deutsches Zentrum für Lungenforschung; National Institutes of Health; M.J. Murdock Charitable Trust; Terry Fox Foundation; University of Pittsburgh; Midwest Athletes Against Childhood Cancer; National Institute of Allergy and Infectious Diseases; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Harry J. Lloyd Charitable Trust; Achievement Rewards for College Scientists Foundation; Dana-Farber/Harvard Cancer Center; National Science Foundation","keywords":"Cancer immunotherapy; Cancer; Immunotherapy; Medicine; Oncology; Immunology; Internal medicine","score_opus":0.01757493342482682,"score_gpt":0.28726839540413324,"score_spread":0.26969346197930644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184786167","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036441606,0.042983416,0.016742783,0.0717142,0.17918333,0.0054488936,0.012885382,0.0028671399,0.63173324],"genre_scores_gemma":[0.03135261,0.017353442,0.0072337775,0.0037235406,0.03325894,0.001637537,0.010170773,0.00074595807,0.89452344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990429,0.00017337836,0.00008273103,0.0001228341,0.00038559694,0.00019247137],"domain_scores_gemma":[0.99702954,0.00013287406,0.00022590398,0.00014331203,0.0010017267,0.0014665804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024209265,0.0011673232,0.00059736613,0.0018308635,0.00085489487,0.0021582055,0.0010094153,0.0018584878,0.1546824],"category_scores_gemma":[0.0019349423,0.00030526103,0.00057111995,0.000978132,0.00039967935,0.0008331366,0.0023679528,0.0016867339,0.09300942],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046488,0.00038697018,0.00258995,0.00043564755,0.00002299583,0.00025192832,0.00006226711,0.00045069383,0.007851246,0.0013451646,0.68642277,0.29971555],"study_design_scores_gemma":[0.00003964484,0.00016558415,0.003965027,0.000112775444,0.000008442484,0.00023032314,0.000037247253,0.0004933687,0.0009932605,0.00048629704,0.9934582,0.000009781748],"about_ca_topic_score_codex":0.0011355338,"about_ca_topic_score_gemma":0.002429469,"teacher_disagreement_score":0.1546824,"about_ca_system_score_codex":0.0010631112,"about_ca_system_score_gemma":0.0031311663,"threshold_uncertainty_score":0.51746416},"labels":[],"label_agreement":null},{"id":"W3185017026","doi":"10.1136/jitc-2021-002673","title":"Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Oncolytics Biotech; King's College London; King's Health Partners; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Oncolytic virus; Medicine; Concomitant; Antibody; Neutralizing antibody; Docetaxel; Immunosuppression; Immunology; Virology; Gemcitabine; Cyclophosphamide; Virus; Pharmacology; Amantadine; Chemotherapy; Internal medicine","score_opus":0.022495464877330132,"score_gpt":0.41544805392018763,"score_spread":0.3929525890428575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185017026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963314,0.0021493004,0.0006099384,0.000035501813,0.000022461054,0.000034404715,0.000069313035,0.000021917069,0.0007258352],"genre_scores_gemma":[0.9991386,0.00023119978,0.00019661174,0.000020413458,0.000016114007,0.00001187649,0.00009088595,0.0000049913533,0.0002892876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977034,0.00008581887,0.000015046556,0.00003806094,0.000041761483,0.000049096474],"domain_scores_gemma":[0.99955875,0.00022808796,0.00007079156,0.000052416166,0.00003289085,0.000057032696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005113395,0.00023451027,0.00036285978,0.00014782198,0.000086898806,0.00028371398,0.00012464874,0.00022156633,0.0011784593],"category_scores_gemma":[0.0006255375,0.000071033224,0.00018600057,0.000111424095,0.00019604669,0.00024750057,0.00009352402,0.00063899165,0.00015513392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019749628,0.0026282873,0.016592683,0.00022951869,0.00018694863,0.00025333837,0.00013535263,0.0016383053,0.8449548,0.0001615183,0.0004969487,0.112972654],"study_design_scores_gemma":[0.0005310698,0.078783296,0.072193794,0.00002329847,0.00036276618,0.001284261,0.000073022624,0.0038727252,0.8393032,0.00009398278,0.0034625134,0.000016088758],"about_ca_topic_score_codex":0.00027364417,"about_ca_topic_score_gemma":0.00034592513,"teacher_disagreement_score":0.0011784593,"about_ca_system_score_codex":0.0002201737,"about_ca_system_score_gemma":0.0001581232,"threshold_uncertainty_score":0.0039423704},"labels":[],"label_agreement":null},{"id":"W3186632176","doi":"10.1136/jitc-2021-002968","title":"Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Moonshot Research and Development Program; University of Texas MD Anderson Cancer Center","keywords":"Evasion (ethics); Mechanism (biology); Immune system; Stem cell; Immunology; Cancer research; Computational biology; Medicine; Biology; Cell biology","score_opus":0.04144192327952301,"score_gpt":0.3072220279034092,"score_spread":0.2657801046238862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186632176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940036,0.000801273,0.0037937795,0.00006788425,0.000010141376,0.000027570039,0.0002919302,0.000111273635,0.0008924974],"genre_scores_gemma":[0.9969187,0.0003627918,0.0016286031,0.000035396737,0.0000054640923,0.000015548701,0.00031439678,0.000008033044,0.0007111144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999138,0.000012000147,0.00000826666,0.000016543518,0.000031228115,0.00001816089],"domain_scores_gemma":[0.9999502,0.000008530814,0.000014748109,0.0000067331553,0.0000060161606,0.000013864347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116485455,0.00021469052,0.00012839939,0.00023986562,0.00009272382,0.000258337,0.00013570156,0.00019086777,0.00068274036],"category_scores_gemma":[0.00007158968,0.00006728626,0.00013302265,0.000132753,0.00015563531,0.00012531038,0.0001413701,0.0003328549,0.00018136171],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051271138,0.000012187223,0.00039384307,0.000015820126,0.0000022319985,0.00003513599,0.000005973969,0.00009034514,0.9980166,0.00010691582,0.000031568652,0.0012380012],"study_design_scores_gemma":[0.000007584591,0.00015426899,0.0038546803,0.0000029021119,0.000010475923,0.00030750205,0.0000105681,0.0010519357,0.99235874,0.00006277605,0.0021765407,0.0000019955876],"about_ca_topic_score_codex":0.0002598245,"about_ca_topic_score_gemma":0.0003878176,"teacher_disagreement_score":0.00068274036,"about_ca_system_score_codex":0.0002825446,"about_ca_system_score_gemma":0.00013758731,"threshold_uncertainty_score":0.0022839904},"labels":[],"label_agreement":null},{"id":"W3190177153","doi":"10.1136/jitc-2020-002287","title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Leukopenia; Internal medicine; Neutropenia; Gastroenterology; Chimeric antigen receptor; Immunotherapy; Chemotherapy","score_opus":0.006887365602533204,"score_gpt":0.2905556143615081,"score_spread":0.2836682487589749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190177153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7845014,0.17129359,0.0066488576,0.0005932175,0.00024764804,0.002931622,0.028411135,0.0003090451,0.0050634015],"genre_scores_gemma":[0.972439,0.014020217,0.0019173902,0.0005201336,0.00020596622,0.0011137477,0.009064429,0.000040861065,0.00067822944],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918138,0.0043476024,0.0013899829,0.00091090036,0.0012771206,0.0002606674],"domain_scores_gemma":[0.988203,0.0046414956,0.0051502096,0.00069047866,0.0010648028,0.0002499513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013815867,0.0009690717,0.0028093783,0.0017053466,0.00022694336,0.0009878635,0.00048859103,0.0006991639,0.0033469717],"category_scores_gemma":[0.015634289,0.00041366613,0.007751953,0.0019331622,0.00026247447,0.0005567505,0.00066697365,0.00069528946,0.00038674305],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20332968,0.00067652884,0.17480257,0.019345552,0.43355143,0.00080710254,0.0002940018,0.005246392,0.006246969,0.00043250096,0.008347505,0.14691979],"study_design_scores_gemma":[0.038387116,0.042843778,0.50384605,0.0021142312,0.37030664,0.0025106736,0.00029830926,0.0048759645,0.0050256853,0.0008327654,0.028812174,0.00014664102],"about_ca_topic_score_codex":0.0012579022,"about_ca_topic_score_gemma":0.0020767308,"teacher_disagreement_score":0.013815867,"about_ca_system_score_codex":0.0010511295,"about_ca_system_score_gemma":0.0011951649,"threshold_uncertainty_score":0.073066175},"labels":[],"label_agreement":null},{"id":"W3190341154","doi":"10.1186/s40425-015-0078-9","title":"Pembrolizumab","year":2015,"lang":"id","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Pembrolizumab; Ipilimumab; Medicine; Melanoma; Oncology; Internal medicine; Lung cancer; Nivolumab; Cancer; Immunotherapy; Cancer research","score_opus":0.06837773108908334,"score_gpt":0.4185399310356333,"score_spread":0.35016219994654996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190341154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051673735,0.98899764,0.00038696412,0.0006173102,0.00045460678,0.00002633756,0.000088068504,0.000034410656,0.008877872],"genre_scores_gemma":[0.0065340456,0.98139405,0.00076699996,0.0013812676,0.0004639786,0.000039620783,0.0002872796,0.000005208643,0.009127537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998877,0.000015291918,0.0000146215425,0.000025483043,0.000042740747,0.000014099537],"domain_scores_gemma":[0.9999474,0.000016102862,0.000011780251,0.0000024000046,0.000014590935,0.000007707353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017499311,0.00057002687,0.000635826,0.0012224627,0.0002539706,0.0006434712,0.00042219926,0.0006312711,0.0075521246],"category_scores_gemma":[0.00032438606,0.00015844619,0.0004028284,0.0006337436,0.00016703315,0.00068973243,0.00037798242,0.0016222647,0.004673371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009955497,0.00006837538,0.00012879919,0.0046060937,0.00007903474,0.0002927926,0.000023675848,0.00013526286,0.0022898703,0.0015861415,0.037504952,0.9531856],"study_design_scores_gemma":[0.000061846265,0.000069602494,0.00052567467,0.0011421441,0.00007615437,0.0027602932,0.000011751159,0.00006284171,0.0010025423,0.0007712179,0.9935076,0.000008429644],"about_ca_topic_score_codex":0.00083509233,"about_ca_topic_score_gemma":0.0018227797,"teacher_disagreement_score":0.0075521246,"about_ca_system_score_codex":0.00046429448,"about_ca_system_score_gemma":0.00040407624,"threshold_uncertainty_score":0.025264323},"labels":[],"label_agreement":null},{"id":"W3192736776","doi":"10.1136/jitc-2021-002863","title":"First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis","keywords":"Medicine; Tolerability; Adverse effect; Pharmacokinetics; Pharmacodynamics; Internal medicine; Pharmacology; Toxicity; Oncology; Gastroenterology","score_opus":0.0333281760727157,"score_gpt":0.38328785776998303,"score_spread":0.3499596816972673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192736776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921468,0.0022624328,0.00088239514,0.0002141435,0.00007593795,0.0023636469,0.00096210715,0.00009043251,0.0010021372],"genre_scores_gemma":[0.98919606,0.001511825,0.0023544407,0.0005496232,0.00016127349,0.0025590062,0.001933759,0.000044454762,0.0016895764],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99931276,0.00030859295,0.000034464516,0.000121366116,0.00007850826,0.00014435693],"domain_scores_gemma":[0.9991642,0.000102335805,0.00016719496,0.00009150134,0.000048493213,0.00042625284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019954238,0.0018858972,0.0024927207,0.00049612724,0.00045506246,0.0010375007,0.0009648142,0.0009472395,0.0030686345],"category_scores_gemma":[0.00087657414,0.00082442205,0.0013837004,0.0005539392,0.0013762867,0.0010878163,0.00054183265,0.003548779,0.0009207952],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6663568,0.14615059,0.008043574,0.0011334985,0.001550642,0.00033686004,0.00056543684,0.0033940447,0.0748558,0.00023460272,0.0037283897,0.09364971],"study_design_scores_gemma":[0.40618858,0.57283276,0.0102112135,0.000029915853,0.0004329237,0.0003354747,0.0000637287,0.00091791607,0.005898561,0.00017994519,0.0028732545,0.000035638983],"about_ca_topic_score_codex":0.0007331039,"about_ca_topic_score_gemma":0.0018346432,"teacher_disagreement_score":0.0030686345,"about_ca_system_score_codex":0.0012233094,"about_ca_system_score_gemma":0.001817738,"threshold_uncertainty_score":0.010552943},"labels":[],"label_agreement":null},{"id":"W3194210289","doi":"10.1136/jitc-2021-003188","title":"Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EUSA Pharma; Ipsen; Pharmacyclics; Eisai; Incyte; Genentech; Les Laboratories Pierre Fabre; AstraZeneca; Pfizer; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Adjuvant; Ipilimumab; Adverse effect; Oncology; Internal medicine; Proportional hazards model; Melanoma; Cancer; Immunotherapy","score_opus":0.03369585980913195,"score_gpt":0.35122985655377575,"score_spread":0.3175339967446438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194210289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983637,0.0009602459,0.00019892621,0.000028759394,0.000004301677,0.00004234426,0.00016148512,0.0000051869324,0.00023519353],"genre_scores_gemma":[0.99922884,0.00019234772,0.00016521855,0.00002180295,0.000011298253,0.000032931053,0.00024783963,0.000001940544,0.000097734825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942505,0.00023850509,0.000062641375,0.00008563204,0.0001345072,0.000053666332],"domain_scores_gemma":[0.99746406,0.00077584205,0.0011814033,0.00012765241,0.00022587573,0.00022508012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029688708,0.00022552103,0.0005270495,0.00027705086,0.000103151884,0.00040308037,0.00020231937,0.00021405423,0.00062025466],"category_scores_gemma":[0.002298673,0.000072836694,0.00067279255,0.00028700536,0.00016956752,0.0002314515,0.00018549456,0.0004277717,0.000087894296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07165655,0.0012324761,0.8389315,0.00048744792,0.0014413771,0.000101975274,0.00008401435,0.0027996278,0.007314311,0.00007913717,0.00046000586,0.07541159],"study_design_scores_gemma":[0.0025831168,0.03514453,0.94751704,0.00006637913,0.0013863087,0.00049040664,0.000058634483,0.0069674454,0.0043259584,0.00021518244,0.0012213113,0.000023627072],"about_ca_topic_score_codex":0.00029897687,"about_ca_topic_score_gemma":0.0006146052,"teacher_disagreement_score":0.0029688708,"about_ca_system_score_codex":0.00038179493,"about_ca_system_score_gemma":0.0003993579,"threshold_uncertainty_score":0.015701115},"labels":[],"label_agreement":null},{"id":"W3195751328","doi":"10.1136/jitc-2021-002973","title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Durvalumab; Tremelimumab; Medicine; Lung cancer; PD-L1; Internal medicine; Oncology; Squamous cell cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.016859926611319694,"score_gpt":0.3365914877365322,"score_spread":0.3197315611252125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195751328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900647,0.0012880756,0.0005830202,0.00050176703,0.00015714914,0.0039042032,0.0014735123,0.000100049576,0.0019275914],"genre_scores_gemma":[0.9862156,0.001009922,0.0016925985,0.00084971084,0.00017255155,0.0044774525,0.0028812797,0.00003099295,0.0026698136],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995073,0.0002579404,0.000020973235,0.000075881515,0.000041039486,0.00009687795],"domain_scores_gemma":[0.9991824,0.00011229287,0.00014475937,0.00006900899,0.000053419313,0.0004381873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001841332,0.0015274436,0.0018802385,0.00040607515,0.00039381578,0.0010057249,0.0010755479,0.0012907855,0.004264408],"category_scores_gemma":[0.0010945095,0.000731496,0.0011362734,0.0003153097,0.00083205965,0.00088038226,0.0004092652,0.0025129835,0.0011020578],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.846944,0.06485683,0.0067650685,0.0005430677,0.0013573132,0.00018102092,0.00036803738,0.0016539033,0.020947123,0.00036550986,0.004196158,0.051822014],"study_design_scores_gemma":[0.73251873,0.25419435,0.008698558,0.000019872828,0.00029877594,0.00015691262,0.000051360716,0.0010290645,0.0011261383,0.00016670336,0.0017210825,0.00001844718],"about_ca_topic_score_codex":0.0014636,"about_ca_topic_score_gemma":0.0047461274,"teacher_disagreement_score":0.004264408,"about_ca_system_score_codex":0.0012466861,"about_ca_system_score_gemma":0.0020570485,"threshold_uncertainty_score":0.014265895},"labels":[],"label_agreement":null},{"id":"W3198525580","doi":"10.1136/jitc-2021-002876","title":"Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Tumor microenvironment; Cancer research; Immune system; Pancreatic cancer; Medicine; Cancer; Immunotherapy; TLR9; Immunology; Internal medicine; Biology","score_opus":0.014385650407572545,"score_gpt":0.3010974693788345,"score_spread":0.28671181897126197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198525580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973326,0.00071777805,0.00078247074,0.000046127945,0.000025606481,0.000028783663,0.000118418415,0.00005829556,0.00088999077],"genre_scores_gemma":[0.9972428,0.00045843443,0.00097061903,0.0000331125,0.00001374329,0.000046427107,0.00021412573,0.000007936458,0.0010127285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999887,0.000015658456,0.000009890518,0.000025405738,0.00002404259,0.000037953014],"domain_scores_gemma":[0.9999367,0.000009449307,0.000017010068,0.0000092115615,0.0000037756176,0.000023727434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011101557,0.00033420086,0.00032718698,0.00023441235,0.000110099965,0.00020602469,0.00013892885,0.00015496169,0.00081849186],"category_scores_gemma":[0.00006778253,0.00009711365,0.00025716407,0.00015399995,0.00022680967,0.00013848167,0.0001430633,0.0006889087,0.00019063478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007355065,0.000523753,0.00039095437,0.000058746624,0.000010802453,0.000044255095,0.00001684312,0.00015198081,0.9940055,0.000054938024,0.000089953035,0.0039167763],"study_design_scores_gemma":[0.00006398175,0.0036525095,0.0032589082,0.0000052444493,0.000037019097,0.00019677867,0.000025739306,0.00077205437,0.9907809,0.000024475923,0.0011786061,0.0000037580892],"about_ca_topic_score_codex":0.00019131908,"about_ca_topic_score_gemma":0.00039929623,"teacher_disagreement_score":0.00081849186,"about_ca_system_score_codex":0.00015771318,"about_ca_system_score_gemma":0.00021982339,"threshold_uncertainty_score":0.0027381182},"labels":[],"label_agreement":null},{"id":"W3200807512","doi":"10.1136/jitc-2021-003032","title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Hope Against Cancer","keywords":"Blockade; Immunotherapy; Medicine; Immune checkpoint; Tumor microenvironment; Mesothelioma; Clinical trial; Oncology; Cancer; PD-L1; Immune system; Cancer research; CTLA-4; Internal medicine; T cell; Immunology; Pathology; Receptor","score_opus":0.024857341948631193,"score_gpt":0.35853161334454514,"score_spread":0.33367427139591394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200807512","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009625957,0.9990884,0.000032205735,0.00029822995,0.00015140725,0.0000014335741,0.000009146817,0.0000018413953,0.000321172],"genre_scores_gemma":[0.0009897219,0.99827623,0.00005844534,0.00023482443,0.00016542239,0.0000031006346,0.000014551082,8.733755e-7,0.00025681467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998435,0.0000361474,0.000022324331,0.00002740425,0.000053382162,0.00001729576],"domain_scores_gemma":[0.9996724,0.00019009363,0.000039472376,0.0000073664646,0.00007168672,0.00001891898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055032596,0.00042403003,0.0009839587,0.0010701118,0.0001817552,0.0010535462,0.0005888189,0.00097112905,0.0022861615],"category_scores_gemma":[0.0009964188,0.00014098025,0.000497295,0.0010562143,0.000387869,0.0011731231,0.00043451326,0.0015870837,0.0007947402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015947377,0.00005085944,0.0002901726,0.029331896,0.00016171021,0.0001750852,0.00008540405,0.0003381028,0.0019708043,0.005990941,0.031925187,0.9295205],"study_design_scores_gemma":[0.00003194716,0.00017994277,0.001991056,0.011277915,0.00021151951,0.0014372836,0.00012182019,0.000121505516,0.00057234283,0.0035778047,0.9804561,0.000020745632],"about_ca_topic_score_codex":0.00072388106,"about_ca_topic_score_gemma":0.001502835,"teacher_disagreement_score":0.0022861615,"about_ca_system_score_codex":0.00050156616,"about_ca_system_score_gemma":0.0011138889,"threshold_uncertainty_score":0.007647991},"labels":[],"label_agreement":null},{"id":"W3201513519","doi":"10.1136/jitc-2021-002954","title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Japan Society for the Promotion of Science; Ono Pharmaceutical; Secom Science and Technology Foundation","keywords":"mTORC1; Mitochondrial ROS; Cancer research; Glutaminolysis; Reactive oxygen species; Mitochondrion; Metformin; Chemistry; Biology; Cell biology; Cancer cell; Cancer; Signal transduction; PI3K/AKT/mTOR pathway; Endocrinology","score_opus":0.01487345650998473,"score_gpt":0.29098705614444154,"score_spread":0.2761135996344568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201513519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581856,0.00097625534,0.0016094134,0.00010776753,0.00002743946,0.00002770324,0.00031157973,0.000070796836,0.0010506309],"genre_scores_gemma":[0.9965796,0.00042021126,0.0012254132,0.0000656177,0.000018818118,0.000060113718,0.00027297955,0.000012662305,0.0013446056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999068,0.00001262058,0.0000099911485,0.000024743687,0.000017429742,0.000028472778],"domain_scores_gemma":[0.9999447,0.000005208878,0.00002245981,0.00000440977,0.0000073246892,0.000015969812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000835812,0.00021455792,0.00015985871,0.00016678932,0.000098548044,0.00016012035,0.00008646163,0.0001973942,0.0018491071],"category_scores_gemma":[0.00006413029,0.00006181072,0.00015316083,0.000088262765,0.00012071891,0.00015702457,0.00011680223,0.00036693815,0.00029730666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037945207,0.000051211646,0.0005854173,0.00006091558,0.000003725227,0.0000543611,0.000015463655,0.00003496026,0.99718565,0.000057819594,0.000058306323,0.0015127851],"study_design_scores_gemma":[0.0000869817,0.00092353165,0.012278716,0.000014296594,0.000029111558,0.00038593865,0.00008705697,0.00091909495,0.9822698,0.000175357,0.002825208,0.000004898358],"about_ca_topic_score_codex":0.00006941704,"about_ca_topic_score_gemma":0.00015246462,"teacher_disagreement_score":0.0018491071,"about_ca_system_score_codex":0.00010399196,"about_ca_system_score_gemma":0.000082170154,"threshold_uncertainty_score":0.0061858892},"labels":[],"label_agreement":null},{"id":"W3201611853","doi":"10.1136/jitc-2021-003122","title":"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Ovarian Cancer Academy; Merck Sharp and Dohme; U.S. Department of Defense","keywords":"Carboplatin; Medicine; Ovarian cancer; Pembrolizumab; Fallopian tube cancer; Oncology; Fallopian tube; Internal medicine; Gynecology; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.017180304316084676,"score_gpt":0.3050659985256309,"score_spread":0.2878856942095462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201611853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552757,0.003534694,0.00015145086,0.00009907283,0.000014238575,0.00012551133,0.00004682735,0.000011076773,0.00048950844],"genre_scores_gemma":[0.9985644,0.00066241407,0.0002281161,0.00009152877,0.00003049349,0.00008533689,0.000117487616,0.0000015501918,0.00021871782],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99983406,0.00008110364,0.000015198922,0.000022710497,0.000022722217,0.000024107854],"domain_scores_gemma":[0.9997483,0.00007992395,0.00006294157,0.000016110038,0.000013156406,0.00007965717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068051735,0.00027933076,0.0005958712,0.00014657796,0.00018662447,0.00019902346,0.0002243203,0.00031646737,0.0008890539],"category_scores_gemma":[0.0006667071,0.000098518445,0.0003050754,0.00014722315,0.00020272682,0.00018209903,0.00013805201,0.0005559903,0.0001246239],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16547106,0.013310957,0.13993433,0.0015082614,0.0014647115,0.0022162744,0.00034479206,0.0026796635,0.09161623,0.00021791975,0.003265959,0.57796985],"study_design_scores_gemma":[0.073279805,0.34084502,0.53619856,0.00022216543,0.0012685372,0.009380913,0.000120706,0.006274184,0.023221392,0.00023783103,0.008915963,0.000034812125],"about_ca_topic_score_codex":0.00041355772,"about_ca_topic_score_gemma":0.0011569589,"teacher_disagreement_score":0.0008890539,"about_ca_system_score_codex":0.00043660545,"about_ca_system_score_gemma":0.00034256882,"threshold_uncertainty_score":0.003598988},"labels":[],"label_agreement":null},{"id":"W3202631322","doi":"10.1136/jitc-2021-003272","title":"Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre; Université Laval","funders":"National Cancer Institute; Ministry of Science and ICT, South Korea; UVA Cancer Center; University of Virginia","keywords":"Medicine; Clinical endpoint; Melanoma; Placebo; Internal medicine; Adverse effect; Adjuvant; Randomized controlled trial; Gastroenterology; Phases of clinical research; Clinical trial; Oncology; Surgery; Pathology","score_opus":0.011307735804506116,"score_gpt":0.2810383951323538,"score_spread":0.2697306593278477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202631322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312896,0.0059738634,0.0010318309,0.0009313524,0.0009247256,0.0052217487,0.0009200779,0.00015803202,0.0017094387],"genre_scores_gemma":[0.98641646,0.0017014035,0.0015814813,0.0009557835,0.000571361,0.0057686022,0.00071074587,0.00001803855,0.0022761822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991272,0.0005452825,0.00005155853,0.00014979046,0.00004621809,0.00007994396],"domain_scores_gemma":[0.9989471,0.0003081087,0.00029843245,0.00009475543,0.00009707708,0.0002546525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023525278,0.0015053026,0.0026726627,0.00030860392,0.0004633938,0.0009232224,0.00069609965,0.0016628,0.0049507055],"category_scores_gemma":[0.0023200014,0.00060292764,0.0012154649,0.00033790097,0.0010044216,0.00075168273,0.00030536376,0.002078351,0.0008780308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98785317,0.003085366,0.00046282608,0.00035242536,0.0005436978,0.00001896021,0.000024901678,0.00012792365,0.001763751,0.000044787255,0.00039635098,0.0053258794],"study_design_scores_gemma":[0.9518598,0.046068605,0.001039439,0.000017698845,0.00022972315,0.000013716879,0.000007449052,0.00022905832,0.00020668314,0.000047086236,0.000274767,0.000005987645],"about_ca_topic_score_codex":0.00047654545,"about_ca_topic_score_gemma":0.00097374734,"teacher_disagreement_score":0.0049507055,"about_ca_system_score_codex":0.00046056006,"about_ca_system_score_gemma":0.0011987288,"threshold_uncertainty_score":0.016561747},"labels":[],"label_agreement":null},{"id":"W3202872245","doi":"10.1136/jitc-2021-003467","title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Thomas Hospital; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Acute kidney injury; Renal function; Internal medicine; Creatinine; Odds ratio; Proportional hazards model; Biopsy; Urology; Gastroenterology","score_opus":0.008752036805244228,"score_gpt":0.2927027088432207,"score_spread":0.28395067203797647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202872245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728787,0.0014769223,0.00013329425,0.00013136557,0.000013768115,0.000017819304,0.0003932079,0.000004684741,0.0005410619],"genre_scores_gemma":[0.99910814,0.00032207704,0.000081470345,0.000069540685,0.0000241386,0.000009244588,0.0003282131,9.3631667e-7,0.00005607471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939084,0.00014362021,0.000093370996,0.00011959383,0.00013706271,0.000115508],"domain_scores_gemma":[0.99773455,0.00031827815,0.0015158475,0.00007109423,0.00011856255,0.00024164165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062609155,0.00013891149,0.0004687296,0.00035425814,0.00036666243,0.000568227,0.00022804481,0.0002435041,0.0011135017],"category_scores_gemma":[0.0023571542,0.00014265001,0.0005298985,0.00092206337,0.00018046472,0.00031713303,0.00043372432,0.0006754163,0.000109441884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115858915,0.000019162471,0.99838173,0.000020061158,0.00004399794,0.00009789852,0.000015396392,0.000038049715,0.000059027218,0.000013909056,0.0000847052,0.001110222],"study_design_scores_gemma":[0.000024659797,0.0001891644,0.99793845,0.00002660444,0.00004543558,0.00096610934,0.00007924566,0.00023448722,0.00006316533,0.000045068282,0.00038431078,0.0000033217657],"about_ca_topic_score_codex":0.0015553086,"about_ca_topic_score_gemma":0.0016826726,"teacher_disagreement_score":0.0015553086,"about_ca_system_score_codex":0.00036257211,"about_ca_system_score_gemma":0.0005017909,"threshold_uncertainty_score":0.0037250519},"labels":[],"label_agreement":null},{"id":"W3202999930","doi":"10.1136/jitc-2021-003476","title":"Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; National Cancer Institute; Natera; MacroGenics; Mirati Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; MorphoSys; Celgene; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Agios Pharmaceuticals; GlaxoSmithKline","keywords":"Nivolumab; Medicine; Oncology; Cancer; Tumor microenvironment; Internal medicine; Gastroenterology; Immunotherapy; Pathology","score_opus":0.01924529420777987,"score_gpt":0.3262464013921124,"score_spread":0.30700110718433254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202999930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989004,0.00063926255,0.000110622284,0.000028778697,0.000013591086,0.000040619394,0.00003760745,0.00000429137,0.00022485181],"genre_scores_gemma":[0.99858993,0.0005158039,0.00020957914,0.000068823254,0.000043177108,0.00008018539,0.00015156018,0.0000035721503,0.0003371951],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982375,0.000044310324,0.000009465538,0.000030992174,0.000034847,0.000056748293],"domain_scores_gemma":[0.99976224,0.000046421785,0.000043229775,0.000027973303,0.000016084654,0.00010405789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004879894,0.00039142487,0.0008552472,0.00015111799,0.00017254014,0.00035698575,0.0002497468,0.00027980842,0.001377995],"category_scores_gemma":[0.0002798823,0.00019938775,0.0007182779,0.00015748943,0.0003182622,0.00033243213,0.0003438911,0.0007406496,0.00022386499],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2302505,0.026868489,0.056780107,0.00080928387,0.0013887174,0.0013183828,0.0005854081,0.0023894808,0.5180003,0.00042501377,0.0018479152,0.15933646],"study_design_scores_gemma":[0.017817184,0.69916165,0.1819618,0.00006538067,0.001853525,0.0023770311,0.0005441704,0.00522344,0.08080338,0.00038057784,0.009757754,0.000054119628],"about_ca_topic_score_codex":0.0004462026,"about_ca_topic_score_gemma":0.0007984012,"teacher_disagreement_score":0.001377995,"about_ca_system_score_codex":0.0004263141,"about_ca_system_score_gemma":0.0007969121,"threshold_uncertainty_score":0.004609883},"labels":[],"label_agreement":null},{"id":"W3203166965","doi":"10.1136/jitc-2021-003329","title":"CXCR6 by increasing retention of memory CD8<sup>+</sup> T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; NIH Office of the Director","keywords":"Immunosurveillance; Ovarian cancer; Tumor microenvironment; CD8; Cytotoxic T cell; Cancer research; Medicine; Biology; Cancer; Immunology; Internal medicine; Tumor cells; Immune system","score_opus":0.008352878838006181,"score_gpt":0.24650940341765806,"score_spread":0.2381565245796519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203166965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936953,0.0034837783,0.0012244459,0.00016391545,0.000028545368,0.000036346657,0.00025832685,0.00009797841,0.0010113613],"genre_scores_gemma":[0.99578387,0.0010074107,0.0016013036,0.000080149555,0.000023437635,0.0000355496,0.00026434465,0.000014913163,0.0011890684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989617,0.000023803306,0.000010032788,0.000016904974,0.000017857223,0.000035206154],"domain_scores_gemma":[0.99993443,0.000007968549,0.000025208046,0.000006441224,0.000008097586,0.000017863782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001451032,0.00017417442,0.00022113918,0.00012834785,0.00009146495,0.00028587203,0.00011374354,0.00014681926,0.0015839451],"category_scores_gemma":[0.000103716746,0.00006892707,0.00014665528,0.000110828354,0.00013179342,0.00017715768,0.00014527266,0.0003734909,0.0002996569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007221665,0.000120885066,0.0025916847,0.00019988294,0.000009375317,0.000051915027,0.000030128404,0.00016541162,0.9822979,0.00012851728,0.0002698444,0.013412379],"study_design_scores_gemma":[0.00015717711,0.0034635698,0.033819955,0.00003135724,0.000067784174,0.0008141365,0.0001186882,0.0022774849,0.95129406,0.000124841,0.007821855,0.0000091022275],"about_ca_topic_score_codex":0.00029003722,"about_ca_topic_score_gemma":0.0004717451,"teacher_disagreement_score":0.0015839451,"about_ca_system_score_codex":0.00016323854,"about_ca_system_score_gemma":0.00018530877,"threshold_uncertainty_score":0.0052987933},"labels":[],"label_agreement":null},{"id":"W3208136450","doi":"10.1136/jitc-2020-001219","title":"Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Imiquimod; Pembrolizumab; Mucosal melanoma; Melanoma; Biopsy; Temozolomide; Dermatology; Hard palate; Surgery; Adjuvant therapy; Adjuvant; Oncology; Internal medicine; Cancer; Radiation therapy; Chemotherapy; Immunotherapy; Cancer research","score_opus":0.03045542805732991,"score_gpt":0.315627695618274,"score_spread":0.28517226756094405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208136450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813064,0.0114574665,0.002144741,0.00046850022,0.00006679468,0.0001044346,0.00004151317,0.00017064055,0.004239635],"genre_scores_gemma":[0.99479526,0.0022587082,0.0013093636,0.00016916369,0.000077105426,0.000026609543,0.000085725624,0.000015333319,0.0012626912],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99990237,0.000014688396,0.0000109934135,0.00001479609,0.000023642304,0.00003355266],"domain_scores_gemma":[0.9999391,0.0000099063645,0.000018063496,0.000009552031,0.0000050760405,0.000018251967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016602376,0.00036638606,0.00042748512,0.00023175291,0.00023985877,0.0001560371,0.00024069403,0.00038124082,0.0005426195],"category_scores_gemma":[0.00029968092,0.00012691155,0.00030791006,0.000093644674,0.00015311119,0.0001308913,0.00014459906,0.00059286057,0.00034752267],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016449068,0.0011233701,0.026951501,0.001033984,0.0001928701,0.083647564,0.00045439665,0.0007047041,0.49085614,0.00038229694,0.0027135205,0.39029473],"study_design_scores_gemma":[0.0011412699,0.022764651,0.22443752,0.0002410446,0.0005057272,0.45955285,0.00039552938,0.004997312,0.24189551,0.00051421084,0.043487143,0.00006728961],"about_ca_topic_score_codex":0.0004195819,"about_ca_topic_score_gemma":0.0010823023,"teacher_disagreement_score":0.0005426195,"about_ca_system_score_codex":0.00023720632,"about_ca_system_score_gemma":0.00014371987,"threshold_uncertainty_score":0.0018151999},"labels":[],"label_agreement":null},{"id":"W3216739419","doi":"10.1136/jitc-2021-003101","title":"Immunization with short peptide particles reveals a functional CD8<sup>+</sup> T-cell neoepitope in a murine renal carcinoma model","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; McGill University; Roswell Park Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Cancer vaccine; Immunology; Adjuvant; Major histocompatibility complex; Immunotherapy; Cytotoxic T cell; Medicine; Immune system; Immunization; Vaccination; CD8; Cancer immunotherapy; Cancer; Cancer research; Biology; Internal medicine","score_opus":0.019522419006735285,"score_gpt":0.2667006303931691,"score_spread":0.2471782113864338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216739419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537957,0.000286621,0.002841743,0.00007682781,0.00002611418,0.00005549025,0.00024447186,0.000094823736,0.0009943316],"genre_scores_gemma":[0.9919104,0.00025915494,0.003845023,0.00006107486,0.0000135757555,0.000085335625,0.00051590236,0.00003522032,0.003274314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984646,0.000022023232,0.000016715898,0.000034821183,0.000044766963,0.000035174002],"domain_scores_gemma":[0.9998474,0.000026093445,0.00004553139,0.000021993912,0.000017425167,0.00004158407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020517487,0.00051932194,0.00022873425,0.00021227321,0.00010617991,0.00019138001,0.00018908353,0.00042392922,0.0010522127],"category_scores_gemma":[0.00010982524,0.00015002582,0.0001987845,0.00007716192,0.00022152472,0.00019001124,0.00013326171,0.0007705454,0.0004903519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009450605,0.000051797593,0.000065421365,0.000011652653,0.000002331731,0.000019605064,0.000005638972,0.00006749317,0.9993242,0.000030905845,0.000018865987,0.00030756023],"study_design_scores_gemma":[0.000022162398,0.00056532706,0.00082579616,0.0000024347212,0.0000072642174,0.00014847075,0.0000068144363,0.0007355785,0.9971641,0.000018021612,0.00050229067,0.0000017426607],"about_ca_topic_score_codex":0.0003083316,"about_ca_topic_score_gemma":0.00043407115,"teacher_disagreement_score":0.0010522127,"about_ca_system_score_codex":0.00028116928,"about_ca_system_score_gemma":0.00019576988,"threshold_uncertainty_score":0.0035199523},"labels":[],"label_agreement":null},{"id":"W4200325010","doi":"10.1136/jitc-2021-003439","title":"Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Eberhard Karls Universität Tübingen; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Medicine; Peripheral blood; Melanoma; Antigen; Peripheral; Metastatic melanoma; Immunology; Oncology; Internal medicine; Cancer research","score_opus":0.02305420118363625,"score_gpt":0.33290988309969516,"score_spread":0.3098556819160589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200325010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990735,0.00024171178,0.0001682041,0.000009091136,0.000004942921,0.000015891204,0.00007255345,0.0000072340335,0.0004068746],"genre_scores_gemma":[0.999373,0.000061284045,0.00010619353,0.00002046732,0.000007692737,0.000020195674,0.00020666668,0.0000031061966,0.00020136047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988055,0.000022158692,0.000009704633,0.000042966476,0.000018412507,0.000026338726],"domain_scores_gemma":[0.9995652,0.00011049149,0.00011544357,0.00003982423,0.000041017523,0.0001280486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026441325,0.00020510759,0.00036872335,0.0002024031,0.00017237701,0.00038457793,0.00009482841,0.0002461791,0.0013542308],"category_scores_gemma":[0.0005996473,0.00011495004,0.000119000775,0.00013701819,0.00016104626,0.00019067967,0.00018085212,0.00060804264,0.00031748094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012107668,0.00094098237,0.6261475,0.00017770551,0.000091070724,0.00081472326,0.00040920376,0.0006299468,0.32155752,0.00008659221,0.0005197488,0.036517363],"study_design_scores_gemma":[0.00023183039,0.010853591,0.95245606,0.00002364433,0.00017045232,0.003074316,0.00015869217,0.0012153597,0.029845782,0.00010142002,0.0018563392,0.000012601533],"about_ca_topic_score_codex":0.00012250169,"about_ca_topic_score_gemma":0.00009855274,"teacher_disagreement_score":0.0013542308,"about_ca_system_score_codex":0.00013515583,"about_ca_system_score_gemma":0.000106349835,"threshold_uncertainty_score":0.0045303106},"labels":[],"label_agreement":null},{"id":"W4205273215","doi":"10.1136/jitc-2021-003497","title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; University of Manitoba","funders":"","keywords":"Blockade; Esophageal squamous cell carcinoma; Chemotherapy; Basal cell; Cell; Neoadjuvant therapy; Programmed cell death","score_opus":0.01985469544806639,"score_gpt":0.3174916672448145,"score_spread":0.2976369717967481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205273215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945257,0.003713569,0.0004425012,0.00012120151,0.00004669086,0.0001051958,0.00008836067,0.000030671406,0.0009261134],"genre_scores_gemma":[0.9978002,0.0010255949,0.0005597938,0.00006724637,0.000039428447,0.000094357616,0.0001879326,0.0000032475157,0.00022225497],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988174,0.00004930527,0.000013283236,0.000015883312,0.000019363413,0.000020479827],"domain_scores_gemma":[0.999824,0.00004896379,0.000044790515,0.000013570403,0.000011591518,0.000057182155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002832999,0.00023596182,0.00067220646,0.00020399452,0.00016308513,0.00019551057,0.00012221713,0.0001533998,0.0007797806],"category_scores_gemma":[0.00030777682,0.00009633841,0.00028033816,0.00014772643,0.00013577055,0.00015466363,0.00016120358,0.00032813285,0.00016690929],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064797394,0.0072778068,0.32185668,0.0010724588,0.0004878759,0.0049272804,0.00020953205,0.0045812186,0.22399457,0.0002604244,0.0036340966,0.36690077],"study_design_scores_gemma":[0.0057746833,0.19603431,0.62427676,0.0002470673,0.0009808758,0.019235779,0.0001917882,0.0112084355,0.12270582,0.00041581964,0.018856283,0.00007241701],"about_ca_topic_score_codex":0.00021080406,"about_ca_topic_score_gemma":0.0009362244,"teacher_disagreement_score":0.0007797806,"about_ca_system_score_codex":0.00031006493,"about_ca_system_score_gemma":0.00030676878,"threshold_uncertainty_score":0.0026085973},"labels":[],"label_agreement":null},{"id":"W4205297406","doi":"10.1136/jitc-2021-003687","title":"Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pathological; Medicine; Oncology; Soft tissue sarcoma; Sarcoma; Multivariate analysis; Internal medicine; Stage (stratigraphy); Immunohistochemistry; Metastasis; Immune system; Pathology; Cancer; Immunology; Biology","score_opus":0.01768678517388356,"score_gpt":0.3139879048871727,"score_spread":0.29630111971328915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205297406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856144,0.00010827842,0.00073586224,0.000020528838,0.0000017137828,0.00001003413,0.00018731202,0.000017633503,0.00035737077],"genre_scores_gemma":[0.99910897,0.000028973334,0.00044786982,0.0000049529963,0.0000028432712,0.000003679926,0.00034194015,0.0000026308076,0.000058160567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998124,0.000043273234,0.000018844878,0.000048399517,0.000043359945,0.000033691493],"domain_scores_gemma":[0.9993167,0.00021610138,0.0002630474,0.000057758007,0.000068032656,0.00007842371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044300535,0.0003021844,0.00035725304,0.0008920523,0.0001632773,0.00040563275,0.00016568248,0.00017277787,0.0012823939],"category_scores_gemma":[0.0010959958,0.0000654441,0.00037109968,0.0005065203,0.00020958012,0.00015967438,0.00023078006,0.00029547472,0.0002409767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010358024,0.000109288034,0.9346227,0.00007341381,0.00013003153,0.00020784409,0.000064034924,0.0035181143,0.036808517,0.000097706514,0.00020779215,0.023124665],"study_design_scores_gemma":[0.00002968854,0.0005773723,0.9679539,0.000012409471,0.00022465563,0.0011936156,0.0000714731,0.020020684,0.0087744985,0.00040053437,0.0007270885,0.000014115423],"about_ca_topic_score_codex":0.0008186642,"about_ca_topic_score_gemma":0.00132782,"teacher_disagreement_score":0.0012823939,"about_ca_system_score_codex":0.00027918856,"about_ca_system_score_gemma":0.00025489533,"threshold_uncertainty_score":0.0042900443},"labels":[],"label_agreement":null},{"id":"W4205349336","doi":"10.1136/jitc-2021-003779","title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Lung cancer; Internal medicine; Adverse effect; Cancer; Retrospective cohort study; Adverse Event Reporting System; Antibiotics; Pharmacovigilance; Logistic regression; Oncology","score_opus":0.008027828496329797,"score_gpt":0.2762625650620914,"score_spread":0.2682347365657616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205349336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124473,0.0045780754,0.0008776297,0.00034864747,0.000051970273,0.000045037643,0.0016754378,0.000013298078,0.001165153],"genre_scores_gemma":[0.9981779,0.0005026062,0.00029616375,0.00013223213,0.00005030385,0.000028784496,0.00068167085,0.0000040703767,0.00012620483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974251,0.0006776547,0.0005394096,0.0005629679,0.0005086816,0.00028623082],"domain_scores_gemma":[0.98915637,0.0022974608,0.007070017,0.00046880136,0.00058731093,0.00042000585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016447023,0.0001923806,0.00046288988,0.0007402164,0.00039387456,0.0006145601,0.00034024278,0.00037469078,0.0018408281],"category_scores_gemma":[0.0068862457,0.00015338897,0.0009023043,0.0015765791,0.00027593394,0.0003764995,0.00042226608,0.000903118,0.00012896911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017396211,0.000021277572,0.9969657,0.00005703244,0.0001349952,0.00005908583,0.000017858216,0.000059819155,0.000080664606,0.000026491482,0.00015095882,0.0022522248],"study_design_scores_gemma":[0.0000152464845,0.00014294086,0.99740297,0.00003487949,0.00014076772,0.0006159277,0.00007761545,0.0003854079,0.00014484304,0.000092852264,0.0009406875,0.000005854787],"about_ca_topic_score_codex":0.0013446952,"about_ca_topic_score_gemma":0.0014492957,"teacher_disagreement_score":0.0018408281,"about_ca_system_score_codex":0.0003909421,"about_ca_system_score_gemma":0.00055515947,"threshold_uncertainty_score":0.008698106},"labels":[],"label_agreement":null},{"id":"W4205941875","doi":"10.1136/jitc-2021-003155","title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children","keywords":"Pharmacology; Immune system; Medicine; Interleukin 2; IL-2 receptor; Immunotherapy; T cell; CD8; In vivo; Cancer immunotherapy; Cancer research; Pharmacodynamics; Immunology; Pharmacokinetics; Biology","score_opus":0.01714246827524964,"score_gpt":0.360369119108195,"score_spread":0.3432266508329454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205941875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982856,0.0025841428,0.008581901,0.00018590449,0.000056484863,0.00017689464,0.0005092115,0.0002718072,0.0047776587],"genre_scores_gemma":[0.98814976,0.0011510657,0.004817184,0.00013201042,0.000025278456,0.00015892439,0.000669285,0.00004526754,0.0048511196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979573,0.000054683635,0.000013024125,0.000052525986,0.000044522316,0.00003948877],"domain_scores_gemma":[0.999858,0.000030828454,0.00004411527,0.000023992741,0.000015594816,0.00002747072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003721813,0.0006044991,0.00024534937,0.00025967023,0.000118277654,0.00038257116,0.00024074683,0.00029171444,0.0015250739],"category_scores_gemma":[0.00016081808,0.0001424309,0.00017439279,0.000100210294,0.00025217328,0.00023574597,0.00014449074,0.00073809293,0.00058072014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043389338,0.0002852521,0.00012761145,0.000059096277,0.000011261504,0.000054825152,0.000026843338,0.00023126275,0.9946385,0.00014470935,0.00023279866,0.0037539601],"study_design_scores_gemma":[0.00014224408,0.00468982,0.001967063,0.000015401116,0.000046587425,0.000668197,0.000027859163,0.0014220292,0.98044455,0.000085530475,0.010481821,0.000008859042],"about_ca_topic_score_codex":0.00026587085,"about_ca_topic_score_gemma":0.0005709771,"teacher_disagreement_score":0.0015250739,"about_ca_system_score_codex":0.00030364946,"about_ca_system_score_gemma":0.0002651375,"threshold_uncertainty_score":0.0051018596},"labels":[],"label_agreement":null},{"id":"W4206536750","doi":"10.1136/jitc-2021-003289","title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"Mitacs; Terry Fox Research Institute; McMaster University","keywords":"Glioblastoma; Tumor microenvironment; Immunotherapy; Medicine; Cancer research; Computer science; Computational biology; Internal medicine; Cancer; Biology; Tumor cells","score_opus":0.012045329031695294,"score_gpt":0.29424844497210195,"score_spread":0.28220311594040665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206536750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98391867,0.008800888,0.0049027544,0.00028358275,0.000035998324,0.000063083186,0.00014396569,0.00014383231,0.0017071366],"genre_scores_gemma":[0.9949844,0.0025289648,0.0014441118,0.00009090661,0.000019432331,0.00002932614,0.0001045724,0.000007887657,0.0007902623],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999267,0.000009615974,0.0000037820666,0.000011706161,0.00002015336,0.000028056724],"domain_scores_gemma":[0.9999747,0.0000024813864,0.000007773447,0.0000023678685,0.0000044056906,0.000008295453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009551323,0.00023492181,0.00021976177,0.00023821148,0.000114221235,0.0002707826,0.00013745695,0.00019493038,0.00066643616],"category_scores_gemma":[0.000051644973,0.000055160293,0.00016334021,0.00012375161,0.00020704594,0.00015060345,0.00020421892,0.00026361633,0.00016337058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013406482,0.000055014527,0.00071299577,0.0001240041,0.000008275298,0.00012438254,0.00002629874,0.000419142,0.98699576,0.00033501268,0.00018801147,0.010877218],"study_design_scores_gemma":[0.000031659092,0.0011918616,0.005419904,0.000017010887,0.00006609116,0.0010202789,0.000054632044,0.0022052615,0.9807499,0.00021220975,0.009023539,0.000007671985],"about_ca_topic_score_codex":0.0006820942,"about_ca_topic_score_gemma":0.0009160924,"teacher_disagreement_score":0.0006820942,"about_ca_system_score_codex":0.0003806712,"about_ca_system_score_gemma":0.0002687802,"threshold_uncertainty_score":0.00276196},"labels":[],"label_agreement":null},{"id":"W4206897023","doi":"10.1136/jitc-2021-003777","title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of Calgary; Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Cohort; Endometrial cancer; Internal medicine; Microsatellite instability; Interim analysis; Interim; Oncology; Adverse effect; Cancer; Clinical trial; Biology; Microsatellite","score_opus":0.033581488453805174,"score_gpt":0.3416970790202096,"score_spread":0.3081155905664045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206897023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731725,0.0016719862,0.0001300779,0.00009983124,0.0000148586405,0.0001285622,0.00020269967,0.00002305103,0.00041174225],"genre_scores_gemma":[0.9979759,0.0005420228,0.0002654936,0.0001506022,0.000028945527,0.00013458566,0.00060305285,0.0000067784463,0.00029269766],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995851,0.00019847599,0.00003588776,0.000068604284,0.000058619724,0.000053313935],"domain_scores_gemma":[0.9994265,0.00013545416,0.00017093513,0.000058956535,0.000032777007,0.0001754006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013917589,0.0006378535,0.001394741,0.0002830437,0.00020623361,0.0005935452,0.00038064926,0.00060101534,0.001061537],"category_scores_gemma":[0.00088851113,0.00025754928,0.00078873546,0.0002560699,0.0004576657,0.0005520717,0.00021066541,0.0011494248,0.00035083355],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5642649,0.020317104,0.059473645,0.0009776795,0.0016052845,0.00047902713,0.00048840896,0.0051474045,0.09169626,0.00022983919,0.0026132728,0.25270712],"study_design_scores_gemma":[0.16935217,0.651706,0.14835621,0.00009262598,0.001349486,0.0014948087,0.00015633044,0.0048551736,0.01731817,0.00037065733,0.0048842574,0.000064104555],"about_ca_topic_score_codex":0.00019659572,"about_ca_topic_score_gemma":0.00045096528,"teacher_disagreement_score":0.001394741,"about_ca_system_score_codex":0.0005613875,"about_ca_system_score_gemma":0.000541156,"threshold_uncertainty_score":0.007360399},"labels":[],"label_agreement":null},{"id":"W4206944818","doi":"10.1136/jitc-2021-003024","title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Oncology; Adverse effect; Immunotherapy; Internal medicine; Cancer; Immune system; Quality of life (healthcare); Intensive care medicine; Immunology","score_opus":0.10129871765778996,"score_gpt":0.45823394637188564,"score_spread":0.35693522871409566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206944818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3075171,0.44119778,0.09562225,0.04240973,0.0035377908,0.002388419,0.004806348,0.0018391127,0.10068144],"genre_scores_gemma":[0.85544425,0.068913266,0.04841596,0.012375221,0.0034462616,0.0014757586,0.003955675,0.0001747409,0.0057988437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686915,0.0010508004,0.0005255543,0.00035535017,0.00087916723,0.000319956],"domain_scores_gemma":[0.9901406,0.0026931793,0.0036900004,0.00053727574,0.0020767231,0.00086221646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062270113,0.0007589245,0.0009490733,0.0013842732,0.00051009987,0.0024799095,0.0006846622,0.0008895429,0.0024972646],"category_scores_gemma":[0.008349621,0.00022870307,0.0008284978,0.00081385736,0.0011745245,0.0024539419,0.0020234268,0.0035178044,0.0010145304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033788178,0.00050545495,0.0988114,0.0043085245,0.00032932326,0.0016023591,0.00066914473,0.003640298,0.052161686,0.04004888,0.038230132,0.756314],"study_design_scores_gemma":[0.0007308215,0.009401442,0.22508651,0.0045523443,0.0010225895,0.038142007,0.0014050915,0.014589806,0.067243755,0.06693086,0.57050866,0.00038609703],"about_ca_topic_score_codex":0.0005160059,"about_ca_topic_score_gemma":0.0008027725,"teacher_disagreement_score":0.0062270113,"about_ca_system_score_codex":0.0016653896,"about_ca_system_score_gemma":0.0013104909,"threshold_uncertainty_score":0.032931983},"labels":[],"label_agreement":null},{"id":"W4207039879","doi":"10.1136/jitc-2021-004310","title":"Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; ECOG-ACRIN Cancer Research Group; University of Pittsburgh; American College of Radiology Imaging Network; Canadian Cancer Society Research Institute; Moffitt Cancer Center; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Internal medicine; Oncology; Melanoma; Proportional hazards model; Adjuvant; Immune system; Population; Primary tumor; Immunotherapy; Hazard ratio; FOXP3; Immunology; Gastroenterology; Metastasis; Cancer; Cancer research; Confidence interval","score_opus":0.008562596039694056,"score_gpt":0.25557831900032485,"score_spread":0.2470157229606308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207039879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99965537,0.00011334655,0.000033002718,0.000011733291,0.0000018695832,0.0000018806937,0.000039010953,0.0000015646968,0.00014221169],"genre_scores_gemma":[0.99982953,0.000027877017,0.000019366871,0.0000069893617,0.0000050600966,0.0000014997009,0.000053866683,4.916615e-7,0.000055448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989295,0.000026135353,0.000006875128,0.000030657073,0.000017412538,0.00002594441],"domain_scores_gemma":[0.99940825,0.00010391832,0.00025755452,0.000038572085,0.000042856787,0.00014880318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024135056,0.00014979669,0.00027295158,0.00024535967,0.00019659591,0.00037282388,0.000113667,0.00020095473,0.0015004219],"category_scores_gemma":[0.0008469933,0.00009289597,0.00015304201,0.00021703767,0.0001592289,0.0002247294,0.00019307045,0.00029953552,0.0002377656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001108419,0.000058442587,0.9921834,0.00001369374,0.00002802459,0.00021128355,0.00004129839,0.000055698805,0.0030123417,0.000013831539,0.00006768599,0.0032059068],"study_design_scores_gemma":[0.000023670142,0.0004436231,0.9972882,0.0000034656962,0.00003626967,0.0011301227,0.00006581584,0.0002948924,0.0005271801,0.000032157117,0.00015220248,0.0000023476746],"about_ca_topic_score_codex":0.00028263623,"about_ca_topic_score_gemma":0.0003434134,"teacher_disagreement_score":0.0015004219,"about_ca_system_score_codex":0.00016722981,"about_ca_system_score_gemma":0.00012124913,"threshold_uncertainty_score":0.0050194263},"labels":[],"label_agreement":null},{"id":"W4210690867","doi":"10.1136/jitc-2021-003551","title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; McGill University Health Centre; McGill University","keywords":"Janus kinase; Immune system; Monoclonal antibody; Medicine; Kinase; Cancer research; STAT protein; Immunology; Proinflammatory cytokine; Antibody; Tyrosine kinase; Signal transduction; Inflammation; Biology; STAT3; Cytokine; Cell biology; Receptor; Internal medicine","score_opus":0.03088694924051371,"score_gpt":0.3364963500272145,"score_spread":0.3056094007867008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210690867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010683177,0.99884915,0.00008948451,0.0002248079,0.0001587391,0.000005086835,0.000010282443,0.0000053721437,0.000550256],"genre_scores_gemma":[0.00073015905,0.998133,0.0001745384,0.0003167628,0.00016325965,0.000009148657,0.000024453719,0.0000015310212,0.0004472039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978477,0.00004502988,0.00003682108,0.000033390745,0.00008078099,0.000019205787],"domain_scores_gemma":[0.9996493,0.00019528718,0.000049639362,0.000008767928,0.00007552615,0.000021424928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006358445,0.00075172493,0.0012440532,0.0019426579,0.00019994978,0.0007964677,0.00078494713,0.001019058,0.0030696355],"category_scores_gemma":[0.00088008406,0.00019883797,0.0007679079,0.0012679072,0.00034133962,0.0009768673,0.0004894965,0.0018448348,0.0012806394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091256,0.000054848428,0.00011914689,0.016747534,0.00013993046,0.00017124784,0.00003448815,0.00023790901,0.0010809705,0.0017496916,0.020840082,0.9587328],"study_design_scores_gemma":[0.000075719865,0.00019315841,0.0010279411,0.008437195,0.00032357912,0.0023394916,0.00005259829,0.00013798459,0.0007560532,0.0018997425,0.98473513,0.000021405525],"about_ca_topic_score_codex":0.0005164153,"about_ca_topic_score_gemma":0.0013545203,"teacher_disagreement_score":0.0030696355,"about_ca_system_score_codex":0.0005038487,"about_ca_system_score_gemma":0.0006556935,"threshold_uncertainty_score":0.010268986},"labels":[],"label_agreement":null},{"id":"W4210910593","doi":"10.1136/jitc-2021-003534","title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novelis (Canada)","funders":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Immunotherapy; Cancer research; Epidermal growth factor receptor; Tumor microenvironment; CD8; Adenocarcinoma; Immune system; Lung cancer; Biology; Cell; Cytotoxic T cell; Immune checkpoint; Medicine; Cancer; Immunology; Pathology; Internal medicine","score_opus":0.01319586278171577,"score_gpt":0.27630196322931394,"score_spread":0.2631061004475982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210910593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453074,0.0005606355,0.0030652883,0.000034548633,0.00001213604,0.000010603743,0.001325585,0.00005381575,0.00040670464],"genre_scores_gemma":[0.9935946,0.00032667466,0.0028977594,0.00006829943,0.0000074965074,0.000039312767,0.0023739561,0.000025268379,0.0006667501],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989676,0.000007924938,0.000006507317,0.000042564632,0.00002837009,0.000017788188],"domain_scores_gemma":[0.9999279,0.000016732636,0.0000147775145,0.000008063611,0.000020187259,0.000012423236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110477195,0.000119891345,0.00033284727,0.0001924718,0.00017985041,0.00030100296,0.00009295835,0.00021227461,0.00048092075],"category_scores_gemma":[0.00016778515,0.00009688795,0.00026531832,0.00023361536,0.00013396666,0.00014001218,0.00016691294,0.00024521817,0.0001798482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106808635,0.0000130885455,0.009179669,0.000052902255,0.000013887368,0.00007597472,0.000076360215,0.00024513903,0.9867951,0.000034819037,0.00008806273,0.0033181594],"study_design_scores_gemma":[0.000014541342,0.00041968905,0.66171193,0.000021418566,0.0001170891,0.0009528191,0.0007368685,0.015064733,0.31572473,0.00030417994,0.004898632,0.0000333555],"about_ca_topic_score_codex":0.00069994596,"about_ca_topic_score_gemma":0.0010977346,"teacher_disagreement_score":0.00069994596,"about_ca_system_score_codex":0.00013617885,"about_ca_system_score_gemma":0.00012919067,"threshold_uncertainty_score":0.0016088486},"labels":[],"label_agreement":null},{"id":"W4212834341","doi":"10.1136/jitc-2021-003490","title":"Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Etelä-Savon Rahasto; Novo Nordisk Fonden; K. Albin Johanssons Stiftelse; Syöpäjärjestöt; Päivikki ja Sakari Sohlbergin Säätiö; Novo Nordisk; Jane ja Aatos Erkon Säätiö; Suomen Kulttuurirahasto; Suomen Lääketieteen Säätiö; Suomalais-Norjalainen Lääketieteen Säätiö; Helsingin Yliopisto","keywords":"Oncolytic virus; Oncolytic adenovirus; Immunotherapy; Medicine; CD8; Immune checkpoint; Melanoma; Cancer; Immune system; Cancer research; Cytotoxic T cell; Cancer immunotherapy; Tumor-infiltrating lymphocytes; T cell; Immunology; Oncology; Internal medicine; Biology","score_opus":0.009075243039969082,"score_gpt":0.25476948698413565,"score_spread":0.24569424394416656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212834341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990897,0.00043702574,0.00020575589,0.00001715541,0.0000028339934,0.0000059258964,0.00008491674,0.000009853534,0.00014675305],"genre_scores_gemma":[0.9992537,0.00013303479,0.00020728781,0.000011681092,0.0000041912717,0.0000069333564,0.00016968866,0.0000018350536,0.00021168041],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999497,0.000010534345,0.0000052061732,0.000012596615,0.000007825923,0.000014043068],"domain_scores_gemma":[0.99984443,0.000035226465,0.00005846574,0.000013826704,0.000014289383,0.00003363924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012759652,0.00012430926,0.0001580382,0.000121692065,0.000065086235,0.00015344984,0.00005888101,0.00011361281,0.0008108396],"category_scores_gemma":[0.00020842114,0.00006334054,0.00010051971,0.00010436648,0.00010502099,0.000098281336,0.00007374223,0.0002421885,0.00012002839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005989431,0.0006061607,0.1372511,0.00010166056,0.000058773083,0.000114350514,0.0000822413,0.00041694418,0.82061595,0.000067828274,0.00031894405,0.034376577],"study_design_scores_gemma":[0.00018263629,0.012117549,0.7012863,0.000009458925,0.0001532134,0.0017157001,0.00014922825,0.0021318987,0.27908877,0.00010538662,0.0030492377,0.000010630473],"about_ca_topic_score_codex":0.00017037673,"about_ca_topic_score_gemma":0.00018415804,"teacher_disagreement_score":0.0008108396,"about_ca_system_score_codex":0.00010822672,"about_ca_system_score_gemma":0.00008637535,"threshold_uncertainty_score":0.0027124882},"labels":[],"label_agreement":null},{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","score_opus":0.011892139948701776,"score_gpt":0.30239322763100274,"score_spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214685750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496573,0.0012815373,0.00051024155,0.0001804735,0.000056076926,0.0015000496,0.00034761176,0.00005391713,0.0011042306],"genre_scores_gemma":[0.9947956,0.0008712543,0.0011939731,0.00028793488,0.00006730622,0.0010688251,0.00070486177,0.0000096654885,0.0010005645],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975246,0.0000999921,0.00001411213,0.000056262674,0.000024591862,0.00005267691],"domain_scores_gemma":[0.99969923,0.00004029127,0.00004963758,0.00002282265,0.00001415266,0.00017376464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009571904,0.001013658,0.0015593227,0.00029418367,0.0002695521,0.00054910564,0.0004365322,0.00049707486,0.00208862],"category_scores_gemma":[0.0004619437,0.00041640358,0.00072337565,0.00024356355,0.0005746095,0.00041731558,0.0002569856,0.0015652948,0.0004428496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53966564,0.0902372,0.019278266,0.00072750665,0.0009998215,0.00040871376,0.0004474836,0.0052810214,0.13798052,0.0005094574,0.00388386,0.20058046],"study_design_scores_gemma":[0.36226955,0.6000337,0.020879798,0.000034892102,0.00046184627,0.00038837647,0.00008270575,0.002112482,0.009741401,0.00026684784,0.0037042273,0.000024093499],"about_ca_topic_score_codex":0.0006390285,"about_ca_topic_score_gemma":0.0014650647,"teacher_disagreement_score":0.00208862,"about_ca_system_score_codex":0.0007178919,"about_ca_system_score_gemma":0.0010981953,"threshold_uncertainty_score":0.006987095},"labels":[],"label_agreement":null},{"id":"W4214902204","doi":"10.1136/jitc-2021-003923","title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Beatrice Hunter Cancer Research Institute; Dalhousie University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Beatrice Hunter Cancer Research Institute; Cancer Research Institute","keywords":"Oncolytic virus; Immunotherapy; Blockade; Medicine; Virotherapy; Cancer research; Pancreatic cancer; Immunology; Immune system; Oncology; Tumor cells; Internal medicine; Cancer; Receptor","score_opus":0.009588304409269253,"score_gpt":0.2990606469923034,"score_spread":0.2894723425830341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214902204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574214,0.0010619739,0.001445392,0.000099823395,0.00006618512,0.000068910434,0.0001333477,0.000108277934,0.0012739111],"genre_scores_gemma":[0.9968815,0.0005962715,0.001165125,0.000045556837,0.000025374851,0.000065824635,0.00017393878,0.000009501269,0.0010368655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997888,0.000029613138,0.000018698516,0.000047175447,0.000041916315,0.000073774645],"domain_scores_gemma":[0.9999119,0.000012595094,0.00002539925,0.000011927264,0.0000044276185,0.000033725544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016260533,0.00050209975,0.00042359653,0.00024148822,0.000103944076,0.00028401572,0.00029202388,0.00028343903,0.0007153695],"category_scores_gemma":[0.0000971633,0.00013683278,0.00043508026,0.00015812079,0.00032192294,0.00023072219,0.00017770108,0.0009404239,0.00023121922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074696686,0.0005491419,0.00030905337,0.000088411616,0.000021655724,0.00005447536,0.000022164308,0.00041557546,0.99253255,0.00014083917,0.00013431063,0.004984849],"study_design_scores_gemma":[0.00026375163,0.0054642158,0.0028735404,0.000014459391,0.000056653796,0.00027125338,0.000023307704,0.0025827358,0.98645186,0.00006242565,0.0019304589,0.0000052602395],"about_ca_topic_score_codex":0.00030035625,"about_ca_topic_score_gemma":0.00047071645,"teacher_disagreement_score":0.0007153695,"about_ca_system_score_codex":0.00024483574,"about_ca_system_score_gemma":0.00033103902,"threshold_uncertainty_score":0.002393186},"labels":[],"label_agreement":null},{"id":"W4220702214","doi":"10.1136/jitc-2021-003569","title":"Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Research and Development; National Cancer Institute; Sanofi; Merck","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Aflibercept; Melanoma; Adverse effect; Population; Cancer; Gastroenterology; Bevacizumab; Immunotherapy; Cancer research; Chemotherapy","score_opus":0.013439187549297058,"score_gpt":0.339573802387077,"score_spread":0.32613461483777995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220702214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039197,0.0023693678,0.00094191585,0.0005224817,0.000085499734,0.0034810114,0.0006421403,0.0000962636,0.0014694406],"genre_scores_gemma":[0.9903716,0.0013481792,0.002691345,0.0005490074,0.00012528952,0.0022860412,0.00166111,0.00002767693,0.00093971257],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995695,0.00019035088,0.000027978818,0.000068897796,0.000051882893,0.000091426075],"domain_scores_gemma":[0.9992964,0.00008360125,0.00015369088,0.000051803658,0.000048597092,0.00036586565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017751008,0.0013499175,0.0016877338,0.0004115063,0.0004211969,0.00081353134,0.000817743,0.0008732566,0.0023531052],"category_scores_gemma":[0.0007174826,0.00052107347,0.0008910138,0.0004684169,0.0007069161,0.0005326792,0.00030899106,0.0033612186,0.00080868363],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45918146,0.1258876,0.02671833,0.001300215,0.0024168734,0.0007970721,0.00069956033,0.0054718414,0.19823323,0.0004861049,0.007813401,0.17099434],"study_design_scores_gemma":[0.47201508,0.4906599,0.020235442,0.00004574634,0.0005428124,0.0008059807,0.000066399436,0.0018561882,0.009646444,0.00017045981,0.003932611,0.00002301045],"about_ca_topic_score_codex":0.00089287583,"about_ca_topic_score_gemma":0.0016955417,"teacher_disagreement_score":0.0023531052,"about_ca_system_score_codex":0.00094987836,"about_ca_system_score_gemma":0.0017319476,"threshold_uncertainty_score":0.009387732},"labels":[],"label_agreement":null},{"id":"W4220720824","doi":"10.1136/jitc-2021-004335","title":"Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada; Ontario Veterinary College, University of Guelph; Terry Fox Research Institute; Cancer Research Society","keywords":"Oncolytic virus; Ovarian cancer; Cancer research; Immunotherapy; Biology; Innate immune system; Immune system; Cancer; Virotherapy; Immunology","score_opus":0.027000529465359756,"score_gpt":0.3315976207972424,"score_spread":0.3045970913318827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220720824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226415,0.00094894605,0.0026686336,0.00008237092,0.000022620055,0.00005556242,0.0030120078,0.00012864788,0.0008171409],"genre_scores_gemma":[0.989852,0.00075038703,0.003657836,0.00005256732,0.00000895831,0.00013342185,0.003631311,0.00004079846,0.0018726235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997999,0.00001502274,0.000019491605,0.00005858207,0.000053001117,0.000053912107],"domain_scores_gemma":[0.99986076,0.000017788583,0.000051658815,0.000024426763,0.000012021456,0.00003332165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001747055,0.00030815732,0.00026440897,0.0005647802,0.0001503383,0.00033868567,0.00015221609,0.00021983073,0.0009469015],"category_scores_gemma":[0.000115609924,0.0001339051,0.00024456278,0.0002937028,0.00023623287,0.0001941963,0.00016871437,0.00061308435,0.00021684695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042237743,0.000057035308,0.0008902233,0.000045394914,0.000007753026,0.000027826258,0.00002091152,0.00018592061,0.9965035,0.00010354171,0.00007678733,0.0016588008],"study_design_scores_gemma":[0.000060781833,0.00092322944,0.013613727,0.000016268166,0.000034805245,0.00031130496,0.000058182413,0.002607943,0.9770857,0.00014837379,0.005130975,0.000008722806],"about_ca_topic_score_codex":0.00049860217,"about_ca_topic_score_gemma":0.0010636036,"teacher_disagreement_score":0.0009469015,"about_ca_system_score_codex":0.00030177188,"about_ca_system_score_gemma":0.00028883188,"threshold_uncertainty_score":0.0031677485},"labels":[],"label_agreement":null},{"id":"W4220847549","doi":"10.1136/jitc-2021-004233","title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Pharmacyclics; Genentech; PharmaMar; Eisai; Syndax Pharmaceuticals; Clovis Oncology; BeiGene; Conquer Cancer Foundation; Merck KGaA; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Princess Margaret Cancer Foundation; Pfizer; Mersana Therapeutics","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Immunotherapy; Cabozantinib; Clinical endpoint; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Cancer; Clinical trial; Gastroenterology; Phases of clinical research; Chemotherapy","score_opus":0.04021511302289515,"score_gpt":0.3943897692277361,"score_spread":0.35417465620484095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220847549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678555,0.0077041695,0.0011096236,0.00244829,0.0009869968,0.014303463,0.0021373555,0.00016886185,0.0032856702],"genre_scores_gemma":[0.9706796,0.0030538132,0.0028059322,0.0023191057,0.00073708163,0.013957276,0.0023671768,0.00003571829,0.0040443316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99880385,0.00080072915,0.000050145278,0.00014628396,0.000060194077,0.00013879637],"domain_scores_gemma":[0.9984504,0.00031305998,0.00043368383,0.00017225828,0.00011839578,0.00051210553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037730092,0.0021315687,0.0027323996,0.00047765276,0.0005813875,0.001331821,0.0010780889,0.0019681791,0.0079828985],"category_scores_gemma":[0.002895598,0.0008221239,0.0019381599,0.00055533065,0.0017861198,0.0011812369,0.000599743,0.0034386641,0.0012294668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9782039,0.006814078,0.0007131044,0.00048668304,0.0008870167,0.000038337377,0.000057058332,0.0003467149,0.0021367453,0.00012643187,0.0010974582,0.009092341],"study_design_scores_gemma":[0.94508964,0.05215827,0.0009801477,0.00002620657,0.00027410308,0.000033504206,0.0000217153,0.00025426707,0.00020357959,0.00021125366,0.00073950295,0.000007815749],"about_ca_topic_score_codex":0.0014683267,"about_ca_topic_score_gemma":0.0043732147,"teacher_disagreement_score":0.0079828985,"about_ca_system_score_codex":0.0017461925,"about_ca_system_score_gemma":0.0028928898,"threshold_uncertainty_score":0.026705503},"labels":[],"label_agreement":null},{"id":"W4221060919","doi":"10.1136/jitc-2021-004191","title":"Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Labex Immuno-Oncology; Horizon 2020 Framework Programme; Institut Carnot Santé Animale; Institut Universitaire de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; Université de Paris; Association pour la Recherche sur le Cancer; Seerave Foundation; Institut Gustave-Roussy; Fondation Leducq; European Commission; Centre National de la Recherche Scientifique; National Institutes of Health; Equipex","keywords":"Prostate cancer; Medicine; Akkermansia; Immune system; Androgen deprivation therapy; Immunology; Cancer; Internal medicine; Cancer research; Biology","score_opus":0.01269978521263206,"score_gpt":0.29391935045288975,"score_spread":0.2812195652402577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221060919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974565,0.0017462226,0.00014423081,0.000018432092,0.0000070321676,0.000015077746,0.000087245455,0.000007866114,0.00051740144],"genre_scores_gemma":[0.99922025,0.00039209964,0.00010134389,0.000018303877,0.000007016549,0.000008595216,0.000097868855,0.0000019359009,0.00015260643],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999881,0.000033656066,0.000007843795,0.000021314268,0.000024579149,0.000031519226],"domain_scores_gemma":[0.9997893,0.00003845553,0.000047430163,0.0000097897755,0.0000203938,0.00009471249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014241353,0.00016983662,0.00025685332,0.00028014794,0.000102045466,0.00023943196,0.0000832846,0.0001459967,0.0010244888],"category_scores_gemma":[0.0002679849,0.00008815451,0.00015778914,0.00016258302,0.00014616706,0.00016507112,0.0001512186,0.00031633285,0.00013897417],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008374475,0.0008247916,0.12570556,0.0001440401,0.00009189434,0.00016937389,0.00008870745,0.00039435292,0.8311723,0.000076625656,0.00019301238,0.032764994],"study_design_scores_gemma":[0.00010866834,0.015240989,0.87957263,0.000022873488,0.00020018908,0.0008886485,0.00017258218,0.0009475343,0.1008038,0.00008535716,0.0019432594,0.000013495962],"about_ca_topic_score_codex":0.0003428709,"about_ca_topic_score_gemma":0.00048381538,"teacher_disagreement_score":0.0010244888,"about_ca_system_score_codex":0.0001411714,"about_ca_system_score_gemma":0.00014013321,"threshold_uncertainty_score":0.003427267},"labels":[],"label_agreement":null},{"id":"W4221112390","doi":"10.1136/jitc-2021-004241","title":"MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Chromosomal and Genetic Variations","field":"Agricultural and Biological Sciences","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Endogenous retrovirus; Medicine; Lung cancer; Oncology; Clinical endpoint; Transcriptome; Proportional hazards model; Internal medicine; Cancer; Gene expression; Immunology; Gene; Biology; Randomized controlled trial; Genetics","score_opus":0.018719100877234055,"score_gpt":0.24922115197429534,"score_spread":0.2305020510970613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221112390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987489,0.00022866316,0.0005561013,0.000017266153,0.000004242502,0.000006833929,0.00022127377,0.00001154996,0.00020513799],"genre_scores_gemma":[0.9987515,0.000050199014,0.00035831166,0.000016771277,0.0000054608995,0.00000907313,0.0006131206,0.0000060498205,0.00018946211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996922,0.00007090757,0.00002803533,0.00009852356,0.000064165986,0.00004625799],"domain_scores_gemma":[0.99920803,0.00024479392,0.00031692133,0.00007101017,0.00009707096,0.00006217354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072703714,0.00027021032,0.00039314752,0.0003421548,0.00016866402,0.000612252,0.00017016179,0.00029273776,0.0017326666],"category_scores_gemma":[0.0011505587,0.00012516421,0.0004575457,0.00030291043,0.00027168484,0.00025247084,0.00022681206,0.0005216425,0.000217995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056352513,0.00028230093,0.8134184,0.00013346133,0.00031488828,0.00038960256,0.00010270573,0.0045239185,0.15134178,0.00016198891,0.00036721528,0.023328513],"study_design_scores_gemma":[0.00009817937,0.0026919178,0.9046556,0.000024209128,0.00038099985,0.0017556471,0.00018944216,0.02103236,0.06656554,0.0004584013,0.0021190958,0.000028614913],"about_ca_topic_score_codex":0.00025273673,"about_ca_topic_score_gemma":0.00026868258,"teacher_disagreement_score":0.0017326666,"about_ca_system_score_codex":0.00031332087,"about_ca_system_score_gemma":0.0001638278,"threshold_uncertainty_score":0.005796373},"labels":[],"label_agreement":null},{"id":"W4221119237","doi":"10.1136/jitc-2022-004560","title":"Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital; Vancouver General Hospital; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; H&E stain; Pathology; Biopsy; Internal medicine; Immunohistochemistry","score_opus":0.03298784563646882,"score_gpt":0.36664944114517334,"score_spread":0.3336615955087045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221119237","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06680335,0.044599134,0.27605486,0.44992873,0.018346366,0.028140066,0.0038596084,0.0034243101,0.10884365],"genre_scores_gemma":[0.107436374,0.023564614,0.781996,0.054920916,0.003581447,0.013290392,0.004603932,0.00048766262,0.010118649],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.92699873,0.03813269,0.015792442,0.0021288823,0.014600907,0.0023463063],"domain_scores_gemma":[0.78260535,0.059111338,0.01714445,0.010740594,0.12330903,0.007089235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08162547,0.0012557523,0.0010946529,0.0070521524,0.001809081,0.0027024997,0.005715774,0.0078022596,0.0026710466],"category_scores_gemma":[0.15101393,0.0010018154,0.0024890075,0.0028414747,0.0020840503,0.0027924958,0.0029953683,0.006517647,0.003471235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050920254,0.0008436875,0.030455029,0.0040224544,0.00016067174,0.0024253135,0.0036134152,0.0033627984,0.013004472,0.0047402754,0.32632372,0.610539],"study_design_scores_gemma":[0.00064598134,0.0014961573,0.10312388,0.031329937,0.0007887579,0.0063793166,0.012422053,0.009433442,0.01363884,0.017259188,0.80291665,0.0005658219],"about_ca_topic_score_codex":0.0059031365,"about_ca_topic_score_gemma":0.010534478,"teacher_disagreement_score":0.08162547,"about_ca_system_score_codex":0.0022615811,"about_ca_system_score_gemma":0.008003596,"threshold_uncertainty_score":0.43168187},"labels":[],"label_agreement":null},{"id":"W4225128983","doi":"10.1136/jitc-2021-004151","title":"Local anesthetics elicit immune-dependent anticancer effects","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Labex Immuno-Oncology; High-end Foreign Experts Recruitment Plan of China; European Research Area Network on Cardiovascular Diseases; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Institut Universitaire de France; China Scholarship Council; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Université Paris-Saclay; Agence Nationale de la Recherche; E-Rare; Fondation Philanthropia; Bristol-Myers Squibb; Association pour la Recherche sur le Cancer; Seerave Foundation; Institut Gustave-Roussy; Fondation Leducq; European Commission","keywords":"Unfolded protein response; Autophagy; Endoplasmic reticulum; ATG5; Immunogenic cell death; Integrated stress response; Medicine; Phosphorylation; Cancer research; Pharmacology; Cell biology; Immunology; Immune system; Chemistry; Biology; Immunotherapy; Apoptosis; Biochemistry; Translation (biology)","score_opus":0.010377446770517789,"score_gpt":0.30995109416371,"score_spread":0.2995736473931922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225128983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286432,0.060608372,0.0032741572,0.00036893645,0.00014973844,0.00033339154,0.000354129,0.00014439096,0.006123678],"genre_scores_gemma":[0.98398596,0.011729317,0.0014617724,0.00036121035,0.00013630018,0.00015375804,0.00032717298,0.0000121656,0.0018323798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978083,0.000050553284,0.00002204242,0.00003582331,0.000051810537,0.00005886034],"domain_scores_gemma":[0.9997639,0.000052199528,0.00009733499,0.000017239403,0.000028545293,0.00004070766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033057728,0.00035562197,0.00036644438,0.00022829152,0.00013023197,0.00022701934,0.00014878542,0.00027435942,0.0030252724],"category_scores_gemma":[0.00023395885,0.000068048976,0.00035302862,0.0001604029,0.00023638924,0.00018791636,0.00018668747,0.00057105324,0.0004568432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046859058,0.0019460132,0.0046766,0.0021179216,0.00014967589,0.0007153611,0.00005376679,0.00053140265,0.8529879,0.0006849659,0.0009412925,0.1305092],"study_design_scores_gemma":[0.0011174245,0.056509655,0.03474177,0.00025760342,0.000466641,0.0053295563,0.00015651534,0.0011145732,0.86940795,0.00032636174,0.030544925,0.000027057858],"about_ca_topic_score_codex":0.00008918386,"about_ca_topic_score_gemma":0.00022518692,"teacher_disagreement_score":0.0030252724,"about_ca_system_score_codex":0.00015325697,"about_ca_system_score_gemma":0.0001562016,"threshold_uncertainty_score":0.010120511},"labels":[],"label_agreement":null},{"id":"W4234138863","doi":"10.1186/s40425-017-0297-3","title":"32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Cancer; Medicine; Internal medicine","score_opus":0.03271945670655681,"score_gpt":0.35928972632851763,"score_spread":0.32657026962196084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234138863","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022331676,0.04404338,0.009254633,0.21965176,0.5003235,0.0026969092,0.0073714815,0.0015964927,0.19273019],"genre_scores_gemma":[0.047719024,0.024186788,0.0060838195,0.017259408,0.1183289,0.001880447,0.011158528,0.0011981997,0.77218497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771476,0.00038119513,0.00013129653,0.00021497162,0.00089391024,0.00066382554],"domain_scores_gemma":[0.9911657,0.00029840285,0.00040322344,0.0002180006,0.0032520613,0.0046625654],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066975346,0.0015937255,0.0008630168,0.0020168936,0.0020213202,0.004609373,0.0014817732,0.0030513273,0.08896677],"category_scores_gemma":[0.0037880477,0.00038413715,0.0009999188,0.0008058153,0.0007401088,0.0015317292,0.0041481736,0.00447598,0.046324085],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003952192,0.00019083358,0.0010057298,0.00024499334,0.000019051744,0.000104699095,0.0000662212,0.0001499904,0.002524972,0.0009710007,0.9325783,0.06174893],"study_design_scores_gemma":[0.00006601636,0.00022882003,0.003269278,0.00023057315,0.000016827707,0.00010734208,0.00019936751,0.00033094353,0.0017172432,0.0009821003,0.992827,0.000024558067],"about_ca_topic_score_codex":0.0018929706,"about_ca_topic_score_gemma":0.0050615543,"teacher_disagreement_score":0.9110332,"about_ca_system_score_codex":0.0023817716,"about_ca_system_score_gemma":0.009019871,"threshold_uncertainty_score":0.29762352},"labels":[],"label_agreement":null},{"id":"W4234912275","doi":"10.1136/jitc-2020-001472","title":"Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Data sharing; Clinical trial; Medicine; Resource (disambiguation); Biomarker; Data science; Biomarker discovery; Data collection; Computer science; Medical physics; Alternative medicine; Pathology","score_opus":0.08466978870647565,"score_gpt":0.4076963484725098,"score_spread":0.3230265597660341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234912275","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041325907,0.005566909,0.081849106,0.6573093,0.056142226,0.013614812,0.01822697,0.0052002496,0.15795784],"genre_scores_gemma":[0.04121534,0.011900021,0.2416065,0.3093655,0.041983426,0.025774734,0.080280006,0.0045671877,0.2433072],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.88265365,0.048825487,0.015012689,0.004970275,0.042621892,0.005916076],"domain_scores_gemma":[0.67230767,0.06827155,0.01839058,0.0700688,0.13340685,0.037554566],"candidate_categories":["metaresearch","open_science"],"consensus_categories":[],"category_scores_codex":[0.17729637,0.0010057967,0.0022050992,0.0043451847,0.0042262524,0.016910229,0.0088837575,0.009215546,0.038762696],"category_scores_gemma":[0.14992853,0.001641668,0.002620095,0.00501196,0.0033346608,0.009691052,0.013378762,0.012721355,0.040956732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011698226,0.00014647655,0.0012002104,0.0003281091,0.000036851616,0.000069118796,0.00016665965,0.00047439238,0.00080396177,0.012253757,0.88992715,0.09447644],"study_design_scores_gemma":[0.00006576416,0.00012699193,0.0012452536,0.0005787401,0.000016190173,0.00013339709,0.00017296417,0.0007256673,0.00051529094,0.0058107222,0.9905681,0.000040932613],"about_ca_topic_score_codex":0.0068872566,"about_ca_topic_score_gemma":0.0060204165,"teacher_disagreement_score":0.9911162,"about_ca_system_score_codex":0.0073574004,"about_ca_system_score_gemma":0.08468863,"threshold_uncertainty_score":0.937644},"labels":[],"label_agreement":null},{"id":"W4243956777","doi":"10.1136/jitc-2020-0485-9corr","title":"Correction: <i>Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy</i>","year":2020,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Tumor microenvironment; Chemoradiotherapy; Medicine; Cancer research; Oncology; Tumor cells; Overall survival","score_opus":0.014953348568983692,"score_gpt":0.2911113908260646,"score_spread":0.2761580422570809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243956777","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000096136224,0.0009852228,0.00032185193,0.043068446,0.9530236,0.000027956034,0.00062793464,0.0002479101,0.001600921],"genre_scores_gemma":[0.010116181,0.010365798,0.003919009,0.13950177,0.7054897,0.00025349387,0.0025311615,0.0014303151,0.12639259],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99529856,0.0005898424,0.00074437563,0.00056951825,0.0023155797,0.00048214983],"domain_scores_gemma":[0.97142404,0.0073477076,0.0018732687,0.001467466,0.01643067,0.0014568794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046456703,0.002618337,0.0019634052,0.0034210356,0.0027138237,0.00422007,0.003919453,0.008430004,0.048140112],"category_scores_gemma":[0.064496554,0.001114925,0.002635538,0.0018068254,0.0026968252,0.0022559306,0.0019874724,0.016301697,0.028823663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003650435,0.0000056534054,0.00005001964,0.00013856513,0.000011356353,0.00025157823,0.00001633485,0.000026237689,0.00005607081,0.00033548323,0.9950299,0.0040421975],"study_design_scores_gemma":[0.00006478965,0.000029895855,0.00063146243,0.00054870837,0.00005791407,0.0012058438,0.000066762324,0.00023662935,0.00052530895,0.001131657,0.99545443,0.000046573627],"about_ca_topic_score_codex":0.012880549,"about_ca_topic_score_gemma":0.011391662,"teacher_disagreement_score":0.048140112,"about_ca_system_score_codex":0.004595172,"about_ca_system_score_gemma":0.0053253663,"threshold_uncertainty_score":0.16104472},"labels":[],"label_agreement":null},{"id":"W4280488168","doi":"10.1136/jitc-2021-003487","title":"Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"T-cell receptor; Cancer immunotherapy; Medicine; Immunotherapy; Translational research; Chimeric antigen receptor; T cell; Cancer research; Immune system; Computational biology; Immunology; Bioinformatics; Biology; Pathology","score_opus":0.05417610846829858,"score_gpt":0.3756960139525929,"score_spread":0.3215199054842943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083939725,0.9935348,0.0028328428,0.00089485385,0.0003193779,0.000030356165,0.00011544905,0.000051693944,0.0013812035],"genre_scores_gemma":[0.00839194,0.98402643,0.004518548,0.001002088,0.0003436732,0.00008753078,0.00024818146,0.00003158205,0.0013500091],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993088,0.00020746498,0.00005964135,0.00011029747,0.00026671897,0.000046998448],"domain_scores_gemma":[0.99832195,0.0010951508,0.00019265042,0.0000437586,0.00030133457,0.000045075627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027079335,0.0010863267,0.0023207334,0.0013566408,0.00012473897,0.0016855003,0.001263909,0.0016717513,0.0020054223],"category_scores_gemma":[0.003207402,0.00036583998,0.0009181031,0.0008654675,0.0005018507,0.0018321048,0.00044254126,0.002214877,0.0018585878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024042031,0.000111766385,0.0009364074,0.013644863,0.00028477362,0.000110628935,0.00005298728,0.0024220012,0.007580895,0.006830416,0.016699439,0.95108545],"study_design_scores_gemma":[0.00013772407,0.0019064692,0.0041240477,0.009285229,0.0011689377,0.0022232234,0.00018729347,0.0051423227,0.018491127,0.01399641,0.94311905,0.00021827771],"about_ca_topic_score_codex":0.0009178647,"about_ca_topic_score_gemma":0.0011107902,"teacher_disagreement_score":0.0027079335,"about_ca_system_score_codex":0.0007770672,"about_ca_system_score_gemma":0.0011905682,"threshold_uncertainty_score":0.014321089},"labels":[],"label_agreement":null},{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","score_opus":0.014477426203594235,"score_gpt":0.32528427437223195,"score_spread":0.31080684816863774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280541127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980617,0.0010091023,0.00015507612,0.00008280504,0.000020702306,0.00015811707,0.00009553006,0.000016792857,0.00040020104],"genre_scores_gemma":[0.99824584,0.000503264,0.00040584186,0.00011462408,0.000035033834,0.0001361,0.0002571836,0.0000051773704,0.0002969419],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997055,0.0001395882,0.00002207625,0.000048305577,0.000035822046,0.000048725924],"domain_scores_gemma":[0.999619,0.00009019605,0.00010230918,0.000026046639,0.000020184836,0.00014222333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053192,0.00054660015,0.0012160063,0.00027909302,0.00018235097,0.00051518413,0.000388647,0.00041023997,0.0009277809],"category_scores_gemma":[0.0006988535,0.00024765494,0.0006913616,0.00026485202,0.0003523924,0.00031533858,0.00020922594,0.0013142626,0.00027410398],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42629844,0.04570897,0.062427085,0.0012179886,0.0018695222,0.0008847377,0.00057790155,0.007895559,0.124287985,0.00028286676,0.0035747197,0.3249742],"study_design_scores_gemma":[0.17480367,0.72279084,0.07572568,0.00008204082,0.0007144657,0.0014153935,0.00006882265,0.005479323,0.0135764275,0.00015306937,0.005153318,0.00003689077],"about_ca_topic_score_codex":0.0004078829,"about_ca_topic_score_gemma":0.0010337471,"teacher_disagreement_score":0.0012160063,"about_ca_system_score_codex":0.0005504628,"about_ca_system_score_gemma":0.0007170311,"threshold_uncertainty_score":0.005569935},"labels":[],"label_agreement":null},{"id":"W4281940442","doi":"10.1136/jitc-2022-004885","title":"Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Paris; Unicancer; Bristol-Myers Squibb; Sorbonne Université; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Institute of Cancer Research; Institut National Du Cancer","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Flow cytometry; Immune system; Clear cell renal cell carcinoma; Immunotherapy; B cell; Prospective cohort study; Immunology; Antibody","score_opus":0.013715196003064773,"score_gpt":0.23272666965966934,"score_spread":0.21901147365660456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281940442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99956423,0.00021251738,0.00004556271,0.000009555846,0.0000020275781,0.0000047491058,0.000075471995,0.000002719925,0.00008320649],"genre_scores_gemma":[0.9996402,0.000036864945,0.00004856613,0.000012960252,0.0000053158087,0.0000059531963,0.0001942232,0.00000121925,0.000054678363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971086,0.00010958104,0.00002554944,0.00006680602,0.000047304027,0.000039963816],"domain_scores_gemma":[0.99931,0.00015009473,0.0002666369,0.00007163177,0.00006322729,0.0001384144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086069974,0.00022046317,0.000388228,0.00021040284,0.00017716274,0.00041561518,0.00021976473,0.0002900632,0.0006830023],"category_scores_gemma":[0.0010056486,0.00012575484,0.0003034336,0.00022001966,0.0001956967,0.00024985924,0.00021387267,0.00045873728,0.000121110825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103144515,0.00021049655,0.9734726,0.00003940787,0.0002263715,0.0000688163,0.00007706898,0.0003147224,0.008426574,0.0000199673,0.00023454119,0.0065949713],"study_design_scores_gemma":[0.00020978451,0.001959012,0.99558604,0.000004894238,0.00011118294,0.00024663017,0.000048882972,0.00052169396,0.0009509859,0.000023060886,0.00033256307,0.0000053079602],"about_ca_topic_score_codex":0.00049879303,"about_ca_topic_score_gemma":0.0007453795,"teacher_disagreement_score":0.00086069974,"about_ca_system_score_codex":0.00018468082,"about_ca_system_score_gemma":0.00019822332,"threshold_uncertainty_score":0.0045518875},"labels":[],"label_agreement":null},{"id":"W4282947288","doi":"10.1136/jitc-2021-004378","title":"Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Vagus Nerve Stimulation Research","field":"Neuroscience","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Merck","keywords":"Pembrolizumab; Medicine; Choline; Internal medicine; Cohort; Phosphocholine; Oncology; Choline acetyltransferase; Cancer; Gastroenterology; Acetylcholine; Immunotherapy; Biology","score_opus":0.031134015736450533,"score_gpt":0.36052166816713554,"score_spread":0.329387652430685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282947288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998823,0.00044266586,0.00011397116,0.000055408662,0.000006530701,0.000008988804,0.0002412344,0.000004447702,0.00030371972],"genre_scores_gemma":[0.99950707,0.00007411571,0.000055726778,0.000018510631,0.000012041295,0.000007155723,0.00022286653,7.983984e-7,0.000101770325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982566,0.000047776008,0.000017849628,0.00004989399,0.00002691443,0.00003184569],"domain_scores_gemma":[0.9990664,0.00026004956,0.00039606306,0.000041469088,0.00006571855,0.0001702819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000528029,0.00021677956,0.00035961848,0.0002459365,0.00022504611,0.00042334627,0.00016459911,0.00031672302,0.0016732289],"category_scores_gemma":[0.0012742074,0.000122024634,0.00039207502,0.00027669448,0.00013125413,0.0002826079,0.00021337872,0.000607209,0.00016780036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002604834,0.00008376448,0.9909945,0.000020005531,0.00009191581,0.000056392128,0.000019898995,0.0002713959,0.001159155,0.00001421896,0.00018209002,0.004501846],"study_design_scores_gemma":[0.000071957875,0.0006201312,0.9975351,0.0000074951017,0.000091543836,0.00020481425,0.0000317023,0.00093094714,0.00020402178,0.00004118459,0.0002580435,0.0000029267635],"about_ca_topic_score_codex":0.0006033752,"about_ca_topic_score_gemma":0.0008487801,"teacher_disagreement_score":0.0016732289,"about_ca_system_score_codex":0.00019752787,"about_ca_system_score_gemma":0.00021896511,"threshold_uncertainty_score":0.005597472},"labels":[],"label_agreement":null},{"id":"W4283022888","doi":"10.1136/jitc-2022-004849","title":"iRECIST and atypical patterns of response to immuno-oncology drugs","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Oncology; Precision oncology; Internal medicine; Bioinformatics; Cancer; Biology","score_opus":0.0556000296636933,"score_gpt":0.43022200263523774,"score_spread":0.3746219729715444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283022888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001165332,0.9978382,0.000079775666,0.00059645146,0.00022126056,0.0000063665243,0.000023414357,0.0000063237603,0.0011117015],"genre_scores_gemma":[0.00134726,0.99691236,0.00018228254,0.00066779816,0.000230988,0.000012301695,0.000052989904,0.0000020392977,0.0005919947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996619,0.00009559438,0.00005370906,0.000045225577,0.000111751775,0.000031759777],"domain_scores_gemma":[0.99938107,0.00032530737,0.000091773254,0.000018505649,0.00015132368,0.000032014956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010480593,0.0004636828,0.0012098149,0.001777806,0.00018177062,0.0010505884,0.0008493011,0.0009035152,0.0029295455],"category_scores_gemma":[0.0015018171,0.00018014014,0.00065840996,0.00144175,0.00037392467,0.0010711444,0.0005696439,0.0021128985,0.0015210131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014228476,0.000057646506,0.00030239517,0.016687224,0.00013332945,0.00020743693,0.00004983559,0.00029142888,0.00071597175,0.0048689954,0.044192754,0.9323507],"study_design_scores_gemma":[0.000042898173,0.000115912364,0.0012094327,0.006503887,0.00013614484,0.0017393043,0.00003460657,0.00008684515,0.00028395513,0.0022239853,0.9876057,0.00001722997],"about_ca_topic_score_codex":0.00061477715,"about_ca_topic_score_gemma":0.0017662059,"teacher_disagreement_score":0.0029295455,"about_ca_system_score_codex":0.0006223459,"about_ca_system_score_gemma":0.0009234423,"threshold_uncertainty_score":0.009800255},"labels":[],"label_agreement":null},{"id":"W4283319121","doi":"10.1136/jitc-2021-004458","title":"Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; National Cancer Institute; National Research, Development and Innovation Office; Radiumhemmets Forskningsfonder; Cancerföreningen i Stockholm; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Knut och Alice Wallenbergs Stiftelse; Kommunfullmäktige, Stockholms Stad; Stiftelsen Tornspiran","keywords":"Auranofin; Cytotoxic T cell; Oxidative stress; Degranulation; Chemistry; Cancer research; CD19; Reactive oxygen species; Flow cytometry; Immunology; Pharmacology; Cell biology; Biology; In vitro; Biochemistry; Receptor","score_opus":0.007982904849460928,"score_gpt":0.2779203625517257,"score_spread":0.2699374577022648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283319121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713945,0.0006968992,0.0011865671,0.00006389675,0.000022607188,0.000026373702,0.00008832159,0.000049969276,0.00072592526],"genre_scores_gemma":[0.9975647,0.00025864047,0.00064316485,0.000038638427,0.000009280733,0.00003597333,0.00016958482,0.000008241043,0.0012718516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992824,0.000012175031,0.0000068934455,0.00001965699,0.000011362596,0.000021706535],"domain_scores_gemma":[0.99996424,0.0000050947333,0.0000095412815,0.000005038347,0.000005507612,0.00001061198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076020806,0.00021078295,0.00022104979,0.00007920637,0.00007677593,0.00016435148,0.00009405662,0.00016642855,0.002033308],"category_scores_gemma":[0.00007805265,0.000044142063,0.00015828824,0.00005319598,0.00011836622,0.00015435395,0.00012826086,0.00030622235,0.0004184824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006917404,0.00015435052,0.00027049912,0.00006439117,0.000006559217,0.00004049278,0.00002385206,0.00012514142,0.99418503,0.000041037823,0.000099160075,0.0042977897],"study_design_scores_gemma":[0.00010687262,0.002387423,0.001843398,0.0000073391307,0.00003503244,0.00034546378,0.00003363701,0.00065682735,0.99156183,0.000041915187,0.0029765735,0.0000037553311],"about_ca_topic_score_codex":0.00012889387,"about_ca_topic_score_gemma":0.00020966887,"teacher_disagreement_score":0.002033308,"about_ca_system_score_codex":0.00009460649,"about_ca_system_score_gemma":0.00013297965,"threshold_uncertainty_score":0.0068020225},"labels":[],"label_agreement":null},{"id":"W4292103594","doi":"10.1136/jitc-2022-004761","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Hôtel-Dieu de Québec","funders":"Foundation Medicine; National Center for Advancing Translational Sciences; Ono Pharmaceutical; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Nivolumab; Internal medicine; Oncology; Cohort; Progression-free survival; Cancer; Urology; Chemotherapy; Androgen receptor; Immunotherapy","score_opus":0.07347743674206077,"score_gpt":0.4234544933584976,"score_spread":0.34997705661643685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292103594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94555014,0.03416805,0.0006380597,0.002123709,0.0006083005,0.0026410623,0.006979989,0.00016099415,0.0071296543],"genre_scores_gemma":[0.97344595,0.007594077,0.0011275538,0.0023589246,0.00055108394,0.0022728606,0.009716159,0.000044276723,0.0028890877],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999403,0.00034604754,0.000027272066,0.0000853952,0.00006324868,0.000075036354],"domain_scores_gemma":[0.9992853,0.00017363389,0.0001716241,0.00006452164,0.00006211866,0.00024286089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019047391,0.00092738983,0.0011491801,0.00022943274,0.00026449998,0.0010875133,0.0006077807,0.00083859527,0.0037405752],"category_scores_gemma":[0.0016231216,0.00022972036,0.0013441727,0.0002776077,0.00032035995,0.0005871108,0.00032112197,0.0015716299,0.00052143843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80819535,0.011444624,0.009462855,0.003250397,0.005661745,0.00015297307,0.0001433691,0.0029337686,0.0077732825,0.00054763455,0.019558653,0.13087529],"study_design_scores_gemma":[0.87486255,0.07688961,0.026300382,0.0003614413,0.0035463504,0.00035718238,0.00007946266,0.0018447231,0.0015557411,0.0008543285,0.013287468,0.000060759776],"about_ca_topic_score_codex":0.0010068815,"about_ca_topic_score_gemma":0.0033062308,"teacher_disagreement_score":0.0037405752,"about_ca_system_score_codex":0.00081674196,"about_ca_system_score_gemma":0.001012437,"threshold_uncertainty_score":0.012513459},"labels":[],"label_agreement":null},{"id":"W4292241648","doi":"10.1136/jitc-2022-004660","title":"Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Universitätsklinikum Hamburg-Eppendorf; Natural Sciences and Engineering Research Council of Canada; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; Université Laval","keywords":"Adenosine; Cancer research; Ceritinib; Cancer cell; Pharmacology; Kinase; Chemistry; Adenosine kinase; Cancer; Medicine; Lung cancer; Biochemistry; Anaplastic lymphoma kinase; Adenosine deaminase; Internal medicine","score_opus":0.013038133883040717,"score_gpt":0.301313983630451,"score_spread":0.2882758497474103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292241648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94629437,0.03964415,0.005570441,0.0004685571,0.00021631947,0.00024077928,0.0010389823,0.00023636597,0.006290026],"genre_scores_gemma":[0.9811094,0.010180748,0.0038204798,0.00014515957,0.00009449751,0.00011169955,0.0016505605,0.00002897411,0.0028584872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998863,0.000017973052,0.000011426165,0.00002075804,0.000029957244,0.000033679167],"domain_scores_gemma":[0.9999422,0.000010359738,0.000017176762,0.0000044540407,0.000011487105,0.0000143661555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015165773,0.00037137038,0.0005301655,0.00028235101,0.00011435889,0.00024023528,0.00021723124,0.0002758458,0.0015088911],"category_scores_gemma":[0.00012862707,0.00006934472,0.00027969023,0.00022728422,0.000119249875,0.00015807104,0.00011457227,0.00039426,0.00057641283],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067580113,0.00023281074,0.00045377735,0.0003282641,0.000033267046,0.0002201794,0.000012905855,0.0004903944,0.97696394,0.00018492049,0.00065063837,0.019753056],"study_design_scores_gemma":[0.00037481962,0.004910943,0.0048705395,0.000037716418,0.0001501815,0.002644039,0.000017429344,0.001618368,0.9638062,0.00010266944,0.021448594,0.00001843358],"about_ca_topic_score_codex":0.00022137482,"about_ca_topic_score_gemma":0.00061752513,"teacher_disagreement_score":0.0015088911,"about_ca_system_score_codex":0.00024397958,"about_ca_system_score_gemma":0.00029276763,"threshold_uncertainty_score":0.0050477386},"labels":[],"label_agreement":null},{"id":"W4294958749","doi":"10.1136/jitc-2022-004913","title":"Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pfizer; G1 Therapeutics; York University; NYU Grossman School of Medicine; Genentech; AstraZeneca; Bristol-Myers Squibb","keywords":"Immune system; CD8; Cancer research; Medicine; Immunotherapy; Immunology; Cytotoxic T cell; Chemotherapy; Tumor microenvironment; Cisplatin; Biology; Internal medicine","score_opus":0.01763794552398114,"score_gpt":0.3215746549365428,"score_spread":0.3039367094125617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294958749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946465,0.0012446349,0.0028628935,0.000074525546,0.000023898709,0.000045971607,0.00024619047,0.00007419862,0.0007811153],"genre_scores_gemma":[0.99587125,0.0007129581,0.0020988055,0.0000312952,0.000008161318,0.00004609072,0.00026796974,0.000009483994,0.00095402566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999926,0.000011522754,0.0000062975428,0.0000145408085,0.000024477538,0.000017162794],"domain_scores_gemma":[0.9999608,0.0000060015886,0.000014527827,0.000004310621,0.0000037798627,0.000010509677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092066904,0.00028769163,0.00017110005,0.00016927172,0.00008132103,0.00015677758,0.0001397429,0.0001818613,0.0005655201],"category_scores_gemma":[0.000053417367,0.000067232955,0.00016753002,0.0000964088,0.0001780829,0.00013236457,0.0001111961,0.00042104116,0.00018123967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011312841,0.000042621577,0.00011201887,0.000021166847,0.0000025262455,0.000017968181,0.0000032306982,0.00013063986,0.99821496,0.000038665417,0.000030852116,0.0012721893],"study_design_scores_gemma":[0.00004954959,0.00089192414,0.0015599927,0.000003579935,0.0000132805135,0.00020269754,0.000009225764,0.0010051031,0.9941626,0.00003233087,0.002066826,0.0000029359971],"about_ca_topic_score_codex":0.00016473337,"about_ca_topic_score_gemma":0.00026293882,"teacher_disagreement_score":0.0005655201,"about_ca_system_score_codex":0.00019877996,"about_ca_system_score_gemma":0.00013013801,"threshold_uncertainty_score":0.001891911},"labels":[],"label_agreement":null},{"id":"W4296661760","doi":"10.1136/jitc-2022-005646","title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"School of Medicine, Stanford University; Universitätsklinikum Heidelberg; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; University of Washington; University of Miami; Universitair Medisch Centrum Groningen; University of Texas MD Anderson Cancer Center; Northwestern University; National Cancer Institute; University of Toronto; National Institute of General Medical Sciences; Massachusetts General Hospital; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Ohio State University; Leonard M. Miller School of Medicine; University of Pennsylvania","keywords":"Medicine; Corticosteroid; Creatinine; Internal medicine; Cohort; Acute kidney injury; Adverse effect; Confounding; Duration (music)","score_opus":0.02640980364461186,"score_gpt":0.32402318233306016,"score_spread":0.2976133786884483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296661760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985474,0.0010597783,0.00007090043,0.00003509572,0.000007559771,0.0000039081356,0.00007785583,0.0000012434114,0.00019618047],"genre_scores_gemma":[0.9996184,0.00012390284,0.00008872637,0.000028126611,0.000018514951,0.000003550554,0.00008635091,9.2597895e-7,0.000031631564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991079,0.00024302978,0.00016550162,0.00017240393,0.00020430096,0.000106877786],"domain_scores_gemma":[0.9902096,0.0020381382,0.006533628,0.00023911419,0.00031154504,0.0006680157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012218393,0.00015359753,0.00028818412,0.0003778446,0.00019464733,0.00046276677,0.00021201107,0.00030174223,0.0019846398],"category_scores_gemma":[0.0040625175,0.0000840627,0.00042996422,0.0004621302,0.00025064085,0.00031121756,0.00027298855,0.0004681444,0.000102890575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009803401,0.00004349548,0.9950996,0.000036646852,0.00011584457,0.00005306205,0.000023999968,0.000071582035,0.000539763,0.000016507856,0.000047395522,0.0029717362],"study_design_scores_gemma":[0.000054620235,0.0008030505,0.99717677,0.000034121458,0.00016516299,0.0008239077,0.00006721391,0.00019101244,0.00034729947,0.000025861795,0.000306323,0.000004582569],"about_ca_topic_score_codex":0.0007044899,"about_ca_topic_score_gemma":0.0008969756,"teacher_disagreement_score":0.0019846398,"about_ca_system_score_codex":0.00028591973,"about_ca_system_score_gemma":0.00033080176,"threshold_uncertainty_score":0.006639242},"labels":[],"label_agreement":null},{"id":"W4297141578","doi":"10.1136/jitc-2022-004725","title":"TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; University of Minnesota","keywords":"Stromal cell; Tumor microenvironment; Cancer research; Lymphokine-activated killer cell; Biology; Interleukin 21; Degranulation; Cytokine; T cell; Immunology; Immune system; Tumor cells; Receptor","score_opus":0.03057813303820549,"score_gpt":0.3280423464682694,"score_spread":0.2974642134300639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297141578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002075,0.0008686694,0.0058410103,0.00008271466,0.000019163599,0.00006591155,0.00021911362,0.000108998895,0.0027738342],"genre_scores_gemma":[0.9921151,0.00030971866,0.004506799,0.000061650826,0.0000086034515,0.000053419513,0.00054556533,0.000014492588,0.0023846903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979097,0.000030099714,0.000018464698,0.000050504546,0.000053802123,0.000056219516],"domain_scores_gemma":[0.99991095,0.000012371773,0.000032734995,0.000013964573,0.000008714438,0.000021183872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013928647,0.00040130157,0.00024493193,0.00012851796,0.00008446705,0.00025355423,0.00023177943,0.00033753715,0.0030792376],"category_scores_gemma":[0.000104324194,0.00011466737,0.00026135173,0.00010220079,0.0001416093,0.00018532856,0.00027831527,0.0005764164,0.001070591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009463586,0.000029323644,0.00025786468,0.000028907236,0.0000054999746,0.00003626032,0.000008992691,0.000090086265,0.9980453,0.00008936382,0.00006185772,0.0012519491],"study_design_scores_gemma":[0.000036411064,0.00046884498,0.0015746519,0.000007637504,0.000016581125,0.0007249563,0.000017410708,0.0015981552,0.9916244,0.000035674067,0.003891212,0.000004017771],"about_ca_topic_score_codex":0.000091796726,"about_ca_topic_score_gemma":0.00015339688,"teacher_disagreement_score":0.0030792376,"about_ca_system_score_codex":0.0002481234,"about_ca_system_score_gemma":0.0001273669,"threshold_uncertainty_score":0.0103010535},"labels":[],"label_agreement":null},{"id":"W4297322118","doi":"10.1136/jitc-2021-004450","title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Cancer Institute; American Association for Cancer Research; Children's Hospital of Philadelphia; Alex's Lemonade Stand Foundation for Childhood Cancer; Damon Runyon Cancer Research Foundation; Kortney Rose Foundation","keywords":"Chimeric antigen receptor; Medulloblastoma; Neuroblastoma; Cancer research; Glioma; Pediatric cancer; Medicine; Flow cytometry; Brain tumor; Cancer; Immunotherapy; Cell culture; Biology; Immunology; Pathology; Internal medicine","score_opus":0.046226171553148024,"score_gpt":0.37651339021005625,"score_spread":0.33028721865690824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96832174,0.001703657,0.02590356,0.00017987133,0.00005159975,0.00047854093,0.0008339119,0.00026310913,0.0022639632],"genre_scores_gemma":[0.96985877,0.002085279,0.024470538,0.00012886507,0.00002175494,0.0003053599,0.0015205091,0.00007763731,0.001531385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975675,0.00003551413,0.000018662555,0.000053455984,0.00007535044,0.000060212904],"domain_scores_gemma":[0.99983966,0.000030184088,0.000044034176,0.00001913906,0.000044998524,0.000022008555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002865668,0.00043317763,0.00027945542,0.0002764532,0.0001199301,0.00040738413,0.00031402573,0.00038254526,0.0012827703],"category_scores_gemma":[0.00029786528,0.00015633272,0.00030389914,0.00022446281,0.0002752337,0.00023733005,0.00022113495,0.0007144677,0.0004967502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065025146,0.00004329696,0.00042786193,0.00006299881,0.000011969156,0.00007619172,0.000036888137,0.0007926101,0.9941958,0.00021687166,0.00014885554,0.0039215726],"study_design_scores_gemma":[0.000037611317,0.0009947566,0.0011862526,0.0000103999655,0.000053047133,0.0004026911,0.000037832593,0.002376885,0.9877166,0.000039652074,0.0071348865,0.0000093842755],"about_ca_topic_score_codex":0.0008857323,"about_ca_topic_score_gemma":0.0009761021,"teacher_disagreement_score":0.0012827703,"about_ca_system_score_codex":0.0005489008,"about_ca_system_score_gemma":0.0004819728,"threshold_uncertainty_score":0.0042913556},"labels":[],"label_agreement":null},{"id":"W4297387081","doi":"10.1136/jitc-2022-005187","title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Mark Hughes Foundation; Medical Research Council; Flinders Foundation; Tour de Cure; Australian Cancer Research Foundation; Fay Fuller Foundation; Cancer Australia; Cancer Council South Australia; Neurosurgical Research Foundation; National Health and Medical Research Council; Hospital Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Glioma; Flow cytometry; Cancer research; Brain tumor; Antigen; Immune system; Immunotherapy; Tumor antigen; Pathology; Oncology; Immunology","score_opus":0.02121667910910916,"score_gpt":0.3714376681463423,"score_spread":0.35022098903723314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297387081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979837,0.0049810405,0.011356483,0.00028383115,0.000049381008,0.00016486131,0.000636415,0.00039408382,0.0022969043],"genre_scores_gemma":[0.986278,0.0022037758,0.008277621,0.00016757674,0.000014187203,0.00008337925,0.0011039848,0.000038787603,0.001832643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999107,0.000009883474,0.000008228597,0.000017680466,0.00003309673,0.000020399448],"domain_scores_gemma":[0.999966,0.0000039783386,0.000010248451,0.0000050186172,0.0000066019716,0.000008116754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015434514,0.00028197005,0.00019340302,0.00031563907,0.00008488945,0.0002685115,0.00016455927,0.00019774289,0.0008463617],"category_scores_gemma":[0.00009214885,0.00008709044,0.0002123815,0.00020731361,0.00021576048,0.00012294287,0.00014129248,0.00030958463,0.00023428052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017699259,0.00005275425,0.0008241292,0.00006267585,0.000012796832,0.00007016069,0.000019142182,0.00023191891,0.98852575,0.00012805642,0.00026086438,0.009634698],"study_design_scores_gemma":[0.000058650436,0.00088842225,0.0057591535,0.000012666277,0.00006598373,0.00044322768,0.00002072622,0.0009190247,0.9840178,0.00012008332,0.007688397,0.0000058180167],"about_ca_topic_score_codex":0.0005362291,"about_ca_topic_score_gemma":0.0011035663,"teacher_disagreement_score":0.0008463617,"about_ca_system_score_codex":0.00025895424,"about_ca_system_score_gemma":0.000355413,"threshold_uncertainty_score":0.0028313398},"labels":[],"label_agreement":null},{"id":"W4304608290","doi":"10.1136/jitc-2022-004653","title":"Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo; Universidade de São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Colorectal cancer; Colitis; Cancer research; Medicine; CD8; Cytotoxic T cell; Mast cell; Immune system; Population; Carcinogenesis; Immunology; T cell; Cancer; Biology; Internal medicine; In vitro","score_opus":0.007699038656310319,"score_gpt":0.23714430713305956,"score_spread":0.22944526847674923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304608290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898258,0.0063875983,0.0017191718,0.00024223304,0.0000750894,0.00008113736,0.000367902,0.00008468324,0.0012164542],"genre_scores_gemma":[0.9952508,0.0021693746,0.0010863229,0.00007679436,0.000027621512,0.000063004045,0.00023866672,0.0000070232786,0.0010803409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991035,0.000013063287,0.000007250512,0.000017746104,0.000019579484,0.000032035914],"domain_scores_gemma":[0.9999404,0.000005996855,0.000020826465,0.000004154585,0.000005558257,0.000022936963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014630232,0.00030916728,0.0002815862,0.00021573127,0.00012253078,0.00022260666,0.00015660844,0.00026236213,0.001494315],"category_scores_gemma":[0.000085865606,0.000093685216,0.00029737497,0.00011868607,0.00021434219,0.00017341893,0.00013391697,0.0008799529,0.00016970646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009161418,0.00020295607,0.0007771592,0.00019610001,0.000016879145,0.000119537566,0.000018391882,0.000111919886,0.9916197,0.00017575659,0.00014933165,0.0056961034],"study_design_scores_gemma":[0.00033192092,0.0078106495,0.022132747,0.00004149045,0.00020661273,0.0009774454,0.00010187691,0.0015419094,0.95790905,0.00025150776,0.00868162,0.000013199383],"about_ca_topic_score_codex":0.00016074955,"about_ca_topic_score_gemma":0.00042501927,"teacher_disagreement_score":0.001494315,"about_ca_system_score_codex":0.00018834346,"about_ca_system_score_gemma":0.00021165922,"threshold_uncertainty_score":0.004998982},"labels":[],"label_agreement":null},{"id":"W4308026783","doi":"10.1136/jitc-2022-005780","title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Juravinski Cancer Centre; Université du Québec à Montréal","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; EMD Serono; Genentech; European Society for Medical Oncology; Shionogi; Natera; Seagen; Pfizer; Incyte; Jounce Therapeutics; Astellas Pharma; Eisai; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; Dana-Farber Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Tolerability; Renal cell carcinoma; Discontinuation; Combination therapy; Hazard ratio; Clinical endpoint; Progression-free survival; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy; Confidence interval","score_opus":0.024101134792033473,"score_gpt":0.3518191333851835,"score_spread":0.32771799859315004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308026783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829915,0.006057871,0.0010217682,0.00035423393,0.00016148375,0.0014623101,0.0010834577,0.0001984387,0.0066689607],"genre_scores_gemma":[0.99355197,0.0008876124,0.0016183472,0.00036610576,0.00008246823,0.00038419617,0.001206189,0.000018812028,0.0018842149],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99969006,0.00005322976,0.000019560595,0.00009152208,0.000045975274,0.00009970211],"domain_scores_gemma":[0.99970454,0.000034569886,0.00005788952,0.000027883741,0.0000171149,0.00015794263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009989814,0.00046092237,0.0009504882,0.00032784612,0.00042108932,0.0006399875,0.00067673065,0.00047048207,0.0037025427],"category_scores_gemma":[0.0003898292,0.00013691449,0.0007413349,0.00027040904,0.0003027531,0.0005268639,0.00036096133,0.00086570217,0.00079965865],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23494756,0.017959386,0.057026725,0.0019073755,0.0018251911,0.0015386179,0.00032679696,0.009104046,0.047463406,0.0013949242,0.011855669,0.61465037],"study_design_scores_gemma":[0.17960854,0.5105132,0.17081946,0.00039603966,0.0022245205,0.008273898,0.00018439724,0.011916351,0.037591074,0.0015304121,0.07679044,0.00015178036],"about_ca_topic_score_codex":0.0013984939,"about_ca_topic_score_gemma":0.005926952,"teacher_disagreement_score":0.0037025427,"about_ca_system_score_codex":0.0015244975,"about_ca_system_score_gemma":0.0019091844,"threshold_uncertainty_score":0.012386262},"labels":[],"label_agreement":null},{"id":"W4310549999","doi":"10.1136/jitc-2022-005732","title":"Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"NIHR Imperial Biomedical Research Centre; European Society for Medical Oncology; Cancer Treatment and Research Trust; National Institute for Health and Care Research","keywords":"Medicine; Cancer; Immune system; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Immune checkpoint; Immunotherapy; Immunology; Oncology; Intensive care medicine; Internal medicine","score_opus":0.050141232009651975,"score_gpt":0.37359630881688566,"score_spread":0.3234550768072337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310549999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959229,0.0011415023,0.00018883475,0.00008694233,0.000012475185,0.000019856207,0.002265698,0.000007197946,0.00035457656],"genre_scores_gemma":[0.99788636,0.00024369682,0.00006605772,0.00002876484,0.000018034289,0.000013927315,0.0016835356,0.0000031296365,0.00005638078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975805,0.0008112081,0.00043011032,0.0004984393,0.00041434847,0.00026534643],"domain_scores_gemma":[0.99156266,0.0012335129,0.0051111844,0.0006846833,0.0006486205,0.000759391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035075678,0.00028936384,0.0007836747,0.0017637929,0.00029629588,0.0010485497,0.00045519587,0.00036579344,0.0009028762],"category_scores_gemma":[0.0056311837,0.00029969547,0.0015145967,0.0026677141,0.0002436388,0.0005554511,0.0012560245,0.00053409435,0.00013897032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008090986,0.000005459981,0.9989969,0.000012313648,0.00028039044,0.00001301861,0.000014546347,0.000043666125,0.00003175936,0.000008026502,0.000086936496,0.00042598377],"study_design_scores_gemma":[0.000014262763,0.0000568405,0.9989587,0.000014841766,0.0002172141,0.00011115126,0.00010876994,0.00029848798,0.000028058957,0.0000104302835,0.00017684829,0.0000044691037],"about_ca_topic_score_codex":0.0071899476,"about_ca_topic_score_gemma":0.010497385,"teacher_disagreement_score":0.0071899476,"about_ca_system_score_codex":0.00046444827,"about_ca_system_score_gemma":0.0005500026,"threshold_uncertainty_score":0.018550038},"labels":[],"label_agreement":null},{"id":"W4310747261","doi":"10.1136/jitc-2022-005360","title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemical, Bioengineering, Environmental, and Transport Systems; York University; New York University; Leukemia and Lymphoma Society; AstraZeneca; National Institute of General Medical Sciences; Cancer Research Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Medicine; T cell; Immunotherapy; Clinical trial; Leukemia; Oncology; Internal medicine; Antigen; Immunology; Cancer; Immune system","score_opus":0.020053779762780204,"score_gpt":0.31615903936231066,"score_spread":0.29610525959953043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310747261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92835516,0.00026994455,0.065092996,0.00065366476,0.000046472825,0.00009879687,0.0012089986,0.00019904257,0.004074897],"genre_scores_gemma":[0.9935197,0.00010133023,0.00462694,0.00006561692,0.000008332459,0.00014492935,0.0004635621,0.000014161938,0.0010553749],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99984956,0.000055429442,0.000008125009,0.000035781384,0.000018702453,0.000032398257],"domain_scores_gemma":[0.9993882,0.0004281522,0.000069120695,0.00002596462,0.000045121444,0.000043454285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043304305,0.00046830665,0.0006157192,0.00032641806,0.00024061855,0.0005111392,0.00061989954,0.00076133665,0.0015117422],"category_scores_gemma":[0.0015401322,0.0003325339,0.00071228476,0.00026701068,0.0003825172,0.00025643516,0.00032962783,0.00043698415,0.00012507188],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035474415,0.000014574757,0.0015933068,0.0000065620316,0.000008432117,0.000026000556,0.0000050928056,0.9973348,0.00016260921,0.0002281918,0.000068160356,0.00051674835],"study_design_scores_gemma":[0.000008318849,0.000015765669,0.00030278836,0.0000010410772,0.0000065824465,0.0000068036215,0.000003004532,0.99928373,0.00011059003,0.00020507761,0.000054457556,0.0000018249914],"about_ca_topic_score_codex":0.012936166,"about_ca_topic_score_gemma":0.0072893295,"teacher_disagreement_score":0.012936166,"about_ca_system_score_codex":0.000763857,"about_ca_system_score_gemma":0.0011985872,"threshold_uncertainty_score":0.025721729},"labels":[],"label_agreement":null},{"id":"W4315780755","doi":"10.1136/jitc-2022-006136","title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Pharmacodynamics; Colorectal cancer; Response Evaluation Criteria in Solid Tumors; Cohort; Pancreatic cancer; Gastroenterology; Cancer; Phases of clinical research; Pharmacokinetics; Clinical trial; Immunotherapy","score_opus":0.03232948702170655,"score_gpt":0.3487401860462075,"score_spread":0.3164106990245009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315780755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665797,0.0006270999,0.0002844539,0.00015790825,0.00005070313,0.0013078045,0.00031229891,0.000047885147,0.0005537885],"genre_scores_gemma":[0.9946074,0.00039206992,0.0010509279,0.00035916409,0.00008664486,0.0018980646,0.0005590486,0.000015445046,0.0010312117],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995858,0.00017548059,0.000020033624,0.000090031754,0.000038065893,0.00009060921],"domain_scores_gemma":[0.9992478,0.00009200357,0.0001668434,0.000054640015,0.0000649393,0.000373774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001506236,0.0013048042,0.0014828255,0.000315246,0.0005364236,0.0007619569,0.0006845585,0.0010484777,0.0031346227],"category_scores_gemma":[0.00075070665,0.0006974606,0.0009958545,0.00025091678,0.00079331856,0.0008326724,0.0003145792,0.002751135,0.00075347774],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7605396,0.1181518,0.011704082,0.00054356025,0.0012578717,0.00016533947,0.00042652793,0.0011946585,0.048590157,0.00015505389,0.0022944093,0.05497701],"study_design_scores_gemma":[0.3627874,0.6176557,0.013890324,0.000022515498,0.0003451657,0.00015814274,0.0000939152,0.0007358839,0.0029364028,0.000107104075,0.001248342,0.000019099763],"about_ca_topic_score_codex":0.00067458255,"about_ca_topic_score_gemma":0.0019706872,"teacher_disagreement_score":0.0031346227,"about_ca_system_score_codex":0.00080128986,"about_ca_system_score_gemma":0.0013492467,"threshold_uncertainty_score":0.010486305},"labels":[],"label_agreement":null},{"id":"W4317500300","doi":"10.1136/jitc-2022-006397","title":"Next-generation ctDNA-driven clinical trials in precision immuno-oncology","year":2023,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Precision oncology; Clinical Oncology; Medicine; Immunotherapy; Clinical trial; Oncology; Precision medicine; Targeted therapy; Cancer immunotherapy; Computational biology; Cancer; Internal medicine; Bioinformatics; Biology; Pathology","score_opus":0.18044064665614404,"score_gpt":0.465082961907514,"score_spread":0.28464231525136996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317500300","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012460168,0.006120544,0.0012814568,0.96080863,0.025057249,0.00006486156,0.00013055844,0.00008361001,0.005207093],"genre_scores_gemma":[0.016245976,0.0054619773,0.0026407284,0.8785237,0.09017959,0.00019283046,0.00015284405,0.000050695427,0.0065516667],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99457425,0.0027060541,0.000489102,0.00042088467,0.0014133868,0.00039638294],"domain_scores_gemma":[0.97354454,0.020410566,0.0008058357,0.00066561194,0.0021269235,0.002446438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076416885,0.0005861835,0.0012473458,0.00043464746,0.0013088376,0.002845685,0.00144964,0.021976441,0.0066844397],"category_scores_gemma":[0.02211032,0.00042711056,0.0012609925,0.000431395,0.0027407347,0.0036314032,0.001249616,0.022613017,0.004409657],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068952877,0.0001418147,0.00120498,0.00023184317,0.000052084208,0.003256094,0.00008824557,0.00059079373,0.0017514676,0.01171049,0.9188595,0.061423194],"study_design_scores_gemma":[0.00072086114,0.0005544244,0.0012486577,0.00031448572,0.000047998943,0.0026044312,0.00013403923,0.0023872654,0.0012735421,0.040364858,0.9502886,0.000060966886],"about_ca_topic_score_codex":0.00062626577,"about_ca_topic_score_gemma":0.0018385944,"teacher_disagreement_score":0.021976441,"about_ca_system_score_codex":0.0024688481,"about_ca_system_score_gemma":0.002014374,"threshold_uncertainty_score":0.040413618},"labels":[],"label_agreement":null},{"id":"W4318773806","doi":"10.1136/jitc-2022-006127","title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"EMD Serono; Ipsen; Universiteit Gent; Astellas Pharma; Eisai; G1 Therapeutics; Sanofi; Apollomics; Agios Pharmaceuticals; University of Texas Southwestern Medical Center; BeiGene; GlaxoSmithKline; Tizona Therapeutics; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Cilag; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Celgene; PTC Therapeutics; Genentech; Aeglea BioTherapeutics; Amgen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Lung cancer; Metastatic melanoma; First line; Cancer; Immunotherapy","score_opus":0.041473298833537224,"score_gpt":0.33657208283311646,"score_spread":0.29509878399957923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318773806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949898,0.0028358053,0.00015184228,0.00009228673,0.000025188101,0.00030658595,0.00049584784,0.00001602486,0.0010866027],"genre_scores_gemma":[0.99573493,0.0011049748,0.00046813308,0.0002561817,0.000048387286,0.00017456534,0.0016707096,0.000004526546,0.0005374786],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99977523,0.00007650402,0.00001667837,0.000052784017,0.000042150044,0.000036614307],"domain_scores_gemma":[0.9995504,0.00008242142,0.000103366605,0.000038936614,0.000050165054,0.00017471511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009502174,0.00033727146,0.0006811331,0.00025947794,0.00031137574,0.0004620058,0.0003620464,0.0002968478,0.0015540998],"category_scores_gemma":[0.0005261944,0.00012384912,0.0007526248,0.00024475963,0.00016908364,0.00025098308,0.000247322,0.00074585376,0.00023257348],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13106336,0.018419614,0.37623233,0.002308731,0.003945272,0.0007785278,0.00039243235,0.0043386114,0.05091593,0.0003316717,0.008404273,0.40286916],"study_design_scores_gemma":[0.048510402,0.26239797,0.65116227,0.00023110164,0.002923847,0.0022464087,0.0001668992,0.003927083,0.012501474,0.00024561974,0.015639778,0.00004709499],"about_ca_topic_score_codex":0.001106575,"about_ca_topic_score_gemma":0.007094131,"teacher_disagreement_score":0.0015540998,"about_ca_system_score_codex":0.0006493707,"about_ca_system_score_gemma":0.0010301656,"threshold_uncertainty_score":0.005199015},"labels":[],"label_agreement":null},{"id":"W4318826747","doi":"10.1136/jitc-2022-005545","title":"Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of Toronto; McGill University","funders":"Canadian Institutes of Health Research; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Canada Foundation for Innovation; Fonds de Recherche du Québec - Santé; Brain Tumor Funders' Collaborative","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Mass cytometry; Immune checkpoint; Immunology; Cancer research; Medicine; Cancer immunotherapy; T cell; Cancer; Biology; Internal medicine; Phenotype","score_opus":0.02469995268454188,"score_gpt":0.31953550746252946,"score_spread":0.29483555477798756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318826747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180543,0.0006565465,0.0065442137,0.000067845715,0.000004097833,0.000018084798,0.0002073809,0.0000634736,0.00063294213],"genre_scores_gemma":[0.99704295,0.00017239121,0.0022509606,0.000028757635,0.000004071448,0.000023008368,0.00013293364,0.0000075481225,0.00033741587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999243,0.0000090739995,0.000004063786,0.00002604739,0.000019335428,0.000017159018],"domain_scores_gemma":[0.99993384,0.000014270724,0.00001973479,0.00000608454,0.000012449306,0.000013663921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012268874,0.00010798539,0.00018972719,0.00027907625,0.00011121137,0.00029040495,0.00014898602,0.00024247754,0.001327782],"category_scores_gemma":[0.00011120841,0.00011391548,0.00012102135,0.00014529718,0.00020134098,0.00023124502,0.00015419257,0.00029118345,0.00018098892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017918728,0.000025467245,0.004950174,0.000041375322,0.00000923033,0.000036824054,0.000043782686,0.0006288334,0.9896909,0.00014993019,0.00007712866,0.004167276],"study_design_scores_gemma":[0.000045406898,0.00039486386,0.10278203,0.000010524262,0.00005213976,0.00052962836,0.00019428089,0.018956115,0.8743284,0.00048599858,0.0022066426,0.000013980021],"about_ca_topic_score_codex":0.00055479765,"about_ca_topic_score_gemma":0.0006687575,"teacher_disagreement_score":0.001327782,"about_ca_system_score_codex":0.00035567133,"about_ca_system_score_gemma":0.00014388743,"threshold_uncertainty_score":0.0044418573},"labels":[],"label_agreement":null},{"id":"W4319316777","doi":"10.1136/jitc-2022-005691","title":"Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"CD28; Mesothelin; Cancer research; T cell; Ovarian cancer; Flow cytometry; Tumor microenvironment; Chimeric antigen receptor; CD19; Immunotherapy; Cytotoxic T cell; Cancer; Biology; Immune system; Immunology; Medicine; In vitro; Antibody; Tumor cells; Internal medicine","score_opus":0.07222553027337288,"score_gpt":0.39572200909368005,"score_spread":0.3234964788203072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319316777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808455,0.00027807578,0.00096186844,0.000025823178,0.0000072414223,0.000024766407,0.00009445852,0.000046111774,0.00047707756],"genre_scores_gemma":[0.9981846,0.00020296984,0.00068914343,0.00001799981,0.0000061682754,0.000033702625,0.0001519991,0.0000082999895,0.0007050532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998894,0.000014043105,0.0000110190595,0.000022158254,0.00002642584,0.0000370264],"domain_scores_gemma":[0.99990964,0.00001727467,0.000027165623,0.000011686207,0.0000094782845,0.000024700637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237397,0.0002738138,0.00021020774,0.00023268085,0.00006790313,0.0001959667,0.0001043642,0.00022551199,0.0008107697],"category_scores_gemma":[0.00008283969,0.00006712283,0.00014296074,0.00011276791,0.00015674469,0.000120034565,0.00013062336,0.000530874,0.00017062611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019071023,0.00012071105,0.00023631596,0.000029442705,0.000003153316,0.000020197673,0.000021397136,0.00019494312,0.99780244,0.00004668281,0.000037237172,0.0012966971],"study_design_scores_gemma":[0.000034930887,0.0012845747,0.0013982138,0.0000036153015,0.000014966813,0.00008958951,0.000017809416,0.0009326548,0.9952537,0.000019177693,0.0009490632,0.0000018940251],"about_ca_topic_score_codex":0.00021129023,"about_ca_topic_score_gemma":0.0003419518,"teacher_disagreement_score":0.0008107697,"about_ca_system_score_codex":0.0002025143,"about_ca_system_score_gemma":0.00015021936,"threshold_uncertainty_score":0.0027123094},"labels":[],"label_agreement":null},{"id":"W4320914885","doi":"10.1136/jitc-2022-005854","title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Meta-analysis; Circulating tumor DNA; Subgroup analysis; Clinical trial; Cancer","score_opus":0.024404445784671096,"score_gpt":0.3410580362663591,"score_spread":0.316653590481688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320914885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021125637,0.9968983,0.00010344039,0.00011930261,0.00005417152,0.000113247035,0.0004471696,0.000007067276,0.00014482348],"genre_scores_gemma":[0.04711236,0.9507778,0.000542863,0.00041563046,0.00011846846,0.00041204417,0.0004877968,0.000008216592,0.0001248668],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960841,0.0012788702,0.0015215736,0.00042785078,0.0005456484,0.00014198135],"domain_scores_gemma":[0.9814315,0.013796017,0.0032939313,0.0002467125,0.0010635749,0.00016825357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052486043,0.0013486198,0.010008802,0.005389092,0.00038415345,0.001849798,0.0014297917,0.0013989034,0.0030730886],"category_scores_gemma":[0.019830862,0.0008321254,0.011938752,0.007302872,0.0005296912,0.0012629246,0.00089434296,0.00093060324,0.00021714446],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007100907,0.000015517337,0.0025850702,0.9066921,0.069155246,0.000078786776,0.000069327274,0.00018109927,0.00019319843,0.00009029366,0.00092266523,0.01930651],"study_design_scores_gemma":[0.0008360995,0.00041778092,0.013933949,0.34421045,0.6298689,0.00035661532,0.00015031408,0.00019996696,0.0002920965,0.00035650717,0.009325367,0.000052004754],"about_ca_topic_score_codex":0.0048933728,"about_ca_topic_score_gemma":0.012381277,"teacher_disagreement_score":0.010008802,"about_ca_system_score_codex":0.00183441,"about_ca_system_score_gemma":0.0038107394,"threshold_uncertainty_score":0.027757585},"labels":[],"label_agreement":null},{"id":"W4327560927","doi":"10.1136/jitc-2022-005301","title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Internal medicine; FOXP3; Pharmacodynamics; Tolerability; Adverse effect; Granzyme; Gastroenterology; Pharmacokinetics; Immunology; Pharmacology; CD8; Oncology; Immunotherapy; Immune system; Cancer","score_opus":0.012898636780171113,"score_gpt":0.3175022932758785,"score_spread":0.30460365649570736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327560927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916727,0.0014957716,0.0007633074,0.00027978222,0.00007451313,0.0032804592,0.0011612688,0.000114860944,0.0011573599],"genre_scores_gemma":[0.9881087,0.0013635396,0.0018193069,0.0004426611,0.00017321928,0.0034706122,0.0021631098,0.000035867277,0.0024230245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995233,0.0002010975,0.000022210786,0.00008672867,0.000054874956,0.00011183596],"domain_scores_gemma":[0.99931896,0.000096051495,0.00016658386,0.00007178074,0.0000420413,0.00030462345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017025716,0.0020736638,0.0019846256,0.00041384538,0.00046667363,0.0010146623,0.0009423395,0.0010686085,0.0043142145],"category_scores_gemma":[0.0007583556,0.0007270389,0.001066886,0.00045632504,0.00097207754,0.0010437344,0.00044767675,0.0036097444,0.000977126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60823417,0.15689494,0.006886568,0.0013443711,0.0013214764,0.00046682335,0.00056975306,0.0026850011,0.11893488,0.0003947893,0.0047985525,0.09746875],"study_design_scores_gemma":[0.33762956,0.64139307,0.007843267,0.000028029202,0.00030869298,0.00036360888,0.00004759551,0.00057049445,0.008833109,0.00011054188,0.002848586,0.00002332757],"about_ca_topic_score_codex":0.00057174766,"about_ca_topic_score_gemma":0.0017789004,"teacher_disagreement_score":0.0043142145,"about_ca_system_score_codex":0.0010274648,"about_ca_system_score_gemma":0.0015664413,"threshold_uncertainty_score":0.01443249},"labels":[],"label_agreement":null},{"id":"W4360613262","doi":"10.1136/jitc-2022-006408","title":"Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University; University of Toronto; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Lundbeckfonden; Canadian Cancer Society; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Terry Fox Research Institute; University of Ottawa; Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"Oncolytic virus; Translation (biology); Transgene; Adaptation (eye); Messenger RNA; Cancer research; Biology; Medicine; Computational biology; Bioinformatics; Virology; Gene; Genetics; Neuroscience; Tumor cells","score_opus":0.05014852488167118,"score_gpt":0.38372096737177036,"score_spread":0.3335724424900992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360613262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895132,0.0010544261,0.007133373,0.000097173724,0.000054513366,0.000043266566,0.00024265681,0.000217181,0.0016441827],"genre_scores_gemma":[0.99096316,0.00070718006,0.00545305,0.000049745653,0.000017064622,0.000027816995,0.00033660734,0.00007850025,0.0023669726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988294,0.000016141921,0.000011540017,0.000031225187,0.000032532284,0.00002558317],"domain_scores_gemma":[0.99992526,0.000016904032,0.000021088006,0.000010585327,0.00001293785,0.000013198777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001521183,0.00028558384,0.00018990836,0.00013517348,0.00009808013,0.00028365586,0.0001302752,0.0001704731,0.0009776559],"category_scores_gemma":[0.00013756068,0.000098702185,0.00014780153,0.00010163788,0.00020902038,0.00012365489,0.00016506654,0.0005199183,0.00029024718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003222677,0.000011102937,0.000056109806,0.00001435327,9.334842e-7,0.00000691549,0.0000045725205,0.00006987109,0.99877864,0.000058535014,0.000018700068,0.0009479291],"study_design_scores_gemma":[0.0000034152038,0.00011109719,0.00054602866,0.0000019924546,0.000004398427,0.000025825979,0.00000460136,0.0005226266,0.9976199,0.000015966192,0.001142348,0.0000017295597],"about_ca_topic_score_codex":0.00057436066,"about_ca_topic_score_gemma":0.0008498832,"teacher_disagreement_score":0.0009776559,"about_ca_system_score_codex":0.0003523934,"about_ca_system_score_gemma":0.00031075475,"threshold_uncertainty_score":0.003270626},"labels":[],"label_agreement":null},{"id":"W4362549334","doi":"10.1136/jitc-2022-006170","title":"Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Ottawa; Queen's University","funders":"Canadian Institutes of Health Research; Queen's University; Institute of Cancer Research; Canada Foundation for Innovation","keywords":"PTEN; Cancer research; Tumor microenvironment; Ovarian cancer; Medicine; Immune system; Biology; Cancer; Immunology; Internal medicine; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.01799954787856017,"score_gpt":0.28620840698745886,"score_spread":0.2682088591088987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362549334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997111,0.00008564389,0.00005926238,0.0000031177492,8.722718e-7,0.0000030605331,0.000034373228,0.0000027404762,0.000099848075],"genre_scores_gemma":[0.9996939,0.000054661275,0.0000684976,0.000004779124,0.0000010647235,0.000004776572,0.000084021674,8.598146e-7,0.00008745542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999424,0.000009955979,0.0000049095443,0.000011730473,0.000013751782,0.00001731383],"domain_scores_gemma":[0.99992704,0.0000106032085,0.00002264876,0.000006541967,0.0000067797655,0.000026419475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006996131,0.00007459925,0.00012215036,0.00023927813,0.000083234256,0.00017857004,0.000042294057,0.00009777608,0.00086116645],"category_scores_gemma":[0.00011757438,0.00005872596,0.00008055861,0.0001483645,0.000105479645,0.00007117195,0.00009598765,0.00013858022,0.00008792691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013947502,0.000090049776,0.08854104,0.000045081237,0.000021725209,0.00031902682,0.000096228076,0.00018139399,0.90474516,0.00006641285,0.00007071243,0.0044284402],"study_design_scores_gemma":[0.00003987713,0.0016830877,0.8035516,0.0000062553286,0.000061587874,0.002723376,0.000317486,0.0013222235,0.18862624,0.000082905026,0.0015784375,0.0000068609024],"about_ca_topic_score_codex":0.00024264868,"about_ca_topic_score_gemma":0.0005218954,"teacher_disagreement_score":0.00086116645,"about_ca_system_score_codex":0.000115012306,"about_ca_system_score_gemma":0.00008269131,"threshold_uncertainty_score":0.0028808713},"labels":[],"label_agreement":null},{"id":"W4366339464","doi":"10.1136/jitc-2022-005839","title":"Ectopic expression of cGAS in <i>Salmonella typhimurium</i> enhances STING-mediated IFN-β response in human macrophages and dendritic cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Center Amsterdam; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Eidgenössische Technische Hochschule Zürich; Albert-Ludwigs-Universität Freiburg; Université de Fribourg; University of Oxford; Imperial College London","keywords":"Sting; Stimulator of interferon genes; Secretion; Immune system; Interferon; Ectopic expression; Cytotoxic T cell; Gene knockdown; Downregulation and upregulation; Microbiology; Innate immune system; In vitro; Cytokine; Biology; Cell biology; Cytotoxicity; Chemistry; Cell culture; Immunology; Gene; Biochemistry","score_opus":0.0141963607539722,"score_gpt":0.3486339116966563,"score_spread":0.3344375509426841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366339464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603206,0.00034275724,0.0021058924,0.000070798094,0.000023861487,0.000037707527,0.0004750812,0.00007242783,0.0008393847],"genre_scores_gemma":[0.99384946,0.00026389508,0.003538306,0.00004352846,0.00000879755,0.000041994062,0.0007247853,0.0000232218,0.0015060813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982953,0.00002716438,0.000028948118,0.00003655297,0.000030871703,0.000046903846],"domain_scores_gemma":[0.9999151,0.000012135203,0.000027674214,0.000013020303,0.000009330801,0.000022777955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015567687,0.0003349188,0.00020414355,0.00014237835,0.00008719963,0.00027726887,0.0001600512,0.0002614654,0.0007251201],"category_scores_gemma":[0.00006948446,0.00014085327,0.0003220012,0.00012509024,0.0002291066,0.00009685082,0.0001617764,0.00048355747,0.00052263966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006923821,0.00001525046,0.0000795869,0.000018238856,0.0000019231866,0.00001947452,0.0000071646173,0.000034813434,0.99950576,0.000031915544,0.000014592768,0.0002020193],"study_design_scores_gemma":[0.000011349005,0.0002746292,0.0010673099,0.0000034753646,0.000009095791,0.00012246236,0.000015573454,0.0004220668,0.99687284,0.000009069313,0.0011893396,0.0000026881773],"about_ca_topic_score_codex":0.0007594527,"about_ca_topic_score_gemma":0.00070789835,"teacher_disagreement_score":0.0007594527,"about_ca_system_score_codex":0.00031003653,"about_ca_system_score_gemma":0.0001727039,"threshold_uncertainty_score":0.0024257898},"labels":[],"label_agreement":null},{"id":"W4378473295","doi":"10.1136/jitc-2022-006595","title":"CD71<sup>+</sup> erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"Medicine; Avelumab; Immunotherapy; Melanoma; Immune system; Cancer; Effector; T cell; Immunology; Internal medicine; Cancer research; Oncology; Pembrolizumab","score_opus":0.009519084047119179,"score_gpt":0.27464340871007614,"score_spread":0.265124324662957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378473295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989806,0.00047303367,0.0000975879,0.000024163362,0.0000022781755,0.0000075435582,0.00008939486,0.0000038293697,0.00032158324],"genre_scores_gemma":[0.99946696,0.00008228566,0.000098468015,0.000015450096,0.000009212504,0.000007137674,0.0001727889,0.0000010786692,0.0001466583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987745,0.00003230937,0.000017842112,0.00002774018,0.000020443094,0.00002411688],"domain_scores_gemma":[0.9996001,0.00010057637,0.00015829087,0.000020787713,0.00004060267,0.000079671496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027337193,0.00017425051,0.00028365204,0.00027172657,0.0001732297,0.00032435916,0.00011928662,0.00018549067,0.0008559284],"category_scores_gemma":[0.00049053464,0.00008147751,0.000103116865,0.00019503506,0.00014835503,0.00016983954,0.00019639621,0.00027808477,0.00022729594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023531849,0.00016708633,0.964465,0.00003859447,0.000036606994,0.00025314916,0.00006252147,0.00025653507,0.019412601,0.000046367633,0.00023153833,0.012676763],"study_design_scores_gemma":[0.000049835267,0.0013699982,0.99007636,0.00000858945,0.00004996337,0.0017323141,0.00009759561,0.0007793451,0.004865531,0.00008927965,0.00087693013,0.0000042589527],"about_ca_topic_score_codex":0.00023469143,"about_ca_topic_score_gemma":0.0003227653,"teacher_disagreement_score":0.0008559284,"about_ca_system_score_codex":0.00013143725,"about_ca_system_score_gemma":0.00010119852,"threshold_uncertainty_score":0.0028633475},"labels":[],"label_agreement":null},{"id":"W4379645119","doi":"10.1136/jitc-2023-006802","title":"Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Eberhard Karls Universität Tübingen; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Medicine; Melanoma; Biomarker; Oncology; Myeloid-derived Suppressor Cell; Immune checkpoint; Immune system; Flow cytometry; Myeloid; Internal medicine; Cancer; Immunotherapy; Cohort; Immunology; Cancer research; Suppressor; Biology","score_opus":0.01955512069351003,"score_gpt":0.2874628456149711,"score_spread":0.2679077249214611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99881727,0.00048101656,0.00025872528,0.000023788189,0.0000044050253,0.000011276507,0.00011805677,0.000013286644,0.0002722108],"genre_scores_gemma":[0.9994287,0.00008553686,0.00021231131,0.000013129092,0.000010550105,0.000008409825,0.00015249642,0.0000021013477,0.00008678715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985576,0.00003180698,0.000016334372,0.000039672785,0.00003449722,0.000021952834],"domain_scores_gemma":[0.99928004,0.00016946041,0.00030663845,0.000044665077,0.0000818167,0.00011738583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004102288,0.00021566465,0.0002941049,0.0005053754,0.0001872303,0.00037823222,0.00016350384,0.00029301728,0.0008380992],"category_scores_gemma":[0.001130123,0.00011080279,0.00011147819,0.00034964317,0.00019497055,0.00021106994,0.00020307717,0.00044654324,0.00020773844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011581511,0.00006845263,0.95675653,0.000041986157,0.000027697246,0.00012955212,0.000065204804,0.00025148585,0.031177353,0.000029680168,0.00014005881,0.0101537695],"study_design_scores_gemma":[0.000011533824,0.00050919474,0.9932227,0.000007052906,0.000030507092,0.00066577824,0.000051898074,0.0006415537,0.0044457107,0.00004154817,0.00036877996,0.0000037111731],"about_ca_topic_score_codex":0.00032771207,"about_ca_topic_score_gemma":0.00043757548,"teacher_disagreement_score":0.0008380992,"about_ca_system_score_codex":0.0002024635,"about_ca_system_score_gemma":0.00018575882,"threshold_uncertainty_score":0.002803743},"labels":[],"label_agreement":null},{"id":"W4380077943","doi":"10.1136/jitc-2022-006624","title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Society for Immunotherapy of Cancer","keywords":"Medicine; Guideline; Immunotherapy; Cancer; Cervical cancer; Endometrial cancer; Clinical Practice; Ovarian cancer; Intensive care medicine; Oncology; Multidisciplinary approach; Clinical trial; Quality of life (healthcare); Internal medicine; Biomarker; Disease; Gynecology; Family medicine; Nursing; Pathology","score_opus":0.07599925134873417,"score_gpt":0.46799917507606126,"score_spread":0.39199992372732706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077943","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003636785,0.13825239,0.037068617,0.54869485,0.027432738,0.013178103,0.017424593,0.001617881,0.21269403],"genre_scores_gemma":[0.03432655,0.21779808,0.26254874,0.31943074,0.009479061,0.019137336,0.067971446,0.0006706732,0.0686374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9890058,0.0043752133,0.0025939122,0.0003981565,0.0030099996,0.0006169542],"domain_scores_gemma":[0.9757201,0.005063098,0.0024781765,0.00050388323,0.014795864,0.0014388947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010089925,0.0011631161,0.0017585133,0.004834975,0.0015437528,0.0025629923,0.004520934,0.008136125,0.005417914],"category_scores_gemma":[0.0263333,0.0008016137,0.0032946216,0.0043866974,0.0012511106,0.0016237313,0.0026146763,0.009522945,0.005441651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041164527,0.00008719144,0.0008941752,0.0023968446,0.000078578596,0.00027770468,0.00020679952,0.0007154967,0.0005405526,0.003478984,0.89658844,0.09469406],"study_design_scores_gemma":[0.00016487107,0.000086847656,0.0023261206,0.011112133,0.00019651506,0.00087793986,0.00016774618,0.00076990575,0.00036194667,0.0041641956,0.97972304,0.000048805752],"about_ca_topic_score_codex":0.02409201,"about_ca_topic_score_gemma":0.048603576,"teacher_disagreement_score":0.02409201,"about_ca_system_score_codex":0.00555003,"about_ca_system_score_gemma":0.025750209,"threshold_uncertainty_score":0.053361237},"labels":[],"label_agreement":null},{"id":"W4381548535","doi":"10.1136/jitc-2022-006589","title":"G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Astellas Pharma; Daiichi-Sankyo; Genentech; Coherus Biosciences; Servier; Moderna; Revolution Medicines; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Mallinckrodt Pharmaceuticals; Boston Scientific Corporation; Pharmavite; Ludwig Center at Harvard; GlaxoSmithKline; Pfizer; Break Through Cancer; National Institute of Allergy and Infectious Diseases; Celgene","keywords":"FOLFIRINOX; Pegfilgrastim; Medicine; Filgrastim; Gemcitabine; Immunology; Pancreatic cancer; Neutropenia; Granulocyte colony-stimulating factor; Chemotherapy; Cancer research; Internal medicine; Cancer; Irinotecan","score_opus":0.02184843116684437,"score_gpt":0.32327058491701505,"score_spread":0.3014221537501707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381548535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827292,0.0059356536,0.004738884,0.00054619776,0.00012052044,0.00029912218,0.0013805487,0.00048111126,0.0037687665],"genre_scores_gemma":[0.9900096,0.0020986502,0.0022366203,0.0004267606,0.00003967842,0.00033684354,0.0012516807,0.000050229115,0.003550007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976724,0.00006223623,0.000020294035,0.000061498184,0.00004010811,0.000048630147],"domain_scores_gemma":[0.999863,0.00002025549,0.000041070147,0.000028644801,0.00000853051,0.000038322574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044606102,0.00067906105,0.00045074226,0.00053694873,0.00022518498,0.00045713244,0.00031319723,0.00074336457,0.0019890384],"category_scores_gemma":[0.00016864922,0.00019280058,0.00040702312,0.00013266214,0.00044366255,0.00027904805,0.00017593219,0.0011035869,0.0005328544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036551058,0.001236356,0.0009996255,0.00014737448,0.000052853913,0.00038276773,0.000084601474,0.0004166002,0.9773316,0.0005687053,0.0013618101,0.013762637],"study_design_scores_gemma":[0.0022051705,0.024658455,0.016020972,0.00015958966,0.00023744865,0.007296353,0.00015526263,0.005334548,0.90923405,0.00061382446,0.03404159,0.000042713316],"about_ca_topic_score_codex":0.00037586654,"about_ca_topic_score_gemma":0.00040152852,"teacher_disagreement_score":0.0019890384,"about_ca_system_score_codex":0.00035172398,"about_ca_system_score_gemma":0.00026279598,"threshold_uncertainty_score":0.0066539645},"labels":[],"label_agreement":null},{"id":"W4383561245","doi":"10.1136/jitc-2023-006863","title":"BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Ovarian Cancer Research Alliance; McMaster University; Roswell Park Cancer Institute","keywords":"Cancer research; T cell; Medicine; Tumor microenvironment; Ovarian cancer; Adoptive cell transfer; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Cancer; Biology; Immune system; Internal medicine; In vitro","score_opus":0.026223649595796015,"score_gpt":0.3397886489431468,"score_spread":0.31356499934735077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534,0.00092306227,0.0019037888,0.00009501775,0.00003845722,0.000049791888,0.0001733308,0.00013893451,0.0013376368],"genre_scores_gemma":[0.9971615,0.0004027415,0.00079498166,0.000047148722,0.0000143488205,0.000027140328,0.00022148513,0.00001253318,0.0013181983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000009453601,0.000007899705,0.000018229712,0.00002806033,0.00002429156],"domain_scores_gemma":[0.9999366,0.0000089431815,0.000022704055,0.000008003188,0.0000067709652,0.000016987662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010123095,0.00030683752,0.00020891914,0.00017494506,0.000069822076,0.000301253,0.00012990182,0.00023259189,0.0011714647],"category_scores_gemma":[0.00010064113,0.00007525143,0.00018202906,0.00012010314,0.00016425342,0.00013570803,0.00012038751,0.00068989623,0.00027239343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039915176,0.00018470659,0.000487253,0.00006199109,0.00001038242,0.000038544888,0.000039714687,0.0003989042,0.9866448,0.00009068287,0.00018153075,0.011462329],"study_design_scores_gemma":[0.00018654902,0.0048817475,0.0044745784,0.000015144972,0.00006177742,0.0003060178,0.000067380446,0.0023062434,0.98027235,0.000079869795,0.0073428378,0.000005592951],"about_ca_topic_score_codex":0.0003111686,"about_ca_topic_score_gemma":0.0003577223,"teacher_disagreement_score":0.0011714647,"about_ca_system_score_codex":0.0001546573,"about_ca_system_score_gemma":0.00014254679,"threshold_uncertainty_score":0.003918946},"labels":[],"label_agreement":null},{"id":"W4385215055","doi":"10.1136/jitc-2023-006994","title":"Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Royal College of Physicians and Surgeons of Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Canadian Institutes of Health Research; V Foundation for Cancer Research","keywords":"Blockade; Medicine; PD-L1; Chemotherapy; Oncology; Cohort; Internal medicine; First line; Lung; Pharmacology; Immunotherapy; Cancer; Receptor","score_opus":0.01725263915675259,"score_gpt":0.3307501556499867,"score_spread":0.31349751649323415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385215055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850523,0.0005943731,0.00019701231,0.000046542442,0.000022205459,0.00006498053,0.00044213526,0.0000056458725,0.00012178088],"genre_scores_gemma":[0.99835795,0.00035330813,0.0002066494,0.000067523404,0.000045781442,0.00007356565,0.0007613776,0.0000055081023,0.00012823826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849474,0.00049865484,0.00012742133,0.00052550546,0.00019094595,0.0001628488],"domain_scores_gemma":[0.99558014,0.00096238556,0.0017984668,0.00070643495,0.00027947917,0.0006729782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038957682,0.0005992034,0.0011097578,0.0004496445,0.00046507403,0.0010152115,0.000626992,0.0006756622,0.0013301763],"category_scores_gemma":[0.0051782243,0.0005002412,0.0028707203,0.0006004577,0.00037235077,0.0007453159,0.0005831718,0.0013100684,0.00028724517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08865858,0.0030621868,0.8789309,0.00020999489,0.00685521,0.00026636577,0.00024535228,0.0008721038,0.0031639726,0.00011537207,0.00090674753,0.01671321],"study_design_scores_gemma":[0.010153019,0.06862254,0.90251094,0.000086441716,0.007539056,0.0012412868,0.000352845,0.0049136747,0.0018136422,0.00021131446,0.0024587489,0.00009647097],"about_ca_topic_score_codex":0.0012137681,"about_ca_topic_score_gemma":0.001384813,"teacher_disagreement_score":0.0038957682,"about_ca_system_score_codex":0.00080097496,"about_ca_system_score_gemma":0.0010610583,"threshold_uncertainty_score":0.02060306},"labels":[],"label_agreement":null},{"id":"W4385532450","doi":"10.1136/jitc-2022-006500","title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"McMaster University","keywords":"Medicine; Adverse effect; Pembrolizumab; Nivolumab; Internal medicine; Endocrine system; Cancer; Immunotherapy","score_opus":0.023318942090214626,"score_gpt":0.34530797997758805,"score_spread":0.32198903788737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385532450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022399542,0.996376,0.00007612953,0.0001348801,0.00005509367,0.00019669608,0.00066975213,0.000005168476,0.00024637266],"genre_scores_gemma":[0.02058364,0.9777796,0.00031437236,0.000399299,0.000077157754,0.00033527534,0.0004000659,0.0000036051765,0.000106971536],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99678755,0.00075188343,0.0015827662,0.00025169383,0.0005347264,0.00009141662],"domain_scores_gemma":[0.98510647,0.00977926,0.0036862376,0.00015367701,0.0011135577,0.00016090124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029266346,0.0008683205,0.005115049,0.007849934,0.00043548984,0.0014837648,0.001071958,0.0011334011,0.0032717616],"category_scores_gemma":[0.01426557,0.0005600992,0.004804702,0.010177432,0.00048599986,0.0013447457,0.0008961734,0.0006663663,0.00020123083],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018304941,0.000013352704,0.0019290157,0.9664453,0.007077687,0.00015829901,0.00012862416,0.00006167672,0.00013413515,0.000084159255,0.0012059673,0.022578858],"study_design_scores_gemma":[0.00036125557,0.0003692023,0.016579887,0.87084866,0.08707533,0.0014469274,0.0003501179,0.000110290996,0.00023115528,0.00024203803,0.022335868,0.000049260736],"about_ca_topic_score_codex":0.0048818276,"about_ca_topic_score_gemma":0.013728039,"teacher_disagreement_score":0.007849934,"about_ca_system_score_codex":0.0017410658,"about_ca_system_score_gemma":0.004339569,"threshold_uncertainty_score":0.015477717},"labels":[],"label_agreement":null},{"id":"W4386295527","doi":"10.1136/jitc-2023-006770","title":"Location of CD39<sup>+</sup> T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EPSRC Centre for Doctoral Training in Medical Imaging; Engineering and Physical Sciences Research Council; Institute of Genetics; Cancer Research UK; GlaxoSmithKline","keywords":"Flow cytometry; Tumor microenvironment; CD8; Cancer research; Lung cancer; Multiplex; Cell; Immunofluorescence; Biology; Stromal cell; Pathology; T cell; Medicine; Immunology; Antigen; Immune system; Bioinformatics; Tumor cells; Antibody","score_opus":0.012809677577280291,"score_gpt":0.2850960522620882,"score_spread":0.2722863746848079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386295527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845994,0.00046239956,0.00028777219,0.000029320387,0.000003874688,0.0000107847845,0.00040358008,0.000011205912,0.0003311659],"genre_scores_gemma":[0.9989549,0.000107518106,0.0002612594,0.000022579594,0.00000792675,0.000015801326,0.0003974301,0.0000040902173,0.00022841278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988484,0.000013476717,0.000011279931,0.000041752846,0.000023737475,0.000024831106],"domain_scores_gemma":[0.99976987,0.000045504334,0.000096766176,0.000018480003,0.00002288514,0.000046501365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018117142,0.0001764037,0.00026232935,0.0002597423,0.00018957818,0.00042042747,0.00013425617,0.00026397497,0.0014938726],"category_scores_gemma":[0.00035599832,0.00008021886,0.00015346754,0.00025500642,0.00021465328,0.00019827153,0.00019129079,0.0002932853,0.00035573152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015091943,0.000052989595,0.8196288,0.0000915744,0.00003673998,0.0003398971,0.00006988832,0.00028341642,0.16271329,0.00005540006,0.0002582188,0.0149607],"study_design_scores_gemma":[0.000013044208,0.00034858708,0.97876006,0.0000088520055,0.00003576481,0.0013884633,0.00014274973,0.0008819948,0.017483152,0.00013503846,0.000797137,0.000005218626],"about_ca_topic_score_codex":0.00053355657,"about_ca_topic_score_gemma":0.0008269973,"teacher_disagreement_score":0.0014938726,"about_ca_system_score_codex":0.00020855971,"about_ca_system_score_gemma":0.00012092215,"threshold_uncertainty_score":0.004997492},"labels":[],"label_agreement":null},{"id":"W4386496099","doi":"10.1136/jitc-2023-007277","title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; T cell; Cancer research; Immunology; Immune system","score_opus":0.06099437135282873,"score_gpt":0.3805189673241266,"score_spread":0.3195245959712979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386496099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97576773,0.0043492946,0.013954065,0.00013794401,0.000051733146,0.00025223652,0.0003102737,0.00028890805,0.004887619],"genre_scores_gemma":[0.99168265,0.0014099409,0.0049133627,0.000069113696,0.000020009156,0.00010051918,0.00035632862,0.000015840234,0.0014321613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984574,0.000020860154,0.000013285557,0.000041698688,0.000040841183,0.000037597405],"domain_scores_gemma":[0.999931,0.000013041872,0.00001962962,0.000014052893,0.000007907098,0.000014429567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012754336,0.0003540716,0.00022183014,0.0002556808,0.00009466325,0.000304921,0.00023018387,0.0003264778,0.0011904252],"category_scores_gemma":[0.00010578506,0.000078373814,0.00019962137,0.00016454577,0.00020449793,0.0001795992,0.00021632593,0.00050439703,0.00038988306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020120105,0.00018602272,0.0010781067,0.00014713041,0.000015701979,0.00016496675,0.000025654846,0.00047966946,0.9840702,0.00045912352,0.00025882173,0.012913404],"study_design_scores_gemma":[0.00010384752,0.002086429,0.0023946282,0.000017961467,0.000078674835,0.002282704,0.00003204889,0.0025737043,0.9756737,0.0001830419,0.014566067,0.0000072410226],"about_ca_topic_score_codex":0.00022399097,"about_ca_topic_score_gemma":0.0002554666,"teacher_disagreement_score":0.0011904252,"about_ca_system_score_codex":0.00022103691,"about_ca_system_score_gemma":0.00020559886,"threshold_uncertainty_score":0.003982365},"labels":[],"label_agreement":null},{"id":"W4387784546","doi":"10.1136/jitc-2023-007354","title":"Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Boehringer Ingelheim Fonds","keywords":"Prostate cancer; Transcriptome; Medicine; Oncology; Internal medicine; Cancer; Cancer research; Biology; Gene; Gene expression","score_opus":0.04261554050152196,"score_gpt":0.3952922527049947,"score_spread":0.35267671220347274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387784546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413526,0.0019028824,0.0015656049,0.00011255114,0.000013531,0.000023047493,0.0014579286,0.00003631936,0.0007528561],"genre_scores_gemma":[0.997269,0.0004529887,0.00066161726,0.00005444944,0.000012365718,0.000029948807,0.0012718256,0.0000069862044,0.0002408035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998319,0.00004260159,0.000012533782,0.000046681856,0.000034946494,0.0000313241],"domain_scores_gemma":[0.9997737,0.000071732975,0.00007890717,0.000017292527,0.000027874104,0.000030545183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023193199,0.00014899753,0.00034112623,0.00036269828,0.00014130365,0.00048097828,0.00010792785,0.0001798506,0.0010457628],"category_scores_gemma":[0.00052832,0.000103928316,0.000189021,0.00040111132,0.00018005117,0.0001837362,0.00022430577,0.00024154187,0.00028629316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023344758,0.00010341273,0.69627887,0.00026735853,0.00019678018,0.00021439367,0.00026933342,0.0019758993,0.2659489,0.00014336912,0.00073807384,0.031529084],"study_design_scores_gemma":[0.000016930982,0.0004633501,0.9727318,0.000021656731,0.00012662503,0.0006124848,0.00030040983,0.0049624764,0.018202065,0.00027163434,0.0022756031,0.0000148864265],"about_ca_topic_score_codex":0.00040495105,"about_ca_topic_score_gemma":0.00049483974,"teacher_disagreement_score":0.0010457628,"about_ca_system_score_codex":0.0001899337,"about_ca_system_score_gemma":0.00016627596,"threshold_uncertainty_score":0.003498435},"labels":[],"label_agreement":null},{"id":"W4388019704","doi":"10.1136/jitc-2023-007047","title":"Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Concordance; Internal medicine; Lung cancer; Adjuvant; Immunohistochemistry; Oncology; PD-L1; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.05075007968482245,"score_gpt":0.45012553697261176,"score_spread":0.39937545728778934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388019704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930836,0.003948857,0.0006178834,0.00024376382,0.00008108867,0.00056586287,0.00058884436,0.000045278444,0.000824839],"genre_scores_gemma":[0.9952165,0.00073373236,0.00095579907,0.00040275828,0.00012219862,0.00071988185,0.0013992696,0.000024992583,0.00042483865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99678135,0.0020697154,0.00016658497,0.00036288454,0.0004531936,0.0001662902],"domain_scores_gemma":[0.9954561,0.00171835,0.0014817171,0.00044131887,0.00030402647,0.0005984723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008278642,0.0012589775,0.0021628025,0.0004884639,0.00023861654,0.0014061668,0.0010073329,0.0012846636,0.0015284008],"category_scores_gemma":[0.005360392,0.00067170046,0.0019161078,0.00040210536,0.001053187,0.00081710314,0.00046161487,0.0026879036,0.0003243678],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9206333,0.004300188,0.02098302,0.00052033114,0.0020560005,0.000040874438,0.000105396204,0.0010504419,0.013501951,0.00014802392,0.0009688298,0.035691556],"study_design_scores_gemma":[0.55599916,0.33915165,0.085838035,0.00012963884,0.0035723585,0.00037671454,0.000082536695,0.0046920343,0.007666844,0.00037871554,0.00202138,0.00009102792],"about_ca_topic_score_codex":0.0003905614,"about_ca_topic_score_gemma":0.00080417667,"teacher_disagreement_score":0.008278642,"about_ca_system_score_codex":0.0010911989,"about_ca_system_score_gemma":0.0009130364,"threshold_uncertainty_score":0.043782175},"labels":[],"label_agreement":null},{"id":"W4389130660","doi":"10.1136/jitc-2023-007353","title":"Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Rash; Adverse effect; Internal medicine; Cohort; Colorectal cancer; Lung cancer; Monoclonal antibody; Gastroenterology; Antibody; Cancer; Oncology; Immunology","score_opus":0.016048132750075172,"score_gpt":0.35549619980918673,"score_spread":0.33944806705911157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389130660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618053,0.0009104931,0.00043187832,0.0002271567,0.00006331817,0.0010557579,0.00038454277,0.00006485039,0.00068150007],"genre_scores_gemma":[0.9933222,0.00090525014,0.0013534673,0.0005282831,0.00011491943,0.0013499737,0.0010933813,0.00002214681,0.0013103251],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995666,0.0001863099,0.000025588251,0.000081906066,0.00004210706,0.00009747089],"domain_scores_gemma":[0.99929667,0.00008690181,0.00014130249,0.00007425276,0.00005324922,0.00034766423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001585676,0.0015870702,0.0018145941,0.00041162022,0.00040695642,0.0008168844,0.0008066377,0.0009237662,0.0020978774],"category_scores_gemma":[0.0007164747,0.0005888467,0.0011830509,0.00040209864,0.0011940775,0.0009220616,0.00040980827,0.0032608344,0.0006243486],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6945888,0.1395372,0.009622504,0.00062052737,0.001326479,0.00025601673,0.0005875951,0.0035504822,0.06377431,0.00024963255,0.0033801398,0.08250634],"study_design_scores_gemma":[0.40472418,0.57726294,0.009473066,0.000019542475,0.00028568186,0.00024075936,0.000072115894,0.0011554686,0.004865848,0.00015925306,0.0017185796,0.000022676415],"about_ca_topic_score_codex":0.0009068871,"about_ca_topic_score_gemma":0.0017390398,"teacher_disagreement_score":0.0020978774,"about_ca_system_score_codex":0.0010978349,"about_ca_system_score_gemma":0.0015997245,"threshold_uncertainty_score":0.008385956},"labels":[],"label_agreement":null},{"id":"W4389130677","doi":"10.1136/jitc-2023-007479","title":"TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Chromatin immunoprecipitation; mTORC1; Cancer research; Immunotherapy; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; PD-L1; Biology; Transcription factor; Immune system; Flow cytometry; Small hairpin RNA; Immunology; Signal transduction; Gene knockdown; Cell culture; Promoter; Cell biology; Gene expression; Gene","score_opus":0.02587258318433669,"score_gpt":0.30907782748007884,"score_spread":0.2832052442957421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389130677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932199,0.0032240127,0.001561104,0.00015418582,0.000030036705,0.00002073247,0.0002955596,0.00010530325,0.0013891434],"genre_scores_gemma":[0.9984769,0.0005213758,0.000238455,0.000029924377,0.0000058476917,0.00001780968,0.00012664225,0.0000060461384,0.00057704933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990857,0.000015089247,0.000006738162,0.000020045614,0.00001658567,0.000032888558],"domain_scores_gemma":[0.999946,0.000005072505,0.000021110456,0.000004292532,0.0000073203623,0.000016277467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012857925,0.00021823123,0.00015898254,0.0002504252,0.00013780725,0.00025465776,0.00012722524,0.00015441033,0.0011378467],"category_scores_gemma":[0.00009073774,0.000097399934,0.00017984494,0.00012655396,0.00022697626,0.00015822666,0.00015366859,0.00035064245,0.00024844558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053234975,0.000066110835,0.0024514573,0.00011390196,0.000015475345,0.00013940288,0.00003243281,0.00025178623,0.99039817,0.00026858234,0.0002616932,0.0054686493],"study_design_scores_gemma":[0.00008628752,0.00092689553,0.06201527,0.000021012265,0.000084470696,0.0006733072,0.0001346346,0.0050996183,0.9241847,0.0003958943,0.006362279,0.000015704476],"about_ca_topic_score_codex":0.00025521632,"about_ca_topic_score_gemma":0.00033174513,"teacher_disagreement_score":0.0011378467,"about_ca_system_score_codex":0.00032234154,"about_ca_system_score_gemma":0.00012668617,"threshold_uncertainty_score":0.0038064718},"labels":[],"label_agreement":null},{"id":"W4389219114","doi":"10.1136/jitc-2023-007631","title":"Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"LAVA Therapeutics; Medical Research Council; National Health and Medical Research Council; Vrije Universiteit Amsterdam","keywords":"CD1D; Antigen presentation; Cell biology; Phosphatidylserine; Biology; Antibody; Immune system; Chemistry; T cell; Immunology; Biochemistry; T-cell receptor; Phospholipid","score_opus":0.03603972794639646,"score_gpt":0.36809400577456336,"score_spread":0.3320542778281669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960828,0.0005042324,0.0020369207,0.00009938262,0.000023699233,0.000020715259,0.00013680746,0.000043990087,0.0010514966],"genre_scores_gemma":[0.99723923,0.00019835473,0.0013043062,0.000052828174,0.000005846924,0.000016889602,0.00015557301,0.000008791983,0.0010181756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990964,0.0000103492,0.0000056015183,0.000018719707,0.000019770612,0.00003584276],"domain_scores_gemma":[0.99993944,0.000008954148,0.000016068432,0.0000049021237,0.0000066835664,0.000023970862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009585228,0.00022497769,0.0001585529,0.000110696434,0.00009593943,0.00023021174,0.00015014375,0.00022626926,0.002157231],"category_scores_gemma":[0.00008929909,0.000062637344,0.00018561151,0.00007575024,0.00012819153,0.0001249217,0.00021193991,0.0004336906,0.0004992592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011043801,0.00003883018,0.00019284533,0.00003833876,0.000005070869,0.00003132839,0.000007395626,0.000077366996,0.99830127,0.000080678285,0.000072356524,0.0010439451],"study_design_scores_gemma":[0.000026938666,0.00018547608,0.0014239808,0.000004447519,0.000011698872,0.00013691782,0.00001181289,0.00096039684,0.99544996,0.000025694835,0.0017604816,0.0000021639787],"about_ca_topic_score_codex":0.00013762918,"about_ca_topic_score_gemma":0.0002081721,"teacher_disagreement_score":0.002157231,"about_ca_system_score_codex":0.00030906795,"about_ca_system_score_gemma":0.00014968275,"threshold_uncertainty_score":0.007216692},"labels":[],"label_agreement":null},{"id":"W4392244637","doi":"10.1136/jitc-2023-008155","title":"CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft","keywords":"Downregulation and upregulation; ICAM-1; Immune system; Immune escape; Medicine; Cancer research; Immunology; Biology; Gene; Cell adhesion molecule","score_opus":0.007697019596176288,"score_gpt":0.26784176051490316,"score_spread":0.26014474091872686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392244637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940042,0.0014819779,0.0024911996,0.00008088952,0.000031400497,0.000045615012,0.00008576821,0.00011832898,0.0016605702],"genre_scores_gemma":[0.9966979,0.00047412267,0.0009595053,0.000040806284,0.000010034909,0.00003643525,0.00015278014,0.000015553862,0.0016130697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997763,0.000028747401,0.000015328262,0.000037324644,0.000043951088,0.000098256336],"domain_scores_gemma":[0.9999268,0.000017058832,0.000013910548,0.000013895978,0.00001218935,0.000016085003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112267924,0.00036164228,0.00045575926,0.00013483853,0.000090153066,0.0003587214,0.00023048233,0.000276988,0.001748072],"category_scores_gemma":[0.00012615949,0.000104504514,0.00021567945,0.000084454165,0.00020149289,0.0002509292,0.00029076095,0.00068704825,0.0004175842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012850495,0.000070653026,0.00018536841,0.00007075356,0.000008336445,0.0000652522,0.000018277207,0.00016311595,0.9962745,0.00015855658,0.00006442289,0.0027923342],"study_design_scores_gemma":[0.000055755434,0.0007021875,0.0017570491,0.000007144322,0.000030501997,0.00043584596,0.000022670161,0.0011986612,0.9923609,0.000037517773,0.003388316,0.0000035250416],"about_ca_topic_score_codex":0.0002766903,"about_ca_topic_score_gemma":0.00040951846,"teacher_disagreement_score":0.001748072,"about_ca_system_score_codex":0.00023927199,"about_ca_system_score_gemma":0.00020391363,"threshold_uncertainty_score":0.005847931},"labels":[],"label_agreement":null},{"id":"W4392303061","doi":"10.1136/jitc-2023-008735","title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iovance Biotherapeutics; Gilead Sciences; Servier; National Cancer Institute; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Pfizer; Moderna; Incyte; Ipsen; BeiGene; Sun Pharma; Sanofi; Moffitt Cancer Center; Exelixis; Seagen; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Context (archaeology); Intensive care medicine; Clinical trial; Cell therapy; Best practice; Internal medicine; Stem cell","score_opus":0.26030052746488336,"score_gpt":0.5246172299582877,"score_spread":0.2643167024934044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392303061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032326195,0.93591833,0.006717581,0.02886121,0.006491673,0.0012203829,0.0013158162,0.00024676934,0.01890493],"genre_scores_gemma":[0.0034754635,0.9397074,0.029322442,0.014276603,0.0014599602,0.0019366727,0.0029183307,0.0000763565,0.0068268534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916067,0.0031827406,0.0021575391,0.00041869763,0.0022567739,0.00037759682],"domain_scores_gemma":[0.98710877,0.0058056135,0.0015223101,0.00036280326,0.0047652125,0.00043524394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012482367,0.0016090124,0.0026823347,0.006370005,0.00090414606,0.0028475933,0.0051698694,0.005077878,0.009746762],"category_scores_gemma":[0.018870173,0.0007039305,0.0042398614,0.0047599114,0.0011502282,0.0024250802,0.0020058947,0.0041377624,0.006097464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119523145,0.00012098072,0.00025074434,0.062455866,0.00031234435,0.0005236964,0.00041549405,0.0007775632,0.0007509862,0.010735297,0.30528054,0.618257],"study_design_scores_gemma":[0.00006111836,0.000050656818,0.0003202874,0.05054962,0.0003753318,0.0005580353,0.0001280145,0.00012587066,0.00024062904,0.0037591876,0.9437993,0.00003191423],"about_ca_topic_score_codex":0.0047742524,"about_ca_topic_score_gemma":0.0071826973,"teacher_disagreement_score":0.012482367,"about_ca_system_score_codex":0.0028221887,"about_ca_system_score_gemma":0.013199653,"threshold_uncertainty_score":0.06601381},"labels":[],"label_agreement":null},{"id":"W4392820515","doi":"10.1136/jitc-2023-008409","title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Oxaliplatin; Nivolumab; Oncology; Colorectal cancer; Clinical endpoint; Irinotecan; Randomized controlled trial; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy","score_opus":0.08274832123584072,"score_gpt":0.43882121467788904,"score_spread":0.3560728934420483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392820515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98115563,0.005230504,0.0006696424,0.0011769313,0.0004714008,0.0052337353,0.003061792,0.000153081,0.0028472764],"genre_scores_gemma":[0.9736223,0.0024710945,0.0031056234,0.0020613873,0.0005981731,0.0065942938,0.0064302804,0.00004200564,0.0050748456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993062,0.0004149902,0.00003775586,0.00010473256,0.00006186421,0.00007447276],"domain_scores_gemma":[0.99905425,0.00022919665,0.00027230184,0.00007147683,0.00006506564,0.00030774175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002926242,0.0012849376,0.0016147246,0.00031338033,0.00029978607,0.0009794052,0.0007684207,0.0013150194,0.0062914044],"category_scores_gemma":[0.0021701592,0.0004721984,0.0015860505,0.0002768502,0.0006617807,0.00071356003,0.00040125684,0.0017028538,0.00064835657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97586536,0.0046010218,0.0010260649,0.0004357051,0.00093658845,0.000031329717,0.000028774064,0.0003960417,0.001930562,0.000101211044,0.001932415,0.012714882],"study_design_scores_gemma":[0.95994246,0.03542575,0.0022618908,0.00003176316,0.0005597337,0.00003523209,0.000007516168,0.0004417063,0.00030608173,0.00009101934,0.00088679534,0.000010049047],"about_ca_topic_score_codex":0.00092106935,"about_ca_topic_score_gemma":0.0025382577,"teacher_disagreement_score":0.0062914044,"about_ca_system_score_codex":0.0010392809,"about_ca_system_score_gemma":0.0014244356,"threshold_uncertainty_score":0.021046877},"labels":[],"label_agreement":null},{"id":"W4392846645","doi":"10.1136/jitc-2023-008295","title":"Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Rutgers Cancer Institute of New Jersey; National Institutes of Health; New Jersey Health Foundation","keywords":"CD16; Cancer research; Antibody-dependent cell-mediated cytotoxicity; Interleukin 12; Ovarian cancer; Cancer cell; Immune system; Metastasis; Immunology; NK-92; Cancer; Interleukin 21; Antibody; Cytotoxic T cell; Medicine; Biology; T cell; In vitro; Monoclonal antibody; CD3; Internal medicine","score_opus":0.014263035926557486,"score_gpt":0.29593898391096224,"score_spread":0.28167594798440476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392846645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305505,0.001040543,0.0037490155,0.00008086678,0.000023770053,0.000053708387,0.000257139,0.000100263656,0.0016397294],"genre_scores_gemma":[0.99258476,0.00062040205,0.0028127534,0.00005195474,0.000008652486,0.000060005827,0.00034623977,0.00002278994,0.0034923337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997714,0.00003104113,0.000024122466,0.000046450958,0.000058299287,0.00006878441],"domain_scores_gemma":[0.9999056,0.000010380363,0.0000332031,0.000012395148,0.000011330526,0.000026997073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021410895,0.0005014433,0.00028643376,0.00027691142,0.000107437125,0.0002564662,0.00021640392,0.00031896785,0.0011983784],"category_scores_gemma":[0.00008477927,0.000109408174,0.00022591185,0.00009409187,0.0002066113,0.00021898682,0.00020633156,0.00056582066,0.0003686977],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001409999,0.00005642763,0.00010536943,0.0000325546,0.000004526887,0.000025035884,0.000009936379,0.00006526216,0.99862313,0.00008286039,0.000024375295,0.00082967384],"study_design_scores_gemma":[0.00001599732,0.0003824449,0.00071368634,0.0000040848736,0.000014354423,0.00017185295,0.000012089319,0.00039290145,0.9967482,0.000018167024,0.0015238614,0.0000022254274],"about_ca_topic_score_codex":0.00037145556,"about_ca_topic_score_gemma":0.0008110923,"teacher_disagreement_score":0.0011983784,"about_ca_system_score_codex":0.00022905943,"about_ca_system_score_gemma":0.0002057124,"threshold_uncertainty_score":0.0040090084},"labels":[],"label_agreement":null},{"id":"W4393091426","doi":"10.1136/jitc-2023-008655","title":"SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Interpretation (philosophy); Oncology; Internal medicine; Medical physics; Bioinformatics; Computer science; Biology","score_opus":0.061669252377449094,"score_gpt":0.44986434410478693,"score_spread":0.38819509172733785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393091426","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000985449,0.003557523,0.00034794124,0.8730288,0.121091746,0.000036890287,0.00022793142,0.000057281213,0.0015534324],"genre_scores_gemma":[0.00094353553,0.00089567935,0.00052235974,0.9229669,0.07276139,0.00008956986,0.000049388527,0.000029175491,0.0017419904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9333587,0.026524557,0.009192537,0.006616295,0.020554466,0.0037535354],"domain_scores_gemma":[0.7439987,0.17894322,0.010787449,0.005669278,0.048037946,0.012563372],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05988005,0.0022715826,0.0051283175,0.0027775986,0.005591529,0.008541577,0.00790237,0.089349926,0.005548225],"category_scores_gemma":[0.17183213,0.0025563878,0.004920829,0.0024536229,0.009593024,0.0055475435,0.0042472985,0.11011442,0.0065153716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107475425,0.000013105866,0.000111151334,0.00016280405,0.000038530132,0.00012573854,0.000052631607,0.000047810696,0.000083266124,0.0023934836,0.99291295,0.003951041],"study_design_scores_gemma":[0.00038475345,0.00014731949,0.0018121713,0.0021875026,0.00025039844,0.00043741916,0.00011698941,0.00041642136,0.0004055633,0.012367673,0.98130155,0.00017228552],"about_ca_topic_score_codex":0.011841079,"about_ca_topic_score_gemma":0.023047907,"teacher_disagreement_score":0.9401199,"about_ca_system_score_codex":0.010692618,"about_ca_system_score_gemma":0.022056164,"threshold_uncertainty_score":0.31667978},"labels":[],"label_agreement":null},{"id":"W4393230681","doi":"10.1136/jitc-2023-008694","title":"Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup> T cells barren human pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Program of Shanghai Academic Research Leader; Shanghai Key Laboratory of Molecular Imaging; Fujian Medical University; China Postdoctoral Science Foundation; Fudan University; National Natural Science Foundation of China; Beijing Xisike Clinical Oncology Research Foundation; Shanghai Municipal Health Commission","keywords":"Pancreatic cancer; Cytotoxic T cell; Cancer; Cancer research; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.02980560795441357,"score_gpt":0.3826889662164464,"score_spread":0.3528833582620328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393230681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994301,0.00018794203,0.00004223998,0.000014367345,0.000002122209,0.0000032005216,0.00009803525,0.0000021353278,0.00021985309],"genre_scores_gemma":[0.9996793,0.000042573887,0.000021801861,0.000006107778,0.000004824145,0.0000040781047,0.00012173724,7.676876e-7,0.000118893055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987566,0.000032124903,0.000013860987,0.000027413758,0.000016677468,0.000034288514],"domain_scores_gemma":[0.9994394,0.00012688116,0.00023154524,0.000042091746,0.000031591535,0.00012849095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028013324,0.00018197941,0.00019064113,0.00061519275,0.0002972395,0.00043591743,0.00014814807,0.000272724,0.0018223814],"category_scores_gemma":[0.0007740385,0.00012614901,0.00014441552,0.00040310132,0.0002957044,0.00024475312,0.0003399424,0.00024137936,0.00035153344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062459713,0.000022794624,0.9944518,0.000011237807,0.00001638405,0.00027809344,0.000049281065,0.00006725589,0.002588318,0.000022646329,0.000051691743,0.0018158908],"study_design_scores_gemma":[0.000015218928,0.00020256598,0.9962717,0.0000046212026,0.0000231143,0.0015092518,0.0002008099,0.0002324786,0.0009223439,0.000111744834,0.0005021433,0.0000039329866],"about_ca_topic_score_codex":0.0003425399,"about_ca_topic_score_gemma":0.00047910993,"teacher_disagreement_score":0.0018223814,"about_ca_system_score_codex":0.00014815993,"about_ca_system_score_gemma":0.00010665116,"threshold_uncertainty_score":0.0060964823},"labels":[],"label_agreement":null},{"id":"W4393989214","doi":"10.1136/jitc-2023-006781","title":"Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Guelph","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Cancer Research Society","keywords":"Pyroptosis; Cytotoxic T cell; Programmed cell death; Immunogenic cell death; CD8; T cell; Immune system; Cancer research; Biology; Acquired immune system; Priming (agriculture); Apoptosis; Cell biology; Immunology; Immunotherapy; In vitro","score_opus":0.012129554037529114,"score_gpt":0.2909093205397937,"score_spread":0.27877976650226455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853571,0.00094402436,0.011098038,0.000058341837,0.000032131356,0.00007296159,0.00033297623,0.000081592174,0.0020228974],"genre_scores_gemma":[0.99362046,0.0005701301,0.004108765,0.000052435164,0.000017874941,0.00004472374,0.00032951395,0.000016652508,0.0012394281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998642,0.00001926949,0.0000122614765,0.00003472676,0.00003489853,0.000034580815],"domain_scores_gemma":[0.9998815,0.000021529419,0.000029086441,0.000021798432,0.000014888422,0.00003113065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011958557,0.00025068532,0.0001686018,0.00015137528,0.00008479996,0.00029971462,0.00009282522,0.0001963097,0.001119462],"category_scores_gemma":[0.00010883058,0.00006992483,0.00019355022,0.000102496604,0.00012934733,0.00019151291,0.000219427,0.0005223595,0.0003911667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007780721,0.000016853664,0.00034167204,0.000023274855,0.0000017871942,0.00006190484,0.0000102399645,0.00008273977,0.9979038,0.00014363509,0.000022658807,0.0013135836],"study_design_scores_gemma":[0.000024054665,0.0003830891,0.004716946,0.000007804597,0.000007870897,0.00068048114,0.000025764642,0.0016118896,0.98971915,0.00021334732,0.0026060655,0.0000035004055],"about_ca_topic_score_codex":0.000049644183,"about_ca_topic_score_gemma":0.00008406503,"teacher_disagreement_score":0.001119462,"about_ca_system_score_codex":0.00020379835,"about_ca_system_score_gemma":0.0001463206,"threshold_uncertainty_score":0.0037449598},"labels":[],"label_agreement":null},{"id":"W4394690662","doi":"10.1136/jitc-2023-007675","title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Eli Lilly Canada; National Institutes of Health; Bausch Health; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Galderma; Amryt Pharma; Incyte; Novocure; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre","keywords":"Medicine; CLARITY; Delphi method; Adverse effect; Grading (engineering); Usability; Medical diagnosis; Family medicine; Disease; Psoriasis; MEDLINE; Vitiligo; Alternative medicine; Dermatology; Internal medicine; Pathology; Artificial intelligence; Computer science","score_opus":0.04581985567053431,"score_gpt":0.340229610841648,"score_spread":0.2944097551711137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394690662","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11800591,0.045553822,0.59406453,0.071447544,0.005043596,0.041324075,0.009976925,0.0017675098,0.11281619],"genre_scores_gemma":[0.24211748,0.010303176,0.7068498,0.007840579,0.0007136969,0.021629816,0.006551914,0.00033309276,0.0036604442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7982502,0.11313894,0.054332457,0.005169509,0.026080798,0.00302811],"domain_scores_gemma":[0.8313652,0.06534542,0.03064595,0.00699461,0.059966028,0.005682739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13953549,0.0016090607,0.0020105431,0.015168021,0.0033278055,0.005727045,0.0047594486,0.0030507399,0.0024673222],"category_scores_gemma":[0.16345884,0.00076777773,0.004721673,0.0068388404,0.004291485,0.006384556,0.012477872,0.0066114897,0.0016983108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009508491,0.0008806501,0.12562282,0.017908294,0.00087822496,0.0011359896,0.03016814,0.006247246,0.0055894842,0.06572998,0.15479688,0.59009147],"study_design_scores_gemma":[0.00071416097,0.0024713825,0.14967895,0.03310813,0.0011964783,0.010982246,0.034461476,0.020104751,0.006142035,0.090919256,0.64910764,0.0011134752],"about_ca_topic_score_codex":0.0048954347,"about_ca_topic_score_gemma":0.007992923,"teacher_disagreement_score":0.13953549,"about_ca_system_score_codex":0.0077794534,"about_ca_system_score_gemma":0.01970476,"threshold_uncertainty_score":0.737943},"labels":[],"label_agreement":null},{"id":"W4396809669","doi":"10.1136/jitc-2023-008460","title":"Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Brain Tumour Charity; Alzheimer Society; National Institute for Health and Care Research; Cancer Research UK; Brain Research UK; Linacre College, University of Oxford","keywords":"Oncolytic virus; Glioma; Virotherapy; NKG2D; Cancer research; Glioblastoma; Medicine; Stem cell; Tumor cells; Cytotoxic T cell; Biology","score_opus":0.012285022321507084,"score_gpt":0.26497405737477836,"score_spread":0.2526890350532713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396809669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979401,0.00047217248,0.0008848343,0.000028915878,0.000007904332,0.000023387265,0.000059107715,0.00003904085,0.0005444882],"genre_scores_gemma":[0.9978022,0.000339041,0.0012026789,0.000027411386,0.0000045082866,0.000027556514,0.00014664432,0.000007203747,0.00044273396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988925,0.00001507801,0.000009340113,0.000016751626,0.000033637927,0.00003598142],"domain_scores_gemma":[0.9999716,0.0000035843152,0.000008604338,0.0000041475737,0.0000028094842,0.0000091607635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086705775,0.0003854976,0.0002475834,0.00016548684,0.00008378077,0.000280051,0.00017167348,0.00023418428,0.0006268185],"category_scores_gemma":[0.00006599888,0.00008579513,0.00019036194,0.00013017573,0.00017501446,0.0001457854,0.00023599739,0.00040357173,0.00023673591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015565139,0.00009474304,0.00025389664,0.000040710096,0.000008620025,0.000049409446,0.000021703543,0.00034707773,0.99655956,0.00009527618,0.000046386453,0.0023269218],"study_design_scores_gemma":[0.00003575937,0.00096338626,0.0016917955,0.0000048078,0.00002708418,0.00028470502,0.000014714842,0.0012334278,0.99432546,0.000032102736,0.0013826052,0.000004230295],"about_ca_topic_score_codex":0.0003202931,"about_ca_topic_score_gemma":0.0004670673,"teacher_disagreement_score":0.0006268185,"about_ca_system_score_codex":0.00031181096,"about_ca_system_score_gemma":0.00015859674,"threshold_uncertainty_score":0.002262354},"labels":[],"label_agreement":null},{"id":"W4396969443","doi":"10.1136/jitc-2023-008435","title":"Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Haematopoiesis; Stem cell; Medicine; Hematopoietic stem cell; Hematopoietic stem cell transplantation; Immunology; Cancer research; Transplantation; Pharmacology; Biology; Internal medicine","score_opus":0.01718153996375349,"score_gpt":0.3227991147229518,"score_spread":0.3056175747591983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396969443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853049,0.0071787867,0.0049959486,0.00010200135,0.00007846054,0.00036579405,0.0004172713,0.00015783988,0.0013989714],"genre_scores_gemma":[0.9918017,0.003061101,0.0032249235,0.00006279875,0.000027232461,0.00027772662,0.0008507934,0.000016010665,0.0006778557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973994,0.000056788365,0.000026009873,0.000053282747,0.00007742856,0.00004649368],"domain_scores_gemma":[0.9997832,0.000040352606,0.00006691198,0.00003598268,0.000025944877,0.00004761415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046783502,0.0005487886,0.00046971158,0.0003834992,0.00015293507,0.0004915171,0.00032580772,0.0003983272,0.0010602009],"category_scores_gemma":[0.0002672315,0.00010709375,0.00029319947,0.00023197554,0.00036759028,0.00030245277,0.00021326542,0.001289674,0.00025609188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037283024,0.0027998704,0.0010563358,0.000553432,0.000067058936,0.00008940726,0.000060646573,0.0015395824,0.9546481,0.0005124869,0.0003162344,0.034628656],"study_design_scores_gemma":[0.00074845337,0.03882919,0.0029993618,0.000040363615,0.000119755394,0.0007506193,0.000041750754,0.0015408702,0.9500739,0.00017772478,0.0046609105,0.000017208133],"about_ca_topic_score_codex":0.00011030531,"about_ca_topic_score_gemma":0.00012778233,"teacher_disagreement_score":0.0010602009,"about_ca_system_score_codex":0.00034669656,"about_ca_system_score_gemma":0.00030445593,"threshold_uncertainty_score":0.0035466552},"labels":[],"label_agreement":null},{"id":"W4399446481","doi":"10.1136/jitc-2024-009028","title":"Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Sanofi Genzyme; Bristol-Myers Squibb Canada; Sanofi Pasteur; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Castle Biosciences; GlaxoSmithKline","keywords":"Melanoma; Medicine; Metastatic melanoma; Term (time); Oncology; Internal medicine; Cancer research","score_opus":0.033451109223183534,"score_gpt":0.3808977893389546,"score_spread":0.34744668011577107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399446481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988141,0.000639917,0.00009440189,0.00003234187,0.0000042915267,0.000012359014,0.00014148567,0.0000047785443,0.00025635952],"genre_scores_gemma":[0.99910766,0.00014348973,0.00005377602,0.000037371356,0.000009395395,0.000015180234,0.00046347216,0.0000012284041,0.00016842189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998222,0.000044631302,0.000015816766,0.0000351286,0.000038921135,0.00004328108],"domain_scores_gemma":[0.99945337,0.000084299274,0.00023594385,0.000030779614,0.000050054194,0.0001455586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007460336,0.00014996533,0.00035365246,0.00019151035,0.00035894514,0.0003287218,0.00014745088,0.00026112882,0.00089255645],"category_scores_gemma":[0.0006858805,0.00008699905,0.0003865593,0.00018074938,0.00015630396,0.0002882072,0.00020174915,0.00050704076,0.00019000145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021064926,0.0012417478,0.90106297,0.00012215447,0.00048881845,0.0008685056,0.00031608235,0.0010534053,0.0151574705,0.000043829863,0.000721063,0.057858914],"study_design_scores_gemma":[0.00058395055,0.019453727,0.97259605,0.00002783166,0.0004131213,0.0010933902,0.00008565915,0.0008831339,0.0031677452,0.000043524484,0.0016374815,0.000014418717],"about_ca_topic_score_codex":0.00080826075,"about_ca_topic_score_gemma":0.0015022611,"teacher_disagreement_score":0.00089255645,"about_ca_system_score_codex":0.0004887233,"about_ca_system_score_gemma":0.00024088184,"threshold_uncertainty_score":0.0039454103},"labels":[],"label_agreement":null},{"id":"W4400892363","doi":"10.1136/jitc-2024-009427","title":"Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Kite Pharma; Moderna; EMD Serono; Ribon Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; Genentech; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biomarker; Medicine; Immunotherapy; PD-L1; Biomarker discovery; Immune system; Oncology; Bioinformatics; Immunology; Biology","score_opus":0.08405559566590562,"score_gpt":0.3973262209989202,"score_spread":0.31327062533301453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022614234,0.93204063,0.0021834027,0.05400766,0.007574278,0.00012924857,0.00014668383,0.00006717129,0.0036247638],"genre_scores_gemma":[0.0018088507,0.95927197,0.0056896606,0.024970558,0.0037220467,0.00021864209,0.00041466157,0.000032691718,0.0038708642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968184,0.0008722304,0.0005507334,0.00028431232,0.0012259232,0.00024821228],"domain_scores_gemma":[0.990807,0.0026380133,0.00078335666,0.00021971342,0.0047330274,0.00081893563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01601249,0.0009756474,0.0026433219,0.003017334,0.0005603491,0.0033479547,0.0029026016,0.005384851,0.0028853938],"category_scores_gemma":[0.00982923,0.0005254403,0.0016730959,0.0024028942,0.001146356,0.0048063733,0.002370052,0.009152049,0.0034511483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014062789,0.00008980002,0.000311032,0.006479651,0.00009292028,0.0001587189,0.0000747018,0.00033136902,0.0014367134,0.013200416,0.24627143,0.73141277],"study_design_scores_gemma":[0.000040445964,0.00010209362,0.00026827454,0.005508993,0.00007256076,0.0003583425,0.0000383102,0.00012676732,0.00043359384,0.0035859277,0.9894434,0.000021366113],"about_ca_topic_score_codex":0.0014277106,"about_ca_topic_score_gemma":0.0021262032,"teacher_disagreement_score":0.01601249,"about_ca_system_score_codex":0.0022328065,"about_ca_system_score_gemma":0.011234381,"threshold_uncertainty_score":0.08468318},"labels":[],"label_agreement":null},{"id":"W4400892533","doi":"10.1136/jitc-2024-009309","title":"Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Adverse effect; Medicine; Osteoporosis; Immune system; Bone remodeling; Intensive care medicine; Bioinformatics; Internal medicine; Oncology; Immunology","score_opus":0.03742799908571104,"score_gpt":0.4110232161316989,"score_spread":0.37359521704598786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007189913,0.9990664,0.00004318646,0.00036103348,0.00015581703,0.000001952273,0.000009700403,0.0000028217914,0.00028724674],"genre_scores_gemma":[0.0008373108,0.9981674,0.000078307225,0.0003770199,0.00027446207,0.000002615516,0.000018917468,9.3903094e-7,0.00024305073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995441,0.00008725605,0.00008960486,0.00006941528,0.00018181872,0.00002780813],"domain_scores_gemma":[0.99922407,0.00038970014,0.00016960678,0.000014912939,0.00017285501,0.000028829534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072568975,0.00060911535,0.0019574948,0.0013956472,0.00024901898,0.000978247,0.00085364294,0.0017349503,0.0031286757],"category_scores_gemma":[0.0016516172,0.0002685558,0.00081032433,0.0014444704,0.00043490634,0.00078972185,0.00044627496,0.0016074453,0.0010227453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013118342,0.00003187763,0.00028005443,0.023899773,0.0002524203,0.00024386213,0.000046299254,0.0001944409,0.0004418224,0.001730973,0.028478347,0.944269],"study_design_scores_gemma":[0.00013412091,0.0002567832,0.0026540007,0.03024,0.0010088953,0.007356064,0.00018845822,0.00025026329,0.0005442668,0.004276165,0.9530438,0.000047243284],"about_ca_topic_score_codex":0.0014476031,"about_ca_topic_score_gemma":0.003116436,"teacher_disagreement_score":0.0031286757,"about_ca_system_score_codex":0.00039938555,"about_ca_system_score_gemma":0.0011791526,"threshold_uncertainty_score":0.010466456},"labels":[],"label_agreement":null},{"id":"W4401037871","doi":"10.1136/jitc-2024-009443","title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Cancer Research UK","keywords":"Oncolytic virus; Melanoma; Tumor microenvironment; Immune checkpoint; Immune system; Cytotoxic T cell; Cancer research; Immunotherapy; Biology; Priming (agriculture); Immunology; T cell; Medicine; In vitro","score_opus":0.017247862124379423,"score_gpt":0.2983928389924288,"score_spread":0.2811449768680494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401037871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99855834,0.00025604613,0.0006609111,0.000040577266,0.000017470647,0.0000286849,0.00006655866,0.000040659077,0.000330863],"genre_scores_gemma":[0.99809414,0.00019669,0.0009407857,0.000017815215,0.000010614461,0.000025656944,0.00013295583,0.000008606352,0.00057281915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998524,0.000032210544,0.000010486943,0.00003065776,0.000032596632,0.000041639836],"domain_scores_gemma":[0.99989605,0.000019200912,0.000029914685,0.000018724773,0.000006652499,0.000029459214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019833939,0.00046558236,0.00036684843,0.00025235701,0.00014456501,0.0002476958,0.00027457613,0.00027368852,0.0006504569],"category_scores_gemma":[0.00010773669,0.00010240204,0.00021297547,0.00011184778,0.00028072117,0.00017058318,0.0001497597,0.00095073227,0.00017230472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004544167,0.0002985424,0.00012032389,0.000022561493,0.000006210905,0.00003609197,0.000026579171,0.00034461016,0.99710184,0.00008798032,0.000047562953,0.0014532981],"study_design_scores_gemma":[0.00013885643,0.0065279305,0.0021366721,0.0000060782418,0.000024394723,0.0002652712,0.000027919732,0.004187187,0.98547584,0.00006833759,0.0011354124,0.0000060979246],"about_ca_topic_score_codex":0.00077245384,"about_ca_topic_score_gemma":0.00083389314,"teacher_disagreement_score":0.00077245384,"about_ca_system_score_codex":0.00029096808,"about_ca_system_score_gemma":0.00019308351,"threshold_uncertainty_score":0.0021760464},"labels":[],"label_agreement":null},{"id":"W4401406952","doi":"10.1136/jitc-2024-008872","title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Department of Science and Technology, Ministry of Science and Technology, India; MacroGenics; Genentech; Actuate Therapeutics; Pfizer; Incyte; Mylan; BeiGene; Clovis Oncology; National Medical Research Council; Exelixis; Karyopharm Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Astex Pharmaceuticals; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.031156298007487766,"score_gpt":0.38733140100864477,"score_spread":0.356175103001157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401406952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851784,0.0015302056,0.000751444,0.00054031576,0.00046288234,0.008010638,0.001433186,0.0001302046,0.0019626457],"genre_scores_gemma":[0.9795195,0.0011528769,0.002339022,0.0013605395,0.00060321833,0.009859509,0.0017722998,0.000034450863,0.003358593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990239,0.00051699945,0.00003989479,0.00021821767,0.00006519017,0.00013577771],"domain_scores_gemma":[0.9988368,0.00030865255,0.00026578904,0.00009693797,0.00006624561,0.00042569076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023273737,0.0023172693,0.0031286937,0.0005471123,0.00042403548,0.001185901,0.0010846896,0.0015851181,0.00829232],"category_scores_gemma":[0.0017987158,0.001082228,0.0014587166,0.00043280493,0.0014331097,0.0014780156,0.0005540169,0.0028205065,0.0013784689],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96598834,0.018548336,0.0011800696,0.00023836562,0.00052363623,0.00004384003,0.000051598137,0.00035768823,0.0031853057,0.00010102473,0.00071356614,0.00906826],"study_design_scores_gemma":[0.9321785,0.065247744,0.001201694,0.000008374831,0.00017247586,0.000025684949,0.000011523754,0.0003763124,0.00024646113,0.00010904902,0.00041298312,0.000009202551],"about_ca_topic_score_codex":0.00080919743,"about_ca_topic_score_gemma":0.0024675792,"teacher_disagreement_score":0.00829232,"about_ca_system_score_codex":0.0012843149,"about_ca_system_score_gemma":0.0017657459,"threshold_uncertainty_score":0.027740538},"labels":[],"label_agreement":null},{"id":"W4404465103","doi":"10.1136/jitc-2024-009962","title":"Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Dental and Craniofacial Research; National Institutes of Health; Charles E. Kaufman Foundation; National Cancer Institute; University of Pittsburgh","keywords":"Medicine; CD8; Immune system; Immunotherapy; Immunosuppression; T cell; Opioid receptor; Cancer research; Opioid; Pharmacology; Immunology; Internal medicine; Receptor","score_opus":0.02187560821429628,"score_gpt":0.33495150404773705,"score_spread":0.31307589583344075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404465103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979747,0.0010118876,0.0003685113,0.000026345971,0.0000058308206,0.000015316407,0.00018310802,0.00002195435,0.00039230645],"genre_scores_gemma":[0.99862576,0.0003869537,0.0003512387,0.000027645645,0.000003693,0.000015673522,0.00039646815,0.000005953698,0.00018663685],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999887,0.0000145522135,0.000008236582,0.000024696732,0.000038774047,0.000026777336],"domain_scores_gemma":[0.9998745,0.000049849245,0.000039795697,0.0000075109665,0.0000128429065,0.000015442898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016566653,0.00017856341,0.00030733258,0.00018700531,0.0001359164,0.00033594674,0.00015792114,0.00021090881,0.0016388273],"category_scores_gemma":[0.00029848926,0.000095427924,0.0003546501,0.00014923327,0.00012984622,0.00011992027,0.00017728408,0.0002301097,0.0002454528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028072689,0.0004058022,0.100086406,0.00057319284,0.00016706034,0.00017984184,0.00007018717,0.008337021,0.8307414,0.00020094517,0.0003901694,0.056040745],"study_design_scores_gemma":[0.00018382995,0.005901436,0.5177719,0.0000986369,0.00057117024,0.0013227322,0.00036313458,0.052238695,0.41211045,0.00057800714,0.008825176,0.00003484207],"about_ca_topic_score_codex":0.00062432775,"about_ca_topic_score_gemma":0.0009369892,"teacher_disagreement_score":0.0016388273,"about_ca_system_score_codex":0.00039605077,"about_ca_system_score_gemma":0.00034198407,"threshold_uncertainty_score":0.005482435},"labels":[],"label_agreement":null},{"id":"W4404567325","doi":"10.1136/jitc-2024-010143","title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; CD8; Cytokine; Oncology; Response Evaluation Criteria in Solid Tumors; Melanoma; Aldesleukin; Adverse effect; Cancer; Interleukin 2; Gastroenterology; Immunotherapy; Immunology; Phases of clinical research; Toxicity; Cancer research; Immune system","score_opus":0.007401104382701864,"score_gpt":0.30071899791223383,"score_spread":0.29331789352953197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404567325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976464,0.0012725607,0.00011340997,0.00004872416,0.000015366606,0.00024442837,0.00010880859,0.000011403167,0.0005388078],"genre_scores_gemma":[0.9986002,0.00040585216,0.00034799596,0.00006589732,0.000029815175,0.00016952498,0.00015394746,0.0000018563783,0.00022482283],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995579,0.00021591394,0.000034590634,0.0000849639,0.000045254783,0.00006140397],"domain_scores_gemma":[0.9996685,0.00008122984,0.00006508936,0.000026512505,0.00002131256,0.00013743094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010986604,0.00043787505,0.0009819097,0.0002778685,0.00023234099,0.00047212775,0.00026662377,0.00039990956,0.0007475744],"category_scores_gemma":[0.0005244384,0.00019143094,0.0004606803,0.00029850606,0.0004903848,0.0004641626,0.00027591604,0.0007668615,0.00019514127],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5288655,0.03750942,0.07041649,0.0011561617,0.000894688,0.00065994513,0.0005797153,0.0063387305,0.14656548,0.00031637438,0.001605506,0.20509195],"study_design_scores_gemma":[0.09138531,0.7924673,0.088941194,0.00006238027,0.00056982506,0.0008728399,0.00018781368,0.0017654682,0.019129474,0.00016191279,0.004420739,0.000035785713],"about_ca_topic_score_codex":0.00037512823,"about_ca_topic_score_gemma":0.0007842746,"teacher_disagreement_score":0.0010986604,"about_ca_system_score_codex":0.00045472753,"about_ca_system_score_gemma":0.0007179716,"threshold_uncertainty_score":0.00581038},"labels":[],"label_agreement":null},{"id":"W4404926477","doi":"10.1136/jitc-2024-009462","title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Cilag; Medac; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene","keywords":"Medicine; Chimeric antigen receptor; Immune system; T cell; Immunotherapy; Immunosenescence; Immunology; Multiple myeloma; Naive T cell; Senescence; Cancer research; Internal medicine; T-cell receptor","score_opus":0.03172640834317397,"score_gpt":0.38804858641614765,"score_spread":0.35632217807297367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404926477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021412356,0.9949491,0.00013545442,0.0014624788,0.00024869418,0.0000058079345,0.000030085872,0.000007854597,0.0010191901],"genre_scores_gemma":[0.020753477,0.9756806,0.00029812258,0.0015897771,0.0010192374,0.000020379723,0.000079181984,0.0000026415446,0.00055661803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976534,0.00008377715,0.000044674074,0.000025396374,0.000055648336,0.000025115964],"domain_scores_gemma":[0.99948055,0.0002530561,0.00012026475,0.000006519289,0.0000950705,0.00004458364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056782825,0.00020802824,0.000431024,0.00047779168,0.00017447611,0.00044398024,0.00017558428,0.0005200139,0.0010280792],"category_scores_gemma":[0.0009875628,0.000051604355,0.00031263698,0.00042421985,0.00017277276,0.0004363402,0.00032220603,0.00062144996,0.00027814496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003761725,0.00005960428,0.004331012,0.009221573,0.00017897398,0.0004725211,0.00012634386,0.00021720573,0.002108866,0.0014024437,0.020769505,0.96073556],"study_design_scores_gemma":[0.000121823745,0.001323985,0.033196043,0.010861685,0.0012690865,0.0067722253,0.00031216425,0.00029840518,0.0021071662,0.002198887,0.9414979,0.00004070809],"about_ca_topic_score_codex":0.00053354277,"about_ca_topic_score_gemma":0.0013131928,"teacher_disagreement_score":0.0010280792,"about_ca_system_score_codex":0.00031959763,"about_ca_system_score_gemma":0.00049959007,"threshold_uncertainty_score":0.0034393072},"labels":[],"label_agreement":null},{"id":"W4405012333","doi":"10.1136/jitc-2024-010094","title":"Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Alberta Cancer Foundation; Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Moncton Hospital; Trillium Health Centre; Juravinski Cancer Centre; Ottawa Hospital; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; Hôpital Charles-Le Moyne; Hôtel-Dieu de Québec; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"Eisai; Taiho Pharmaceutical; Natera; Exelixis; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Immune system; Hazard ratio; Biomarker; Cancer; Gastroenterology; Immunology; Biology; Confidence interval","score_opus":0.018310539268710155,"score_gpt":0.3701782868469034,"score_spread":0.3518677475781932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405012333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951807,0.0022860498,0.00011979637,0.00025531318,0.000048223203,0.00026196218,0.0011415536,0.000013258157,0.00069312693],"genre_scores_gemma":[0.9960407,0.000568127,0.00023342586,0.00018032627,0.00015647069,0.00032375104,0.0020484969,0.000010924679,0.00043780394],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983551,0.000988874,0.00008211648,0.00027092666,0.00014892251,0.00015401996],"domain_scores_gemma":[0.9940316,0.0018716436,0.002403584,0.0004653197,0.000400126,0.0008276366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029070862,0.00073090935,0.001826834,0.00036775935,0.00030254907,0.0008743535,0.0005267607,0.0008511714,0.0016570323],"category_scores_gemma":[0.00472856,0.0002764055,0.001135861,0.00085021043,0.00048630405,0.000404776,0.00036764142,0.0011598516,0.00023356415],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78587997,0.0017756616,0.18325004,0.00072457216,0.0041398327,0.00016897314,0.00008311334,0.0010898391,0.0037338762,0.00011967362,0.0022611138,0.016773285],"study_design_scores_gemma":[0.21934426,0.089972526,0.66760397,0.00024668235,0.0120681245,0.00048440963,0.0001577462,0.004290459,0.0019007683,0.00030220376,0.0035165644,0.00011238328],"about_ca_topic_score_codex":0.0017919632,"about_ca_topic_score_gemma":0.0044322982,"teacher_disagreement_score":0.0029070862,"about_ca_system_score_codex":0.0009982331,"about_ca_system_score_gemma":0.0013630326,"threshold_uncertainty_score":0.015374303},"labels":[],"label_agreement":null},{"id":"W4406093333","doi":"10.1136/jitc-2024-009435","title":"Anti-PD-1 amplifies costimulation in melanoma-infiltrating T<sub>h</sub>1-like Foxp3<sup>+</sup> regulatory T cells to alleviate local immunosuppression","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Institute of Infection and Immunity; McGill University Health Centre; McGill University","keywords":"Immunosuppression; FOXP3; Melanoma; Medicine; Metastatic melanoma; Cancer research; Immunology; Immune system","score_opus":0.010074564758653613,"score_gpt":0.28256035646270344,"score_spread":0.27248579170404985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406093333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765944,0.0004649881,0.0009576625,0.00006117838,0.00001763351,0.000021943082,0.00016042293,0.00006566281,0.0005910981],"genre_scores_gemma":[0.9962547,0.00024611276,0.0016494065,0.00007147708,0.000017156903,0.000038252354,0.00019897983,0.00001792633,0.0015060147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989986,0.000016444097,0.000006788199,0.00002077254,0.000021770973,0.00003427117],"domain_scores_gemma":[0.999938,0.0000105916615,0.000017877019,0.0000069291514,0.0000057339425,0.000020901829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013570479,0.00023844416,0.00024968918,0.00014714006,0.00006586615,0.00017924745,0.0001172108,0.00013311971,0.0012679985],"category_scores_gemma":[0.000051493313,0.000084833366,0.00015714277,0.000072509865,0.00014783762,0.00010111238,0.00009100186,0.00067524664,0.00031071654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001489353,0.00005386579,0.00012017049,0.00001630984,0.0000018093274,0.000011404089,0.0000056298845,0.000062731226,0.9983895,0.000023250323,0.000039100025,0.001127297],"study_design_scores_gemma":[0.000050048766,0.0013054626,0.0041447054,0.0000038849075,0.000012836093,0.00011760367,0.000015718953,0.0011986447,0.99198604,0.000022786817,0.0011402046,0.0000020410462],"about_ca_topic_score_codex":0.00023262671,"about_ca_topic_score_gemma":0.00048703913,"teacher_disagreement_score":0.0012679985,"about_ca_system_score_codex":0.00014605575,"about_ca_system_score_gemma":0.00013798382,"threshold_uncertainty_score":0.0042418838},"labels":[],"label_agreement":null},{"id":"W4406487264","doi":"10.1136/jitc-2024-010579","title":"Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Blood properties and coagulation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Deutsche Forschungsgemeinschaft","keywords":"Secretion; Tissue transglutaminase; Cancer research; Microtubule; Cancer; Cell biology; Pancreatic cancer; Cell; T cell; Medicine; Biology; Immunology; Internal medicine; Immune system; Enzyme","score_opus":0.014144229235313381,"score_gpt":0.30323917629353736,"score_spread":0.28909494705822397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406487264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271566,0.0009562821,0.004431661,0.00006103846,0.000016113847,0.000033812954,0.0006404241,0.00009727471,0.0010477772],"genre_scores_gemma":[0.994395,0.00059789344,0.0024193425,0.000039051887,0.000008510048,0.00003939926,0.0007256588,0.000020571206,0.0017545585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998882,0.0000152062685,0.000012158577,0.000031064363,0.000029733132,0.000023698809],"domain_scores_gemma":[0.99993145,0.000010212631,0.000023025696,0.00000915265,0.000009787609,0.000016448772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010496323,0.00029411106,0.0002023294,0.0001416004,0.000078757475,0.00024406429,0.00008495602,0.00014631433,0.00079199934],"category_scores_gemma":[0.00006335051,0.000062216044,0.00023963797,0.00013327772,0.00012264932,0.00010886307,0.00012238715,0.0003923132,0.0002953694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027996397,0.000007978828,0.00012246179,0.000014212666,0.000001559491,0.0000151695685,0.0000035181265,0.000035571145,0.9993298,0.000017824432,0.000013361308,0.00041052653],"study_design_scores_gemma":[0.000007123809,0.00017770739,0.002409462,0.0000026330033,0.000009979263,0.00013382676,0.000012805223,0.00055294303,0.9950381,0.000017087696,0.0016366835,0.0000016714918],"about_ca_topic_score_codex":0.00015878846,"about_ca_topic_score_gemma":0.00025885153,"teacher_disagreement_score":0.00079199934,"about_ca_system_score_codex":0.00015586505,"about_ca_system_score_gemma":0.0001113163,"threshold_uncertainty_score":0.002649486},"labels":[],"label_agreement":null},{"id":"W4406683378","doi":"10.1136/jitc-2024-010207","title":"Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.12186916104096639,"score_gpt":0.48237948766339306,"score_spread":0.36051032662242666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406683378","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012779688,0.30630845,0.008646892,0.6298445,0.029899066,0.000061283085,0.00011122276,0.00016492899,0.02368563],"genre_scores_gemma":[0.043325227,0.53704476,0.014735572,0.31627932,0.07028754,0.00021503,0.0002159315,0.00023416714,0.017662408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622583,0.001446913,0.00024775194,0.00039992132,0.0013017685,0.00037791548],"domain_scores_gemma":[0.99135596,0.004559378,0.00033804018,0.0006186314,0.0020100817,0.0011179327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010075922,0.0006892042,0.0008922576,0.0014271655,0.0016683779,0.0066932095,0.0016815532,0.006831534,0.0062532304],"category_scores_gemma":[0.009915668,0.00031434922,0.00089547614,0.00088592945,0.009074269,0.008931482,0.0036603943,0.02018693,0.002477722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015706153,0.00018824695,0.00038770842,0.0014728571,0.000051081835,0.00040277577,0.0007517575,0.0009562841,0.001708646,0.30661497,0.3842898,0.30301896],"study_design_scores_gemma":[0.000032832002,0.00013061718,0.00015254451,0.0012154025,0.000018290568,0.00046353298,0.0003120288,0.00027668432,0.0004910171,0.04923882,0.94764227,0.000026041052],"about_ca_topic_score_codex":0.0024293547,"about_ca_topic_score_gemma":0.0047191796,"teacher_disagreement_score":0.010075922,"about_ca_system_score_codex":0.0036985835,"about_ca_system_score_gemma":0.008246149,"threshold_uncertainty_score":0.053287208},"labels":[],"label_agreement":null},{"id":"W4407288611","doi":"10.1136/jitc-2024-009890","title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Iovance Biotherapeutics; Janssen Research and Development; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; bluebird bio; Pharmacyclics; Takeda Oncology; Legend Biotech; U.S. Navy; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; CytoSen Therapeutics; MorphoSys; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; CSL Behring; Kyowa Kirin Pharmaceutical Development; Atara Biotherapeutics; Vertex Pharmaceuticals; Anthem Foundation; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Jazz Pharmaceuticals; Omeros Corporation; U.S. Department of Defense; Medical College of Wisconsin; StemCyte; AbbVie; Actinium Pharmaceuticals; Gilead Sciences; Stanford University; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Merck; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma US; Be The Match Foundation; Novartis Pharmaceuticals Corporation; Dana-Farber Cancer Institute; Allogene Therapeutics; Incyte; Pfizer; Amgen; Boston Children's Hospital; HistoGenetics","keywords":"Medicine; Cytokine release syndrome; Fludarabine; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Salvage therapy; Cohort; Lymphoma; Transplantation; Chimeric antigen receptor; Immunotherapy; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.04027750660366552,"score_gpt":0.41093005155627,"score_spread":0.37065254495260447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407288611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346394,0.0022024773,0.0003978655,0.000116687785,0.000022554463,0.0001812434,0.012223622,0.000026166601,0.0013655169],"genre_scores_gemma":[0.9891149,0.00028978108,0.00016602305,0.0000601326,0.00002678725,0.00018734866,0.0100001665,0.000022489849,0.00013243417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940352,0.0021934002,0.0012525943,0.0010158378,0.00091023685,0.0005928229],"domain_scores_gemma":[0.99000835,0.0020965622,0.0049265143,0.0017723481,0.00070555735,0.0004906253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062243026,0.000472587,0.0011759122,0.0025148033,0.00032121077,0.0015152171,0.0008797982,0.0004991129,0.0020553411],"category_scores_gemma":[0.011114768,0.0003048149,0.0032306782,0.003948549,0.00029927347,0.00084791676,0.0013952458,0.00068961154,0.00043963583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004223731,0.00006473072,0.9835556,0.00029172038,0.004303541,0.00020450317,0.00016013061,0.00054923905,0.00020153109,0.000095843956,0.0013777444,0.0049716104],"study_design_scores_gemma":[0.0003949298,0.00045991043,0.99249387,0.000090858935,0.0026184698,0.00057650026,0.00042112853,0.0008045787,0.00014273138,0.00012679184,0.0018378084,0.000032400334],"about_ca_topic_score_codex":0.003958053,"about_ca_topic_score_gemma":0.005978825,"teacher_disagreement_score":0.0062243026,"about_ca_system_score_codex":0.00090189266,"about_ca_system_score_gemma":0.000814334,"threshold_uncertainty_score":0.03291768},"labels":[],"label_agreement":null},{"id":"W4407302463","doi":"10.1136/jitc-2024-010584","title":"TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Healthcare KGaA","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Tolerability; TIGIT; Gastroenterology; Internal medicine; Neutropenia; Chills; Pharmacology; Antibody; Oncology; Immunology; Chemotherapy; T cell; Adverse effect; Immune system","score_opus":0.01596827262127317,"score_gpt":0.38408734006559386,"score_spread":0.3681190674443207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407302463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933274,0.0034377105,0.00020502503,0.00037245825,0.000097130745,0.0007166837,0.0004801264,0.00008597744,0.0012776054],"genre_scores_gemma":[0.99188834,0.0029127758,0.0007215469,0.0006180276,0.0001296477,0.0007725168,0.0010582163,0.000022211223,0.0018767674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99981374,0.00007029276,0.000009885268,0.000036147638,0.000020126905,0.000049822647],"domain_scores_gemma":[0.9996221,0.00005346163,0.00007824609,0.00002561289,0.00002352046,0.00019698023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009130251,0.001375971,0.001749513,0.00039221635,0.00033375667,0.00095536414,0.00068756833,0.0008749115,0.0035047638],"category_scores_gemma":[0.00057253323,0.00041347195,0.0010498691,0.00040925504,0.0005728828,0.00075084186,0.00028873028,0.0025941285,0.0007763925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6877817,0.05434028,0.0050111837,0.001962667,0.0023453338,0.00039368303,0.00058695086,0.0047984864,0.04475492,0.00040352406,0.008496052,0.18912521],"study_design_scores_gemma":[0.601274,0.3770106,0.009567626,0.00009319384,0.00080172834,0.0005037065,0.00009775716,0.00182659,0.0039753965,0.00029731385,0.004509507,0.00004256613],"about_ca_topic_score_codex":0.0009215693,"about_ca_topic_score_gemma":0.0026732082,"teacher_disagreement_score":0.0035047638,"about_ca_system_score_codex":0.0009848817,"about_ca_system_score_gemma":0.0011191309,"threshold_uncertainty_score":0.011724591},"labels":[],"label_agreement":null},{"id":"W4407984288","doi":"10.1136/jitc-2024-010541","title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Moonshot Research and Development Program; National Center for Advancing Translational Sciences; Cancer Moonshot; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Conquer Cancer Foundation","keywords":"Medicine; Oncology; Internal medicine; Cabozantinib; Nivolumab; Endometrial cancer; Cancer; Immunotherapy; Immunology","score_opus":0.024854151554562647,"score_gpt":0.3635282175853181,"score_spread":0.33867406603075545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407984288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862075,0.0009871755,0.00010453622,0.000031998534,0.000004342996,0.00001562843,0.0000920887,0.0000073015885,0.00013624516],"genre_scores_gemma":[0.99933285,0.00011900166,0.00027081594,0.000024736963,0.000008396757,0.000017427848,0.0001656902,0.0000013085778,0.00005982393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959856,0.00014708946,0.000045089902,0.00008161892,0.00007806246,0.0000497061],"domain_scores_gemma":[0.998933,0.0002607499,0.0004971203,0.000060838818,0.00011381666,0.00013438701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012360853,0.00026780766,0.00046170465,0.0006304949,0.00014289164,0.00043440537,0.00027760927,0.00031088098,0.00044332622],"category_scores_gemma":[0.0021792825,0.00016072043,0.00028369098,0.00041432303,0.00022980975,0.00021438388,0.00020698673,0.0003879692,0.00009815629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016038314,0.0002725802,0.9226403,0.00010339368,0.00041101465,0.00014415511,0.00010709888,0.0011957691,0.014099065,0.00003858164,0.0002791587,0.044670496],"study_design_scores_gemma":[0.00034584934,0.0025267592,0.98678815,0.000014540915,0.0002505464,0.00068178884,0.00006770094,0.0038577963,0.004723244,0.00007818451,0.00065290695,0.000012511465],"about_ca_topic_score_codex":0.0010148957,"about_ca_topic_score_gemma":0.0014425747,"teacher_disagreement_score":0.0012360853,"about_ca_system_score_codex":0.0006338061,"about_ca_system_score_gemma":0.00032768582,"threshold_uncertainty_score":0.00653708},"labels":[],"label_agreement":null},{"id":"W4408099016","doi":"10.1136/jitc-2024-009364","title":"Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Metastasis; Adverse effect; Retrospective cohort study; Oncology; Cancer; Cardiology; Surgery","score_opus":0.012594358853010409,"score_gpt":0.32544774661509596,"score_spread":0.31285338776208554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408099016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959351,0.0023391305,0.0002917767,0.00006868271,0.000008619866,0.000053530977,0.0006453615,0.00000546977,0.00065230444],"genre_scores_gemma":[0.99819297,0.0004843887,0.00015215384,0.00006810953,0.000033191245,0.000046877336,0.0009595778,0.0000040765412,0.00005869841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878985,0.00040209614,0.00020049911,0.00033304514,0.00017589422,0.00009870564],"domain_scores_gemma":[0.9950831,0.0007516963,0.0030546316,0.00033159784,0.00037378704,0.0004052482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023068048,0.00033227974,0.0005289667,0.00092087814,0.00033346884,0.0007241143,0.00038044303,0.0003938644,0.00092032936],"category_scores_gemma":[0.0035736437,0.0002130492,0.00067576265,0.0013986783,0.0003845783,0.00045786158,0.00036770696,0.00047781898,0.00020566238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007606754,0.00006481916,0.9960997,0.00004346991,0.00015891188,0.00009717322,0.000043030104,0.00005151203,0.00021880788,0.000019256991,0.00012991687,0.002312754],"study_design_scores_gemma":[0.00015292385,0.0013681259,0.99503595,0.00003394031,0.00033697873,0.0011744143,0.0001509023,0.0002792004,0.00019975717,0.000036731664,0.0012181514,0.0000128365455],"about_ca_topic_score_codex":0.0008193783,"about_ca_topic_score_gemma":0.000602506,"teacher_disagreement_score":0.0023068048,"about_ca_system_score_codex":0.00036725626,"about_ca_system_score_gemma":0.00051716866,"threshold_uncertainty_score":0.0121997},"labels":[],"label_agreement":null},{"id":"W4408213392","doi":"10.1136/jitc-2024-010928","title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Immunotherapy; Biomarker; Clinical trial; Cancer immunotherapy; Oncology; Cancer; Immunology; Internal medicine; Biology","score_opus":0.048968913838723954,"score_gpt":0.4640198424156276,"score_spread":0.4150509285769036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408213392","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002830258,0.048966244,0.063002355,0.7253765,0.047428593,0.01353777,0.0051499913,0.0015094702,0.092198856],"genre_scores_gemma":[0.026694875,0.066759765,0.31874573,0.440194,0.023054762,0.043166853,0.025532536,0.0010864685,0.054765105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.87606406,0.06856179,0.021516938,0.0029929683,0.024629708,0.006234432],"domain_scores_gemma":[0.744311,0.06566374,0.0190187,0.010802453,0.14146341,0.018740788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14735402,0.002255011,0.0033194371,0.007578575,0.0043596737,0.009678073,0.011097899,0.026552087,0.009325952],"category_scores_gemma":[0.15577438,0.002144457,0.006769966,0.00682283,0.0052051097,0.0055938703,0.009948143,0.026292253,0.0137573285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002922151,0.0002191093,0.0015159921,0.00422941,0.00012744468,0.0003127712,0.00067707285,0.0014771933,0.0014210759,0.02363354,0.83309716,0.13299687],"study_design_scores_gemma":[0.00015327657,0.00024081273,0.0015319723,0.009390305,0.00015099857,0.00059981825,0.00040194363,0.0008557401,0.0010046286,0.016043711,0.9695314,0.00009529692],"about_ca_topic_score_codex":0.0059960308,"about_ca_topic_score_gemma":0.0057363925,"teacher_disagreement_score":0.14735402,"about_ca_system_score_codex":0.00979348,"about_ca_system_score_gemma":0.086508356,"threshold_uncertainty_score":0.77929187},"labels":[],"label_agreement":null},{"id":"W4408802828","doi":"10.1136/jitc-2024-010681","title":"Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Conquer Cancer Foundation","keywords":"Immune system; Antibody; Immunology; Immunity; CD14; Medicine; Gut flora; Microbiome; Immunoglobulin G; Flow cytometry; FOXP3; Peripheral blood mononuclear cell; Biology; In vitro; Bioinformatics","score_opus":0.015914387534118456,"score_gpt":0.3244449996153729,"score_spread":0.30853061208125443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408802828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990947,0.00019454182,0.0002779005,0.00003628419,0.000012632093,0.00004487337,0.000096475334,0.000016429507,0.00022619795],"genre_scores_gemma":[0.99798846,0.00012990959,0.00061586883,0.00011988954,0.000014956089,0.000110910165,0.00031181975,0.00000993934,0.00069825957],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999803,0.000050725946,0.0000123943255,0.00004408996,0.000035257235,0.000054527703],"domain_scores_gemma":[0.9997973,0.000022833861,0.00006470781,0.000015430312,0.000018264858,0.00008153828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003267225,0.0003086872,0.00039307406,0.00018529216,0.00016577603,0.00025851317,0.00015675306,0.00027469656,0.0013319763],"category_scores_gemma":[0.00032011085,0.00013024626,0.00026225232,0.000114723574,0.0001925959,0.00022354082,0.00029394063,0.00062263216,0.00020209976],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018258927,0.003488056,0.025314601,0.0001881072,0.000100256315,0.0001313637,0.00013009962,0.0003790069,0.9188534,0.00007665498,0.00043343598,0.03264599],"study_design_scores_gemma":[0.0021501672,0.28206718,0.25885475,0.00006887038,0.0005130581,0.0013616239,0.00048777272,0.004032329,0.44194776,0.0003745412,0.008088578,0.00005339541],"about_ca_topic_score_codex":0.00020849607,"about_ca_topic_score_gemma":0.0004091698,"teacher_disagreement_score":0.0013319763,"about_ca_system_score_codex":0.00024239595,"about_ca_system_score_gemma":0.00026984964,"threshold_uncertainty_score":0.004455924},"labels":[],"label_agreement":null},{"id":"W4408881986","doi":"10.1136/jitc-2024-010791","title":"Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Oxaliplatin; Cancer research; Colorectal cancer; Tumor microenvironment; Immune system; Antibody; Cancer; Immunology; Internal medicine","score_opus":0.02051684446937839,"score_gpt":0.31750323658377405,"score_spread":0.29698639211439565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408881986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892976,0.00393633,0.0023578056,0.00017857624,0.00013621703,0.00015817961,0.0008365766,0.0003156578,0.002783032],"genre_scores_gemma":[0.98844403,0.0021868905,0.002118349,0.00011591289,0.000034672037,0.00017034388,0.00069605495,0.00003468752,0.006199151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997892,0.000031791853,0.000018943001,0.00005310781,0.00004923835,0.000057787354],"domain_scores_gemma":[0.99989796,0.000007331713,0.000033453307,0.000014965011,0.000008078625,0.000038138583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016105716,0.0005588958,0.00052786065,0.00045713744,0.00013870872,0.00024257838,0.00023371539,0.0003343841,0.0017333531],"category_scores_gemma":[0.000067981586,0.00024659137,0.0003605758,0.00021955966,0.00030088532,0.00025410406,0.00014512314,0.0009894298,0.00036845298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026111521,0.00089659716,0.0002795242,0.00012552286,0.000025367186,0.00005430267,0.000021845202,0.00028356645,0.9893824,0.00016248653,0.00024070768,0.005916585],"study_design_scores_gemma":[0.00044014666,0.014163067,0.0037906917,0.00002289459,0.000066541936,0.00040831853,0.000036325193,0.0012701061,0.9730663,0.00007839091,0.0066441754,0.000013083768],"about_ca_topic_score_codex":0.0005438998,"about_ca_topic_score_gemma":0.0011874976,"teacher_disagreement_score":0.0017333531,"about_ca_system_score_codex":0.0002696061,"about_ca_system_score_gemma":0.0003535675,"threshold_uncertainty_score":0.0057986975},"labels":[],"label_agreement":null},{"id":"W4408922776","doi":"10.1136/jitc-2024-011273","title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; NIH Office of the Director; National Heart, Lung, and Blood Institute; U.S. Food and Drug Administration; Fiona and Stanley Druckenmiller Center for Lung Cancer Research; National Cancer Institute; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Princess Margaret Cancer Foundation; Larry L. Hillblom Foundation","keywords":"Discontinuation; Adverse effect; Immune system; Medicine; Immune checkpoint; Immunology; Immunotherapy; Internal medicine","score_opus":0.01334862461884169,"score_gpt":0.3210786169146588,"score_spread":0.3077299922958171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408922776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974915,0.00051971007,0.00082044234,0.00010235095,0.000014558013,0.0000079079855,0.0005642742,0.00002346594,0.0004559102],"genre_scores_gemma":[0.9994579,0.00005100161,0.00013067748,0.000018413746,0.000009122215,0.0000018976993,0.000240635,0.000002161313,0.000088158355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993399,0.0001875632,0.000051328887,0.00023304849,0.0000861483,0.00010196098],"domain_scores_gemma":[0.9959313,0.001423004,0.0018751257,0.00029092704,0.0001528953,0.0003266766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012145118,0.00024633337,0.00027955614,0.0004554027,0.00017427061,0.00045648686,0.00032893498,0.00031217057,0.002321733],"category_scores_gemma":[0.0041280948,0.00014489706,0.0010873507,0.00043405767,0.00019901853,0.00023076555,0.00035655365,0.00052934675,0.00015940072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015503819,0.000010856092,0.996454,0.00000680674,0.00013125935,0.000036273213,0.000006921636,0.0005309562,0.00021966256,0.00003099773,0.000090246795,0.0023269916],"study_design_scores_gemma":[0.000015388989,0.00015053556,0.99592125,0.000006025219,0.00011159394,0.00029242202,0.000016063253,0.0030255965,0.00015862829,0.000112014786,0.00018638239,0.000004076692],"about_ca_topic_score_codex":0.003065204,"about_ca_topic_score_gemma":0.003100522,"teacher_disagreement_score":0.003065204,"about_ca_system_score_codex":0.00022458076,"about_ca_system_score_gemma":0.00026474218,"threshold_uncertainty_score":0.0077669024},"labels":[],"label_agreement":null},{"id":"W4408943423","doi":"10.1136/jitc-2024-010419","title":"SITC strategic vision: prevention, premalignant immunity, host and environmental factors","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University; Lawson Health Research Institute; Ontario Institute for Cancer Research","funders":"University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer","keywords":"Immune system; Immunotherapy; Medicine; Immunology; Cancer; Immunity; Cancer immunotherapy; Microbiome; Bioinformatics; Internal medicine; Biology","score_opus":0.047144551982480264,"score_gpt":0.3938186957324736,"score_spread":0.34667414374999334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408943423","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000815746,0.10992347,0.0034285223,0.53216976,0.29055792,0.00036820836,0.0015765103,0.00093442295,0.060225397],"genre_scores_gemma":[0.01826683,0.21173602,0.012972223,0.25783062,0.27224317,0.0007295275,0.0054604732,0.0009485179,0.21981263],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525803,0.0014372892,0.00036471046,0.0005215738,0.0016356773,0.00078278536],"domain_scores_gemma":[0.9810426,0.0021534618,0.0008473119,0.00055486494,0.006539285,0.008862456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010169701,0.0015979795,0.0016576974,0.0024804804,0.0026138346,0.010293842,0.0028883133,0.012369067,0.05620917],"category_scores_gemma":[0.012594196,0.000594325,0.0014935924,0.0014511655,0.0025121493,0.0046508876,0.0060937023,0.014691182,0.030139143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006410852,0.000049810198,0.0004283413,0.00067387737,0.000019814868,0.00010914674,0.00007893082,0.00009330671,0.00031193148,0.005458651,0.9061002,0.08661176],"study_design_scores_gemma":[0.00002957608,0.000081193524,0.00053233263,0.0013480192,0.000024384251,0.00020417599,0.00014442872,0.00010377523,0.00017234088,0.005152349,0.9921834,0.000024080913],"about_ca_topic_score_codex":0.004234355,"about_ca_topic_score_gemma":0.009535568,"teacher_disagreement_score":0.05620917,"about_ca_system_score_codex":0.004862925,"about_ca_system_score_gemma":0.023827957,"threshold_uncertainty_score":0.18803841},"labels":[],"label_agreement":null},{"id":"W4409252004","doi":"10.1136/jitc-2024-011049","title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Project Data Sphere","keywords":"Medicine; Uveitis; Delphi method; Adverse effect; Family medicine; Disease; Usability; Ophthalmology; Internal medicine; Artificial intelligence; Computer science","score_opus":0.025072726287116723,"score_gpt":0.3355969537691115,"score_spread":0.31052422748199476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409252004","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09805861,0.12696329,0.49154514,0.08089384,0.011496955,0.038340356,0.006978463,0.0006792109,0.1450442],"genre_scores_gemma":[0.22907215,0.027532773,0.6773511,0.012473789,0.0020569242,0.033340108,0.010403431,0.00022303191,0.007546685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8832415,0.05420827,0.04105294,0.0031041345,0.015769025,0.0026242016],"domain_scores_gemma":[0.86098295,0.0381892,0.023002958,0.006172156,0.06862137,0.003031349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08789173,0.0015461126,0.0022122976,0.010072385,0.003071685,0.0030419638,0.0049937973,0.0032190138,0.0030061516],"category_scores_gemma":[0.11040286,0.0007256976,0.0044236146,0.004140713,0.00233756,0.0031305174,0.007623158,0.005084172,0.0012612471],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012392161,0.00083837437,0.07941882,0.020807343,0.0009069797,0.0018648558,0.021547845,0.009907973,0.0060461652,0.1599541,0.15234108,0.5451273],"study_design_scores_gemma":[0.0007758903,0.0018234357,0.0750133,0.029093893,0.0010117602,0.00892725,0.013100583,0.014536863,0.004947072,0.07786638,0.77223307,0.0006704789],"about_ca_topic_score_codex":0.0053333,"about_ca_topic_score_gemma":0.0057669575,"teacher_disagreement_score":0.08789173,"about_ca_system_score_codex":0.0058896,"about_ca_system_score_gemma":0.015508831,"threshold_uncertainty_score":0.46482146},"labels":[],"label_agreement":null},{"id":"W4409535425","doi":"10.1136/jitc-2024-010684","title":"Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Flow cytometry; T cell; Cancer research; Biology; In vivo; Leukemia; Ex vivo; T-cell receptor; Cell; Single-cell analysis; Phenotype; Cancer; RNA; Jurkat cells; Molecular biology; Immunology; Gene; Immune system; Genetics","score_opus":0.055193438543429695,"score_gpt":0.3742840893308047,"score_spread":0.31909065078737503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409535425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97199506,0.00078347384,0.023637325,0.000051199822,0.000021548725,0.00005516973,0.0013654414,0.0001377057,0.001953138],"genre_scores_gemma":[0.9822642,0.00047967266,0.013755399,0.00007015011,0.000014081552,0.00007243714,0.0018300792,0.000052109768,0.0014618777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998399,0.000017658538,0.000010622851,0.00006775785,0.00004381548,0.000020203568],"domain_scores_gemma":[0.99987125,0.000036839367,0.00003148335,0.000019201423,0.000026532327,0.000014695268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001371778,0.00018840937,0.00013272795,0.00020931414,0.0001403014,0.0003250293,0.000089205976,0.00022037742,0.0007464678],"category_scores_gemma":[0.00024700575,0.00007866951,0.00013977662,0.00015587144,0.0001838929,0.00009627219,0.000112704045,0.00019078515,0.00036044896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029807725,0.000003387566,0.00048889656,0.000013701389,0.0000013421417,0.000019749523,0.000012900808,0.0000985665,0.99806505,0.00004755608,0.0000138469495,0.0012051362],"study_design_scores_gemma":[0.000005933362,0.00020103483,0.010155904,0.000006956777,0.000016662549,0.00034877655,0.000054747576,0.001977795,0.9844769,0.00016655156,0.0025845962,0.00000399908],"about_ca_topic_score_codex":0.00014803144,"about_ca_topic_score_gemma":0.000398417,"teacher_disagreement_score":0.0007464678,"about_ca_system_score_codex":0.00013896794,"about_ca_system_score_gemma":0.00014256801,"threshold_uncertainty_score":0.0024971366},"labels":[],"label_agreement":null},{"id":"W4409613957","doi":"10.1136/jitc-2025-011829","title":"MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Stem Cell Network; Institute of Infection and Immunity; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Chimeric antigen receptor; Receptor; Immune system; T cell; Cancer immunotherapy; Modular design; Immunotherapy; Cancer research; Antigen; Biology; Immunology; Medicine; Computer science; Internal medicine","score_opus":0.015918664833253077,"score_gpt":0.3158186075849806,"score_spread":0.2998999427517275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409613957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547912,0.0048269616,0.034051932,0.00042993366,0.00012547905,0.00010587306,0.00024076163,0.00048384423,0.0049441117],"genre_scores_gemma":[0.98384905,0.0016180978,0.011628803,0.00013795395,0.000024082146,0.000044184115,0.0001856853,0.000033385775,0.0024788058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999043,0.000013448964,0.0000053037566,0.000023187784,0.000030086052,0.000023806404],"domain_scores_gemma":[0.9999161,0.000007442584,0.000035847228,0.0000075092735,0.000011290044,0.000021766635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000169413,0.00037191494,0.00018581339,0.00020336686,0.00007503661,0.0002693582,0.00027921944,0.00035078573,0.00072778127],"category_scores_gemma":[0.00017774207,0.00009703959,0.0002994447,0.00009503843,0.00020727685,0.00028951507,0.00023358554,0.00042577254,0.00037524823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006505195,0.000032597603,0.00016057104,0.00006042203,0.0000080775035,0.00007249164,0.000013888957,0.00060344033,0.9927247,0.00082701485,0.00017803468,0.0052536237],"study_design_scores_gemma":[0.000053125932,0.001504497,0.0017004781,0.000013763905,0.00005357223,0.0011075891,0.00002553365,0.0067575164,0.9714955,0.00017723799,0.017081734,0.000029398865],"about_ca_topic_score_codex":0.0001934185,"about_ca_topic_score_gemma":0.00020421189,"teacher_disagreement_score":0.00072778127,"about_ca_system_score_codex":0.0002526459,"about_ca_system_score_gemma":0.00018020938,"threshold_uncertainty_score":0.002434671},"labels":[],"label_agreement":null},{"id":"W4410186945","doi":"10.1136/jitc-2024-010073","title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"China Postdoctoral Science Foundation; Ministry of Education; National Natural Science Foundation of China","keywords":"Venetoclax; Cancer research; Chimeric antigen receptor; Antigen; In vivo; Medicine; In vitro; Cancer; Immunology; Immunotherapy; Biology; Leukemia; Internal medicine","score_opus":0.01716655082443336,"score_gpt":0.350663301073179,"score_spread":0.33349675024874564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410186945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942173,0.0023778817,0.0009140706,0.00009599199,0.00005602336,0.00011573435,0.00015844902,0.00013028542,0.0019342406],"genre_scores_gemma":[0.99723536,0.0008530878,0.000737205,0.000028958935,0.000022067721,0.000050636027,0.00024820506,0.0000075286207,0.00081695284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999052,0.000019223182,0.0000064325395,0.000014944669,0.00002356444,0.000030534404],"domain_scores_gemma":[0.999936,0.000013659377,0.000011267971,0.0000073680694,0.000005509206,0.000026204914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016296374,0.00035936816,0.00043579377,0.00030740118,0.00015544724,0.00021279907,0.00026539978,0.00027425378,0.0012622715],"category_scores_gemma":[0.00007647729,0.000104631945,0.00030568213,0.00022707539,0.0001933407,0.00019236539,0.00015732086,0.00068027066,0.00023017202],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017002985,0.0011479697,0.0009831735,0.0002176663,0.00004972579,0.0001360449,0.000045931116,0.0008282062,0.97406036,0.0001682728,0.0005056957,0.020156672],"study_design_scores_gemma":[0.0007696318,0.016843555,0.0097873425,0.000019911964,0.00023196904,0.0009022913,0.00004758082,0.0043446706,0.95995545,0.000079147576,0.007003372,0.0000151138365],"about_ca_topic_score_codex":0.00063481514,"about_ca_topic_score_gemma":0.0011544989,"teacher_disagreement_score":0.0012622715,"about_ca_system_score_codex":0.00019532723,"about_ca_system_score_gemma":0.00038373747,"threshold_uncertainty_score":0.0042227507},"labels":[],"label_agreement":null},{"id":"W4410268064","doi":"10.1136/jitc-2024-010548","title":"The cold immunological landscape of ATM-deficient cancers","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; Starr Cancer Consortium","keywords":"Cancer research; Biology; DNA repair; Olaparib; Immune system; Immune checkpoint; Tumor-infiltrating lymphocytes; PARP inhibitor; DNA damage; Immunotherapy; Immunology; Poly ADP ribose polymerase; Gene; DNA; Polymerase; Genetics","score_opus":0.015149643538691459,"score_gpt":0.3357400251105151,"score_spread":0.3205903815718236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410268064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98458976,0.0071342345,0.0023691277,0.0003442896,0.000080113925,0.000037195725,0.0005033688,0.00016605294,0.004775922],"genre_scores_gemma":[0.99574006,0.001398505,0.000800654,0.00030865314,0.00006116151,0.00004677802,0.0003624968,0.000029780802,0.001251914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998604,0.000026169919,0.000009733747,0.00003516259,0.000034300123,0.000034192348],"domain_scores_gemma":[0.9998925,0.000010704891,0.0000295425,0.000009959954,0.000013028715,0.00004424521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015705527,0.00025181985,0.00020581107,0.0002784809,0.00014712814,0.00030652527,0.00015362815,0.00022261836,0.002038203],"category_scores_gemma":[0.00015601434,0.00007555595,0.00014536134,0.00009570962,0.00019459668,0.00020279216,0.00027045803,0.0004200974,0.00045627542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038010936,0.000045054272,0.0033687034,0.000101291225,0.000014237235,0.00026654,0.000029420697,0.00008261293,0.9864118,0.00039520787,0.00056175614,0.008343269],"study_design_scores_gemma":[0.0001895398,0.0053146854,0.19693643,0.00012941785,0.00020721444,0.025958313,0.00046802737,0.0023007651,0.71034,0.0026549033,0.055453744,0.000046874404],"about_ca_topic_score_codex":0.000073780706,"about_ca_topic_score_gemma":0.000084980806,"teacher_disagreement_score":0.002038203,"about_ca_system_score_codex":0.00017999986,"about_ca_system_score_gemma":0.000081698,"threshold_uncertainty_score":0.0068184733},"labels":[],"label_agreement":null},{"id":"W4410548822","doi":"10.1136/jitc-2024-010570","title":"Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Institut Du Cancer de Montréal; National Institutes of Health; Université de Montréal; Fondation du cancer du sein du Québec","keywords":"Oncolytic virus; Adjuvant; Vesicular stomatitis virus; Immune system; Vaccination; Virology; Antigen; Virus; Immunology; Immunotherapy; Medicine; Biology","score_opus":0.020014269570507916,"score_gpt":0.3711631262187259,"score_spread":0.351148856648218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410548822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969097,0.0007542573,0.0016922419,0.000029468589,0.000012047883,0.0000111920135,0.0001265687,0.00003083026,0.00043377263],"genre_scores_gemma":[0.9969398,0.0002670041,0.0017482174,0.000016366545,0.0000054304464,0.000011203778,0.00036540368,0.000007180621,0.0006393613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999205,0.000010610887,0.000007380262,0.000015386098,0.000023586836,0.000022475891],"domain_scores_gemma":[0.99989855,0.00003038411,0.00003115604,0.000012225724,0.000015486232,0.00001222955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106912434,0.0003253105,0.00014222244,0.00012634162,0.00004344994,0.00021929333,0.00010118386,0.00023078446,0.00058383244],"category_scores_gemma":[0.00012034137,0.00007107862,0.00017273487,0.00011140402,0.00012570665,0.00017381937,0.00009331262,0.00037390876,0.00013866402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062573825,0.00002294202,0.00014528832,0.000018403043,0.0000023391956,0.0000070499495,0.0000038423386,0.00019297787,0.99884546,0.000030099223,0.000015320915,0.00065358327],"study_design_scores_gemma":[0.000010956417,0.0003886214,0.0010967123,0.0000025737418,0.000009457163,0.000060710572,0.0000036533045,0.00091869297,0.99667716,0.000014632266,0.00081482437,0.0000020162959],"about_ca_topic_score_codex":0.00021562187,"about_ca_topic_score_gemma":0.0002713729,"teacher_disagreement_score":0.00058383244,"about_ca_system_score_codex":0.00025214395,"about_ca_system_score_gemma":0.00012463589,"threshold_uncertainty_score":0.001953125},"labels":[],"label_agreement":null},{"id":"W4410712213","doi":"10.1136/jitc-2024-011404","title":"IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Cancer Institute; Ludwig Institute for Cancer Research; National Foundation for Cancer Research","keywords":"Medicine; Pancreatic cancer; Oncology; FOLFIRINOX; Immune checkpoint; Internal medicine; Blockade; Cancer; Cardiotoxicity; Chemoimmunotherapy; Chemotherapy; Immunotherapy; Receptor","score_opus":0.007628141211374882,"score_gpt":0.28763999250250477,"score_spread":0.2800118512911299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410712213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887552,0.0030663903,0.003873542,0.00050409365,0.0001738163,0.00011725553,0.0008552711,0.0005170755,0.0021373513],"genre_scores_gemma":[0.9864792,0.002872365,0.0046569654,0.0003600982,0.00006853182,0.00029518869,0.0013003498,0.0001015631,0.003865684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972194,0.000037541515,0.000031439162,0.000067581044,0.00005745432,0.00008405794],"domain_scores_gemma":[0.9996575,0.000019715944,0.00013770848,0.000030440411,0.000019429244,0.00013519249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031601425,0.0011844069,0.0007338511,0.0009161815,0.0002570606,0.0004591586,0.00047073464,0.00059684337,0.00140232],"category_scores_gemma":[0.00018365022,0.00032261084,0.0005508397,0.0003085445,0.0005150749,0.00046672902,0.00021501131,0.0024401785,0.0004073197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024865954,0.0012066935,0.0006409428,0.00011000012,0.000036832917,0.00007066624,0.000025648837,0.00037190755,0.98732775,0.00016908596,0.00031076514,0.0072430265],"study_design_scores_gemma":[0.0011203315,0.013070114,0.010676147,0.00007388996,0.00016877116,0.0005371399,0.00008475493,0.0031641321,0.96548235,0.00020736274,0.005387711,0.000027427424],"about_ca_topic_score_codex":0.00045722834,"about_ca_topic_score_gemma":0.0009730602,"teacher_disagreement_score":0.00140232,"about_ca_system_score_codex":0.00034362398,"about_ca_system_score_gemma":0.00053705234,"threshold_uncertainty_score":0.004691243},"labels":[],"label_agreement":null},{"id":"W4410791528","doi":"10.1136/jitc-2024-011184","title":"Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Adjuvant; Stage (stratigraphy); Delphi method; Adjuvant therapy; Adverse effect; Oncology; Perioperative; Internal medicine; Neoadjuvant therapy; Cancer; Surgery; Breast cancer","score_opus":0.04205604431233636,"score_gpt":0.3922910191002602,"score_spread":0.35023497478792387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410791528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850749,0.000589864,0.0045322143,0.0021925587,0.00008283761,0.0039206184,0.00022138956,0.000011510721,0.0033741898],"genre_scores_gemma":[0.9880756,0.0004510731,0.0049740965,0.0009021045,0.000024493975,0.0052137533,0.00013467678,0.0000081985245,0.00021589825],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.86289626,0.11494984,0.009169067,0.002929724,0.005348766,0.0047062817],"domain_scores_gemma":[0.80830246,0.14833464,0.011295556,0.0035427932,0.024817782,0.0037068431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12001375,0.00072266976,0.0009113029,0.0021202809,0.002208846,0.0020407992,0.0012621664,0.0017908274,0.0018465935],"category_scores_gemma":[0.15785068,0.0007726604,0.0021917461,0.0017533312,0.0027972946,0.0028459462,0.005056461,0.001938051,0.00034195947],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028987078,0.0014398103,0.3300567,0.007389583,0.0012970476,0.0012483285,0.50813353,0.0029811834,0.0030434015,0.0038408872,0.007831032,0.12983984],"study_design_scores_gemma":[0.00086106407,0.00499315,0.29382882,0.0050686663,0.000694501,0.001359295,0.6464631,0.012268669,0.003085463,0.006488088,0.024290824,0.00059832144],"about_ca_topic_score_codex":0.0036170185,"about_ca_topic_score_gemma":0.0048026005,"teacher_disagreement_score":0.12001375,"about_ca_system_score_codex":0.0048403814,"about_ca_system_score_gemma":0.010068724,"threshold_uncertainty_score":0.63470095},"labels":[],"label_agreement":null},{"id":"W4410918597","doi":"10.1136/jitc-2025-011682","title":"Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; St. Thomas Hospital; University Health Network","funders":"Guy's and St Thomas' Charity; British Skin Foundation; Royal Society; Cancer Research UK; Wellcome Trust","keywords":"Immunology; Antibody; Medicine; Melanoma; Memory B cell; Immune system; Immunoglobulin E; B cell; Toxicity; Immunotherapy; Immune checkpoint; Cancer research; Internal medicine","score_opus":0.017328475149311004,"score_gpt":0.3499550727543015,"score_spread":0.33262659760499047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410918597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992951,0.0003137557,0.00014592928,0.000011414488,0.0000015568202,0.0000052697396,0.000053374566,0.000005509819,0.00016804978],"genre_scores_gemma":[0.999546,0.000067132896,0.00019532454,0.000015552378,0.0000035536368,0.0000050924186,0.00008646199,0.0000011773179,0.00007964682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99992883,0.000013921633,0.0000069904163,0.000023661447,0.000016108137,0.000010495999],"domain_scores_gemma":[0.9997528,0.000044300927,0.00011434554,0.000010036181,0.000026702168,0.000051835428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021002123,0.00016550452,0.00017970987,0.00034015556,0.00009957361,0.00022668127,0.00009679357,0.0001904126,0.00075430755],"category_scores_gemma":[0.0003645588,0.00007597877,0.00010130328,0.00016455,0.000098851946,0.00012248498,0.00012673777,0.00024734487,0.00013472504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011856168,0.0001209142,0.93740255,0.000048954913,0.00005123488,0.00020508538,0.00008009987,0.00026550068,0.046296455,0.00002479805,0.00012681143,0.014191991],"study_design_scores_gemma":[0.000020361413,0.0009019937,0.99237263,0.000008129343,0.000039457365,0.0013814955,0.000058849804,0.000833537,0.0040206136,0.000046424124,0.00031384034,0.000002758394],"about_ca_topic_score_codex":0.00022811006,"about_ca_topic_score_gemma":0.00029925205,"teacher_disagreement_score":0.00075430755,"about_ca_system_score_codex":0.000112029236,"about_ca_system_score_gemma":0.00008247372,"threshold_uncertainty_score":0.0025233626},"labels":[],"label_agreement":null},{"id":"W4411219862","doi":"10.1136/jitc-2025-011474","title":"IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Natural Science Foundation of China","keywords":"Medicine; Immunotherapy; Tumor microenvironment; Immune system; Head and neck squamous-cell carcinoma; Cancer research; Head and neck; Basal cell; T cell; Immunology; Pathology; Head and neck cancer; Internal medicine; Radiation therapy","score_opus":0.008342048639066858,"score_gpt":0.28647507645391207,"score_spread":0.2781330278148452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411219862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826413,0.000716725,0.0003702466,0.000039008824,0.000014780303,0.000010576009,0.00025057467,0.000029645797,0.00030428654],"genre_scores_gemma":[0.998566,0.0003557548,0.0002819004,0.000036117024,0.0000048846637,0.000014166726,0.0003567872,0.000003015367,0.00038155768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989486,0.0000106041825,0.000010376927,0.000015059168,0.000032672964,0.000036478745],"domain_scores_gemma":[0.9999442,0.0000054884795,0.000016484582,0.0000058748224,0.000007053109,0.000020934674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001155298,0.00019285316,0.00022774887,0.00024156399,0.000120148165,0.00022662313,0.0000997851,0.00013672962,0.0007580623],"category_scores_gemma":[0.00006955917,0.00007869457,0.00024011779,0.00020574908,0.00021797689,0.000085928434,0.00014624165,0.00040771984,0.00018367649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004546753,0.00009517255,0.0071976897,0.000118755546,0.000020627509,0.00012525597,0.000019375957,0.00028608722,0.98771477,0.000051832678,0.00017409316,0.0037415912],"study_design_scores_gemma":[0.0000689935,0.0017565443,0.13284676,0.00002238697,0.00015057783,0.0011225165,0.00026322398,0.005735597,0.85392135,0.00020283055,0.003895719,0.000013616247],"about_ca_topic_score_codex":0.0007798898,"about_ca_topic_score_gemma":0.0014867301,"teacher_disagreement_score":0.0007798898,"about_ca_system_score_codex":0.00030194453,"about_ca_system_score_gemma":0.00039476957,"threshold_uncertainty_score":0.0025359392},"labels":[],"label_agreement":null},{"id":"W4411319666","doi":"10.1136/jitc-2024-011364","title":"Blockade of colon cancer metastasis via single and double silencing of <i>PCSK7</i> / <i>PCSK9</i> : enhanced T cells cytotoxicity in mouse and human","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"Canada Research Chairs; Québec Consortium for Drug Discovery; Cancer Research Society","keywords":"Proprotein convertase; Cancer research; T cell; Kexin; Cytotoxic T cell; Immune checkpoint; Biology; Immune system; CD8; Immunotherapy; Immunology; LDL receptor; Endocrinology; Cholesterol","score_opus":0.025767333762424804,"score_gpt":0.360806984194092,"score_spread":0.3350396504316672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002236,0.0013583957,0.0043065385,0.00024658235,0.00007068712,0.00009507802,0.0011377911,0.00033452437,0.0024280066],"genre_scores_gemma":[0.9916501,0.0008422331,0.0020051643,0.000089444,0.000016928409,0.000113026086,0.0009203058,0.000046581084,0.00431631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981624,0.000020753776,0.000017798026,0.000052805215,0.000044754128,0.000047773963],"domain_scores_gemma":[0.9999256,0.000009341032,0.000019373369,0.000012803756,0.0000068762183,0.000025906018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014087275,0.00044302858,0.0003034553,0.00030313,0.00012454251,0.00023796697,0.00016516101,0.0003158594,0.0014280608],"category_scores_gemma":[0.00007472919,0.00014925319,0.000306925,0.00014734647,0.00030628484,0.00012726177,0.00013156715,0.0009242482,0.0004196901],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024625007,0.000043723234,0.00010042749,0.00003455858,0.0000079118245,0.000030968804,0.000009052275,0.00009489522,0.9982803,0.00007495892,0.0001115503,0.00096559915],"study_design_scores_gemma":[0.00005671322,0.0007854438,0.0015381615,0.000004097774,0.000026751008,0.00025109918,0.000012754166,0.00084570015,0.9944905,0.000036824786,0.0019483127,0.0000036166211],"about_ca_topic_score_codex":0.001129641,"about_ca_topic_score_gemma":0.0013692362,"teacher_disagreement_score":0.0014280608,"about_ca_system_score_codex":0.00030029955,"about_ca_system_score_gemma":0.0003045497,"threshold_uncertainty_score":0.004777372},"labels":[],"label_agreement":null},{"id":"W4411417552","doi":"10.1136/jitc-2025-012391","title":"Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Glycomics Network; Canadian Institutes of Health Research; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Mizutani Foundation for Glycoscience","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Cancer immunotherapy; Cancer; Context (archaeology); Immune checkpoint; Immunology; Medicine; Cancer research; Cancer immunology; Biology; Internal medicine","score_opus":0.023587444712330544,"score_gpt":0.3899546320237682,"score_spread":0.36636718731143764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411417552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014698193,0.9971404,0.00021917398,0.00041613178,0.0004829872,0.000007253771,0.000021482789,0.0000129474365,0.0015525778],"genre_scores_gemma":[0.0008276489,0.9969933,0.00023160895,0.00024923222,0.00026173147,0.000009532459,0.000044291537,0.0000022025504,0.0013803642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998796,0.000020049873,0.000012195216,0.00001739211,0.000050874936,0.000019832203],"domain_scores_gemma":[0.99987566,0.00003811937,0.000016803335,0.000005412099,0.000039892944,0.000024029667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039534803,0.0008212282,0.0009252699,0.0016889112,0.00024953234,0.0010332981,0.0005834789,0.0011555381,0.003094335],"category_scores_gemma":[0.00033974284,0.00024074956,0.0003449691,0.0017204791,0.00037347095,0.0011628955,0.00057242246,0.0021128273,0.0027589775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010092667,0.00010588883,0.00013242011,0.010577448,0.000060442595,0.00020449767,0.000042764637,0.00048290644,0.0057289,0.007823644,0.04868642,0.92605376],"study_design_scores_gemma":[0.000009649985,0.00006578532,0.0003543708,0.0011061159,0.0000325223,0.0006839478,0.000027876624,0.000078272635,0.00083386217,0.002497421,0.9942994,0.000010753107],"about_ca_topic_score_codex":0.00062939647,"about_ca_topic_score_gemma":0.001016922,"teacher_disagreement_score":0.003094335,"about_ca_system_score_codex":0.0007448796,"about_ca_system_score_gemma":0.0008304133,"threshold_uncertainty_score":0.010351598},"labels":[],"label_agreement":null},{"id":"W4411534009","doi":"10.1136/jitc-2024-010739","title":"SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Drug development; Biomarker; Medicine; Drug; Immunotherapy; Intensive care medicine; Cancer; Oncology; Internal medicine; Pharmacology","score_opus":0.021173314319618167,"score_gpt":0.36744862160887887,"score_spread":0.3462753072892607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411534009","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006155537,0.025969861,0.27635825,0.63904446,0.0076409965,0.0008480067,0.0012451531,0.0018693896,0.040868327],"genre_scores_gemma":[0.25932714,0.043630827,0.44297996,0.21710211,0.015970327,0.0013733534,0.0021079192,0.00070835627,0.01679998],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98454076,0.009691793,0.00057543995,0.0013768103,0.0028713995,0.0009438137],"domain_scores_gemma":[0.96827644,0.014862324,0.0020324735,0.0026592412,0.008069854,0.004099674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0374721,0.0015329674,0.0014940526,0.002859041,0.0012381055,0.009213135,0.0031099648,0.0063105063,0.008138343],"category_scores_gemma":[0.032510146,0.00057646475,0.002440514,0.0019205796,0.0066459305,0.006255255,0.004075687,0.010990979,0.0033319832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006269783,0.00069577876,0.006297811,0.0014085147,0.00048715418,0.00036762157,0.000407297,0.021414632,0.0050190636,0.4536399,0.18888092,0.32075447],"study_design_scores_gemma":[0.0004339461,0.0015123927,0.0019723335,0.001342097,0.0003417274,0.00046640474,0.000405157,0.03976811,0.0071108807,0.5187475,0.42769313,0.00020618836],"about_ca_topic_score_codex":0.0028240492,"about_ca_topic_score_gemma":0.004508215,"teacher_disagreement_score":0.0374721,"about_ca_system_score_codex":0.0053884634,"about_ca_system_score_gemma":0.018082064,"threshold_uncertainty_score":0.19817376},"labels":[],"label_agreement":null},{"id":"W4412940298","doi":"10.1136/jitc-2025-012659","title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Canadian Cancer Society; Lotte and John Hecht Memorial Foundation; London Health Sciences Centre","keywords":"Medicine; Internal medicine; Transplantation; Melanoma; Post-hoc analysis; Oncology; Fecal bacteriotherapy; Gastroenterology; Progression-free survival; Surgery; Overall survival; Clostridium difficile; Antibiotics; Cancer research","score_opus":0.0198921299049257,"score_gpt":0.33525427973694233,"score_spread":0.3153621498320166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534506,0.0024553118,0.00021899874,0.00034655922,0.00008615002,0.00042571427,0.00035797662,0.000036255384,0.0007279151],"genre_scores_gemma":[0.9945451,0.0015605176,0.0007999163,0.00056120695,0.00017969168,0.0007321819,0.00081653026,0.000010380755,0.0007945092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99970394,0.00015873364,0.000014416403,0.000044048695,0.000026455833,0.00005242563],"domain_scores_gemma":[0.99967825,0.000060254068,0.00006794974,0.000030983585,0.000024584808,0.00013807192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011787422,0.00080501626,0.0014900346,0.00021806442,0.00028746022,0.00065629586,0.0003308418,0.00065926835,0.0011518027],"category_scores_gemma":[0.00069769163,0.00023452278,0.0011768349,0.0001900665,0.00036063627,0.0004879873,0.00029843155,0.0011257752,0.00021002002],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72853214,0.029556183,0.02190412,0.00082970114,0.002803603,0.00030555617,0.00020045458,0.0026250663,0.032456227,0.00025434728,0.004146674,0.17638595],"study_design_scores_gemma":[0.348599,0.6065226,0.034195986,0.00007518572,0.0016906224,0.00032636712,0.000055399836,0.001972165,0.0034877954,0.00037106843,0.00266723,0.000036573503],"about_ca_topic_score_codex":0.00038805872,"about_ca_topic_score_gemma":0.001359821,"teacher_disagreement_score":0.0014900346,"about_ca_system_score_codex":0.00052853476,"about_ca_system_score_gemma":0.000663329,"threshold_uncertainty_score":0.006233871},"labels":[],"label_agreement":null},{"id":"W4412940313","doi":"10.1136/jitc-2024-010777","title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Melanoma; Pharmacodynamics; Internal medicine; Pharmacokinetics; Clinical endpoint; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.00830114669991602,"score_gpt":0.29845379804716465,"score_spread":0.29015265134724866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828488,0.012241161,0.00019619544,0.0005417938,0.00013094372,0.0008427878,0.0012355985,0.000033385248,0.0019292837],"genre_scores_gemma":[0.99067616,0.0034312091,0.0006593751,0.0008428836,0.00023308379,0.00062359206,0.0024290874,0.0000104163455,0.0010940124],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99925584,0.00043332335,0.000052147334,0.00012124352,0.00006893584,0.00006849143],"domain_scores_gemma":[0.9990402,0.00021293714,0.000276925,0.00008334708,0.00005851964,0.00032815104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027616601,0.0007436578,0.0013243544,0.00024364716,0.00025617515,0.00091853837,0.0006735082,0.0008018757,0.0017931063],"category_scores_gemma":[0.0013399693,0.0002945519,0.0014631713,0.000323774,0.00060330384,0.00067592016,0.00041647247,0.0016072233,0.00032879954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8736692,0.011881105,0.02364336,0.0016938131,0.0040447335,0.0001942698,0.00014305854,0.0016290625,0.014537835,0.00023967258,0.003776007,0.064547956],"study_design_scores_gemma":[0.7548849,0.18427268,0.050409038,0.00014491982,0.0022077626,0.00040645048,0.00010867956,0.0011289135,0.0020609826,0.0003193143,0.004011488,0.000044835022],"about_ca_topic_score_codex":0.0005482166,"about_ca_topic_score_gemma":0.0017542695,"teacher_disagreement_score":0.0027616601,"about_ca_system_score_codex":0.0006152097,"about_ca_system_score_gemma":0.00095749233,"threshold_uncertainty_score":0.014605224},"labels":[],"label_agreement":null},{"id":"W4413107688","doi":"10.1136/jitc-2025-011475","title":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunogenicity; CD8; Pharmacokinetics; Pharmacodynamics; Cytotoxic T cell; Agonist; Tolerability; Adverse effect; Pharmacology; Receptor; Antibody; CD28; T cell; Internal medicine; Immune system; Immunology; In vitro; Chemistry","score_opus":0.011388662550833616,"score_gpt":0.34751192627272615,"score_spread":0.33612326372189255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413107688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332315,0.001274763,0.0003767977,0.0002947928,0.000056087967,0.002270546,0.0010222399,0.00006392546,0.0013177468],"genre_scores_gemma":[0.99223,0.0008661438,0.0010043392,0.0005623617,0.00010090689,0.0017347359,0.0014850221,0.000022640643,0.0019938916],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995437,0.00019517273,0.00001700583,0.00007348947,0.000043991513,0.00012656036],"domain_scores_gemma":[0.99946934,0.00008152094,0.000114337105,0.000041977793,0.000045973975,0.0002467791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017202809,0.0015954261,0.001669491,0.0003222395,0.0005138693,0.00079727254,0.00048854144,0.0008148693,0.0034876612],"category_scores_gemma":[0.00066152244,0.00047447826,0.000971392,0.00024920353,0.0007589626,0.0007536512,0.00034766254,0.0023580359,0.00082453166],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5062814,0.13338013,0.033801485,0.0016387331,0.0020908774,0.0010693844,0.0010309406,0.0059867837,0.10866976,0.00044390952,0.010559459,0.19504716],"study_design_scores_gemma":[0.21841715,0.72665447,0.03484404,0.0000474333,0.00059438,0.0006831238,0.00015283193,0.0013523092,0.010774879,0.00022995297,0.0062128324,0.00003652959],"about_ca_topic_score_codex":0.0010008018,"about_ca_topic_score_gemma":0.003078664,"teacher_disagreement_score":0.0034876612,"about_ca_system_score_codex":0.0012706872,"about_ca_system_score_gemma":0.0016676052,"threshold_uncertainty_score":0.011667311},"labels":[],"label_agreement":null},{"id":"W4413112190","doi":"10.1136/jitc-2025-012478","title":"Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"EMD Serono; LEO Pharma; PharmaMar; Servier; Eisai; Fred Hutchinson Cancer Research Center; Regeneron Pharmaceuticals; Springworks Therapeutics; Advanced Accelerator Applications; Incyte; Les Laboratories Pierre Fabre; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Merkel cell carcinoma; Tolerability; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy; Surgery; Carcinoma; Adverse effect; Clinical trial","score_opus":0.013898712855573774,"score_gpt":0.34620984755114265,"score_spread":0.3323111346955689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413112190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959264,0.0016120963,0.00037198985,0.00017053154,0.000038450973,0.0008517361,0.0003737682,0.00005320904,0.00060190365],"genre_scores_gemma":[0.9957765,0.0006841224,0.00083443656,0.00037300482,0.000050248243,0.00064864935,0.00074848253,0.000009499457,0.00087514025],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976915,0.00011241444,0.0000118432545,0.000034805675,0.000023584907,0.000048202583],"domain_scores_gemma":[0.999524,0.00008104687,0.00012849424,0.000036633293,0.000035211753,0.00019457453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014019242,0.0006784031,0.0009631512,0.00018992955,0.00021931654,0.00045060244,0.0004479484,0.00050385424,0.0016202435],"category_scores_gemma":[0.00058080483,0.00027975504,0.0006116107,0.00016491002,0.00033304055,0.00034701763,0.00018334157,0.0011859698,0.00044734168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48545513,0.07627334,0.045180652,0.00148569,0.0025054566,0.00076405756,0.00076505804,0.0048516993,0.12964714,0.00025545285,0.0069123986,0.24590391],"study_design_scores_gemma":[0.39607018,0.5313695,0.054165885,0.00004876645,0.00083137996,0.0011246247,0.00010410039,0.0022815869,0.008811578,0.00011605732,0.0050441236,0.00003234311],"about_ca_topic_score_codex":0.00075295806,"about_ca_topic_score_gemma":0.0025590577,"teacher_disagreement_score":0.0016202435,"about_ca_system_score_codex":0.0006496967,"about_ca_system_score_gemma":0.000866236,"threshold_uncertainty_score":0.0074142218},"labels":[],"label_agreement":null},{"id":"W4413863367","doi":"10.1136/jitc-2025-012083","title":"HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"German Network for Bioinformatics Infrastructure; Boehringer Ingelheim Stiftung; Deutsche Forschungsgemeinschaft; Bosch-Forschungsstiftung","keywords":"Atlas (anatomy); Mass spectrometry; Medicine; Ligand (biochemistry); Computer science; Computational biology; Information retrieval; Data mining; Internal medicine; Chemistry; Biology; Receptor; Chromatography","score_opus":0.013838170003798262,"score_gpt":0.2896823738356229,"score_spread":0.2758442038318246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413863367","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14295012,0.015958535,0.18631783,0.0016563309,0.0009784,0.0007392651,0.54751927,0.089591846,0.014288399],"genre_scores_gemma":[0.12419137,0.002775266,0.20173037,0.0014453954,0.00026235718,0.0011114439,0.65546095,0.008538054,0.0044847736],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997815,0.00039724715,0.00019001079,0.000882386,0.00055177533,0.0001635136],"domain_scores_gemma":[0.9978163,0.0005595723,0.00025576315,0.0007639924,0.00041589752,0.0001884858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036186946,0.0017677298,0.0013988328,0.0028472997,0.0010069741,0.0029638815,0.0022708261,0.0013189983,0.007252086],"category_scores_gemma":[0.0057986937,0.00077079725,0.0015204259,0.0016601029,0.0005563325,0.0014932283,0.0035247984,0.0015982594,0.008844224],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063274843,0.00072850595,0.062361673,0.006231566,0.0033874037,0.0023790128,0.00088025327,0.012318363,0.2830744,0.006273066,0.41217417,0.20386411],"study_design_scores_gemma":[0.00074617605,0.00064828375,0.06385006,0.0005790085,0.0008993368,0.0049397624,0.00036262374,0.07542838,0.1311733,0.018478299,0.70239604,0.00049856916],"about_ca_topic_score_codex":0.0027082544,"about_ca_topic_score_gemma":0.0057289316,"teacher_disagreement_score":0.007252086,"about_ca_system_score_codex":0.00073065405,"about_ca_system_score_gemma":0.0018019436,"threshold_uncertainty_score":0.0242607},"labels":[],"label_agreement":null},{"id":"W4413872129","doi":"10.1136/jitc-2024-011331","title":"Nanofilament immunotherapy induces potent antitumor vaccine responses","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institute for Research in Immunology and Cancer; Université de Montréal; Université de Sherbrooke","funders":"Génome Québec","keywords":"Medicine; Immunotherapy; Immunology; Cancer research; Pharmacology; Immune system","score_opus":0.029796957230199976,"score_gpt":0.40757027692994685,"score_spread":0.37777331969974687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413872129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987609,0.0012250927,0.009027437,0.00008828292,0.00005106038,0.0000854168,0.00016030153,0.00014851251,0.0016047935],"genre_scores_gemma":[0.9920258,0.00047534629,0.0057315016,0.00008681414,0.000020524269,0.00008375135,0.00024452643,0.000024222414,0.0013073788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999928,0.000008332107,0.000005349418,0.000017744524,0.000019847846,0.000020605532],"domain_scores_gemma":[0.9999435,0.000013753239,0.000017790038,0.0000044777607,0.000010846122,0.000009684109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011915349,0.00044704136,0.00014883309,0.00017377778,0.0000674131,0.00017776123,0.000092850176,0.0003164034,0.00075812836],"category_scores_gemma":[0.00011305086,0.00006535118,0.00021605693,0.00007348594,0.00012215514,0.00017917671,0.00016067967,0.00042173045,0.0002255034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000346653,0.000030038018,0.000053407643,0.000029186738,0.0000028473548,0.000010435415,0.0000050046706,0.0000997651,0.9980338,0.000046531695,0.0000413805,0.0016129673],"study_design_scores_gemma":[0.000018870689,0.0005435637,0.0007600306,0.0000059696426,0.000013670436,0.000093718336,0.000005174342,0.0011521354,0.99565166,0.000045570723,0.0017070617,0.00000261089],"about_ca_topic_score_codex":0.00010178452,"about_ca_topic_score_gemma":0.00016443692,"teacher_disagreement_score":0.00075812836,"about_ca_system_score_codex":0.0002336314,"about_ca_system_score_gemma":0.00014115256,"threshold_uncertainty_score":0.0025362372},"labels":[],"label_agreement":null},{"id":"W4414257148","doi":"10.1136/jitc-2025-012496","title":"MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Government of Ontario; Cancer Research Society","keywords":"Tumor microenvironment; Regulatory T cell; T cell; Bladder cancer; Tumor cells; Cell; Tumor progression; Cancer","score_opus":0.011157772161539669,"score_gpt":0.31164109957560004,"score_spread":0.30048332741406036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414257148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417144,0.0017195579,0.002199174,0.00006256714,0.000021771644,0.000030756662,0.0008139381,0.00015631501,0.0008243868],"genre_scores_gemma":[0.9958171,0.0005315535,0.0016651583,0.000069697395,0.0000300472,0.00005083313,0.00087186915,0.000027434604,0.0009362385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997664,0.000027447697,0.000016618555,0.00007546315,0.000050085106,0.00006406209],"domain_scores_gemma":[0.9995796,0.00005512626,0.00014661749,0.000035280867,0.000042656324,0.00014080582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021670123,0.00022700006,0.0002776024,0.00046972165,0.00021070881,0.00044316208,0.00010037728,0.00021309307,0.002053171],"category_scores_gemma":[0.00034719534,0.00015366024,0.00021493998,0.00031384826,0.00022728638,0.00017777803,0.00030143055,0.0007410747,0.00038459554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001058203,0.000082753766,0.01754765,0.00020260923,0.000024089586,0.0001601993,0.00013027801,0.00046859644,0.97142,0.00016319547,0.0003088126,0.008433582],"study_design_scores_gemma":[0.00013640538,0.0023382634,0.28739938,0.00009867758,0.0002518219,0.001969496,0.00052258687,0.00942713,0.6757002,0.00073919597,0.021378586,0.000038338647],"about_ca_topic_score_codex":0.00033877156,"about_ca_topic_score_gemma":0.0004569721,"teacher_disagreement_score":0.002053171,"about_ca_system_score_codex":0.00017151168,"about_ca_system_score_gemma":0.00021865821,"threshold_uncertainty_score":0.0068685412},"labels":[],"label_agreement":null},{"id":"W4414444386","doi":"10.1136/jitc-2024-010792","title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"European Regional Development Fund; Instituto de Salud Carlos III; Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Fundación Científica Asociación Española Contra el Cáncer","keywords":"Immune system; Immunogenicity; Peripheral blood mononuclear cell; Monoclonal antibody; Antigen; Antibody; Chimeric antigen receptor; Immunotherapy","score_opus":0.0330377316831344,"score_gpt":0.38629744154714707,"score_spread":0.35325970986401267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414444386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438125,0.0021153935,0.0004466024,0.00028407114,0.0000078544435,0.000017815863,0.00006271315,0.000019196255,0.0026650957],"genre_scores_gemma":[0.999025,0.00037156203,0.00009822006,0.000086844055,0.00001676411,0.0000066629887,0.00008200733,0.0000030474591,0.00030982465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998186,0.000039755658,0.000020067666,0.000027131462,0.000034747765,0.00005966244],"domain_scores_gemma":[0.99972314,0.00009867725,0.00009504244,0.000017059472,0.000019033883,0.000046998834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028951067,0.00014443274,0.00023204146,0.00020960553,0.00016701788,0.0004925083,0.0001513568,0.00034529087,0.00093401887],"category_scores_gemma":[0.0005679544,0.000058658236,0.00018808593,0.00012815963,0.00020416867,0.00022877853,0.00013927558,0.000518865,0.00018849778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056583337,0.0009816041,0.51185036,0.00042029255,0.00015266228,0.05580471,0.0013888272,0.0016474637,0.18062256,0.0015981507,0.0023484977,0.23752658],"study_design_scores_gemma":[0.00040385593,0.008805765,0.65845615,0.00014470355,0.00045369967,0.19722869,0.0011464288,0.0055099754,0.103544265,0.0013027549,0.022956612,0.00004711251],"about_ca_topic_score_codex":0.0005135239,"about_ca_topic_score_gemma":0.00051163795,"teacher_disagreement_score":0.00093401887,"about_ca_system_score_codex":0.00034492306,"about_ca_system_score_gemma":0.00013829944,"threshold_uncertainty_score":0.003124535},"labels":[],"label_agreement":null},{"id":"W4415655717","doi":"10.1136/jitc-2025-012355","title":"Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Acetaminophen; Immune system; Immune checkpoint; Causality (physics); Drug; Nivolumab","score_opus":0.009689728968450075,"score_gpt":0.3244373792283184,"score_spread":0.31474765025986834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415655717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40741476,0.25828385,0.015954513,0.28459468,0.0033966561,0.00023325814,0.0022761093,0.00014195082,0.027704239],"genre_scores_gemma":[0.93291587,0.03502733,0.0035609151,0.02217461,0.0042669447,0.00006464041,0.00046381008,0.000019606008,0.0015062011],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99433386,0.002972127,0.0006917463,0.00058689783,0.0011364042,0.0002789409],"domain_scores_gemma":[0.9307924,0.053026713,0.012425989,0.0013187574,0.0015888269,0.000847386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008610243,0.00053593196,0.001433698,0.00092194777,0.00060011126,0.0014523615,0.0007531472,0.0023887372,0.006593382],"category_scores_gemma":[0.046615973,0.00031036185,0.0015396895,0.0013868416,0.0018377631,0.0021812236,0.00075068267,0.0033785354,0.00043667457],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002969117,0.00022657117,0.78275007,0.003003751,0.005718914,0.0074651246,0.0008575835,0.0005124453,0.00038717993,0.007872518,0.017144384,0.17109223],"study_design_scores_gemma":[0.0008694899,0.0016418207,0.78955305,0.0081881,0.007591652,0.048645288,0.0034044567,0.007990077,0.0014498403,0.08469398,0.04569923,0.00027298593],"about_ca_topic_score_codex":0.0036811694,"about_ca_topic_score_gemma":0.0041943337,"teacher_disagreement_score":0.008610243,"about_ca_system_score_codex":0.0005520849,"about_ca_system_score_gemma":0.0010559326,"threshold_uncertainty_score":0.045535862},"labels":[],"label_agreement":null},{"id":"W4415896981","doi":"10.1136/jitc-2024-011382","title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics and Genomics of Geneva; Université de Genève; Ligue Genevoise Contre le Cancer; University of Pennsylvania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Fondation ISREC; Institut National Du Cancer; National Science Foundation; McMaster University; Fondation privée des Hôpitaux universitaires de Genève","keywords":"Bystander effect; Glioblastoma; Extracellular matrix; Cytotoxic T cell; Domain (mathematical analysis); T cell; Extracellular","score_opus":0.036324732330809476,"score_gpt":0.3776838244149533,"score_spread":0.34135909208414383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918249,0.002075505,0.0027791818,0.00017773968,0.00007038364,0.0001999113,0.00055747246,0.0002979252,0.0020169225],"genre_scores_gemma":[0.9915835,0.0019822298,0.0024645696,0.00009319719,0.00003360001,0.00025526548,0.0008406723,0.000042997286,0.002703903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998233,0.000024499543,0.000011614371,0.000026918035,0.000035730693,0.000078009456],"domain_scores_gemma":[0.9998642,0.000014175543,0.000029685076,0.000014387273,0.000022011383,0.000055447705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035869094,0.000868938,0.00051017693,0.0006717725,0.0001571396,0.00034909765,0.0003745606,0.00042873598,0.0012352149],"category_scores_gemma":[0.00012267996,0.00017987101,0.00036567522,0.00025810878,0.0002543821,0.00027187815,0.00017460326,0.0012564403,0.00039957537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012795251,0.0015658131,0.00026755568,0.0001585782,0.000033392844,0.00008727646,0.00006288716,0.00080231915,0.9867732,0.00015303069,0.0005228713,0.00829358],"study_design_scores_gemma":[0.00037100102,0.019806527,0.0029393346,0.000034374676,0.0001450522,0.0002928308,0.00005239493,0.0029083875,0.9699103,0.00009852225,0.003428574,0.000012624987],"about_ca_topic_score_codex":0.001398274,"about_ca_topic_score_gemma":0.0023565623,"teacher_disagreement_score":0.001398274,"about_ca_system_score_codex":0.00042161267,"about_ca_system_score_gemma":0.00056270184,"threshold_uncertainty_score":0.004132211},"labels":[],"label_agreement":null},{"id":"W4416135787","doi":"10.1136/jitc-2025-012138","title":"Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Helsinki Institute of Life Science, Helsingin Yliopisto; Suomen Farmaseuttinen Yhdistys; Business Finland; Biocenter Finland; Syöpäsäätiö; Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Academy of Finland; Medicinska Understödsföreningen Liv och Hälsa; Helsingin Yliopisto","keywords":"Tumor microenvironment; Downregulation and upregulation; Cancer immunotherapy; Immune system; Extracellular vesicles; Immunotherapy; Cancer; Microvesicles","score_opus":0.004744796303308903,"score_gpt":0.29958771211942237,"score_spread":0.29484291581611344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416135787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892926,0.004404605,0.003797624,0.00019057584,0.000100699355,0.00010263065,0.00035753901,0.00012517974,0.0016285541],"genre_scores_gemma":[0.9943949,0.0013445944,0.0027183269,0.00004371844,0.000012831568,0.00008365374,0.00026867073,0.00002040158,0.0011129255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999088,0.000016607042,0.0000092125865,0.00001959761,0.000018477725,0.000027329985],"domain_scores_gemma":[0.9999502,0.000008482253,0.000014470608,0.0000057959846,0.000006974863,0.000014040959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001618727,0.00029780198,0.00028131437,0.00012992548,0.00009686606,0.0002630148,0.00018104707,0.00029163493,0.00097264955],"category_scores_gemma":[0.00009715218,0.00008850617,0.00024816312,0.000094666866,0.00014598572,0.0002381229,0.00021665641,0.00048761818,0.00020086853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029264923,0.00009088505,0.00007626781,0.00010714259,0.000011651216,0.00002683763,0.000013358389,0.00020217546,0.9955428,0.00014528888,0.0000983385,0.0033926303],"study_design_scores_gemma":[0.00004636765,0.000574591,0.000453734,0.000007083771,0.000025018839,0.000059506307,0.000007807159,0.0009391388,0.99526775,0.000027179587,0.0025882686,0.0000036396555],"about_ca_topic_score_codex":0.00029068446,"about_ca_topic_score_gemma":0.0004744529,"teacher_disagreement_score":0.00097264955,"about_ca_system_score_codex":0.00021199975,"about_ca_system_score_gemma":0.00017711325,"threshold_uncertainty_score":0.0032538772},"labels":[],"label_agreement":null},{"id":"W4416827100","doi":"10.1136/jitc-2025-013214","title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Adverse effect; Prospective cohort study; Refractory (planetary science); Immune checkpoint; Cohort study; Clinical trial; Immune system; Safety profile","score_opus":0.011013981859586493,"score_gpt":0.31381246585524136,"score_spread":0.30279848399565484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416827100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953296,0.0014096365,0.00025202316,0.0000991154,0.000031921558,0.000119487835,0.0020696153,0.000008598064,0.00067999127],"genre_scores_gemma":[0.99708027,0.00061096915,0.0001745861,0.00014379028,0.000050214905,0.00007221029,0.0015336341,0.000007392867,0.00032686512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908245,0.00016975362,0.00008403654,0.00034212222,0.00015288165,0.00016860873],"domain_scores_gemma":[0.9981268,0.00021241789,0.00074246345,0.0002558137,0.00023561045,0.00042695412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237672,0.0005342756,0.0006952235,0.0006625901,0.00084852974,0.0012965736,0.00050730933,0.0006382776,0.0026875753],"category_scores_gemma":[0.002122044,0.00058971724,0.0015119612,0.0012078598,0.00026087026,0.0006676904,0.00058033975,0.0013697428,0.00047764074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015787146,0.00017849948,0.99482685,0.00003645874,0.000701194,0.00023590893,0.000045980818,0.00004926473,0.00027637658,0.000042687105,0.00050807046,0.0015199438],"study_design_scores_gemma":[0.00051594153,0.0008684074,0.995374,0.00003243844,0.0006764089,0.0008954679,0.00019949334,0.00036113936,0.000082872546,0.000048976282,0.0009239773,0.000020941994],"about_ca_topic_score_codex":0.008262039,"about_ca_topic_score_gemma":0.008651164,"teacher_disagreement_score":0.008262039,"about_ca_system_score_codex":0.00064795476,"about_ca_system_score_gemma":0.0011094438,"threshold_uncertainty_score":0.016427875},"labels":[],"label_agreement":null},{"id":"W4416910450","doi":"10.1136/jitc-2025-013420","title":"The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"School of Medicine, Emory University; National Cancer Institute; National Institutes of Health; University of Connecticut Health Center; Society for Immunotherapy of Cancer; Ohio State University; University of Pittsburgh; Emory University; Massachusetts General Hospital","keywords":"Tumor-infiltrating lymphocytes; T cell; Immunotherapy; Cancer; Immune system; Immune checkpoint; Adoptive cell transfer; Blockade; Clinical trial","score_opus":0.027962384859575633,"score_gpt":0.3661467783282843,"score_spread":0.33818439346870866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416910450","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001041729,0.11339846,0.00072124746,0.78737885,0.0861942,0.000055489636,0.00016190232,0.000074061965,0.010974127],"genre_scores_gemma":[0.017359788,0.25897104,0.0038151287,0.46758768,0.1811772,0.00029034988,0.0006430418,0.00018161074,0.06997417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960813,0.00088827714,0.00034950615,0.00046043916,0.0016837732,0.0005367503],"domain_scores_gemma":[0.9862422,0.002113098,0.0004946374,0.000468479,0.0057833297,0.0048983116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012565328,0.0014314246,0.00083305134,0.001219827,0.0019155928,0.0059064673,0.0017046916,0.0098987315,0.008021595],"category_scores_gemma":[0.0071659633,0.00035583225,0.0010658574,0.00095669174,0.003578143,0.0043255403,0.002777065,0.017647274,0.0045747827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011135566,0.00015495953,0.00052412733,0.00022095234,0.000009979015,0.00011830291,0.00007900162,0.00014457956,0.0007112551,0.008397371,0.9132933,0.07623484],"study_design_scores_gemma":[0.000032269236,0.00011794729,0.0005363989,0.00036909746,0.000007565883,0.00015334832,0.00007791283,0.0001184087,0.00022773213,0.0033344445,0.99500495,0.000019926283],"about_ca_topic_score_codex":0.0054201297,"about_ca_topic_score_gemma":0.011592492,"teacher_disagreement_score":0.012565328,"about_ca_system_score_codex":0.003181106,"about_ca_system_score_gemma":0.016994158,"threshold_uncertainty_score":0.06645262},"labels":[],"label_agreement":null},{"id":"W4416931943","doi":"10.1136/jitc-2025-013518","title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Perelman School of Medicine, University of Pennsylvania; Children's Hospital of Philadelphia; Children's National Hospital; Universitat de Barcelona; University of Pennsylvania; Gilead Sciences; Bristol-Myers Squibb","keywords":"Transformative learning; Genetically modified organism; Cancer immunotherapy; Ethical issues; Bridge (graph theory); Translational research; Genetically engineered; Public funding","score_opus":0.15005957271258458,"score_gpt":0.39586612709767544,"score_spread":0.24580655438509086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416931943","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044348463,0.037243366,0.06712032,0.81828773,0.017354472,0.00019690445,0.00024919867,0.00038622896,0.054726895],"genre_scores_gemma":[0.17066988,0.0811791,0.06260555,0.6216132,0.020947041,0.0008632338,0.00038572826,0.00055172987,0.041184507],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98030764,0.006639079,0.0012873879,0.0022506607,0.0078123575,0.0017029707],"domain_scores_gemma":[0.965976,0.024470458,0.002206882,0.0019442391,0.004511146,0.00089130044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020588167,0.000806964,0.0008447861,0.0010186217,0.0021894127,0.008379843,0.0052918503,0.012260449,0.008383089],"category_scores_gemma":[0.039069876,0.00063716754,0.0022194996,0.00069891976,0.009668294,0.011234164,0.005142477,0.016354665,0.0016709556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001258542,0.000054721855,0.00031967973,0.00073342194,0.00004537622,0.0003955781,0.0011668792,0.0041505974,0.0031408586,0.7838022,0.14986199,0.056202706],"study_design_scores_gemma":[0.00003639943,0.00009782278,0.00024794726,0.00083588646,0.000026989921,0.00021886131,0.00039762218,0.000957225,0.002108629,0.12481096,0.87019515,0.000066501445],"about_ca_topic_score_codex":0.006619211,"about_ca_topic_score_gemma":0.012987117,"teacher_disagreement_score":0.020588167,"about_ca_system_score_codex":0.007129461,"about_ca_system_score_gemma":0.014525774,"threshold_uncertainty_score":0.10888195},"labels":[],"label_agreement":null},{"id":"W4417535946","doi":"10.1136/jitc-2025-012280","title":"Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Johns Hopkins University","keywords":"Checklist; Multiplex; Standardization; Best practice; Immunotherapy; Biomarker; Cluster analysis","score_opus":0.019491286129122657,"score_gpt":0.3678711952094522,"score_spread":0.34837990908032956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417535946","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013943385,0.026673447,0.5251849,0.22056645,0.05719321,0.042182367,0.01379694,0.015902987,0.08455631],"genre_scores_gemma":[0.034652837,0.017384704,0.7922384,0.057738975,0.0069144717,0.04080667,0.025234072,0.0030626755,0.021967126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.6474162,0.14566259,0.13431019,0.0070949933,0.05810323,0.007412723],"domain_scores_gemma":[0.3502588,0.14224696,0.072049074,0.0605343,0.3624312,0.012479703],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.27684596,0.00209135,0.0033927278,0.020640416,0.005452072,0.014265491,0.009577068,0.013263855,0.0063552544],"category_scores_gemma":[0.35697317,0.0033065858,0.005200953,0.011917912,0.00812929,0.00575625,0.012779836,0.018286522,0.017150365],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004117263,0.00051491195,0.005422877,0.008342856,0.00027270993,0.00091861293,0.0039217984,0.0019157181,0.0130658755,0.025360065,0.6220943,0.31775853],"study_design_scores_gemma":[0.00011501919,0.00032172122,0.005986326,0.009504245,0.00017544471,0.0010915225,0.0015984413,0.0021911995,0.007753049,0.012471304,0.95853734,0.00025433523],"about_ca_topic_score_codex":0.00766507,"about_ca_topic_score_gemma":0.0069520003,"teacher_disagreement_score":0.72315407,"about_ca_system_score_codex":0.010301613,"about_ca_system_score_gemma":0.057684112,"threshold_uncertainty_score":0.8917777},"labels":[],"label_agreement":null},{"id":"W4417539105","doi":"10.1136/jitc-2025-012205","title":"Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; Canadian Institutes of Health Research; Foundation Medicine; EMD Serono; Genentech; National Institutes of Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lung cancer; Selection (genetic algorithm); Tumor microenvironment; Smoking history; Cancer; Differential (mechanical device)","score_opus":0.013308753787749896,"score_gpt":0.3321649297811176,"score_spread":0.31885617599336774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417539105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543273,0.0020231407,0.0006619982,0.00023856151,0.000012963506,0.000011533611,0.0013337551,0.000019052339,0.00026636766],"genre_scores_gemma":[0.99796486,0.0003174784,0.00040032764,0.00010092874,0.000019279421,0.000008983129,0.0010991686,0.0000045438273,0.0000844153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925333,0.00022255891,0.00007957234,0.00023513834,0.00010379239,0.000105593106],"domain_scores_gemma":[0.99846256,0.00061114837,0.0005491307,0.00014584749,0.000101121506,0.00013008625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013569057,0.00036925756,0.0010299525,0.001142517,0.00035615874,0.00108666,0.0003207426,0.00043381462,0.0009872947],"category_scores_gemma":[0.0016847645,0.00019612952,0.0013346272,0.0016016375,0.00028388796,0.00041300693,0.00068423327,0.00046074178,0.0001667003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004380945,0.000036178553,0.98837715,0.000045591318,0.0006310916,0.000047636157,0.000036805384,0.00041781485,0.0035368481,0.00004146191,0.00016417986,0.0062271366],"study_design_scores_gemma":[0.000010525393,0.00010086888,0.9956927,0.00001100492,0.00030995012,0.000119448916,0.00007938989,0.002561817,0.0005027232,0.00021271603,0.0003912439,0.000007687011],"about_ca_topic_score_codex":0.0015491549,"about_ca_topic_score_gemma":0.0026728876,"teacher_disagreement_score":0.0015491549,"about_ca_system_score_codex":0.00037239408,"about_ca_system_score_gemma":0.0003451316,"threshold_uncertainty_score":0.0071760416},"labels":[],"label_agreement":null},{"id":"W7117233846","doi":"10.1136/jitc-2025-012235","title":"AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; National Cancer Institute; National Institutes of Health; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Moderna; Johns Hopkins University; Division of Cancer Prevention, National Cancer Institute; Mark Foundation For Cancer Research; Regeneron Pharmaceuticals; Melanoma Research Alliance; Bristol-Myers Squibb","keywords":"Relational database; Biomarker discovery; Longitudinal data; Biomarker; Relational model; Patient data","score_opus":0.01237569453298951,"score_gpt":0.33085278266460383,"score_spread":0.3184770881316143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117233846","genre_codex":"methods","genre_gemma":"software","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"software","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009078981,0.001091065,0.72461116,0.0030761478,0.00041674054,0.0020903735,0.12295703,0.12468644,0.011992053],"genre_scores_gemma":[0.06878328,0.0011715285,0.65668344,0.0013178741,0.00020519995,0.0018698232,0.2564811,0.008177726,0.005309911],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99176496,0.0016865782,0.0017858552,0.0016874953,0.0027148607,0.00036026307],"domain_scores_gemma":[0.97584754,0.006989921,0.0019555755,0.0091036605,0.0043653855,0.001737841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015313363,0.0012948902,0.001479525,0.006597877,0.0017298787,0.007541796,0.006106255,0.0012155557,0.0144289825],"category_scores_gemma":[0.04217257,0.001632311,0.0018357884,0.0076516713,0.0012471029,0.010235957,0.0088133365,0.0024507116,0.009663949],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014400694,0.00038423206,0.01990043,0.0021695702,0.00045088583,0.0010026874,0.0024281389,0.01719878,0.013210253,0.1213617,0.5244293,0.29602394],"study_design_scores_gemma":[0.00064923416,0.00043915244,0.0071281074,0.0006460517,0.0002669177,0.0013543202,0.0014797399,0.11133469,0.022105528,0.09216182,0.7619611,0.0004733292],"about_ca_topic_score_codex":0.010961505,"about_ca_topic_score_gemma":0.010731977,"teacher_disagreement_score":0.015313363,"about_ca_system_score_codex":0.002513684,"about_ca_system_score_gemma":0.0075487588,"threshold_uncertainty_score":0.080985725},"labels":[],"label_agreement":null}]}